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Preface
Preface
Ladies and Gentlemen, Dear Colleagues,
As Minister of Science, Education and Sports of the Republic of Croatia I am pleased to welcome all participants
gathered for the International Workshop on Human Papillomaviruses and Consensus Recommendations for Cervical
Cancer Prevention & Colposcopy Training.
It is a great honor to have experts and scientists from all over the world here in Croatia discuss an exceptionally im-
portant health risk factor, at this distinguished event.
Human Papilloma Virus (HPV) is known to play a significant part in the etiology of cervical cancer, which is the sec-
ond most frequent malignancy in women worldwide. The mortality rate is growing, especially in younger women, so it
is extremely necessary to carry out cervical cancer prevention programmes, as it is obvious that systematic and well-or-
ganized cervical cancer screening programmes can greatly reduce incidence and mortality rates from the disease.
The World Health Organization recommendation from 2006 bears witness to the importance of this issue, as it sug-
gests that cervical screening should be presented with organized programmes. Additionally, the European Union Coun-
cil declared in its recommendation from 2003 that all EU member-states should conduct organized cervical cancer
screening programmes.
The development of science and technology, particularly HPV DNA testing, HPV RNA testing, HPV vaccination as
well as the use of a selection of different other molecular markers, etc., allow you, as leading experts in the field, to
make best possible Consensus Recommendations for Cervical Cancer Prevention.
This important scientific event will feature the latest advances concerning Human Papillomaviruses, cervical cancer
screening and prevention through many remarkable lectures. It is also important to mention that the special issue of
Collegium Anthropologicum, published on this occasion, includes interesting themes related to the most recent re-
search findings, different aspects and experiences in the field. This will certainly be a considerable contribution in de-
fining further guidelines in cervical cancer prevention in Croatia and abroad.
We are fully aware of how significant your scientific achievements are and how huge an impact your decisions will
have in this very important field, therefore in improving the quality of life of this and future generations.
I sincerely wish you a memorable, inspirational and very successful gathering, in hopes that all of us will greatly
benefit from this event.
Professor Dragan Primorac, MD, PhD
Minister of Science, Education and Sports
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Introduction
Introduction
Cancer is the second major cause of death in Croatia, every fourth of our citizens dies of it. From 1978 to 2004, the
incidence of cancer has increased by 58%, while deaths from cancer from 1978 to 2005 have increased by 59%. This
means that there are about 20,000 new cancer cases per year in our country with 4,4 million inhabitants. Meanwhile,
the cancer mortality rates in Croatia are higher than those seen in the countries of the European Union or in countries
that have implemented cancer prevention and early detection programmes. Among Croatian women, breast cancer is
the most common cancer overall. Cancer of the cervix is the second one in women, aged 25–49 years.
The burden of cervical cancer in Croatia is considerable as we have about 350 (332 in year 2004) incident cases and
about 100 deaths from cervical cancer yearly. Although, invasive cervical cancer incidence is only the 8th most common
cancer among Croatian women, the important distinction with cervical cancer is that it is almost entirely preventable.
Effective, organised cervical screening programmes have been shown to prevent about 80% of cervical cancers and we
need to work toward the implementation of these programmes in our country. In addition, we now have vaccines
against the two most common types of HPV, the virus that can cause cervical cancer, and the implementation of vacci-
nation programmes for pre-adolescents before the start of sexual activities carries with it the promise of even further
reduction in cervical cancer rate.
Cervical cancer screening is available in Croatia but this is not being offered within a national, organised
programme that effectively screens all Croatian women. Following the publication of the European Council’s recom-
mendations for cancer screening of December 2003, a working group of the Croatian Ministry of Health and Social Wel-
fare was convened and in 2005, recommended a national programme for early detection of cancer. This represents a ba-
sic document for the implementation of organised screening programmes for cervical, breast and colorectal cancer in
Croatia. Under the direction of the Croatian Ministry of Heath and Social Welfare, a programme for the early detection
of breast cancer started in Croatia in 2006 enrolling about 560,000 women. Now, the Croatian Ministry of Heath and
Social Welfare is planning a pilot project for cervical cancer screening programme and this should start before the end
of the year.
In this context the Croatian Ministry of Health and Social Welfare supports the editing of this special issue of
Collegium Aiitropologicum, which is dedicated to the International Workshop on Human Papillomaviruses and Con-
sensus Recommendations for Cervical Cancer Prevention that will be held in Dubrovnik – Cavtat, Croatia from 18 to 21
April, 2007.
Professor Neven Ljubi~i}, MD, PhD
Minister of Health and Social Welfare
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Editorial
Editorial
Magdalena Grce1,2 and Philip Davies1
1 European Cervical Cancer Association, Lyon, France
2 Ru|er Bo{kovi} Institute, Department of Molecular Medicine, Zagreb, Croatia
Cervical cancer still remains an important public health
issue in Europe where it is the 7th most common cause of
cancer deaths in women1. Each year in Western Europe,
13,000 women develop cervical cancer and 6,000 women
die from this disease, while the situation in Eastern Eu-
rope is much worse with approximately 31,000 women
developing cervical cancer and about 17,000 dieing every
year1. The differences within Europe are largely due to
the absence of effective cervical screening in Eastern Eu-
rope and the implementation of properly organised cervi-
cal screening programmes would inevitably have a major
impact on this disease.
Cervical cancer screening based on the Pap smear can
reduce cervical cancer rates by 80% and it is the only
method that has been proven to do this. However, cervical
screening will only achieve these high rates of prevention
if implemented within programmes that achieve high lev-
els of population coverage together with extensive quality
assurance procedures to monitor performance at all levels
and promptly rectify failures when they occur. Without
these elements, you essentially revert to opportunistic
screening which has been demonstrated to be less effec-
tive and to promote health inequalities by over-screening
the wealthy and well-educated while under-screening low-
er socioeconomic groups and minorities.
This has been recognised by many international, Eu-
ropean and national institutions including:
1) The World Health Organisation’s recommenda-
tion2 from 2006 stating that cervical screening should
only be offered in organised, rather than opportunistic,
programmes in which screening is centrally managed,
achieves high population coverage particularly among
the women at highest risk and include appropriate qual-
ity control procedures.
2) The Council of the European Union which stated in
it recommendation of December 20033 that all EU Mem-
bers States should implement organised cervical cancer
screening programmes.
3) The new European Guidelines for Quality Control
in Cervical Cancer Screening4 that specifically note cervi-
cal cancer screening should not be offered opportunisti-
cally and the publication of these guidelines will raise se-
rious ethical concerns for the many European countries
that still rely on opportunistic screening.
The last 20 years has seen an explosion of new tech-
nologies for cervical cancer prevention. These include
the liquid-based cytology methods together with an array
of new technologies that stem from the discovery that
cervical cancer is caused by certain types of the Human
papillomavirus (HPV) such as HPV DNA testing, HPV
RNA testing, HPV vaccination and the use of a selection
of other molecular markers. Many of these new technolo-
gies will have an impact on cervical cancer prevention
and it is extremely important for those who are responsi-
ble for national cervical screening programmes to care-
fully consider benefits and drawbacks that all these tech-
nologies may be able to offer when deployed within
comprehensive organised cervical cancer prevention prog-
rammes that effectively integrate the technologies that
are appropriate for the country in question. Further, it is
clear that the field will continue to evolve and it would
therefore be advantageous to establish these prevention
programmes on the basis that they are evolving pro-
cesses that continuously evaluate new developments and
integrate them as appropriate.
It was the recognition of these issues that led to the
International Workshop on Human Papillomavirues and
Consensus Recommendations for Cervical Cancer Pre-
vention and to the publication of this Special Issue of the
Collegium Antropologicum. Both are intended to bring
Croatian public health officials, medical specialists and
academic experts together with their counterparts from
around the world for a free and open exchange of the lat-
est scientific results on cervical cancer prevention. This
information can then serve as the basis for the develop-
ment of Croatian recommendations for cervical cancer
prevention and the subsequent implementation of na-
tional programmes for cervical cancer prevention.
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The Burden of Cervical Cancer in South-East
Europe at the Beginning of the 21st Century
Marc Arbyn1,2, Maja Primic-@akelj3, Amidu O. Raifu1, Magdalena Grce4, Evangelos Paraskevaidis5,
Emanuel Diakomanolis6, Vesna Kesi}7, Florian A. Nicula8, Ofelia Suteu8 and Lawrence von Karsa9
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4 Ru|er Bo{kovi} Institute, Division of Molecular Medicine, Zagreb, Croatia
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A B S T R A C T
The situation of cervical cancer prevention in South-East Europe is hardly documented, in spite of the fact that it en-
closes the most affected countries of Europe. We estimated the number of cases of cervical cancer, the number of deaths from
this malignancy and the corresponding rates for 11 countries located in South-East Europe, in the period 2002–2004. Each
year, approximately 9,000 women develop cervical cancer and about 4,600 die from the disease in this subcontinent. The
most affected country is Romania with almost 3,500 cases and more than 2,000 deaths per year. High world-age standard-
ised mortality rates (>7.5 [expressed per 100,000 women-years]) are observed in 7 countries: FYROM (7.6), Moldova (7.8),
Bulgaria (8.0), Bosnia & Herzegovina (8.0), Albania (9.8), Serbia & Montenegro (10.1) and Romania (13.0). A matter of
concern is the increasing mortality rate, in younger women, in the countries with the highest burden of cervical cancer.
Thus, appropriate cervical cancer prevention programmes should be set up without delay in this part of Europe.
Key words: cervical cancer, prevention, mortality, incidence, Europe, South-East Europe
Introduction
This paper has been written as a contribution to a
special issue of Collegium Anthropologicum edited at the
occasion of the International Workshop on Human Pa-
pillomaviruses and Consensus Recommendations for
Cervical Cancer Prevention, Dubrovnik-Cavtat (Croa-
tia), 18–20 April, 2007. This workshop offers an excellent
opportunity to attract the attention of clinicians, epi-
demiologists and health authorities on a public health
problem which is responsible for considerable human
suffering and loss of lives but which is highly preventable
if preventive activities are well organized. In the present
study, we evaluate the burden of cervical cancer in 11
countries in the South-Eastern part of Europe based on
the most recent available data and on estimates of the in-
cidence and the cause-specific mortality, computed by the
International Agency for Research on Cancer, for the pe-
riod 2002–2004.
Material and Methods
We describe the estimated number of cases of cervical
cancer, the number of deaths from cervical cancer and
the corresponding crude and age-standardised rates with
the world standard population as reference for 11 coun-
tries located in the South-Eastern part of Europe (Alba-
nia, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus,
Greece, FYROM [Former Yugoslavian Republic of Mace-
7
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donia], Moldova, Romania, Serbia & Montenegro and
Slovenia) for the period 2002–2004. We identified coun-
tries as defined in 2004, therefore we did not separate
Serbia and Montenegro. Registered data were available
from the Cancer Registry of Slovenia for the year 20031.
Estimates for 2004 were available for two countries (Cy-
prus and Greece)2. For the other 8 countries, estimates
were derived from GLOBOCAN 20023.
Methods used for estimation have been described
previously3,4. Shortly: the most recent mortality rates
were derived from the published vital statistics, stored at
the World Health Organisation (WHO) Mortality Data-
base (http://www.who.int/whosis/mort) for all countries
except Cyprus and Bosnia & Herzegovina. Mortality for
Bosnia & Herzegovina was estimated by averaging rates
from neighbouring countries. The mortality in Cyprus
was estimated from national incidence and pooled Euro-
pean survival data. For Albania, reported mortality rates
were multiplied with a correction factor to compensate
for under-registration of deaths. Mortality from cancer
of the cervix uteri were adjusted by reallocating deaths
from uterus cancer not otherwise specified using age-
specific rules. Incidence data were available from na-
tional cancer registries for Bulgaria, Croatia, Cyprus and
Slovenia. The incidence for Serbia & Montenegro was
computed by taking the average of the regional registries
of Vojvodina and Central Serbia. For the other countries
incidence was estimated from reported or estimated na-
tional mortality rates using incidence/mortality (I/M) ra-
tios computed by Poisson regression using representa-
tive regions where both incidence and mortality data
were available.
Number of cases and deaths were computed by multi-
plying the most recent age-specific rates with the corre-
sponding population size for 2002 or 2004, derived from
the World Population Prospects published by the United
Nations Population Division (http://esa.un.org/unpp/).
For Slovenia, the mid-year population of 2003, published
in Cancer Incidence in Slovenia 2003 was used1.
Results
The number of cases and deaths and the correspond-
ing rates by country are shown in Table 1. The standard-
ised rates, ranked by increasing mortality are displayed
in a bar graph (Figure 1). The geographical distribution
of the standardised mortality is mapped in Figure 2. In
total, each year, approximately 9,000 women in South-
Eastern Europe developed cervical cancer and about
4,600 died from the disease. A low to moderately high
age-standardised mortality was observed in the North-
West and the South-East margin of the region: Slovenia
(4.1/105), Croatia (5.0/105), Greece (2.1/105) and Cyprus
(5.6/105). However, in the core of the region, high to very
high mortality rates were noted varying between 7.8/105
(Moldova) and 13.0/105 (Romania). The standardised in-
cidence rate varied from 7.2/105 in Greece to more than
20.0/105 in Albania, Romania and Serbia & Montenegro.
In general the crude incidence and mortality correlated
well (r=0.88). The parameter 1-M/I, a surrogate index
for survival, varied between 39% in Albania and 66% in
Serbia & Montenegro. However, the correlation coeffi-
cient and the survival surrogate index are rather artificial
indicators since incidence often was derived from mortal-
ity.
Discussion
South-East Europe is a region of major contrasts. It
contains the 2 countries with the highest burden for the
M. Arbyn et al.: Cervical Cancer in South-East Europe, Coll. Antropol. 31 (2007) Suppl. 2: 7–10
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TABLE 1
INCIDENCE OF AND MORTALITY FROM CERVICAL CANCER IN 11 SOUTH-EAST EUROPEAN COUNTRIES: NUMBER OF CASES AND
















Albania 3.9 25.1 25.2 1.5 9.4 9.8 2002 2
Bosnia & Herzegovina 5.5 26.6 21.3 2.3 11.1 8.0 2002 2
Bulgaria 9.8 24.4 18.7 5.1 12.6 8.0 2002 2
Croatia 4.3 18.0 13.3 2.1 8.7 5.0 2002 2
faautoCyprus 0.5 13.2 12.5 0.3 6.1 5.6 2004 1
Greece 4.8 8.9 7.2 2.1 3.9 2.1 2004 1
FYROM 1.7 16.4 13.9 1.0 9.7 7.6 2002 2
Moldova 4.8 21.4 18.0 2.2 9.9 7.8 2002 2
Romania 34.5 30.3 23.9 20.9 18.4 13.0 2002 2
Serbia & Montenegro 18.2 34.4 27.3 8.2 15.5 10.1 2002 2
Slovenia 2.1 20.4 18.5 0.8 7.9 4.1 2003 3
The estimates are derived from a recent study of the burden of cervical cancer in member states of the European Economic Area for
20042, the Cancer Registry of Slovenia for 20031 and from GLOBOCAN 20023 for the other countries, figures are adjusted for mortal-
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whole of Europe: Romania and Serbia & Montenegro. It
contains, together with the Baltic countries, in Northern
Europe, the 7 most affected states of the European conti-
nent with standardised rates of mortality from cervical
cancer reaching 8/100,000 or higher (Romania, Serbia &
Montenegro, Lithuania, Albania, Bosnia & Herzegovina,
Bulgaria, Latvia)2,5. Otherwise, South-East Europe con-
tains countries where the burden is low, for instance in
Greece, where the standardised incidence is 3 to 4 times
and the mortality 5 to 6 times lower than in Serbia &
Montenegro or Romania.
The current cervical cancer incidence and mortality
reflects exposure of successive generations to the main
risk factor (infection of the cervix with oncogenic human
papillomavirus [HPV] types) and the impact of cytologi-
cal screening for HPV induced cervical lesions and
treatment of those lesions. A generally observed phe-
nomenon in industrialised countries is that women born
after 1940 are at higher risk compared to older cohorts
due to changed sexual behaviour (and hence increased
HPV transmission) since the 1960s6–8. Increased fre-
quency of smoking and use of oral anti-conception might
have enhanced this cohort effect6. In the Nordic and
some West- European countries, incidence of and mortal-
ity from cervical cancer dropped substantially subse-
quent to cytological screening7,9–11. Little information is
available on the screening situation in South-East Eu-
rope but it is expected that, in general, the coverage and
quality are moderate to poor. Only in Slovenia, a formally
organised cervical cancer screening programme is in
place since 200312. The current particularly high burden
of cervical cancer in Romania and other South-East Eu-
ropean countries can be explained most plausibly as an
effect of elevated HPV transmission, over the past de-
cades, not counteracted by screening. On the other hand
the low incidence in Greece might be due to the rather
low background risk, also observed in other Mediterranean
countries such as Spain and Italy13. It is expected that on-
going studies assessing the prevalence and the geograph-
ical distribution of HPV types throughout Europe, con-
ducted in the framework of the introduction of HPV
vaccination, will clarify this hypothesis.
The data estimated in this study should be considered
with caution, since their reliability is determined by the
quality and completeness of cancer and death registra-
tion and further by the appropriateness of external data
used to model unavailable data. In particular, the propor-
M. Arbyn et al.: Cervical Cancer in South-East Europe, Coll. Antropol. 31 (2007) Suppl. 2: 7–10
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Fig. 1. Burden of cervical cancer: world age-standardised inci-
dence and mortality in 11 countries of South-East Europe, esti-
mates for 2002/2004 (Source: Globocan 20023, Cancer Registry of
























Fig. 2. Geographical distribution of the world age-standardised mortality (W-ASMR) from cervical cancer in 11 countries of
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tion of deaths from uterine cancer without specification
of the exact topographic origin compromises the accu-
racy of the cause of death certification. We are currently
conducting detailed trend studies, within the framework
of the EU Network for Information on Cancer, where we
look for the best possible solutions for the death cause
certification problem and try to disentangle the dynam-
ics of cervical cancer in all European countries. Prelimi-
nary results indicate that the mortality from uterus can-
cer, in age groups younger than 45 years – where nearly
all deaths are caused by cervix uteri cancer, is falling in
Greece, Croatia and Slovenia but continues to rise or re-
mains stable at a high level in Bulgaria, Moldova, Roma-
nia and Serbia & Montenegro.
Conclusion
We have highlighted the elevated burden of cervical
cancer in some South-East European countries – in par-
ticular in Romania. The present study should motivate
public health authorities to set-up well-organised cervi-
cal cancer prevention programmes without delay as rec-
ommended by the European Council14. It is hoped that
the pending publication of the new European Guidelines
for Quality Assurance in Cervical Cancer Screening will
contribute in establishing this goal15. It is particularly
challenging for public health experts to define, in the fu-
ture, how prophylactic HPV vaccination besides screen-
ing will contribute in tackling this highly preventable
disease.
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BREME RAKA VRATA MATERNICE U JUGOISTO^NOJ EUROPI NA PO^ETKU 21. STOLJE]A
S A @ E T A K
Stanje prevencije raka vrata maternice u jugoisto~noj Europi je slabo zabilje`eno, unato~ ~injenici da ovaj rak poga-
|a najvi{e te dr`ave u Europi. Procijenili smo broj slu~ajeva raka vrata maternice, smrtnost od ove bolesti te odgova-
raju}e odnose izme|u njih za 11 zemalja jugoisto~ne Europe, u razdoblju od 2002. do 2004. g. Svake godine na ovom
potkontinentu oboli od raka vrata maternice pribli`no 9.000 `ena, a oko 4.600 ih umre od ove bolesti. Najvi{e slu~ajeva
bilje`i Rumunjska, gotovo 3.500 te vi{e od 2.000 smrtnih slu~ajeva godi{nje. Visoka godi{nja stopa smrtnosti u svijetu
(>7,5 [brojevi se odnose na 100,000 `ena godi{nje]) je zabilje`ena u 7 zemalja: Biv{a Jugoslavenska Republika Make-
donija (7,6), Moldavija (7,8), Bugarska (8,0), Bosna i Hercegovina (8,0), Albanija (9,8), Srbija i Crna gora (10,1) te
Rumunjska (13,0). Pitanje od va`nosti je porast stope smrtnosti kod mla|ih `ena u zemljama s visokom stopom obola od
raka vrata maternice. Stoga bi, u ovom dijelu Europe, bez odgode trebali biti uspostavljeni odgovaraju}i programi pre-
vencije raka vrata maternice.
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A B S T R A C T
Cervical cancer remains a significant source of disease and death in Europe. However, we now have the means to pre-
vent virtually every case of cervical cancer through comprehensive, population-based, organised cervical cancer preven-
tion programmes that effectively integrate cervical screening with the new technologies and vaccines that are now available.
Given the potential health benefits of these programmes in reducing disease incidence and mortality, their establishment
is now an ethical imperative for all European countries.
Key words: Cervical cancer, screening, vaccination, prevention
Introduction
Cervical cancer is the second most common cancer in
women worldwide and is the most common female can-
cer in the Caribbean, East / Central / Southern Africa and
in South-Central Asia. Globally, an estimated 471,000
women develop cervical cancer and 233,000 die from it
every year (estimate for 2000)1. The disease primarily af-
fects younger women with the majority of cases appear-
ing between the ages of 30 and 502, an age when many
are actively involved in their careers, caring for their
families or both and the impact on society as a whole is
therefore greatly increased.
Cervical cancer still remains an important public health
issue in Europe where it is the 7th most common cause of
cancer deaths in women1. Each year in Western Europe,
13,000 women develop cervical cancer and 6,000 women
die from this disease, while the situation in Eastern Eu-
rope is much worse with approximately 31,000 women
developing cervical cancer and about 17,000 dieing every
year3. This difference is largely due to the absence of ef-
fective cervical screening in Eastern Europe and the im-
plementation of properly organised prevention program-
mes would inevitably decrease the burden of this disease
in these countries.
Cervical Cancer Screening
Squamous cervical cancer is particularly amenable to
screening as it has a long pre-clinical phase and identifi-
able precursor lesions that, if detected early, can be
treated with high efficacy using simple outpatient proce-
dures. Indeed, effective organised cervical cancer screen-
ing programmes have been proven to reduce cervical can-
cer incidence and mortality by more than 80%4. However,
recent studies indicate that screening has limitations.
Data available from organised screening programmes
show that the initial declines in disease incidence seen
following the establishment of screening have now lev-
elled-off, indicating that the maximum effect of Pap
smear-based screening has been reached in these co-
untries4. Further, a meta-analysis of studies unaffected
by verification bias has shown that the pooled sensitivity
of the Pap smear was 77% (95% CI: 58% to 97%) when
using low-grade squamous intra-epithelial lesions (LSIL)
as the threshold to detect histologically confirmed cervical
intraepithelial neoplasia of grade 2 or worse (CIN2+)5.
Given these data, an enormous amount of research ef-
fort has gone into the evaluation of new technologies
such as liquid-based cytology and HPV testing, together
with HPV vaccination that offer the potential to make
11
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further progress in the battle against this disease. How-
ever, it must be remembered that achieving reductions in
the incidence and mortality of cervical cancer is entirely
dependent upon the effective operation of the entire
programme including primary prevention strategies such
as vaccination, screening, diagnosis and treatement of
pre-invasive or invasive disease. For these reasons, new
techologies with the potential to be deployed must also
be studied within the programme so the overall effect, in-
cluding all the benefits and drawbacks, can be properly
evaluated. Further, they should be evaluated within ran-
domised controlled trials in order to obtain un-biased
etimates of their effects.
The Human Papillomavirus
and Cervical Cancer
There is now an overwhelming body of evidence dem-
onstrating that persistent infection with certain types of
the Human papillomavirus (HPV) is the primary risk
factor for the development of cervical cancer and its pre-
cursor lesions6,7. More than 100 different HPV types
have been identified with approximately 40 of these in-
fecting the anogenital epithelium that have been classified
as either low-risk (LR) or high-risk (HR) for the develop-
ment of cervical cancer based upon their identification in
cervical tumour samples8. A recent analysis of 11 studies
has designated 15 anogenital HPV types as HR (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), with a
further 3 types designated as probably HR (26, 53 and
66)9 although some of these designations have been dis-
puted by others10.
This body of evidence is strong, consistent across dif-
ferent populations, and conclusively demonstrates that
HPV is a necessary (although not a sufficient) cause of
cervical cancer7,11. On the basis of these data, it is logical
to conclude that HPV testing could be a useful cervical
cancer screening tool12–18 and that vaccination against
HPV could be used for primary prevention of cervical
cancer.
HPV Testing for Primary Cervical
Cancer Screening
For primary screening, a number of research studies
(Table 1) have demonstrated that, compared to the Pap
smear, HPV testing has a higher sensitivity and higher
negative predictive value (NPV) for the detection of prev-
alent cervical cancer precursors, albeit with a lower spec-
ificity and lower positive predictive value (PPV)19–24.
However, it is important to note, these studies used a
cross-sectional design with double testing (cytology +
HPV testing) of all women and short-term follow-up by
colposcopy with biopsy for those having one or more posi-
tive screening tests. While this is appropriate to assess
the relative sensitivity of each test to detect prevalent
high-grade cervical intra-epithelial lesions (CIN2+), the
design is subject to verification bias and it does not ac-
count for the long duration of pre-cancerous stages and
the consequent increase in sensitivity that accompanies
repeated Pap smear testing (i.e. programme sensitivity).
Further, the high regressive potential of CIN2+ lesions
means that its increased detection may be accompanied
by the diagnosis and treatement of non-progressive le-
sions and the cross-sectional results therfore cannot be
used to study the impact of different screening strategies
on the incidence of invasive cancer25,26. As such, most ju-
risdictions have regarded these studies as insufficient to
merit the introduction of HPV testing for primary scre-
ening, while an international expert group convened by
the International Agency for Research on Cancer (IARC)
has concluded that HPV testing has at least the same
cross-sectional sensitivity as the Pap smear and that it
could be used within organised screening programmes,
either alone or in combination with the Pap smear, once
rigorous evaluation of effectiveness and efficacy have
been completed4. Such studies are underway in Europe
where a number of researchers have established large-
-scale randomised controlled trials (RCTs) of HPV test-
ing for primary screening which follow-up women for at
least one screening round, and the Finnish Cancer Regis-
try has initiated a randomised public health implementa-
tion evaluation of HPV screening27–32 (Table 2).
Importantly, some of these RCTs have moved to the
evaluation of HPV testing as a single primary screening
test followed by cytology for the triage of women having a
positive test on the basis that:
– screening would be undertaken with the test having
higher sensitivity and triage undertaken with the test
having higher specificity, in compliance with accepted
principles of screening, and as is already the case with
syphilis and HIV screening,
– it would maximise specificity and PPV while achieving
95–100% of the sensitivity and NPV of the combined
HPV/cytology primary test. This would provide the
same level of safety but with improved cost-effective-
ness by minimising the number of women with false
positive results that need to be followed-up,
– it would allow 85–90% of women to return immedi-
ately to routine recall without incurring the cost of cy-
tology, which would be reserved only for the triage of
the remaining 10–15% of women with a positive HPV
test,
– the high-volume testing of screening samples would be
undertaken with a non-subjective test that can be au-
tomated, while the subjective, labour-intensive test
would be restricted to high-risk samples only, so they
could be screened more intensively because of the re-
duced number that need to be processed.
The interim results of these trials confirm the earlier
studies with HPV testing (either alone or in combination
with cytology) having a higher sensitivity and lower spec-
ificity than cytology alone for the detection of CIN2+.
However, those studies reporting the performance of
HPV testing as a single primary screening test with cy-
tology triage indicate that this HPV screening algorithm
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also has a higher sensitivity than cytology alone but now
with a specificity that is at least equivalent to cytology. In
the Finnish trial, HPV testing with cytology triage de-
tected 1.45 times as much CIN2+ compared to cytology
alone, while the specificities were not significantly differ-
ent at 98.9% (95% CI: 98.6–99.2) and 99.3 (95% CI:
99.0–99.5), respectively27. Similar results were reported
by Bulkmans et. al in the preliminary prospective results
from the POBASCAM trial in which indicate that HPV
testing followed by cytology triage compared to cytology
alone can be more sensitive (92.9 vs 64.3% respectively;
p=0.065) and more specific (96.8 vs 95.1% respectively;
p= 0.05)29. While the differences in sensitivity, NPV
(99.96 vs 99.78% respectively; p=0.098) and PPV (14.6
P. Davies et al.: Cervical Cancer Prevention in Europe, Coll. Antropol. 31 (2007) Suppl. 2: 11–16
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TABLE 1
SENSITIVITY AND SPECIFICITY OF HPV TESTING COMPARED TO CERVICAL CYTOLOGY FOR THE DETECTION







Sen Spec Sen Spec Sen Spec
Cuzick et al.19 United Kingdom: n = 1,703
Conventional Pap Smear, HC2,  ³ 35 years
95 95 79 99 NA NA
Schiffman et al.20 Costa Rica: n = 1,119
Conventional Pap Smear, HC2,  ³ 18 years
88 89 78 94 NA NA
Ratnam et al.21 Canada: n = 2,098, 69% HC1/31% HC2,  18–69













Clavel et al.22 France: n = 5,651
LBC, HC2,  ³ 15 years
100 86 88 93 NA NA
Petry et al.23 Germany: n = 8,468
Conventional Pap Smear, HC2,  ³ 30 years
98 96 44 98 100 94
Cuzick et al.24 United Kingdom: n = 10,358
Conventional Pap Smear, HC2,  ³ 30 years
HC2 using an elevated threshold (³ 2pg)













ASC-US — Atypical Squamous Cells – Undetermined Significance, CIN – Cervical Intraepithelial Neoplasia, Sen — Sensitivity, Spec
— Specificity; HC2 — Hybrid Capture 2 HPV test and HC1 — Hybrid Capture 1 HPV test (Digene Inc. Gaithersburg, MA), LBC —
Liquid Based Cytology, * Sensitivity of HC1 was suboptimal and would have contributed to the difference seen between HPV testing
alone and the combination of HPV testing with Pap
TABLE 2










Finland 200,000 25–65 HC2 Conventional
Pap smear
Cumulative incidence of CIN2,
CIN3 and cancer after
initial screening







at the exit screen






confirmed CIN3+ found at any
time during the trial from
recruitment to exit screen
ARTISTIC31 United Kingdom 25,000 20–64 HC2 LBC Comparative prevalence of
histologically confirmed CIN3+
at the exit screen





from the recruitment screen up
to and including the exit screen
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vs 7.3% respectively; p=0.085) are not significant, it
must be remembered that these are only the preliminary
results on 2,810 women from a total of over 44,000
women that were recruited to the trial.
Taken together, these results indicate that HPV test-
ing, if used as a primary screening test followed by cytol-
ogy for the triage of women testing HPV positive, has the
potential to provide improved sensitivity for the detec-
tion of clinically relevant disease without decreasing
specificity or otherwise adversely affecting the efficacy of
screening programmes.
Vaccination Against HPV for Primary
Prevention of Cervical Cancer
A number of studies have now been conducted on the
two first generation prophylactic HPV vaccines33–38. Both
vaccines target HR-HPV types 16 & 18 (which are to-
gether responsible for over 70% of cervical cancers world-
wide), while one (GARDASIL®, Merck and Co.) also in-
cludes types 6 and 11 which are non-oncogenic but still
responsible for a substantial proportion of lower-grade
cervical disease and the other (CERVARIX™, Glaxo-
SmithKline) has demonstrated to provide a degree of
cross-reaction to HPV types 31 & 45 (which are the next
most common oncogenic HPV types after 16 & 18)38. The
result of the phase IIb and III trials have shown these
vaccines to be safe, well tolerated and highly immu-
nogenic. Further, both vaccines have been shown to offer
HPV naive women high levels of protection against HPV
infection with the HPV types contained in the vaccine as
well as their resulting cervical lesions33–38. However, the
GARDASIL licensing submissions filed with both the US
Food and Drug Administration and the European Medi-
cines Agency included data to show there was no clear ev-
idence of protection from disease caused by HPV types
which subjects were DNA positive and/or seropositive for
at the time of vaccination39,40. Further data were pre-
sented to show that in the general public where a propor-
tion of women will have prior or current HPV infections,
GARDASIL can be expected to reduce the overall rate of
CIN2/3 or adinocarcinoma in situ caused by vaccine or
non-vaccine types by 12.2%39.
The results of these trials have now led to the li-
censure of one of the vaccines in many countries with the
second expected to follow shortly and it is anticipated
that these vaccines will play a very important role in the
prevention of cervical cancer going forward. However,
the availability of these vaccines raises several imple-
mentation issues that must be addressed if the vaccines
are to achieve their full potential in Europe where cervi-
cal cancer screening is already widespread and substan-
tial efforts are underway to ensure the uniform imple-
mentation of properly organised cervical cancer screening
programmes. In Europe, the enormous potential of HPV
vaccination must be considered together with its limita-
tions which are chiefly 1) its high cost (currently around
450 per person in France), 2) that the first-generation
vaccines do not protect against all HR HPV types, and 3)
inability to protect women who are already infected with
HPV types 16 and 18. In addition, an important question
remains about whether HPV vaccination will provide
any supplemental protection against the development of
cervical cancer in women who have been exposed to HPV
16 or 18 but subsequently mounted their own effective
immune response and cleared the virus. This is a particu-
larly important question for public health programmes
where the cost for the vaccine must be taken from finite
healthcare budgets and which will therefore lead to a
diminution in other services. Clearly, there is an ethical
concern about the implementation of vaccination pro-
grammes for women who may derive little or no addi-
tional benefit over that provided by their own immune
system when the money must come from other program-
mes with clear and proven health benefits.
Under these conditions, there is little dispute that the
vaccination of girls before the commencement of sexual
activities is not only a public health priority but an ethi-
cal imperative. However, the use of vaccination in older
girls and women will yield diminishing public health re-
turns as the proportion of women exposed to HPV 16 &
18 increases, and this needs to be balanced against the
clearly established protective effect of cervical screening
in these populations. Unfortunately, it is not possible to
have a single formula and each country must undertake
its own cost-benefit analysis to establish the appropriate
balance depending on their national priorities, health-
care budgets and the status of existing resources such as
screening programmes. But what is clear that all Euro-
pean countries now need to implement comprehensive
cervical cancer prevention programmes which integrate
cervical screening together with HPV vaccination as it is
the combination of these that will offer the most effective
long-term protection against cervical cancer. Further,
these new measures of cervical cancer prevention must
be offered within population-based organised prevention
programmes to ensure that the protection is equitably
available to all women in the population.
The Effective Integration of Technologies
for the Prevention of Cervical Cancer
Although the Pap smear has been the mainstay of cer-
vical cancer prevention for more than 50 years, it now
must be recognised that the ongoing uptake of HPV vac-
cination against HPV 16 & 18 will have a progressively
detrimental effect on cytology based screening. Evalua-
tions of the prevalence of HPV 16 & 18 among women
with abnormal cytology indicate that ASC-US, LSIL and
HSIL rates could be reduced by as much as 30%, 36% and
55% respectively in a population that was fully vacci-
nated with a vaccine having 100% efficacy41–43. If HPV 6
and 11 are also included, ASC-US, LSIL and HSIL could
eventually be reduced by a total of 40%, 46% and 60%
respectively41–43. Here, it is important to note that the re-
ductions are likely to be greater for HSIL than for
ASCUS or LSIL. Therefore, vaccination will both reduce
the overall prevalence of cytological abnormalities and
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shift the balance to the lower grades which have a lower
PPV. These characteristics mean that vaccination will in-
evitably lead to a substantial deterioration in the efficacy
of cytology-based screening because:
1) A decrease in disease prevalence will produce a di-
rect and simultaneous decrease in the PPV of screening.
Even with current disease rates in adequately screened
populations, the PPV of cervical cytology ranges from
only 10 to 30% for the detection of CIN2+ in well
screened populations19–24 a situation that is only toler-
ated because of the seriousness of the disease that cervi-
cal screening prevents. However, reductions in disease
rates subsequent to widespread vaccination, together
with the shift to the lower-grades of cytological abnor-
malities, will further reduce the PPV of cytology-based
screening programmes, eventually to a point where the
stress, morbidity and costs involved in the follow-up of
these false-positive women may no longer be either ethi-
cally or financially justifiable relative to the yield of true
disease.
2) Reductions in disease rates would also mean that
cytology screeners would have less exposure to cytologi-
cal abnormalities during the course of their working day
with two possible outcomes. First, regular exposure to
cytological abnormalities is necessary for the mainte-
nance of cytology screening skills. Therefore, reductions
in disease rates could be accompanied by a simultaneous
reduction in the cytology screeners’ ability to recognise
these abnormalities and a reduction in the sensitivity of
the screening program. Second, a reduction in the num-
ber of true abnormalities could lead cytology screeners to
compensate by over-classifying inflammatory changes or
reactive atypias leading to further decreases in specific-
ity and PPV of the screening programme.
Although these changes will only be seen with the
progressive implementation of HPV vaccination and the
gradual expansion of the vaccinated cohort, it is nonethe-
less essential for screening programmes to make plans
for the changes that will be required to maintain proper
levels of protection against cervical cancer. One way this
could be achieved is by stratifying the population to be
screened according to their risk and then applying cytol-
ogy based screening only to the subpopulation of women
that is at increased risk of having clinically relevant cer-
vical disease, i.e. those women who are HPV positive. On
this basis, the uptake of HPV vaccination will necessitate
a shift to HPV testing for primary screening together with
cytology for the triage of women with a positive result in
order to maintain the efficacy of screening in an environ-
ment with a reduced prevalence of cervical disease.
Conclusions
In Europe, cervical cancer remains a significant so-
urce of disease and death although we now have the
means to prevent virtually every case through compre-
hensive cervical cancer prevention programmes. How-
ever, if we are to achieve this goal, it is essential that
these prevention programmes effectively integrate cervi-
cal screening together with the new technologies and
vaccines to ensure that the optimal protection is afforded
to all age groups. In addition, they must be popula-
tion-based to ensure that the protection is equitably
available to all women and they are run in the most
cost-effective fashion. The science has been done and the
tools are now available to effectively prevent cervical
cancer in Europe. What we now need is the political will
to make this a reality.
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Cervical Cancer Screening Programme in
Finland with an Example on Implementing
Alternative Screening Methods
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A B S T R A C T
In Finland (population 5 million) the organised Pap screening programme for preventing cervical cancer has been in
action already for 45 years. Women aged 30 to 64 are targeted (N 1.25 million) and the screening interval is five years.
The programme invites women seven times in a lifetime; the attendance rate per one screening invitational round is 73%.
The programme has affected markedly the cervical cancer rates in our country. During the decennia of its action there
has been about 80% decrease in the age-adjusted cervical cancer incidence and mortality rates. The current age-stand-
ardised incidence rate is 4 and mortality rate 1 per 100,000 woman-years. In the current article we describe the organisa-
tional aspects of the programme; and pay attention to renovation of the programme taken place during the last decade
when novel technological alternatives have been started to be used as the screening tests. By expanding the coverage and
compliance of screening we still expect to increase the impact of the programme. Same time, efforts are needed to avoid
overuse of services due to spontaneous screening, in order to decrease potential adverse effects and improve overall cost-
effectiveness. A large-scale public health policy trial on Human papillomavirus (HPV) screening is on-going. Cross-sec-
tional information available thus far suggests promising results. Follow-up of cancer rates after screening episodes are
still required to evaluate optimal screening policies (e.g., screening intervals by age groups, and starting and stopping
ages). We propose speeding up the use of modern technological alternatives in organised screening programmes.
Key words: Cervical cancer, incidence, mortality, organised screening, effectiveness, cytological screening, HPV-DNA
screening
Introduction
In Finland (population 5 million) organised cervical
screening was introduced in the early 1960s; piloting
first within the area of three municipalities in 1963 and
extending within a few years time to most parts of the
country. From the early 1970s onwards, the registered
screening invitational coverage has been almost com-
plete within the centrally targeted screening ages.
During 1955–1964 the incidence of invasive cervical
cancer in Finland was at a level of 15 cases per 100,000
woman-years; age-adjusted to the world standard popu-
lation, with a slight increasing trend within the period.
Mortality from cervical cancer was around 7 cases per
100,000 woman-years, respectively. Subsequent to imple-
mentation of organised screening, there was a rapid de-
crease in the invasive cervical cancer incidence and mor-
tality rates. Currently the age-adjusted rates are 4 and 1
per 100,000 woman-years (Figure 1). Most of the reduc-
tion has occurred in the incidence of squamous cell carci-
nomas, whereas the incidence rate of cervical adenocar-
cinoma has been quite stable over the decades1,2.
Effectiveness of Conventional Screening
Screening effectiveness in Finland was demonstrated
first by a very large-scale cohort follow-up study among
women invited in the implementation phase of the pro-
gramme3,4. The study followed subsequent cervical can-
cer rates, based on about 425,000 invitations in 1963–
17
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1972. Most part of the women had been screened once
during the study period. The efficacy estimate among
screened was 80%. The attendance rate was 85% and the
effectiveness of the programme was estimated at 60%.
Among invited but not attended there was about 60% in-
crease in the subsequent cervical cancers in comparison
with the rates in the population before screening. It is
likely that thereafter the effectiveness of the programme
has increased, as more testing rounds have become avail-
able. However, there are mainly a number of ecologi-
cal-level trend studies performed in the later years in our
country (see IARC, 20054, for a recent synthesis on
these). According to a cohort follow-up study among a
A. Anttila and P. Nieminen: Cervical Cancer Screening Programme in Finland, Coll. Antropol. 31 (2007) Suppl. 2: 17–22
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Fig. 1. Cervical cancer incidence and mortality rates in Finland






































































Fig. 2. Observed (Finnish Cancer Registry, 2007) and predicted
(from Hristova & Hakama, 19976) mortality rates from cervical
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sample of women with a negative cytological result in the
programme, the absolute rate of cervical cancer after
screening negative is about 5 cases per 100,000 woman-
years5.
It is estimated based on the trends that each year al-
most 300 deaths are prevented due to Pap-screening;
these deaths would have occurred at a broad set of ages
from rather young (30 or 35 years) up to very old (more
than 85 years) women (Figure 2)6. In the oldest age
groups the incidence and mortality rates from cervical
cancer are still expected to decrease due to ageing of fe-
male population screened previously in their life. There
are still some 60 deaths per year, and the number of inci-
dence cases is 160.
The incidence of cervical cancer has somewhat in-
creased during the last decade in ages 25–39 (Figure 3)
even though the number of cases in this age group is still
small, below 30 cases annually (Figure 4). There are al-
most no deaths from this cancer type in ages below 50
years and the death rate among young women has not in-
creased.
Growing Concerns on Opportunistic
Screening
In the early days, opportunistic screening was not
available in large-scale. Later on, use of such services has
increased. There are no data to study the trends in the
use of opportunistic screening. According to information
from an annual population survey as available from late
1990s7, any Pap smears (the estimate including also the
opportunistic and diagnostic smears in addition to the
programme smears) have been taken during a five-year
period roughly for 93% of the women at target ages of the
programme. The estimated coverage of any smears life-
time is 98%, respectively8,9. Trend studies4 and a popula-
tion-based case-control study using questionnaire-based
self-reported information on the screening history (ever
vs. never screened)8 have suggested that the overall ef-
fect in decreasing cervical cancer incidence with sponta-
neous smears is up to 40%. In the latter study the effect
among women participating in organised screening was
about two-fold compared to those who had never partici-
pated (but given only spontaneous smears); spontaneous
screening showed no additional impact among those sub-
jected to organised screening.
One problem in the national screening policy is that
there are apparently wide testing practices outside scree-
ning, also in rather young women – where almost all of
the pre-cancerous lesions would regress naturally (see
IARC, 20054 for estimates of regression probabilities).
Figure 4 illustrates the numbers of CIN3/CIS incidence
and treatments as available from cancer registry files:
about 60% of these are diagnosed already in age before
screening. More evaluation research, including also re-
search on the potential adverse effects, on any screening
is needed. There are yet no register-based data available
on the spontaneous screening; such data is required in
order to evaluate that activity and reduce the unneces-
sary actions. Recently, efforts have been started to in-
clude any smears in register-based evaluations.
Organisation of Cervical Cancer Screening
The screening activities have become an integral part
of the health care system. Women in ages 30 to 60 years
are invited with help of population registry, using a
five-year interval when normal screening results. The
two older age groups (55, 60) were added to the pro-
gramme only in 1990s. There are nowadays thus seven
invitations lifetime. Some municipalities invite also wo-
men in ages 25 and/or 65; women at a younger age than








































































Fig. 4. Cumulative number of cases of severe dysplasia or carci-
noma in situ (CIN3/CIS), cervical cancer incidence,0 and deaths
from cervical cancer in Finland, annual averages in 1998 over














Coverage, % of female population
Screened Invited
Fig. 5. Invitational and screening coverage within the Finnish











 $  
25 are not encouraged to be screened (http://www.kay
pahoito.fi/). In the organised programme the present cov-
erage of invitations is 95% of the target age (http://www.
cancerregistry.fi/statistics). In one calendar year, there is
about 250,000 invitations in the programme. The atten-
dance rate is more than 70%.
Even though the attendance rate is satisfactory, close
to 80%, in the older targeted ages, one main problem in
the programme is the fact that among young targeted
ages, particularly, in ages 25 to 35, the rate is very low,
only slightly above 60%. This has lead to the situation
that hardly half of the targeted population participates
in those ages (Figure 5).
Attending organised screening for women is free of
charge. Sample taking is done by trained nurses or mid-
wives in the local primary health care centres or clinics.
The sample quality is under continuous control done by
the cytology laboratories, based on individual coding for
sample-takers for a potential personal feed-back. The
samples taken are VCE smears; i.e., samples from poste-
rior vaginal fornix, cervix, and from endocervical canal
are taken separately, using Ayre’s spatula and endo-
cervical brush, and are placed on the same slide. The
samples are stained with modified Papanicolaou stain-
ing. The samples are screened by cytotechnicians, and
the cytologist checks every abnormal smear and a pro-
portion of normal smears. More recently, also the Human
papillomavirus (HPV)-DNA samples are taken in con-
tracted municipalities (see below).
There are some 15 cytology laboratories contracted by
the municipalities to the programme. Confirmation and
treatment is integrated into the normal health care rou-
tines. Treatment is provided for women with relatively
mild lesions (CIN1) or with a more severe finding. All the
data on the confirmation are included on the personal
screening cards kept for every woman in the cytology lab-
oratory; they are registered and the compliance and ade-
quacy of treatment followed by the cytology laboratory
and also by the mass screening registry.
The average referral rate is constantly about 1%, and
the detection rate for an CIN+ (cervical intraepithelial
neoplasia, or a worse histologically confirmed finding)
about 0.3–0.5%. In addition, about 6% of the screened
women get a re-invitation within a shorter interval, usu-
ally one year, based on borderline cytology (Table 1).
There is still some variation in the detection rates and
performance parameters which appear not to reflect di-
rectly the effectiveness aspects but, rather, some varia-
tion in the local cost-effectiveness10.
Data collection infrastructures
Screening laboratories are responsible for recording
screening visit and confirmation and treatment informa-
tion within the programme. The invitational and screen-
ing data of the programme, including cytological and
histological screening findings, are filed centrally at the
Mass Screening Registry that it a subunit within the na-
tional Finnish Cancer Registry. This makes an efficient
tool for evaluation and monitoring of the programme.
The Finnish Cancer Registry provides complete data on
cancer incidence and mortality, arranged individually
with the help of the unique personal identifier. The mor-
A. Anttila and P. Nieminen: Cervical Cancer Screening Programme in Finland, Coll. Antropol. 31 (2007) Suppl. 2: 17–22
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TABLE 1
CERVICAL CANCER SCREENING PROGRAMME IN FINLAND IN 2004: THE NUMBER AND PERCENTAGE DISTRIBUTION OF
SCREENING TESTS IN THE ORGANISED SCREENING PROGRAMME, BY SCREENING TEST RESULTS, REFERRALS AND FINAL
HISTOLOGICAL DIAGNOSIS (MASS SCREENING REGISTRY, 2007, PRELIMINARY INFORMATION BASED ON DATA FROM 437





Cervix cancer CIN3/CIS CIN2 CIN1 Other or normal
N N % N % N % N % N % N %
Pap-test 170205 1290 0.8 18 0.01 178 0.1 192 0.1 175 0.1 727 0.4
I 158894 – – – – – – – – – – – –
II 10022 132 0.1 1 0.0 4 0.0 6 0.0 10 0.01 111 0.07
III–V 1161 1158 0.7 17 0.01 174 0.1 186 0.1 165 0.1 616 0.4
Inadequate 128 – – – – – – – – – – – –
HPV-test 14585 186 1.3 4 0.03 14 0.1 48 0.3 32 0.2 88 0.6
Negative 13433 7 0.05 – – 1 0.01 – – 1 0.01 5 0.03
Positive 1152 179 1.2 4 0.03 13 0.09 48 0.3 31 0.2 83 0.6
All 184790 1476 0.8 22 0.01 192 0.1 240 0.1 207 0.1 815 0.4
CIN – Cervical Intra-epithelial Neoplasia, CIS – Carcinoma in situ, Pap – Papanicolaou, HPV – Human papillomavirus, – magnitude
nil, women with Papanicolaou group I or II or HPV test negative are not referred for further examinations unless repeated cytology or
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tality records are obtained from the files of the Cause-
of-Death Registry at the Statistics Finland. The cancer
registry notifies also carcinoma in situ cases of the cervix
uteri (CIS, including both squamous and adenocarcino-
ma in situ cases), as well as cases of severe intraepithelial
neoplasia (dysplasia gravis, or CIN3 not specified in more
detail).
Quality assurance
In the normal screening practice of the organised
programme there is a number of quality control activi-
ties, such as control of sample quality that takes place
mainly within the cytological laboratories within the
programme9; and re-reading, consultation and training
meetings; even though there have been no systematic
publications on their results. Important for developing
the screening specificity criteria, there are, normally,
weekly sessions between cytology and pathology units/
laboratories. Since 1999 a systematic re-reading pro-
gramme of potentially false negative smears have been in
action; including re-reading of these smears together
with control slides both in a reference laboratory and in
the original screening laboratory. This material is based
on linkages between the screening and cancer registry
files.
Novel Screening Methods
The main aim of the evaluation of alternative screen-
ing techniques is to assess screening effectiveness, i.e.,
comparing incidence of subsequent cervical cancers as
the outcome and screen-detected pre-cancers as surro-
gates. Also performance e.g. in form of screen-detected
findings will be monitored and compared. It is important
to verify that, if the treatment rates would increase, it re-
flects, respectively, to better efficacy and effectiveness.
Modifications on the screening policy need also to be con-
sidered, e.g. the need of lifetime number of tests in the
programme. For the time being, approximately 860,000
women have been allocated to automation-assisted cyto-
logy, HPV DNA testing, or to conventional cytology with-
in the organised screening programme11,12,13. In the HPV-
-DNA screening arm, run within a restricted area, the
plan is to invite about 100,000 women in 2003–2008. In
numerical terms, almost 10% of the whole national tar-
get population will be subjected to HPV screening. Fol-
low-up results on subsequent cervical cancers will become
available during 2007– 2015.
First reports on screening detection rates are avai-
lable12,13. Screening detection rates as well as specificity
estimates in automation-assisted screening are very sim-
ilar to conventional screening. Based on early results
from HPV screening, the detection rate of mild pre-can-
cerous lesions was in excess in the HPV screening pro-
tocol12; see also Table 1 on the routine statistics on 2004.
CIN3+ detection rates were about the same as in con-
ventional screening. There is a cytological triage protocol
after a positive primary HPV test. Noteworthy, when
considering the referral to colposcopy, based on the cytol-
ogy triage, the cross-sectional specificity and positive
predictive value estimates were closely resembling those
of the conventional screening.
Discussion
Historically, the overall incidence of invasive cervical
cancer, as well as that of in situ carcinoma of the cervix
uteri, has drastically decreased in those ages subject to
organised screening activities. Organised screening is ef-
fective. There is no similar decrease in the CIN detection
frequencies, however. On the contrary, the detection ra-
tes of CIN grades 2 and 3 have even slightly increased2,
indicating that the biologic background risk has been
likely increased. Also invasive cervical cancer incidence
has increased in ages 25–39 years, even though based on
a small number of cases registered annually. This still
warrants improvements in the rather poor attendance
rate in the programme in the above young targeted ages.
Interventions testing written reminder or, preferably, re-
minding by phone, are required14. Self-sampling could
also be tested in order to check whether one can increase
compliance meaningfully.
On the other hand, based on the finding that a very
large proportion of registered CIN3/CIS cases have been
detected and treated outside the organised programme,
e.g. in opportunistic screening, in parallel with improv-
ing the population-based coverage and access to the ser-
vices, also decrease and stopping of unnecessary actions
should take place.
Concluding Remarks
Following from the 45-year period of its action the
cervical cancer screening programme in Finland has con-
tributed to a large decrease in cervical cancer incidence
and mortality rates. The purpose of cervical cancer scree-
ning is to prevent mortality and incidence from the dis-
ease. One can conclude that organised screening is effec-
tive in combating cervical cancers. With introducing mo-
dern screening technologies and more systematic quality
control activities in the programme, and moderately ex-
panding the coverage and as well as compliance – partic-
ularly, at the young target ages of the programme – we
still aim to increase the effectiveness of the programme.
Alternative methods in screening, such as automation-
assisted screening and HPV testing, have shown promis-
ing cross-sectional findings. We propose speeding up the
use of modern technological alternatives in organised
screening programmes. Follow-up information of cervical
cancers in still required, to acquire evidence for possible
modifications on the screening policies.
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PROGRAM PROBIRA RAKA VRATA MATERNICE U FINSKOJ S PRIMJEROM
UVO\ENJA ALTERNATIVNIH METODA PROBIRA
S A @ E T A K
U Finskoj (5 milijuna stanovnika) je organizirani program Papa-testiranja u prevenciji raka vrata maternice u upo-
trebi ve} 45 godina. Testiranje obuhva}a `ene u dobi od 30 do 64 godine (1,25 milijuna), a period izme|u dva testiranja
je pet godina. Prema programu, `ene se poziva sedam puta tijekom `ivota; odaziv jednoj rundi poziva na testiranje je
73%. Ovaj program je zna~ajno utjecao na stopu pojave raka vrata maternice u na{oj zemlji. Tijekom desetlje}a njegove
primjene zabilje`en je pad od oko 80% u dobno-standardiziranim stopama pojavnosti i smrtnosti od raka vrata ma-
ternice. Trenutna stopa pojavnosti, obzirom na dob je 4, a stopa smrtnosti 1 na 100.000 `ena godi{nje. U ovom ~lanku
opisujemo organizacijske zna~ajke programa; sva pa`nja je usmjerena na obnovu programa tijekom zadnjeg desetlje}a s
novim, alternativnim metodama koje su se po~ele koristiti u sklopu testova probira. Pove}anjem pokrivenosti i su-
glasnosti s programom, o~ekujemo pove}anje utjecaja programa. Istovremeno, potreban je napor kako bi se izbjegla
pretjerana upotreba slu`bi zahvaljuju}i spontanom probiru, sa svrhom smanjenja mogu}ih {tetnih u~inaka te sma-
njenja tro{kova. Trenutno se poku{ava uvesti pokrivanje tro{kova testiranja na HPV kroz zdravstveno osiguranje.
O~ekujemo povoljne rezultate. Pra}enje stope raka nakon testova probira je potrebno i dalje kako bi se procijenila
najbolja strategija probira (vremenski razmaci izme|u testiranja po dobnim skupinama te po~etna i zavr{na dob). Pred-
la`emo br`e uvo|enje novih, modernih metoda u organiziranim programima probira.
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Cervical Cancer Screening: A Slovenian
Experience
Maja Primic-@akelj1 and Alenka Rep{e-Fokter2
1 Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia
2 Department of Cytopathology, General Hospital Celje, Celje, Slovenia
A B S T R A C T
In Slovenia, opportunistic screening was introduced in regular gynaecological practice in 1960. The proportion of
population screened was unknown, as well as there were no standards for quality assurance and control. Despite great
number of smears read, there were no major changes in invasive cervical cancer incidence in the period 1979 till 1993,
but in 1994 the incidence rate started to increase again to reach its peak in 1997 (23,1/100.000, 241 new cases). Based on
the experiences from the countries with effectively organised screening programmes, a decision was made in 1996 by the
Minister of Health to nominate a group of experts to prepare a proposal for organised cervical cancer screening pro-
gramme after testing the methodology in pilot study. In the pilot the central computerised information system (Screening
Registry) was gradually established to register all smears from the whole country, to identify women who do not attend
for screening to send them invitation for screening and to monitor screening activity and its quality. The aim of pilot was
also to develop guidelines for quality assurance and control of all procedures involved in cervical cancer screening and
treatment of intraepithelial lesions. In three years since the beginning of the national programme, nearly 70% of women
in the target age group were registered with at least one smear. All other results are presented in regular programme re-
ports. There is still place for further development of the programme, but the incidence of cervical cancer already started to
decline especially among younger women, who attend for screening more often than those aged over 50.
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Introduction
Cancer is one of the major public health problems as it
is the most common cause of morbidity and mortality to-
day, with more than 5.8 million new cases and more than
3.8 million of deaths each year in Europe1. It is projected
that by 2020 there will be 3,4 million of new cancer cases
and 2,1 million deaths. Much of this increase in absolute
numbers derives from the ageing of populations. It repre-
sents a significant and growing burden on public health
services today.
There is now sufficient understanding of the causes to
prevent at least one third of all cancers. Information is
also available that would permit the early detection and
effective treatment of a further one third of all cancers
worldwide. The overall goal of cancer control is to reduce
the incidence and mortality of cancer and to improve the
quality of life of cancer patients and their families. A well
conceived national cancer control programme is the most
effective instrument to bridge the gap between knowl-
edge and practice and achieve this goal. Integrated into
existing health systems and related services, this pro-
gramme ensures systematic and equitable implementa-
tion of control strategies across the continuum of preven-
tion, early detection, treatment and palliative care.
Screening for cancer consists of the identification of
preclinical disease by a relatively simple test. The objec-
tive of screening is to reduce the risk of death, i.e. mortal-
ity from cancer subjected to screening. For cervical can-
cer the screening test is aimed at detection of preinvasive
lesions. Therefore, reduction in the incidence of invasive
disease is the objective of screening for cervical cancer
and the indicator of the effect is the change of incidence
between those subjected to screening.
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Screening for cervical cancer is fundamental to the
provision of health care in Europe and, depending on
each health system, performed by general practitioners,
the gynaecologist or trained nurses. The dissemination
of the cervical smears depends both on the professional
interest and on the method of payment. The major in-
crease in use was in those settings where smears were
paid for through a public health insurance scheme.
Cervical Cancer Screening in
Slovenia till 2002
In Slovenia, opportunistic screening was introduced
in regular gynaecological practice in 1960, but in some
regions already in 1955 and 1956. A preventive gynaeco-
logical exam (smear included) has been practised since
then on a yearly basis and recommended to women by
gynaecologic community and paid by the health insur-
ance. The payment did not stimulate examinations of
more women, as only attendances have been paid regard-
less on how many women the exams have been per-
formed. Since 1998, a regular yearly gynaecological exam
with a smear (endo- and ecto-cervical) and colposcopy
has been paid from the obligatory health insurance and
supposed to be the right of every woman from 20 years of
age onwards. It was performed by gynaecologists work-
ing in primary reproductive health care, where changes
have also been happening, because of introduction of reg-
istration with personal gynaecologists and in some places
the accessibility to this service diminished.
Most of the smears were taken from young women,
while older women and women from the lower socio-eco-
nomic groups were frequently missed out altogether by
the system. These women are at higher risk, but make
less use of screening services, especially if attendance re-
quires individual initiative (inequalities in risk and use
of screening). In Slovenia it was found out that despite
the formally equal accessibility, only 30% of women per-
formed gynaecological examination yearly, less than half
once in every three years, depending on the region of res-
idence, and mostly those with better education. On the
other hand, the number of smears examined in the labo-
ratories (more than 300,000) could suffice to examine ev-
ery women aged 20–64 at least every three years.
In Slovenia there is one of the oldest Cancer Regis-
tries in Europe so we can monitor the incidence of cervi-
cal cancer since 1950. The time trend of invasive cervical
cancer is supposed to reflect the effectiveness of cervical
screening in our country. The crude incidence rate of in-
vasive cervical cancer increased from 22.5/100,000 in
1950 to 34/100,000 in 1962 and then decreased to 14/
100,000 in 1979, when the incidence was the lowest2.
Since then till 1993 there were no major changes (though
nothing had changed in gynaecological recommendati-
ons) but in 1994 the incidence rate started to increase
again. Furthermore, an increase of the invasive cancer
incidence in the younger age groups (30–39) has been ob-
served. In the period 1994–1998, the age specific inci-
dence rate in the age groups 30–34 and 35–39 was nearly
the same as in the period 1959–1963, at the start of the
opportunistic screening. In 2000, the incidence rate was
20/100.000, one of the highest in Europe3.
The descriptive epidemiologic analysis of cervical can-
cer in Slovenia revealed the inefficiency of opportunistic
screening in Slovenia, where lots of resources have been
wasted for a small effect on the female reproductive
health. Even though the baseline risk of cervical cancer
may have changed due to more liberal sexual behaviour
of generations, born after the Second World War, the ef-
fective screening programme should cope at least with a
part of this risk, resulting in better detection of precan-
cerous lesions and not leading to such an increase of in-
vasive cervical cancer.
Based on the experiences from the countries with ef-
fectively organised screening programmes4, a decision
was made in 1996 by the Ministry of Health and Health
insurance Company to start a pilot study to gradually in-
troduce organised cervical cancer screening. After initial
preparations, the pilot started in 1998 in the central re-
gion of Slovenia, covering approximately 300,000 wo-
men, i.e., one third of the whole female population of
Slovenia.
The objectives of this study were:
¿ to establish the central computerised information sys-
tem (Screening Registry) linked to the Central Popula-
tion Registry of Slovenia to register all smears and
monitor screening activity and to identify women who
do not attend for screening;
¿ to invite women aged 25–64, who supposedly had not
been screened in the previous five years, as they have
not been yet registered with a gynaecologist or did not
have a smear registered in the study period and to esti-
mate the proportion of women who attend screening as
a result of personal invitation;
¿ to develop guidelines for quality assurance and control
of all procedures involved in cervical cancer screening
and treatment of intraepithelial lesion and of cervical
cancer.
First, a uniform smear report form and skeleton of a
computer database were constructed. From the Central
Population Register, samples of women from the target
population were regularly made and invited to pre-ar-
ranged gynaecologic exams. In the period 1998–2001,
28,804 invitations were sent to the samples of women
mentioned. Personal invitations have resulted in nearly
50% participation rate in the group of women who do not
regularly attend the opportunistic screening. All smear
reports (in the electronic form) from all cytological labo-
ratories in the region were gathered. A central database
of the Screening Registry was thus created and then reg-
ularly updated. In the following years the reporting of
smears from all cytological laboratories from the whole
country was established, so since 2003 the register is cov-
ering the whole country and constant monitoring of the
coverage and quality has been established. National gui-
delines for cytopathology and for management of women
with abnormal smear have been published5–7.
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The legal basis for the programme was also estab-
lished: the contents of the database is included in the law
on health statistics8, the special regulation for cyto-
pathology laboratories then was published by the Minis-
try of Health9, and laboratories then have been reviewed
to evaluate whether they comply with these standards.
With the ministry’s recommendation on preventive ex-
aminations in primary reproductive health care where
screening policy was introduced, the national program-
me started in 200310.
Organised Cervical Cancer Screening
Programme in the Primary (Reproductive)
Health Care
In 2003, the Ministry of Health supported the intro-
duction of National Programme of Organized Cervical
Cancer Screening. It has a name ZORA after Slovenian
initials for organised cervical cancer screening program-
me. The central coordination office with the Screening
Registry is at the Ljubljana Institute of Oncology.
The programme advocates the population-wide active
cervical cancer screening based on quality-controlled pro-
cedures. The aim of this programme is to achieve that at
least 70% of the female population aged 20–64 will have a
smear taken in a the three-year interval.
Each woman between ages 20 and 64 is to be invited
to perform a preventive gynaecological examination to-
gether with Papanicolau smear once in every three years
(after two negative smears) either by her »personal« gy-
naecologist with whom she has already been registered
or from the Screening Centre in case she has not been
registered yet. Women aged 65 to 74 years are not invited
but are offered screening when they attend gynaecologist
for other reasons.
As it was decided that gynaecologists would invite
women already registered with them, the initial stage in-
cluded active involvement of gynaecologists in the pri-
mary health care, who had to review all their records and
make lists of women to be invited. Different computer
programmes in different practices hampered this but the
difficulties should be overcome in the future. The coordi-
nation of the programme is assured through regional co-
ordinators and national coordinator, nominated by the
Minister of Health.
Regardless of the ability to pay, the universal access to
ZORA programme is assured by including the ZORA ex-
penditure into the Slovenia’s compulsory Health Insur-
ance Fund. Thus, the organized cervical cancer screening
programme is based on all fundamental principles of eq-
uity, solidarity and participation.
The results show that in some regions the goal of 70%
of women having a smear in the last three years, has al-
ready been achieved and preliminary data from the Can-
cer Registry do not show an upward trend of cervical can-
cer any more. The invitations resulted also in greater
percentage of women being registered with their gynae-
cologists, which is currently about 80% in the target age
group. Annual reviews on the cervical cancer screening
programme ZORA is published regularly and available
on the programme’s web site also (http://www.onko-i.si/
zora/)11.
Conclusions
Systematic screening is a public health intervention
often performed in primary health care. For its sus-
tainability it should receive political support and sup-
porting legislation. An advantage is the funding system
for public health services separate and independent from
the cure and care budget, but adequate resources are
needed for management of women with abnormal sme-
ars. But in any case the health insurance systems should
incorporate funds for screening that is evidence based as
this means lower costs for treatment of advanced dis-
ease. The key for success of such a programme is organi-
sation, existence of national standards for quality assur-
ance and control and constant monitoring of short- and
long-term indicators.
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PROBIR RAKA VRATA MATERNICE – SLOVENSKO ISKUSTVO
S A @ E T A K
Oportunisti~ki probir je uveden 1960. g. u ginekolo{ku praksu u Sloveniji. Udio testirane populacije je bio nepoznat,
a nije bilo niti standarda za osiguranje kvalitete i kontrole. Unato~ velikom broju testiranih obrisaka vrata maternice
nije bilo ve}ih promjena u pojavnosti invazivnog raka vrata maternice u periodu od 1979. do 1993. g., no od 1994. g.
stopa pojavnosti je po~ela ponovo rasti kako bi dosegla vrhunac u 1997. g. (23,1/100.000, 241 novi slu~aj). Zahvaljuju}i
iskustvu zemalja s u~inkovito organiziranim programima probira, 1996. g. Ministarstvo zdravstva je donijelo odluku o
imenovanju skupine stru~njaka koja }e pripremiti prijedlog organiziranog programa probira raka vrata maternice na-
kon testiranja metoda u sklopu pilot-studije. U pilot-studiji je uspostavljen sredi{nji kompjuterski informati~ki sistem
(Registar za probir) koji prikuplja podatke o uzorcima iz cijele zemlje, identificira `ene koje nisu pristupile probiru, {alje
im poziv za testiranje te bilje`i aktivnost i kvalitetu probira. Cilj pilot-studije je tako|er bio razvoj vodi~a za osiguranje
kvalitete te kontrola svih procedura uklju~enih u probir raka vrata maternice i lije~enje intraepitelnih lezija. U tri
godine provo|enja nacionalnog programa gotovo 70% `ena ciljane dobne skupine je pristupilo probiru barem jednom.
Ostali rezultati su predo~eni u klasi~nim izvje{}ima o programu. Me|utim, jo{ uvijek ima mjesta budu}em razvoju
programa, iako je stopa pojavnosti raka vrata maternice po~ela padati, pogotovo me|u mla|im `enama, koje dolaze na
probir mnogo ~e{}e nego one u dobi iznad 50 godina.
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A B S T R A C T
Cytological diagnosis of atypical cells of cervix uteri by the Papanicolaou method was introduced in the Czech Repub-
lic (CR) very early – in 1947. The first data on the incidence of cervical cancer in CR are available from 1960 when the
rate was 32.3 cases/105 women. In 1966 the Czech National Health Law was passed that guaranteed women a yearly pre-
ventive examination by a gynaecologist including screening for cervical carcinoma that would be covered by the compul-
sory health insurance. Notwithstanding high frequency of screening visits and the fact that all women are eligible, the
incidence of CC has not changed in the last 34 years. The reasons for this include the coverage of Czech women, which is
estimated to be low (50% at the most), and that none of the cytology laboratories are accredited for screening, there are no
national registries for any aspect of screening and there are no mechanisms for evaluation of the screening process. As a
result, it is likely that the majority of cervical screening activity that is undertaken is ineffective and the implementation
of an organised and quality controlled screening programme, in compliance with the recommendations of many Euro-
pean Institutions, is urgently required to ensure that Czech women are properly protected against this disease and that
scarce healthcare resources are used in the most cost-effective manner.
Key words: cervix, cancer, screening
Introduction
Cervical cancer prevention in the Czech Republic
(CR) had a very auspicious start. Cytological diagnosis of
atypical cells of cervix uteri by the Papanicolaou (Pap)
method was introduced very early – in 1947 – and by
1954, Herold and Luksch had already published the man-
ual, »Cytodiagnostics of cancer of female genitals«, in the
Czech language1. In 1960, cytological consultation cen-
tres were established and these resulted in a drop in inci-
dence 32.3 cases/105 women to 27.2 cases/105 women by
1965. Then, in 1966 the Czech National Health Law was
passed which guaranteed women a yearly preventive ex-
amination by a gynaecologist, which included a Pap test
and the incidence of cervical cancer decreased again,
from 28.8 in 1966 to 21.9 in 1983. A further decline in in-
cidence from 21.9 to 20.7 in the period of 1984–90 can be
attributed to the establishment of a system of Centres of
Gynaecology–Oncology Prevention. However, since 1990,
no further decreases in the incidence of cervical cancer
have been observed (Figure 1)2.
Guidelines
In 1999, a committee of experts including gynaecolo-
gists, pathologists, cytologists and virologists prepared
the first Guidelines for the management of patients with
lesions of cervix uteri, which also included suggestions
for algorithms for primary screening. However, these
guidelines were never introduced into routine clinical
practice. Subsequently, the Ministry of Health has on
three occasion’s convened committees for screening for
cervical carcinoma with the first two of these cancelled
shortly after their establishment. Then, in July 2004, the
third committee published recommendations that in-
cluded a 1-year screening interval with classical cytology
as the primary screening test and HPV detection for the
triage of borderline findings up to 4% of the amount of
Pap smears for each laboratory. The recommended age
range is 25–60 and the insurance companies should send
invitation to women. If woman does not respond, the in-
vitation should be repeated after 2 years. The basic re-
quirement for cytological laboratory to be able to apply
27
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for accreditation is a minimum amount of 15,000 cervical
smears per year. Originally, the start of the screening was
expected in July 2006, but it has not yet begun.
The Current Situation
In 2003, there were 1,007 new cases of cervical carci-
noma and 398 women died from this disease in the CR2.
The highest incidence of cervical cancer occurs in the
45–49-age category (Table 1). In the age category of
15–34 years the death rate is low – 3.3%, but it is very
high in the category of 35–59 – 38.4%. These numbers
are smaller in the age category of 60–74 – 28.9% as well
as in the category of 75+ years of age – 29.4%.
The Czech National Health Law from 1966 is still
valid and it is the basis for screening in CR today where
all women (no age is specified) are entitled to a free pre-
ventive gynaecological examination once per year. This
preventive visit includes basic colposcopy and a Pap test.
All gynaecologists can perform basic colposcopy in their
office and it is paid for by the compulsory health insur-
ance ( 1.7). Only those specialists who are certified per-
form expert colposcopy and it is more expensive ( 10).
To become certified, a gynaecologist has to prove that he
diagnoses ³50 high-grade lesions annually and he has to
pass an exam in one of two accredited colposcopy centres
in CR. Altogether, there are about 2,000 private gynae-
cologists in the CR who provide this service.
For the cytological analyses of cervical smears in the
CR, there are about 50 laboratories but only three of
these process ³50,000 slides per year as recommended by
the European guidelines3 and only about half of them
that process ³15,000 slides per year as required by the
new recommendations of the screening committee of the
Ministry of Health of the CR4. For the evaluation of cyto-
logical slides the 2001 Bethesda system5 is used. Mortal-
ity and incidence data are available from the National
cancer registry which was established in 1976 and since
1991 is a member of the International Association of
Cancer Registries (IACR).
In the CR, there are 5,2 million women in total and
2.9 million women in the screening age (25–65 years of
age). The Institute of statistics and health information
reported more than 2.9 million preventive visits to gy-
naecologists in 2005 but as the identification number of
the women is not recorded, these data are of limited
value because it is impossible to distinguish repeat visits
from new visits or in any way relate the number of visits
to the number of women in the target population. In-
deed, there are no data sources concerning screening cov-
erage, but it is estimated to be 30–50%.
























































Fig. 1. Incidence and mortality of cervical cancer
in the Czech Republic2.
TABLE 1
INCIDENCE AND MORTALITY FOR CERVICAL CANCER (C53) BY AGE GROUPS IN THE CZECH REPUBLIC IN 20032
Total
Age group
15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
New cases 1007 1 7 38 70 105 110 124 115 132 73 62 60 55 34 21
Incidence* 19.2 0.3 1.9 8.5 19.2 30.8 34.9 33.2 28.7 34.8 25.8 27.0 25.4 26.9 26.2 30.3
Dead 398 – – 2 11 12 17 43 43 38 48 35 32 49 44 24
Mortality* 7.6 – – 0.4 3 3.5 5.4 11.5 11.5 10 17 15.2 13.5 24 34 34.6
*per 100,000 women/year
TABLE 2





in the last 3 years
No examination
>5 years >10 years
IB-1 105 44.7 59 (56.2%) 21 (20%) 2 (1.9%)
IB-2 42 44.1 20 (42.9%) 14 (33.3%) 4 (9.5%)
IIB 91 54.5 31 (34%) 35 (38.4%) 14 (15.4%)
IIIB-IV 14 74 1 (7%) 6 (43%) 6 (43%)
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Data from the Clinic of Obstetrics and Gynaecology in
Motol also show that 44.0% of women diagnosed with in-
vasive cervical cancer had visited a gynaecologist for
colposcopy/cytology within the 3 year, and 60.0% had vis-
ited within the 5 years before being diagnosed with can-
cer (Table 2). These data clearly indicate that the diag-
nostic process is failing a large proportion of the Czech
women who are attending for screening.
Conclusion
Screening cervical carcinoma in the Czech Republic
has been opportunistic since 1966. Despite a very high
frequency of screening visits and a historically wide age
range, the incidence of cervical cancer has not changed in
the last 34 years. The coverage of Czech women by the
screening is not known exactly but it is estimated to be
50% at the most. Further, for those who are attending for
screening, the high percentage of women with IB-2 cervi-
cal cancer, who have been examined by cytology and
colposcopy within the last 3 years, suggests that the
screening and diagnostic processes are inadequate.
It has been clearly established that organised cervical
cancer screening programmes with quality control at all
levels of the process offer the most cost-effective protec-
tion against cervical cancer and can prevent up to 80% of
cervical cancers in the populations they serve. Because of
these facts, the Council of the European Union, the Eu-
ropean Commission, the International Agency for Re-
search on Cancer, the European Parliament Cervical
Cancer Interest Group, together with a number of other
prestigious organisations has recommended that all Eu-
ropean countries should implement organised cervical
cancer screening programmes. The data noted above
clearly indicate that the Czech Republic is not fulfilling
its obligations to the women of this country and the im-
plantation of these programmes must now be a priority.
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PROBIR RAKA VRATA MATERNICE U REPUBLICI ^E[KOJ
S A @ E T A K
Citolo{ka dijagnoza atipi~nih stanica vrata maternice metodom Papanicolaou-a je uvedena ve} 1947. g. u Republici
^e{koj. Prvi podaci o pojavnosti raka vrata maternice u Republici ^e{koj su dostupni od 1960. g. kada je stopa po-
javnosti iznosila 32,3 slu~aja/105 `ena. 1966. g. ^e{ko nacionalno zdravstveno pravo je donijelo jamstvo `enama da }e
godi{nji preventivni ginekolo{ki pregled uklju~uju}i probir raka vrata maternice biti pokriven obaveznim zdravstvenim
osiguranjem. Unato~ visokom odazivu na probir i ~injenici da su sve `ene podobne, stopa pojavnosti raka vrata ma-
ternice se nije mijenjala u posljednje 34 godine. Razlozi za to uklju~uju nisku pokrivenost `ena u Republici ^e{koj
(najvi{e 50%), ~injenicu da niti jedan citolo{ki laboratorij nije ovla{ten za probir, nepostojanje nacionalnih registara za
bilo koji aspekt programa te nepostojanje na~ina procjene procesa probira. Kao rezultat se mo`e o~ekivati da }e ve}ina
aktivnosti probira raka vrata maternice biti neu~inkovita te je uvo|enje organiziranog programa probira s kontrolom
kvalitete, zajedno s preporukama mnogih Europskih institucija, hitno potrebno kako bi se `enama u Republici ^e{koj
osigurala pravilna za{tita od ove bolesti te da oskudni izvori zdravstvenog osiguranja budu upotrijebljeni na naju~in-
kovitiji na~in.
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Cervical Cancer Screening in Serbia
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A B S T R A C T
Cervical cancer is the second most common female malignancy in Serbia, after breast cancer, with 1089 new regis-
tered cases and an age-standardized incidence rate of 27.2 per 100,000 women in 2002. It is the fourth leading cause of
cancer death with 452 deaths and an age-standardized death rate of 7.2 per 100,000 women. Compared with other Euro-
pean countries, the incidence of cervical cancer in Central Serbia is the highest. Regional differences in incidence are
pronounced in Serbia with the lowest age-standardized incidence rate (16.6 per 100,000 women) registered in the Ma~-
vanski region and the highest in eastern Serbia and the region of Belgrade where the rates are double at 32.5–38.1 per
100,000 women. Cervical cancer prevention in Serbia has relied on opportunistic screening that is characterized by high
coverage in younger and low coverage in middle-aged and older women. Screening of selected groups of women em-
ployed in large companies is performed annually by many regional hospitals but this approach has little effect on mor-
bidity and mortality. Recently, the Ministry of Health nominated an Expert Group to develop and implement a national
cervical cancer screening program. A number of pilot projects have been undertaken with the results used for develop-
ment of a national programme for cervical cancer screening. This is expected to be finalized in 2007, and launched over a
3-years period in order to cover all women aged 25–64 in entire Serbia.
Key words: cervical cancer, screening, Serbia
Introduction
The aim of the present study was evaluate the burden
of cervical cancer in Serbia and present the status of cer-
vical cancer prevention. The sources used to develop this
report were official the Statistical Office of Serbia and
the Cancer Registry of Serbia, as well as the results of
the studies and projects related to cervical cancer screen-
ing conducted in Serbia during the period of 2002–2007.
Global Situation
Cervical cancer is the second most common malig-
nancy in women worldwide, with about 490,000 newly
registered cases every year. There are large differences in
the incidence rate which varies from 2.0 per 100,000
women in Syria to 87.3 per 100,000 women in Haiti (age
standardized rates). The highest rates are observed in
Eastern and Southern Africa, Melanesia, Caribbean and
Central America; the lowest rates are observed in East-
ern and Western Asia, Australia, Northern America,
Northern and Western Europe1.
Several factors contribute to regional differences in
cervical cancer rates and their trends. Persistent infec-
tions with the Human papillomavirus (HPV) are a neces-
sary but not sufficient cause of cervical cancer. HPV is
primarily transmitted by sexual contanct but differences
in sexual behavior cannot entirely account for the geo-
graphic variation in cervical cancer. The most important
factor is the availability of screening. In many developed
countries where screening has been in place for a num-
ber of years, a decline in cervical cancer incidence and
mortality has been observed over the last 30 years.
Cervical Cancer – a Major Health
Problem in Serbia
From 1973–1982, the European extremes in cervical
cancer incidence were the German Democratic Republic
with an incidence of 33.2 and Spain with the one of 4.12.
At that time, the incidence in regions of Central Serbia
where the cancer registries were functioning properly
was 14.7 to 18.2 per 100,0003.
31









 $  
In 1995, the cancer registry in Central Serbia was re-
organized with all new cases from Serbia’s 16 regions
registered centrally and the average age-standardized in-
cidence rate for 1999 was 20.8/100,000 while the average
standardized incidence rate for the European Union was
9.94. Today, according to the data of the Cancer Registry
of Central Serbia, cervical cancer is the second most com-
mon female malignancy after breast cancer with 1,089
new cases per year and the age-standardized incidence
rate of 27.2 per 100,000 women in the year 20025. How-
ever, there are also significant differences in cervical can-
cer incidence between the regions of Central Serbia (Fig-
ure 1). In 2002, the lowest age-standardized incidence
rate (16.6 per 100,000 women) was registered in the
Ma~vanski region. The highest rates, more than twice
higher, were registered in eastern Serbia, near the border
with Romania, and in the region of Belgrade (32.5–38.1
per 100,000 women)5.
When compared with data from European countries,
the incidence of cervical cancer in Central Serbia is the
highest in Europe. Similar high rates are observed in
neighboring countries such as Romania, Albania and
Bosnia & Herzegovina (Figure 2).
In 2002, according to the data of the Statistical Office
of Serbia, cervical cancer was the fourth leading cause of
cancer death in females in Serbia with 452 deaths and
the age-standardized death rate of 7.2 per 100,000 wo-
men5. As for mortality, Romania is the country with the
highest mortality rate in Europe, while Serbian rate is
significantly lower (Table 1). However, cervical cancer
mortality depends on incidence and survival rates. As
both Serbia and Romania have similar high incidence
rates, difference in mortality could be explained by better
availability and efficacy of cervical cancer treatment ser-
vices in Serbia.
Age Distribution of Cervical Cancer
in Serbia
The risk for cervical cancer increases with age. In
Central Serbia very few cases are diagnosed before the
age of 25. After that age, the incidence increases and
reaches maximum in the 45 to 49 and 50 to 54 age
groups6 (Table 2).
Potential Target Population for Cervical
Cancer Screening
Decisions on the target age group and frequency of
screening are usually made at the national level, on the
basis of local incidence and prevalence of cancer, HIV
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Fig. 1. Age-standardized cervical cancer incidence rates in Serbia,
by regions, (per 100,000 women); average 27.3/100,000 women-
-year. Source: Cancer Registry of Serbia, 20026.
Fig. 2. Age-standardized cervical cancer incidence rates in European
countries (per 100,000 women). Source: Ferlay J et al. Globocan
20021.
TABLE 1
COUNTRIES WITH HIGHEST CERVICAL CANCER MORTALITY
RATES IN EUROPE (AGE-STANDARIZED MORTALITY RATES PER
100,000 WOMEN IN 2002)


























 $  
prevalence, availability of resources and infrastructure.
WHO recommends that new programmes should start by
screening women aged 30 years and more, and include
women 25 to 29 only when the higher risk groups have
been covered. Screening should not include women un-
der 25 and for women over 65, screening is not necessary
if they have had two previous negative smears7.
The incidence of cervical cancer is high in all age
groups from 35 to 69. The upper age limit of the target
group should be set at least at the age of 64 so that there
would not be many cases missed by screening in older age
groups. On the other hand, lower age limit should be set
at 30 so that as many lesions as possible would be discov-
ered in precancerous lesions.
There is about 1,5 million women in the age group 30
to 59 and about 1,8 million women in the age group 30 to
64 in Serbia. With a three year interval, it would mean
0,5 or 0,6 million to be screened yearly.
Cervical Cancer Control Programme
A comprehensive, centalized screening programme
for cervical cancer has never been implemented in Serbia
and cervical cancer prevention has relied on opportunis-
tic screening. This type of screening has been character-
ized by high coverage in younger and low coverage in
middle-aged and older women. Screening of selected
groups of women employed in large companies is per-
formed annually by many regional hospitals. This ap-
proach, however, has had little effect on morbidity and
mortality.
In spite of some efforts to initiate screening during
the period between 1990 and 1999, the difficult situation
in the country did not enable more organized approach.
Besides the other effects on health service, the economic
crisis left significant the consequences to general health:
• Economic resources for health were lowered.
• Investments for health were decreased (from  150 per
person in 1997 to less than  50 in 1999).
• Prevention became inadequate.
• Overall mortality and morbidity increased.
In this situation, disease prevention through mass
screening in central Serbia did not seem to be the pri-
mary problem and cervical cancer control in Serbia had
unsatisfactory levels of effectiveness. This was primarily
due to the absence of national strategy for cancer preven-
tion, a lack of programme funds for cancer prevention or
early detection, as well as an insufficient public and polit-
ical awareness of the importance of cancer prevention.
Primary prevention programs did exist but were carried
out without well-defined methodology or objectives and
without appropriate effectiveness analysis. As a conse-
quence, a high proportion of cervical cancers were diag-
nosed when already well-advanced and metastatic, lead-
ing to a low probability of cure and high mortality rates.
Actions Against Cervical Cancer –
Preparing the Foundation for Organised
Cervical Cancer Screening
Beginning in the year 2000, the basic strategies ap-
plied to achieve the cervical cancer control in Serbia were
focused on cancer prevention and early detection strate-
gies. The main risk factors on the national level were de-
fined and monitored. The efforts were made to improve
the system for cancer registration. This could not be
achieved without introduction of unique information
system to help in overcoming communication problems
on the local, regional and national level. To achieve these
goals it was mandatory to increase the support of govern-
ment, as well.
Becoming aware of the increasing incidence and mor-
tality of cervical cancer in Serbia and the importance of
early detection and treatment of this disease, the Minis-
try of Health nominated an Expert Group for the preven-
tion and early detection of cervical cancer in 2003. The
aim was to develop and implement national screening
programme. It was expected that the systematic screen-
ing of non-symptomatic women would increase the pro-
portion of localized tumors, but also the need of treat-
ment resources for these cancers.
As a result, several projects have been completed to
study the psycho-social aspects of cervical screening in
this region and to improve the local screening infrastruc-
ture:
• A study conducted by the Institute of International So-
cial Affairs in 2002 showed that an educational cam-
paign on the importance of screening can increase par-
ticipation by more than 60%8.
• A survey sponsored by the Alliance for Cervical Cancer
Prevention (ACCP) and conducted by Programme for
V. Kesi} et al.: Cervical Cancer Screening in Serbia, Coll. Antropol. 31 (2007) Suppl. 2: 31–36
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TABLE 2
AGE DISTRIBUTION OF CERVICAL CANCER CASES
IN CENTRAL SERBIA
Age group No of cases % of all cases Age specific rate
0–14 0 0 0
15–19 1 0.1 0.6
20–24 1 0.1 0.6
25–29 23 2.3 12.4
30–34 40 4 22.7
35–39 75 7.5 42.9
40–44 108 10.8 56.7
45–49 162 16.1 75.3
50–54 173 17.2 77.9
55–59 105 10.5 66.3
60–64 89 8.9 55.4
65–69 93 9.3 52.2
70–74 77 7.7 46.5
75+ 57 5.7 29.5
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Appropriate Technology in Helath (PATH) in 2003–4,
explored women’s knowledge and perceived barriers
towards cervical screening, so adequate campaigns can
be designed.
The research was focused on urban women residing in
the capital city and one major regional city. The study
was comprised of qualitative (phase I) and quantitative
(phase II) research. The main determining factors were
the age and education of the women. The first phase has
been realized through focus group discussions (62 wo-
men participated, recruited by network sampling) and
in-depth interviews (conducted with 22 women)9. Data
deriving from the qualitative study were used to develop
a questionnaire on women’s understandings and knowl-
edge of cervical cancer. The survey was distributed to 800
women from a selected number of community health
services10.
The population sampled showed a broad lack of know-
ledge about the necessity of screening and shared attitu-
dinal barriers with women in other regions. Results re-
vealed that most of women do not regularly visit a
gynaecologist, do not understand the purpose of Pap
smear (even if they regularly have it), think that absence
of symptoms means that they are healthy and do not
need Pap smear, do not know the procedure of Pap smear,
are often embarrassed about being examined (this was
independent of the gynecologist’s sex), believe that little
can be done to prevent cancer and an unwillingness to
talk about the illness. Education and economic status
were not highly related to knowledge about cervical
screening10.
Thematic analysis identified that the interplay of so-
cial and personal barriers influenced women’s poor pre-
sentation for screening. It found that the socio-economic
situation prevented women from focusing on their health
and it identified a number of problems with the delivery
of health services in the region. Inadequate public health
education, lack of patient-friendly health services, socio-
-cultural health beliefs, gender roles, and personal diffi-
culties were the most salient barriers to screening9.
The study findings suggest how, within the context of
opportunistic screening, patient education maybe em-
ployed. The introduction of compulsory cervical cancer
screening, suggested by some participants, may be a pos-
sible approach9. The success of public awareness cam-
paigns elsewhere suggests that a media-centered ap-
proach could also have good results in Serbia. The lack of
media attention noted in the study focus groups supports
this conclusion.
In general, study findings was used to inform and fa-
cilitate the change in government’s policy regarding cer-
vical screening and to develop the public health cam-
paign targeting cervical cancer.
• Clinical Center of Serbia was one of the partners in
European Consortium for Cervical Cancer Education
(ECCCE) project granted by European Commission
and conducted from 2002–2004. This project has lead
to the foundation of The European Cervical Cancer As-
sociation (ECCA). The ECCA was founded by 15 differ-
ent organisations from across Europe, which included
cancer charities, cancer treatment centres, university
teaching hospitals and health education organisations.
One of them was Clinical Center of Serbia. The ECCA
was established specifically to co-ordinate a Europe-
-wide public health education programme that would
raise awareness of cervical cancer and how it can be
prevented. For the general public in Serbia the project
was developing an educational programme to provide
women with the information they need to reduce their
risk of cervical cancer. This project has adopted the
materials developed by ECCCE and ECCA. These ma-
terials are approved by Serbian Ministry of Health and
widely distributed in Serbia through the network of re-
gional health centres.
• Project »Improving Preventive Health Services in Ser-
bia« (IPHSS) has started in September 2004. Its goal
was to reduce the mortality by improving preventive
health services. To achieve it, this project, funded by
European Union, managed by European Agency for
Reconstruction and realised by EPOS Health Consul-
tants, targets both health professionals and women.
IPHSS edited guidelines for prevention of cervical car-
cinoma elaborated in line with EU recommendations
and will distribute them in 25 regional Serbian health
centres11. It also supports the establishment of a na-
tional School for cytology. In parallel, IPHSS wishes to
contribute to the education of women on the preven-
tion of cervical cancer.
• A Pilot Programme for Cervical Cancer Screening was
implemented 2004 in Branicevo, a region in eastern
Serbia with a particularly high incidence of cervical
cancer12. This project, supported by the French gov-
ernment and implemented by WHO, was the first orga-
nized screening programme in Serbia.
Screening Implementation
»Branicevo project« was the first organized screening
in Serbia. In 2001, the French donor, the WHO and
health authorities of the Republic of Serbia jointly agre-
ed that the high mortality and incidence of cervical can-
cer in Serbia presents a major public health problem that
needs urgent intervention. The French donor approved a
grant for implementation of a pilot project for organized
screening of cervical cancer that would serve as a basis
for developing a national programme. The project man-
agement was entrusted to WHO Regional Office for Eu-
rope – WHO Country Office in Serbia (at the time Serbia
and Montenegro) and was planned for implementation
through the national health system (public health insti-
tutes and health service).
The project went through the following phases:
• Design of social mobilisation, action plan and imple-
mentation of social mobilisation.
• Setting up the Central Cytology Laboratory and the
quality assurance system for cervical screening.
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• Developing the Information Technology (IT) for scre-
ening.
• Training in software application and continuous on-
-site IT support.
• Regular weekly quality assurance visits to cytological
laboratory.
• Setting up monitoring and evaluation system.
• Drafting of national strategy – process support.
Screening invitations were sent to 22,300 women
aged 30–49 years in the Branicevo district and 12,763
women were screened. Sixty three high-grade squamous
intraepithelial lesion (H-SIL) and 6 invasive cancers
were detected in the screened population with the esti-
mated cervical cancer incidence of 47.01 per 100,000 and
49.36 H-SIL lesions per 100,000 women (Table 3).
The specific project objectives were achieved:
• 60 % of target population (women aged 30–49 years of
age) in the Branicevo district were screened for cervi-
cal cancer with cytological methods.
• Local Health experts were trained in methods of cyto-
logical screening and a system of quality assurance
was set up.
• Bethesda system of cytological classification was suc-
cessfully introduced into the practice.
• 16 % of all slides were re-screened through quality as-
surance system, all slides with positive findings at first
screening and 10 % of slides assessed as negative at
first screening.
• 95 % of matching between 1st and 2nd screening was
identified.
• 1.32 % of slides were inadequate for cytology and had
to be repeated.
• All women identified with pre-malignant lesions through
the screening project were referred for full diagnostic
procedure and required treatment.
• Effects of the pilot project on mortality for cervical
cancer screening in the district will be monitored but
will be visible only after a longer time period.
Conclusions
The results and experiences from the Branicevo pilot
project have been used for development of a National
programme for cervical cancer screening, which is ex-
pected to be finalized in 2007, and launched over a
3-years period in order to cover all Serbian women aged
25–64.
The development of national strategy is essential for
the sustainability of the effects of the project in the pilot
district and in Serbia in total. The Ministry of Health of
Serbia had set up a National Committee for Prevention
of Cervical Cancer, in July 2006. WHO will continue to
provide technical support to the National Committee in
2007 (through its regular programme) until a National
Programme for Cervical Cancer Screening and action
plan for nation wide implementation over a 3-years pe-
riod are fully developed.
In addition to supporting the development of the Na-
tional Programme, the WHO also supported the National
Cancer Registry so they were able to update the national
cancer data-base. It is expected that in 2007, the Na-
tional Cancer Registry will be able to start to monitor
pre-malignant lesions of the cervix (from the pilot dis-
trict) and when a national programme starts to be imple-
mented to monitor pre-malignant cervical lesions nation
wide. The Institute of Public Health (IPH) has been spe-
cifically supported to strengthen the Cancer Registry De-
partment and to prepare and print Annual Cancer Regis-
tries for 2002 and 2003 (2004 and 2005 were prepared as
well and will be published with internal resources of the
IPH of Serbia in 2007).
At the end of 2006 the process of development of a Na-
tional Programme for Cytological Screening of Cervical
Cancer and preparing of a national action plan is fully
under way. However, the operationalisation of the Pro-
gramme and its implementation will depend on integrati-
on of this new public health programme into the financing
mechanisms of the Serbian health system (combination
of the national health insurance for individual services
and Ministry of Health budget for the support to the pub-
lic health component – social mobilisation, organisation
of programme, programme monitoring and implementa-
tion).
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TABLE 3
THE DISTRIBUTION OF CERVICAL SMEAR RESULTS IN THE SCREENED POPULATION OF BRANICEVO REGION





PAP IV PAP V Unsatisfacotry Total
Number of women examined 554 11057 520 340 94 26 4 168 12,763
% 4.34 86.63 4.08 2.66 0.74 0.20 0.03 1.32 100.00
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PROBIR RAKA VRATA MATERNICE U SRBIJI
S A @ E T A K
Rak vrata maternice zauzima drugo mjesto me|u bolestima `ena u Srbiji, odmah iza raka dojke, sa 1.089 regis-
triranih novih slu~ajeva te dobno-standardiziranom stopom pojavnosti od 27,2 na 100.000 `ena u 2002. g. Na ~etvrtom
je mjestu po smrtnosti sa 452 smrtna slu~aja te dobno-standardiziranom stopom smrtnosti od 7,2 na 100.000 `ena. U
usporedbi s ostalim europskim zemljama pojavnost raka vrata maternice u Centralnoj Srbiji je najvi{a. Regionalne
razlike u pojavnosti ovog raka su jako izra`ene u Srbiji, sa najni`om dobno-standardiziranom stopom pojavnosti (16,6
na 100.000 `ena) zabilje`enom u podru~ju Ma~vanski, a najvi{om u isto~noj Srbiji te podru~ju Beograda gdje su stope
pojavnosti dvostruko vi{e (32,5–38,1 na 100.000 `ena). Prevencija raka vrata maternice u Srbiji se temelji na opor-
tunisti~kom probiru koji je karakteriziran visokom pokrivenosti mladih te niskom pokrivenosti starijih i `ena srednjih
godina. Probir odabranih skupina `ena zaposlenih u velikim tvrtkama se provodi u mnogim podru~nim bolnicama
jednom godi{nje, me|utim ovaj pristup ima mali utjecaj na bolest i smrtnost. Nedavno je Ministarstvo zdravstva ime-
novalo Grupu stru~njaka koja bi razvila i provela program probira raka vrata maternice na nacionalnoj razini. Provodi
se velik broj pilot-projekata rezultati kojih se koriste za razvoj nacionalnog programa probira za rak vrata maternice.
O~ekuje se da }e to biti dovr{eno u 2007. g. te, kroz razdoblje od 3 godine, pokretanje programa probira koji bi pokrivao
sve `ene Srbije u dobi izme|u 25 i 64 godine.
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Cervical Cancer in Croatia: State of the Art
and Possibilities for Prevention
Ariana Znaor and Marija Strnad
Croatian National Institute of Public Health, Zagreb, Croatia
A B S T R A C T
In Croatia, there are about 355 incident cases and about 100 deaths from cervical cancer every year. The aim of this
study is to present the trends of cervical cancer incidence and mortality and to propose preventive strategies for cervical
cancer in Croatia. Age-standardised and age-specific cervical cancer incidence rates were calculated for the period
1985–2004. For cervical cancer mortality data, the WHO Mortality Database was used. After an early decrease of cervical
cancer incidence and mortality following the introduction of opportunistic screening in Croatia, no further decrease has
been observed since the 1990s. An increase in incidence over the last 20 years was observed in the age-groups 40–44 and
45–49 years. To reduce cervical cancer rates, an organised cervical cancer screening programme is essential. In addition,
HPV vaccination should be introduced in the school vaccination programme to achieve further reductions in cervical
cancer incidence in the future.
Key words: cervical cancer, prevention, Croatia
Introduction
Cervical cancer is the second most common female
cancer worldwide with about 493,000 incident cases per
year, and it is the most common female cancer in Africa,
South America and Asia1. There are about 273,000 cervi-
cal cancer deaths in the world yearly, 85% of which take
place in developing countries1. In Europe, there are
about 50,000 new cases, and about 25,000 deaths yearly2.
The majority of incident cases occur between ages 30 and
50. The highest incidence of cervical cancer in Europe is
observed in Eastern European countries. As a conse-
quence of cervical cancer screening by Papanicolaou (Pap)
smear, cervical cancer incidence and mortality rates have
been decreasing over the last three decades in most of the
European countries. In countries with organised cervical
cancer screening programmes, cervical cancer is usually
the 10th most common female cancer1–3.
The Croatian population as assessed by the 2001 cen-
sus was 4.4 million4. The annual cancer incidence is
about 20,000 cases and cervical cancer is the 8th most
common female cancer in this country. There are on av-
erage 355 new cases, and about 100 deaths each year5,6.
Croatia has a lower cervical cancer incidence than most
Central and Eastern European countries, but it is still
much higher than in countries with organised cervical
cancer screening programmes1. Relative 5-year survival
of cervical cancer patients in Croatia diagnosed in the pe-
riod 1994–1998 was 74%7.
A possibility for primary prevention of cervical cancer
is vaccination against the Human papillomavirus (HPV)
that has been identified as a necessary cause of cervical
cancer8. About 60% of cervical cancer cases are attrib-
uted to HPV type 16, and additional 10–20% to HPV type
18 infection9–12. The currently available HPV vaccines
that have recently been approved in the US and Europe,
protect against the oncogenic HPV 16 and HPV 18 (qu-
adrivalent HPV types 6, 11, 16, 18 recombinant vaccine
GARDASIL®, Merck and Co.). Because the genital types
of HPV are primarily transmitted by sexual contact, the
optimal age for vaccination of girls is before the onset of
sexual activity. Vaccination of males has not been consid-
ered cost-effective13–15. The report on GARDASIL® effi-
ciency provided to the US Food and Drug Administration
and the European Medicines Agency, states that the vac-
cine can reduce HPV 16 or 18 related cervical intra-
epithelial neoplasia grade 2 and 3 (CIN 2/3) or adeno-
carsinoma in situ (AIS) by 39.0% (95% CI: 23.3–51.7),
while reducing treatment rates for any CIN by 16.5%
(95% CI 2.9–28.2)13,14.
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The current HPV vaccines will not prevent all onco-
genic HPV infections and therefore cannot replace the
traditional cervical cancer screening. However, screening
methods and intervals may be modified to account for
changes in population risk for the development of this
disease15–18.
Historically, cervical cancer screening by Pap smear,
when followed by adequate therapy, has been proven to
substantially reduce cervical cancer incidence and mor-
tality. Following the introduction of such effective prog-
rammes, cervical cancer incidence and mortality has
been reduced by more than 80% particularly in British
Columbia and the Nordic countries19. The Pap smear was
introduced in the mid 1940s, and entered wider use in
the late 1950s. Organised national cancer screening prog-
rammes are currently available only in 8 EU countries
(Finland, Denmark, Iceland, Italy, Norway, Sweden, Slo-
venia and UK). The European guidelines specify that
cervical cancer screening programmes should target the
age-group 25–64 years20–22. The International Agency for
Research on Cancer (IARC) also recommends the intro-
duction of HPV-DNA screening within organised prog-
rammes in such a way that the efficacy and effectiveness
can be evaluated9.
Croatia does not have an organised national cervical
screening programme. Following the recommendations
for cervical cancer screening in Europe, a Working Group
of the Croatian Ministry of Health and Welfare has pro-
posed a national cervical cancer screening programme,
although this has not yet been introduced23. The pro-
posed programme comprises screening of women aged
25–64 years every three years by Pap smear in the first
phase. In the second phase of the programme, in addition
to Pap smear, HPV test would be introduced for women
aged 30–64, with five-year screening intervals23.
The aim of this study was to present the trends of cer-
vical cancer incidence and mortality between 1985 and
2004 in Croatia, and to propose preventive strategies for
cervical cancer in Croatia.
Materials and Methods
The source of data on cervical cancer mortality in
Croatia for the period 1985–2004 was the WHO mortal-
ity database24. Only the data for cervical cancer (ICD-10
code C53), without data on death associated to »Uterus
not otherwise specified« (NOS) (ICD-10 code C55) are
presented. However, the data on cervical cancer deaths
are likely to be underestimates since there are over one
hundred deaths per year from cancer of uterus NOS in
Croatia and a proportion of these will be due to cervical
cancer as well. For the data on cervical cancer incidence,
we used the Croatian National Cancer Registry data5. To
calculate the age-specific rates for the year 1985, we used
the Croatian population census for 1981; for the period
1986–1995 we used the Croatian population census for
1991; and for the period 1996–2004, we used the Cro-
atian population census for 20014,25,26. Age-standardised
rates of cancer incidence in Croatia for the period 1985–
2004 were calculated by the direct standardization method,
using the World standard population as a reference27.
Results
The age-standardised cervical cancer incidence rates
show a decreasing trend until the year 1991 but no fur-
ther consistent decrease in cervical cancer incidence has
been observed afterwards. The age-standardised rates of
cervical cancer mortality remained at a low level during
the entire period but no decrease was observed over the
last decade (Figure 1).
Table 1 shows the age-specific rates of cervical cancer
in Croatia for the age-groups targeted by the proposed
screening programme23. In the age groups between 25–
39 years, a decreasing trend of cervical cancer incidence
is observed. An increase of cervical cancer incidence over
the last 20 years has been observed in the age-groups
40–44 and 45–49 years. In the age groups between 50 and
64 years, a decrease of cervical cancer incidence is ob-
served, which is most prominent in the age group 60–64,
being over 5-fold over the 20-year period.
Discussion
Opportunistic cervical cancer screening was intro-
duced in Croatia in the 1960s and this was accompanied
by decreasing cervical cancer incidence and mortality
trends through to 1991. However, no substantial further
decreases in cervical cancer incidence and mortality were
observed subsequently (Figure 1). The largest decrease
of cervical cancer incidence over time is observed in
women between 25 and 39 years of age (Table 1). In addi-
tion to a higher awareness of the importance of preven-
tive medical examinations in these women, this could be
accounted for by opportunistic screening in scope of
gynecological examinations for either pregnancy or con-
A. Znaor and M. Strnad: Cervical Cancer in Croatia, Coll. Antropol. 31 (2007) Suppl. 2: 37–40
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Fig. 1. World age-standardised rates (ASRW per 100,000 women-
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traceptive use counselling. However, the lack of a de-
creasing trend in women between 40 and 49 years of age
is more worrying, since this age-group comprises over a
quarter of the incident cervical cancer cases in Croatia
(Table 1). Meanwhile, the decrease of incidence in age-
-groups 50–64 probably reflects higher awareness of post-
menopausal women about the importance of gyneco-
logical examinations (Table 1).
The available evidence indicates that opportunistic
cervical cancer screening in Croatia has had an impact.
The number of Pap smears taken yearly is still increas-
ing and reached 433,671 in 2005. However, in the ab-
sence of an organised population-based programme it is
difficult to assess the efficacy of this screening and it is
clear that a large proportion of target population still re-
mains un-screened or under-screened23.
In spite of the decrease of cervical cancer incidence
following its introduction, opportunistic screening is not
an optimal method for the prevention of this disease as it
tends to overscreen the wealthy and well-educated while
under-screening the less affluent and minorities, thereby
creating inequalities in the healthcare that is delivered
to the population20. The only way to resolve this problem
and to achieve further reductions in cervical cancer cases
is through the introduction of an organised cervical can-
cer screening programme. Following the introduction of
such programmes, cervical cancer incidence and mortal-
ity has been reduced by more than 80% particularly in
British Columbia and the Nordic countries (Finland,
Denmark, Iceland, Norway and Sweden)19. In addition,
organised screening programmes are the only way that
countries will be able to derive the maximum benefit
from the new HPV vaccines that will soon be launched in
Croatia.
Conclusion
There is now a very urgent need to move forward with
the introduction of a comprehensive organised cervical
cancer prevention programme in Croatia. Indeed, this is
the only way that we will be able to further reduce cervi-
cal cancer rates while providing equitable, cost-effective
protection to all the women of Croatia.
A. Znaor and M. Strnad: Cervical Cancer in Croatia, Coll. Antropol. 31 (2007) Suppl. 2: 37–40
39
TABLE 1
AGE-SPECIFIC INCIDENCE RATES (PER 100,000 WOMAN-YEARS) OF CERVICAL CANCER IN CROATIA IN THE PERIOD 1985–2004
Year
Age-group
25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64
1985 9.4 22.6 38.7 17.7 20.7 28.7 39.1 66.1
1986 10.6 14.4 17.5 22.5 36.8 31.7 36.4 40.0
1987 10.0 15.0 19.1 17.8 29.1 24.6 32.1 36.7
1988 7.1 18.8 14.2 17.8 16.9 31.7 25.9 35.4
1989 15.3 15.5 20.2 18.4 23.0 24.6 31.4 42.0
1990 10.6 13.8 24.6 26.7 16.1 16.8 25.3 26.9
1991 5.9 18.3 20.2 18.4 26.1 16.2 18.5 30.2
1992 5.3 14.4 17.5 27.2 23.8 17.5 25.3 28.2
1993 11.8 17.7 38.8 26.7 19.9 25.3 21.0 23.0
1994 9.4 17.7 27.3 26.7 29.1 22.0 20.3 31.5
1995 7.1 15.5 26.2 34.9 30.7 22.7 26.5 26.2
1996 6.2 10.9 21.4 32.4 24.2 20.5 30.6 24.8
1997 9.6 13.6 30.9 30.0 24.2 19.8 19.0 21.2
1998 6.2 11.5 20.2 28.2 25.4 19.1 25.6 25.5
1999 6.9 20.3 21.4 25.2 21.8 23.8 32.2 33.3
2000 11.0 21.7 29.0 29.4 39.9 23.8 22.3 23.3
2001 7.5 12.9 30.9 28.2 21.8 18.5 13.2 21.9
2002 4.8 16.9 25.8 26.4 23.0 29.0 16.5 24.1
2003 4.8 10.8 18.3 24.6 25.4 19.8 23.9 18.4









 $  
R E F E R E N C E S
1. FERLAY J, BRAY F, PISANI P, PARKIN DM: GLOBOCAN 2002:
Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base
No. 5. Version 2.0. (IARC Press, Lyon, 2004). — 2. EUROPEAN CERVI-
CAL CANCER ASSOCIATION: Fact sheet I, October 2005. (European
Cervical Cancer Association, Lyon, 2005). — 3. STUVER S, ADAMI HO,
Cervical cancer, In: ADAMI HO, HUNTER D, TRICHOPOULOS D (Eds.):
Textbook of Cancer epidemiology (Oxford University Press, New York,
2002). — 4. REPUBLIC OF CROATIA – CENTRAL BUREAU OF STA-
TISTICS: Census of population, households and dwellings 31st March
2001. (Central Bureau of Statistics, Zagreb, 2001). — 5. CROATIAN NA-
TIONAL INSTITUTE OF PUBLIC HEALTH: Cancer incidence in Cro-
atia. Bulletins No. 1–29. (Croatian National Institute of Public Health,
Zagreb, 1983–2006). — 6. CROATIAN NATIONAL INSTITUTE OF PUB-
LIC HEALTH: Health Statistics Yearbook 2005. (Croatian National Insti-
tute of Public Health, Zagreb, 2006). — 7. STRNAD M, ZNAOR A, Can-
cer Survival in Croatia, 1988–1998. (Croatian National Institute of Public
Health, Zagreb, 2006). — 8. WALBOOMERS JMM, JACOBS MV, MANOS
MM, BOSCH FX, KUMMER JA, SHAH KV, SNIJDERS PJF, PETO J,
MEIJER CJLM, MUNOZ N, J Pathol, 189 (1999) 12. — 9. INTERNA-
TIONAL AGENCY FOR RESEARCH ON CANCER: Human Papilloma-
viruses. IARC Monographs on the Carcinogenic Risk of Chemicals to Hu-
mans. (International Agency for Research on Cancer, Lyon, 1995). — 10.
PALEFSKY JM, MINKOFF H, KALISH LA, LEVINE A, SACKS HS,
GARCIA P, YOUNG M, MELNICK S, MIOTTI P, BURK R, J Natl Cancer
Inst 91 (1999) 226. — 11. MORENO V, BOSCH FX, MUNOZ N, MEIJER
CJ, SHAH KV, WALBOOMERS JM, HERRERO R, FRANCESCHI S; IN-
TERNATIONAL AGENCY FOR RESEARCH ON CANCER. MULTI-
CENTRIC CERVICAL CANCER STUDY GROUP, Lancet, 359 (2002)
1085. — 12. MUNOZ N, FRANCESCHI S, BOSETTI C, MORENO V,
HERRERO R, SMITH JS, SHAH KV, MEIJER CJ, BOSCH FX; INTER-
NATIONAL AGENCY FOR RESEARCH ON CANCER. MULTICEN-
TRIC CERVICAL CANCER STUDY GROUP, Lancet, 359 (2002) 1093. —
13. Gardasil Product Approval Information – FDA Licensing Action, Avail-
able from: http://www.fda.gov/cber/label/hpvmer013007LB.pdf, accessed
28 January 2007. — 14. European Medicines Agency, European Public
Assessment Report (EPAR) Gardasil, Available from: http://www.emea.eu.int/
humandocs/Humans/EPAR/gardasil/gardasil.htm, accessed 28 January
2007. — 15. HARPER DM, FRANCO EL, WHEELER CM, MOSCICKI
AB, ROMANOWSKI B, ROTELI-MARTINS CM, JENKINS D, SCHUIND
A, COSTA CLEMENS SA, DUBIN G, Lancet, 367 (2006) 1247. — 16.
VILLA LL, COSTA RL, PETTA CA, ANDRADE RP, PAAVONEN J,
IVERSEN OE, OLSSON SE, HOYE J, STEINWALL M, RIIS-JOHAN-
NESSEN G, ANDERSSON-ELLSTROM A, ELFGREN K, KROGH G,
LEHTINEN M, MALM C, TAMMS GM, GIACOLETTI K, LUPINACCI
L, RAILKAR R, TADDEO FJ, BRYAN J, ESSER MT, SINGS HL, SAAH
AJ, BARR E, Br J Cancer, 95 (2006) 1459. — 17. MAHDAVI A, MONK BJ,
Oncologist, 10 (2005) 528. — 18. RODEN R, WU TC, Nat Rev Cancer, 10
(2006) 753. — 19. IARC WORKING GROUP ON THE EVALUATION OF
CANCER PREVENTIVE STRATEGIES. Cervix cancer screening. In: IARC
Handbooks of Cancer Prevention. Volume 10 (IARC Press, Lyon, 2005).
— 20. LINOS A, RIZA E, Eur J Cancer, 36 (2000) 2260. — 21. EURO-
PEAN COMISSION AGAINST CANCER PROGRAMME: Evaluation and
Monitoring of Screening Programmes. (Office for Official Publications of
the European Communities, Brussels – Luxembourg, 2001). — 22. CO-
UNCIL OF EUROPEAN UNION: Recommendations of the Council of
European Union (2003/878/EC). — 23. ZNAOR A, BABIC D, CORU[I]
A, GRCE M, MAHOVLI] V, PAJTLER M, [ERMAN A, [in Croatian],
Lije~ni~ki Vjesnik, 2007 [in press]. — 24. WORLD HEALTH ORGANISA-
TION: WHO Mortality Database, Available from: http://www-dep.iarc.fr/.
accessed December 22, 2006. — 25. REPUBLIC OF CROATIA – CEN-
TRAL BUREAU OF STATISTICS: The Croatian population census 1981.
(Central Bureau of Statistics, Zagreb, 1981). — 26. REPUBLIC OF CRO-
ATIA – CENTRAL BUREAU OF STATISTICS: The Croatian population
census 1991. (Central Bureau of Statistics, Zagreb, 1991). — 27. JENSEN
OM, PARKIN DM, Cancer registration: Principles and Methods. IARC
Scientific Publications. (International Agency for Research on Cancer,
Lyon, 1991). — 28. EUROPEAN CERVICAL CANCER ASSOCIATION.
Fact sheet IV, March 2006 (European Cervical Cancer Association, Lyon,
2006).
A. Znaor
Croatian National Institute of Public Health, Rockefellerova 7, 10000 Zagreb, Croatia
e-mail: ariana.znaor@hzjz.hr
RAK VRATA MATERNICE U HRVATSKOJ: POSTOJE]E STANJE I MOGU]NOSTI ZA PREVENCIJU
S A @ E T A K
U Hrvatskoj godi{nje oko 355 `ena obolijeva, a oko 100 umire od raka vrata maternice. Cilj ovog rada bio je prikazati
trendove incidencije i mortaliteta od raka vrata maternice u Hrvatskoj te predlo`iti strategije za prevenciju. Izra~unate
su dobno-standardizirane i dobno-specifi~ne stope incidencije raka vrata maternice za razdoblje 1985–2004. Za podatke
o mortalitetu od raka vrata maternice koristili smo bazu podataka Svjetske zdravstvene organizacije. Nakon ranog
pada incidencije i mortaliteta od raka vrata maternice u Hrvatskoj koji je pratio uvo|enje oportunisti~kog probira,
daljnji pad se ne primje}uje nakon 1990-ih godina. Opa`en je porast incidencije u zadnjih 20 godina u dobnim sku-
pinama 40–44 i 45–49 godina. Da bi se smanjile stope incidencije i sprije~ile smrti od raka vrata maternice, potrebano je
{to prije uvo|enje organiziranog programa probira. Da bi se postiglo daljnje smanjenje incidencije raka vrata maternice,
potrebno je tako|er uvo|enje cjepiva protiv humanog papilomavirusa (HPV) u program obaveznog cijepljenja {kolske
djece.










 $  
Coll. Antropol. 31 (2007) Suppl. 2: 41–46
Professional paper
Cervical Screening in the UK and Laboratory
Quality Control in the Context of the 2007
European Guidelines
Amanda Herbert
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A B S T R A C T
The first part of this article will provide an overview of cervical cancer screening in the UK during the years before,
during and after the introduction of a highly successful centrally organised cervical screening programme in 1988: since
then the incidence of invasive cervical cancer has fallen by more than 40%. Screening was introduced in a background of
opportunistic screening with poor quality control during a period of time when risk of disease was increasing, which will
be demonstrated by national registrations of carcinoma in situ as well as invasive cancer. The programme is still facing
new challenges and has recently recorded falling screening coverage in younger women, the causes of which have yet to
be established. Liquid-based cytology is in the process of being rolled out nationally but high-risk human papillomavirus
testing has yet to be introduced into the National Health Service (NHS) programme. Lessons from our experience may be
relevant to countries introducing and maintaining organised programmes elsewhere under similar circumstances. The
second part of the article will consider laboratory quality control as practiced in the UK and as recommended in the sec-
ond edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening. These evidence-based guide-
lines provide recommendations for organising and monitoring quality control as well as for introducing new technology
and standardising terminology, which are equally relevant for new and existing programmes. Invasive cancer audit may
highlight areas where procedures could be improved in any programme but also can also demonstrate the effectiveness of
screening.
Key words: Organised cervical screening, quality control, invasive cervical cancer incidence, carcinoma in situ, cer-
vical intraepithelial neoplasia, new technology
Introduction
Across Europe in 2002 there were approximately
60,000 new cases and 30,000 deaths from invasive cervi-
cal cancer with a 5-fold variation in those rates1. The
lowest were in countries such as the United Kingdom
(UK) with organised programmes, which can maximise
the positive and minimise the adverse effects, but there
are many different models of care. The aim is to reach
the population at risk and provide a high quality service
that takes account of specificity as well as sensitivity of
the test. Demographic differences and changes of risk
with time must also be considered when comparing pro-
grammes in countries as diverse as the whole of Europe.
Although rates of mortality and incidence relate to
screening coverage of the population at risk, no amount
of screening will be successful without good quality con-
trol. The second edition of the European Guidelines for
Quality Assurance in Cervical Cancer Screening provides
a comprehensive overview of cervical cancer control in
Europe and describes methodology for all aspects of quality
control1. These guidelines are equally relevant to exist-
ing and new programmes with respect to target popula-
tions, intervals for screening, evidence-based indications
for new technology, methodology for quality control, mo-
nitoring the effectiveness of screening and the impor-
tance of standardising terminology across a diverse and
increasingly mobile group of nations.
Cervical screening has been successful in the UK
since a centrally organised National Health Service Cer-
vical Screening Programme (NHSCSP) was introduced
41
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in 1988, which can be demonstrated by national registra-
tions of invasive and in situ carcinoma of the uterine cer-
vix (www.statistics.gov.uk). Registrations prior to 1992
can be obtained from the Office for National Statistics on
CD ROM2. The effects of changing risk of disease, screen-
ing coverage and quality control continue to influence
the evolution of the programme and may provide lessons
for other countries. The challenge of new technology af-
fects new and existing programmes alike and should be
introduced as and when it can be shown to improve sen-
sitivity or specificity of the test. The experience of intro-
ducing liquid-based cytology (LBC) to the NHSCSP will
be discussed as well as the role of high-risk human
papillomavirus (hrHPV) testing, which is yet to be intro-
duced nationally.
Screening in the UK Before and After
Organised Screening Was Introduced
During the 1970s and 1980s general practitioners
were paid a supplement to screen women aged 35–64, or
earlier for women with three or more children. A rela-
tively ineffective paper-based system of 5-yearly recall
was in place but most screening was opportunistic, ma-
inly in young women, and quality control was poor. Inci-
dence per 100,000 total female population remained al-
most steady at 15.0 to 16.0 throughout the 1970s and
1980s when UK rates were the highest in Europe. How-
ever, there was a striking change in the pattern of disease
during those decades3. Although overall numbers of can-
cers changed little during a 10-year period there was a
nearly 3-fold increase in rates of deaths, invasive can-
cers, registrations of carcinoma in situ and high-grade
cytological abnormalities in women born since the mid-
-1940s almost certainly because of the greater sexual
freedom allowed by the availability of reliable contra-
ception4. Screening coverage was poorly documented un-
til 1990 but was lower in older (over age 40) than youn-
ger women. National registrations of carcinoma in situ,
which include cervical intraepithelial neoplasia (CIN)
grade 3 since 1983, provide evidence that many young
women were effectively screened, albeit opportunisti-
cally: the number of registrations of carcinoma in situ
had already overtaken those of invasive cancer as early
as 1981 (Figure 1 and 2). Shortly before the introduction
of organised screening in 1988 incidence of invasive can-
cer had started to rise, reaching a maximum 17.4 in
1988: the age distribution reflects the increased risk in
younger women (Figure 3). It was recognised at the time
that quality control was poor5.
The organised programme aimed to improve all as-
pects of quality control as well as setting up a centralised
register to invite all eligible women aged 20–64 at least
every five years. Incidence fell steadily during the 1990s
to a figure fluctuating between 8.0 and 9.0 since 2001.
Mortality rates declined from 1988 in all birth cohorts
(from 1922) screened at least once in the new programme
but declined earlier in life for women first screened when
they were younger (the latest in the study were born in
1952) in whom the death rate was substantially lower
throughout life6. This evidence is supported by the obser-
vation that high-grade cervical intraepithelial neoplasia
(CIN) is predominantly treated in young women: more
than 80% of CIN3 was found in women aged less than 40
before, during and after the introduction of organised
screening (Figure 4). There has been some concern about
a recent decision in the UK no longer to invite women
aged 20–24 for screening7, which was based on results of
a national audit8 and is consistent with EU guidelines1.
However, a recent study in Iceland showed the benefit of
lowering the age limit to include women aged 20–249,
which is in accordance with recommendations in the
USA (www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr).
The NHSCSP is facing a new challenge since a fall in
screening coverage has been recorded in young women,
particularly those aged 25–29 in whom the highest preva-
lence of CIN3 is recorded. The reasons for the fall in cover-
age have yet to be established but the evidence suggests a
need to encourage young women to be screened even
though there is debate about the age of the first invitation.
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Fig. 1. Registration of invasive and in situ carcinoma of the uterine
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Fig. 2. Registration of invasive and in situ carcinoma of the uterine
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Quality Control of all Aspects of
the Screening Programme
The European guidelines emphasise the importance
of quality control of all aspects of the screening pro-
gramme1. Invitations for screening should be clear but
informative, smear-takers should receive training and
should be able to explain the test results to women; labo-
ratories should have the infrastructure required for a
high-quality service in terms of accommodation, equip-
ment, adequate numbers and levels of non-medical and
clerical staff, availability of training and update, infor-
mation technology and medical supervision; colposcopy
clinics should similarly be equipped, staffed, trained, su-
pervised and monitored; and terminology should at least
be translatable into nationally recognised systems. The
NHSCSP also addresses all aspects of the programme,
providing evidence-based guidelines and monitoring per-
formance through regional quality assurance reference
centres (QARCs). A centralised computer-based register
of screening records is essential and ideally should in-
clude histology and colposcopy records and should be
linked to regional and national cancer incidence and
mortality registries.
Quality Control in the Laboratory
The mechanisms of laboratory quality control will be
considered with respect to the interlinked functions of
primary screening, final cytology reports and comparison
with outcome. At each level accuracy depends on the sub-
sequent as much as the previous step and the final out-
come itself depends on the accuracy of the histology re-
port, which should not be regarded as a »gold-standard«
unless it is also subjected to audit and quality control.
Quality control of primary screening
Accurate primary screening is central to the cervical
screening process and its quality control is essential. One
of the strengths and weaknesses of cervical cytology
screening is the ease with which the glass slide may be
reviewed, often with the benefit of hindsight, and meth-
ods of quality control should recognise that no test will
be perfect10,11. The most powerful methods of primary
screening quality control involve re-screening the slides
before the reports are issued, thus reducing false nega-
tive rates at the same time as monitoring individual and
laboratory performance. Rapid re-screening of all nega-
tive and inadequate smears (or liquid-based slides) has
been shown to be an effective method of minimising false
negative results12. Rapid pre-screening may be even more
effective13 and both methods are recommended in the
European guidelines. Both are preferable to proportional
re-screening of 10% of negative slides or targeted re-
-screening of supposedly high-risk cases. Where rapid
re-screening or pre-screening is in place, as in the UK, it
may be possible to avoid targeted re-screening altogether.
It should be recognised that either method may fail to de-
tect the very abnormalities that are so easily missed:
slides with small numbers of abnormal cells as well as
pale and small cell dyskaryosis have been shown to be »at
risk« for not being detected at primary screening of con-
ventional smears14,15 and small numbers of abnormal
cells may equally well be missed in liquid-based cyto-
logy16. Sensitivity of primary screening for the individual
and laboratory may be calculated against the final report
after the second screen has taken place and should be
calculated for high-grade cytology alone and for all ab-
normalities. It may be helpful to calculate the »detection
rates« of the final report as part of a performance profile
for each screener17. Performance profiles should be moni-
tored confidentially and sensitively, expectations should
not be too high, and procedures to deal with genuine poor
performance should be agreed in advance.
Pathologists’ and laboratory reporting rates
Apparent sensitivity of primary screening may be in-
fluenced by the accuracy of the final report. A pathologist
with an inappropriately low threshold for reporting atyp-
ical or borderline changes may spuriously reduce the sen-
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Fig 3. Incidence of invasive cervical cancer in England in 2001
(Source: www.statistics.gov.uk/statbase), and England & Wales
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5-year age group
Total registrations(n) in each year
Fig. 4. Registrations of carcinoma in situ, England and Wales
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sitivity of the screener. Conversely it is possible for a pa-
thologist to override a screener’s opinion and report a
genuine abnormality as reactive or benign. Pathologists
and laboratory performance may be monitored by com-
paring reporting rates of high-grade and low-grade cytol-
ogy results between observers and between laboratories,
which can improve consistency18. Comparison of high-
-grade reporting rates is used for laboratory quality con-
trol in the NHSCSP and achievable ranges are set each
year based on the 10th and 90th percentiles of national re-
porting rates (www.cancerscreening.nhs.uk/cervical/sta-
tistics). Rates are monitored internally by laboratory
staff, externally by QARCs and are published nationally
each year. While the low limit of high-grade cytology
rates provides a surrogate for sensitivity, the high limit of
low-grade cytology reflects specificity.
Positive predictive value
Positive predictive value (PPV) provides a convenient
measure of accuracy of high-grade cytology reports and
may be regarded as a surrogate for specificity. In the UK
PPV is measured as the percentage of high-grade cytol-
ogy results that are confirmed by at least CIN2 on biopsy
(using cases with known colposcopy outcome as the de-
nominator). Thus PPV may be influenced by the »mov-
ing target« of the histological distinction between CIN1
and CIN2 and by the sensitivity of detection of high-
-grade cytology: high PPVs may be seen with low detec-
tion rates of high-grade cytology. In the UK an achievable
range of PPV is monitored rather than a lower limit only.
Sensitivity of the test is more difficult to measure as
women with negative cytology are seldom referred for
colpsocopy. The rate at which referrals for persistent
low-grade cytology or less are found to have at least CIN3
may be used as a surrogate for sensitivity and provides a
useful balance for PPV (www.cancerscreening.nhs.uk/
cervical/statistics).
Quality control of histology
Because of its central role in the screening process, cy-
tology reporting has been subjected to far more intense
quality control than histology reporting although the lat-
ter forms the basis for decisions about treatment and
management of CIN and invasive cancer. This is stressed
in the European guidelines as well as in the UK pro-
gramme and the NHSCSP provides illustrated guidelines
for reporting cervical biopsies19. It is more difficult to
monitor reporting rates in histology because of the ab-
sence of a population baseline. Nevertheless, quality is
greatly be improved by colposcopic biopsies being re-
ported by specialist teams and slides being reviewed and
presented along with the cytology at multidisciplinary
meetings. Immunohistochemistry is more readily appli-
cable to histology than cytology and difficult distinctions
between low-grade and high-grade CIN may be aug-
mented by Ki67 and P16ink4a staining20. CIN reflects a
continuous spectrum of precancerous changes carrying
an increasing risk of progression so there will always be
inter-observer variation about the dividing lines between
HPV infection and CIN1, between CIN1 and CIN2 and
between CIN2 and CIN3. CIN3 has been shown to be the
most robust of these diagnoses21 and for this reason the
EU guidelines are justified in maintaining the CIN clas-
sification for histological diagnosis although decisions for
treatment are usually made at the level of CIN2.
Principles of laboratory quality control
Quality control should be a continuous process involv-
ing correlation of all parameters and taking account of
the nature of the spectrum of CIN. It requires good re-
cord-keeping and communication – both personal and
electronic – at all stages of the process. Communication
is greatly improved by standardising terminology, which
is naturally more difficult with so many different lan-
guages in use across Europe. The EU guidelines have
solved this problem by recognising that all terminologies
should be locally agreed and should at least be translat-
able into the Bethesda system (Figure 5), which is widely
used throughout the world22. TBS is recommended for
cytology, for which it was originally developed, and the
CIN system is retained for histology.
Testing and Introducing New Technology
The European guidelines are being published at a
time of greatest change since the Pap smear was intro-
duced as a screening test more than 60 years ago. Labo-
ratories, gynaecologists, politicians and women have been
A. Herbert: Quality Control is the Hallmark of Effective Screening, Coll. Antropol. 31 (2007) Suppl. 2: 41–46
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placed under enormous pressure to introduce expensive
new technology including LBC, hrHPV testing and auto-
mated screening. Technology is gradually converting a
simple inexpensive test into a highly complex and much
more costly multi-step process. Whether this new tech-
nology has saved any lives has yet to be determined23.
LBC was introduced throughout the UK after implemen-
tation at pilot sites in Scotland, Wales and three screen-
ing centres in England. The report recommending its im-
plementation made the guarded statement that »overall
sensitivity was at least as good as, and may be better
than, the Pap smear« 24. The main advantage in the UK
was the striking fall in the pilot sites in rates of inade-
quate tests, which were higher with Pap smears com-
pared with elsewhere in the world. There are several ca-
veats to this dramatic decline in rates of inadequate
tests25. Firstly, as NICE pointed out, »there is no way of
verifying that a sufficient number of cervical cells have
been harvested by the smear taker«24. Secondly, all non-
-normal rates are higher in the UK, with 3–5 yearly
screening than in places with annual screening because
there are fewer negative tests. Thirdly, »quality indicator
comments« about poor cellularity, lack of transformation
zone sampling and inflammatory exudate, which are al-
lowed with the Bethesda system22, are not allowed in the
UK. Furthermore, litigation is relatively common in the
UK and cytologists are aware that inadequate smears in-
appropriately reported as negative have been sited as
reasons for »false negative« cytology preceding invasive
cancer26. A multi-centre study has been funded by the
Health Technology Assessment programme to develop
criteria for LBC adequacy appropriate for a 3–5 year
programme. The European guidelines recognise that cri-
teria may be different for organised programmes with re-
stricted intervals and age ranges for screening and, while
regarding LBC as an acceptable method of cell collection,
have not recommended it in place of conventional cytol-
ogy in the absence of a randomised clinical trial to dem-
onstrate its superiority1.
One of the main advantages of LBC is that it facili-
tates hrHPV testing using residual material in the vial.
Some would say that hrHPV testing could replace cytol-
ogy for primary screening27 but this would probably only
be feasible for women over 35 because of high prevalence
of hrHPV in younger women. hrHPV testing is develop-
ing a firmer place in the triage of women with borderline
or atypical cytology almost half of whom may not need
investigation or frequent surveillance28,29. Similarly it is
likely to have an important role in follow-up after treat-
ment of high-grade CIN when the minority of women
with persistent hrHPV could be monitored more closely,
while the majority could be returned to routine screen-
ing. Essentially, hrHPV is the one development that has
the potential to increase specificity of the test by reduc-
ing the number of women investigated for borderline and
ASCUS smears.
HPV vaccination is the one new development that
may fundamentally change cervical cancer screening and
is the subject of a supplement in the European guidelines
and as a separate publication30. Suffice it to say here that
vaccination will not remove the necessity to screen the
current generation of women, including women who are
vaccinated in adult life. Falling rates of abnormal cytol-
ogy in vaccinated women coupled with a false sense of se-
curity might present additional challenges to screening
programmes. There will be even more need to maintain
quality control and high sensitivity of the test – to the ex-
tent that hrHPV testing might be needed as a primary
investigation. There is no doubt that vaccination will
radically affect screening programmes worldwide but lit-
tle is yet known of its likely uptake and even the duration
of protection provided.
Invasive Cancer Audit and its Role
in Quality Control
The ultimate audit of cervical screening lies in moni-
toring invasive cancer incidence and mortality but, as in-
dicated above, these rates should be assessed in relation
to levels of high-grade CIN or CIN3 successfully detected
– both as a measure of effectiveness of screening and of
risk of disease. Invasive cancer rates are likely to be low
in local screening centres and are therefore inappropri-
ate as a local guide of effectiveness. However, audit of
mode of presentation, stage of cancer and screening his-
tory provides a valuable method of monitoring local, re-
gional and national screening programmes. Screening
histories identify areas where screening processes may
be improved – not only with respect to screening and re-
porting the slides. There are multiple factors that may
lead to cancers not being prevented in screened women:
screening may have been intermittent or infrequent, ab-
normalities may have been missed on slides, samples may
have been inadequate, low-grade abnormalities may have
been under-interpreted or not followed up, high-grade ab-
normalities may have been reported but not investigated
and treatment of CIN may have been incomplete or not
followed up31. Isolated reasons or combinations of those
reasons may be implicated in an individual case and bear
witness to the effectiveness of the screening process itself
if correctly and accurately conducted. In well-screened
populations such as the UK it has proved to be easier to
prevent invasive cancer in older age groups8, presumably
because there are more screening opportunities to detect
a lesion that does not progress to invasion until later in
life. Although cancers in young women are more difficult
to prevent, and must have arisen in more aggressive le-
sions, they are frequently detected by positive cytology in
asymptomatic women. These screen-detected cancers are
almost invariably diagnosed at stage 1 (either 1A or 1B)
and present a benefit of screening that provides a benefit
in terms of survival that is not evident from incidence
rates32.
Conclusion
Experience of introducing a highly effective national
screening programme in the UK, in a partially screened
population during a period of increasing risk of disease,
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may provide lessons to other countries introducing na-
tional programmes in the inevitable background of op-
portunistic screening. Auditing screening histories of the
unfortunate few women who develop invasive cancer in
well-screened populations may identify processes that
could be improved. The latest European guidelines for
quality assurance are being published as a time of enor-
mous changes in technology and provide evidence-based
advice to all of us, whether maintaining existing pro-
grammes or starting new ones, to help us navigate those
changes in a cost-effective manner that carries cervical
cancer control forward into the 21st century.
A. Herbert: Quality Control is the Hallmark of Effective Screening, Coll. Antropol. 31 (2007) Suppl. 2: 41–46
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PROBIR RAKA VRATA MATERNICE U UJEDINJENOM KRALJEVSTVU I LABORATORIJSKA
KONTROLA KVALITETE U KONTEKSTU VODI^A EU 2007
S A @ E T A K
Prvi dio ~lanka }e dati osvrt na probir raka vrata maternice u UK za godine prije, za vrijeme i nakon uvo|enja vrlo
uspje{nog organiziranog programa probira raka vrata maternice 1988. g., od kada je stopa pojavnosti invazivnog raka
vrata maternice pala za vi{e od 40%. Organizirani probir je uveden u sjeni oportunisti~kog probira sa lo{om kvalitetom
kontrole u vremenu kada je rizik za bolest rastao, na {to }e ukazati nacionalni registri za rak vrata maternice in situ te
za invazivni karcinom. Program jo{ nailazi na nove izazove, a nedavno je zabilje`io pad u pokrivenosti mla|ih `ena,
uzrok ~ega jo{ mora biti utvr|en. Teku}inska citologija je u procesu uspostave na nacionalnoj razini, ali testiranje na
visokorizi~ne humane papilomaviruse jo{ mora biti uvedeno u program Nacionalnog zdravstvenog sustava (NHS – Na-
tional Health Service). Lekcije iz na{eg iskustva bi mogle biti od zna~aja zemljama koje uvode ili provode organizirane
programe probira pod sli~nim okolnostima. Drugi dio ~lanka }e se baviti laboratorijskom kontrolom kvalitete na na~in
kako se provodi u UK te kako je to preporu~eno u drugom izdanju »Europskog vodi~a za osiguranje kvalitete u probiru
raka vrata maternice«. Ovakvi vodi~i pru`aju preporuke za organiziranje i pra}enje kontrole kvalitete, kao i za uvo-
|enje novih metoda te standardiziranja terminologije, {to je jednako va`no za nove i postoje}e programe. Ispitivanje
invazivnog karcinoma bi moglo ukazati na podru~ja gdje bi postupci mogli biti pobolj{ani bez obzira na vrstu programa,
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A B S T R A C T
This presentation highlights strengths and weaknesses of cervical cytology screening in Croatia, with particular ref-
erence to the opportunistic screening, the use of conventional Papanicolaou (Pap) test and the analysis of some organiza-
tional, educational and performance issues that are associated with it. Its aim is to propose measures to improve the effi-
cacy of cervical cytology screening in order to reduce cervical cancer mortality. Currently, in excess of 450,000 Pap tests/
year are examined at 35 laboratories scattered throughout the country. All of these laboratories use standard operating
procedures including internal and external quality control. They employ a total of 68 cytologists and 91 cytotechno-
logists. The sensitivity of cervical screening in Croatia is 90.0%, specificity 98.6%, positive predictive value 92.3%, nega-
tive predictive value 98.1% and overall diagnostic accuracy 97.2%. The high diagnostic accuracy of cervical cytology is
attributed to the long-standing tradition of education and training of cytologists (postgraduate MSc course since 1967,
independent residency since 1974) and cytotechnologists (since 1968). This tradition spanning more than half a century
means that today in Croatia there is a developed network of cytology laboratories staffed by highly competent cytologists
and trained cytotechnologists. The high accuracy of cancer detection through Pap tests provides strong evidence in sup-
port of cervical cytology screening remaining the basic method of prevention for cervical carcinoma. However, some modi-
fications to the current situation are needed. These relate primarily to opportunistic screening. The current screening
coverage rate is 68%, although there is capacity, which would allow for all women at risk, i.e. those aged 25–64, to be
screened once in three years. The screening coverage relates mainly to those women visiting gynecological out patient
clinics for unrelated conditions. A properly organized and controlled national screening programme should replace this.
This should be accompanied by the introduction of alternative, highly sensitive methods of sample collection and prepa-
ration, such as are available through the introduction of new technologies, e.g. liquid based cytology.
Key words: Pap test, cervical carcinoma, cervical screening programme, Croatia
Introduction
Cytological diagnosis of conventional cervicovaginal
smear or Pap test is one of the most efficient screening
tests known to date, which has been credited with the
significant decline in the incidence and mortality of uter-
ine carcinoma all over the world. In Croatia, it has been
used as the main method of secondary prevention of
uterine carcinoma for more than half a century now, be-
ing at the same time employed as a classic screening test
for lesion detection and as a differential diagnosis me-
thod predicting histological diagnosis. The rate of cervical
carcinoma in Croatia, directly resulting from the large-
scale use of Pap test, reflects the indisputable value of
the method, while also pointing to some shortcomings.
The current state of cervical cytology in Croatia is
presented. In addition to its achievement, the aim was to
identify the weaknesses, such as opportunistic screening,
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the use of conventional Pap test and analysis of the orga-
nizational, educational and performance issues with the
aim to propose measures to upgrade the efficacy of cervi-
cal screening.
The History of Gynecological Cytology
in Croatia
In Croatia, as in the rest of Europe, gynecologists
were the first to perform microscopic analysis of cervical
cytological specimens. The first laboratory headed by E.
Bar{i}, a gynecologist, was established in 1953 at Univer-
sity Department of Gynecology, School of Medicine, Uni-
versity of Zagreb, now University Department of Gyne-
cology and Obstetrics, Zagreb University Hospital Center.
Jasna Ivi}, MD was the first to devote exclusively to
gynecological cytology since 1959. In 1968, she was ap-
pointed Head of the Laboratory of Cytology, which devel-
oped into Institute of Gynecological Cytology in 1984;
Jasna Ivi} organized cytology service in line with the
principles adopted worldwide, and is most credited for
the progress of cervical cytology in Croatia1–3. During the
past fifty years, Institute of Gynecological Cytology in
collaboration with other institutions, Department of Cy-
tology and Clinical Genetics, University Department of
Gynecology and Obstetrics, Merkur University Hospital
in particular, has stimulated continuous development of
gynecological cytology in the professional, scientific and
educational aspects in Croatia, while promoting due rec-
ognition of the Croatian gynecological cytology abroad.
At the beginning of the third millennium, these efforts
have also been intensified at Department of Gyneco-
logical Cytology, University Department of Gynecology
and Obstetrics, Rijeka University Hospital Center and
Department of Clinical Cytology, Osijek University Hos-
pital, which also became the leading laboratories in the
field in Croatia.
The key events in the development of clinical cytology
in Croatia are mentioned in Table 1, for which merit goes
to many professionals1, amongst others: Professor Ante
Zimolo, Professor Erik Hauptmann, Professor Inga ^re-
pinko, and already mentioned Professor Jasna Ivi}.
Specialist Education of Cytologists
and Cytotechnologists
The 1967–1974 period characterized by the establish-
ment of organized education of cytotechnologists (con-
tinuing education course for cytotechnologists in 1968)
and cytologists (Postgraduate Study in Medical Cytology
in 1967 and respective residency in 1974, both subse-
quently renamed as Clinical Cytology). Both played a key
role in the development of diagnostic as well as gyneco-
logic cytology in Croatia.
The Postgraduate Study in Medical Cytology was es-
tablished at the Zagreb University School of Medicine in
1967, with 31 courses attended by 397 postgraduate stu-
dents held until 2006. The study underwent two revi-
sions, first in 1996 with the introduction of professional
studies, and second in 2005 as residency study.
In 1974, independent residency in Medical Cytology,
subsequently renamed as Clinical Cytology, was intro-
duced. Initially, residency took three years (pathology
one year and cytology two years, with postgraduate study
as a form of organized education). Twenty years later, it
grew into four-year residency (pathology one year and
cytology three years, also with two terms of postgraduate
study), within the frame of general revision of residency
curricula in Croatia. The introduction of independent
residency resulted in appropriate education of these pro-
fessionals, qualified to meet the very demanding chal-
lenges posed by the profession.
In the process of approaching the European Union,
the phase of adjustment of education in clinical morphol-
ogy professions of cytology, pathology and forensic medi-
cine has begun, resulting in a new proposal of residency
in all three until now independent professions.
The education of cytotechnologists is an important
part of education in cytology. Professor Inga ^repinko or-
ganized the first course of additional education of medical
technicians for cytology technicians. During the 1968–
M. Pajtler et al.: Cervical Cytology Screening in Croatia, Coll. Antropol. 31 (2007) Suppl. 2: 47–54
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Postgraduate Study in Medical Cytology, later Clinical Cytology at the School of Medicine of the University of Zagreb
Continuing education course for cytotechnologists at the Medical College of Zagreb
Section of Cytology and Cytological Diagnosis established at the Croatian Medical Association (CMA), to be later
renamed as the Croatian Society of Clinical Cytology of the CMA
Later, continuing education courses for the cytologists, cytology technicians, gynecologists, etc., organized by
the Croatian Society of Clinical Cytology of the CMA and Zagreb University School of Medicine
Residency in Medical Cytology, later Clinical Cytology, as independent residency regulated by the Ministry of Health
and Social Welfare of the Republic of Croatia
Fifth grade qualification – laboratory technician at the Medical College, Zagreb
Continuing education for cytotechnologists at the Ministry of Health and Social Welfare of the Republic of Croatia
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1977 period, the education of cytotechnologists was per-
formed in the form of six-month course upon completion
of medical technician high school education at Medical
College in Zagreb. One-year programme in the form of
fifth grade education was offered from 1981 to 1992 at
the same College; however, the status of thus trained
professionals was not properly solved. The pursuit for
continuing, complete and officially recognized education
led to the development of two-year programme, initially
delivered at the Medical College. The program was veri-
fied by the Medical College and the School of Medicine
(at the time, College was part of the School of Medicine);
however, it has not yet been performed in practice.
Since 2000, sixty cytotechnologists have received edu-
cation at three courses organized by the Ministry of
Health and Social Welfare of the Republic of Croatia, in
collaboration with the Croatian Society of Clinical Cytol-
ogy of the Croatian Medical Association (CMA), and held
by Assist. Professor @eljka Znidar~i}, having thus at least
in part mitigated the worrying shortage of these ex-
tremely important team members.
The one-year course consisted of 630 periods of practi-
cal and theoretical education in all fields of cytology diag-
nosis with 200 periods of education in particular cytology
services. Adjustment to the Bologna Process has opened
new options for cytotechnologists at the Medical College;
harmonization of the new form and curriculum of their
education has just been under way.
Current Organization, Medical Staff
and Number of Cytological Analyses
Presentation of the current structure in terms of orga-
nization, staff profile and number of Pap tests performed
is based on a survey performed by the Croatian Society of
Clinical Cytology of the CMA in 2003 and 2005.
According to the above survey, gynecological cytology
is performed at 35 of 48 (73%) organizational units.
Twenty-seven of these are at state-owned health institu-
tions (25 at hospitals and 2 at health centres) and eight
in private offices (6 specialist practices and 2 at private
polyclinics). Of the twenty-five hospital units, eight are
organized as independent departments and seventeen
are combined with other professions, i.e. fourteen within
pathology, two at the University Departments of Gyne-
cology and Obstetrics, and one at the Department of Lab-
oratory Diagnosis. Eight cytology laboratories are pre-
dominantly engaged in gynecological cytology, whereas
the remaining 27 laboratories are equally dealing with
general diagnostic by cytology and gynecologic cytology.
Two private cytology laboratories were excluded from
analysis because their heads failed to submit current
data, and one hospital laboratory was excluded due to the
very low proportion of Pap tests in their overall perfor-
mance; thus, data on 32 units are presented (Figure 1).
Sixty-two professionals with university education
(not including residents), i.e. 58 clinical cytologists, two
pathologists, one anaesthesiologist and one graduated bi-
ologist, along with 91 cytotechnologists, and 43 techni-
cal, administrative and auxiliary staff members are em-
ployed in 32 cytology laboratories. The cytologists to
cytotechnologist to other personnel ratio is 1:1.4:0.6. An
ideal screening team would consist of one cytologist, two
cytotechnologists and one laboratory technician; accord-
ingly, the majority of cytology teams in Croatia are in
part incomplete.
A total of 574,290 cervical smears were taken in 2005
in a whole country, of which 452,809 (79%) Pap tests
were successfully performed. The proportion of Pap tests
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Fig. 1. Number of Pap tests per cytologists/cytology team at 32 cytology units in Croatia in 2005.
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out of the total number of tests varied from 59% to 100%
in different counties. Forty-nine cytologists and seventy-
one cytotechnologists performed these Pap tests. Com-
parison of the number of Pap tests and number of cytolo-
gists and cytotechnologists engaged in their performance
showed that one cytologist with the respective team have
performed a mean of 9,241 Pap tests, whereas one cyto-
technologist examined a mean of 6,378 Pap smears (ap-
proximately 28 per day!). The laboratories included in
the analysis varied greatly according to the number of
tests performed, Pap test in particular (Figure 1). The
number of Pap tests per cytologists/cytology team ranged
from 2000 to 16,000, and per cytotechnologist from 3300
to 10,000.
The highly uneven pattern of performance recorded
in the cytology service across Croatia according to orga-
nizational unit and localization, number and profile of
professional staff, and number of tests per team per-
formed imposes the need of developing distinct legal reg-
ulations to standardize the mode of organization, loca-
tion, staff structure and performance standards in the
field of cytological diagnosis, consistent with the respec-
tive catchments population. Taking into account more
than 30 years of residency in clinical cytology, it is not
justifiable that cytology testing is performed by anyone
but physicians-cytologists.
Overall, the high number of specialists in cytology
and properly educated cytotechnologists, and the num-
ber of Pap tests performed (n=452,809) offer a capacity
adequate to cover the female population at risk aged
25–64, if screened once in three years. According to the
2001 census, there were 1,178,052 women of these age
groups in Croatia4; thus, screening per year should cover
392,684 women.
»Zagreb 2002« Uniform Classification
of Uterine Cervix Cytological Findings
in Croatia
In Croatia, a uniform classification named »Zagreb
2002«5, a modification of »Zagreb 1990«6 and »NCI Be-
thesda System 2001«7, has been used in cytological anal-
ysis of cervical smears. Two groups of »satisfactory« and
»unsatisfactory« (explaining the reason for the latter)
are used on assessment of specimen adequacy. According
to general classification, findings are categorized as »ne-
gative for intraepithelial or invasive lesion« (normal
finding, changes with reactive and reparatory reactions,
a finding suggesting certain risk) and »abnormal cells«
(cellular changes that are morphologically consistent with
intraepithelial or invasive malignant lesions).
Descriptive diagnosis includes the items »microorgan-
isms« (listing the microorganisms that can be identified
directly or based on the specific cytopathic effect), »other
non-neoplastic findings«, and »abnormal cells« (squa-
mous, glandular, of undetermined significance, and other
malignant neoplasms). The group of »other non-neoplastic
findings« that may be found with or without abnormal
cells includes reactive cell changes, reparatory epitheli-
um, spare cells, parakeratosis, dyskeratosis, hyperkera-
tosis, a post-hysterectomy finding of cylindrical cells, a
finding of endometrial cells beyond the cycle or in meno-
pause, and a conclusion that the cytohormonal status
does not correspond to the patient’s age and/or history.
Squamous lesions are divided into three groups, as
follows: »atypical squamous cells« (ASC), »squamous in-
traepithelial lesion« (SIL), and »squamous cell carcino-
ma«. The ASC group is further subdivided into »undeter-
mined significance« (ASC-US), »high-grade SIL cannot
be excluded« (ASC-H), and »invasion cannot be exclu-
ded«. Considering SIL group, all three terms currently in
use have been retained, with the addition of »invasion
cannot be excluded«. This parallel terminology (dyspla-
sia – CIS, cervical intraepithelial neoplasia – CIN and
SIL) has been retained to avoid diagnostic-therapeutic
identification of moderate dysplasia (CIN 2) with severe
dysplasia and carcinoma in situ (CIN 3), thus leaving an
opportunity for cytological and colposcopical follow- up
of the lesion up to its regression or progression.
Glandular lesions are also classified into three groups,
as follows: »atypical glandular cells« (three subgroups:
probably reactive, probably intraepithelial, and probably
invasive), »adenocarcinoma in situ« (AIS), and »adeno-
carcinoma«, with a note on its origin.
The groups of »abnormal cells of undetermined signif-
icance« and of »other malignant neoplasms« refer to ab-
normalities where differential cytological diagnosis can-
not be established.
This uniform classification enables both internal and
external quality control of the laboratory performance,
along with appropriate reproducibility of cervical cytol-
ogy relative to the terminology adopted in the world.
Methods of Quality Assurance in
Cervical Cytology
All laboratories have been structured in line with the
standard work protocols, to include internal and external
quality control8–11.
Internal quality control of laboratory performance in-
cludes the following:
a) control of material sampling,
b) control of technical processing (preparation) and smear
staining,
c) primary screening using the following methodology8,10:
• selected pre-screening – refers to pre-screening of
cervical smears in patients with particular clinical
entities such as abnormal bleeding, clinically sus-
pect cervix, etc. In this case, all slides should be ob-
served as having evidence for abnormality, i.e. they
should be examined twice by a cytotechnologist and
also by a cytologist if some abnormality has been
demonstrated;
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• double screening – it is a reliable method of internal
control, ensuring continuous caution on test perfor-
mance. It is used in all diagnostical specimens;
• proportional re-screening – so-called random scre-
ening of some 10% of negative specimens;
• rapid screening – it includes re-screening of all neg-
ative and inadequate smears by use of the known
rapid screening technique, performed by cytotech-
nologists that have not previously analyzed the re-
spective specimens12;
• previous cytology review – it is performed when
high-grade dyskaryosis/dysplasia is found in cyto-
logical specimen, and previous cytology was nega-
tive or has been inadequate for 5-years back, when
carcinoma or high-grade CIN is histopathologically
diagnosed following negative cytology, and when cy-
tological finding is negative following previous cyto-
logical abnormalities;
d) slides and findings are stored for at least 10 years;
e) result analysis by daily cyto-histological correlation of
findings; and
f) continuing education.
External quality control implies control of perfor-
mance of a number of cytology laboratories by a commis-
sion consisting of the representative profession and na-
tional health authorities. The commission controls the
work of a cytological laboratory and tests skill of the
cytotechnologists and/or cytologists either by mail or by
testing organized at a previously agreed location13. Prep-
aration exchange includes several (e.g., four or five) labo-
ratories, each submitting up to 10 slides sent from one to
another laboratory for screening. Eventually, they all
meet together to discuss their results. Verification tests
make an alternative method of external quality control,
where 10 slides are analyzed within 2 hours; all slides in-
cluded in cervical carcinoma screening can be analy-
zed8,10.
The Value of Opportunistic Screening
by Conventional Pap Test
The efficacy of conventional Pap test in opportunistic
screening is assessed on the basis of its detection and dif-
ferential diagnostic value, and population coverage. In
addition to accurate Pap test may also produce inaccu-
rate diagnosis, i.e. false negative or false positive results.
A false negative finding may be due to insufficient sam-
pling, inappropriate laboratory processing, screening
failure, or erroneous evaluation of the cells present in the
respective smear. A false positive cytology finding is by
definition a positive cytology finding in a woman free
from cervical lesion. It also includes erroneous interpre-
tation as well as so-called falsely false positive findings,
referring to a positive cytology finding in a patient with
cervical lesion but negative biopsy finding. The propor-
tion of cytological screening error can be defined as the
number of false negative findings in the total number of
cytology smears analyzed over a period of observation,
yielding a very low error rate, or as the number of false
negative findings in the total number of women with cer-
vical lesion, which yields a much greater error percent-
age. As about 95% of smears negative for CIN lesions, the
value of cytological screening lies in the possibility of de-
tecting those 5% of specimens that are abnormal; thus,
the error proportion may be expressed also as the number
of false negative findings out of the total number of wo-
men with cervical lesion. When thus expressed, the rate
of false negative findings varies from nil to 29.7%14–27.
The measures of cervical cytology appropriateness as
a screening test are its sensitivity, specificity, predictive
values, and diagnostic accuracy. In case of cervical cytol-
ogy, sensitivity is the rate of positive cytology findings in
a group of women with intraepithelial or invasive cervi-
cal lesion, ranging from 30 to 87%28. Specificity is the
rate of negative cytology findings in a group of women
free from intraepithelial or invasive cervical lesion, vary-
ing from 86 to 100%28. Sensitivity and specificity are not
independent measures. An increase in sensitivity with a
seemingly decreased rate of false negative findings may
be accompanied by an increase in the number of false
positive findings, and vice versa. The relationship be-
tween sensitivity and specificity is best illustrated by
predictive values.
Positive predictive value (PPV) is a measure of proba-
bility that an individual with positive finding is ill. In cer-
vical cytology, it is a useful measure of finding accuracy
in case of lesions that require additional diagnostic pro-
cedures. On determining PPV, the time to histologic veri-
fication should be limited to a maximum of six months. In
case of a longer period, the inconsistency between his-
tological and cytological diagnoses resulting in a low PPV
may be due to lesion regression rather than inaccurate
cytological finding. Negative predictive value (NPV) is a
measure of probability that an individual with negative
finding is healthy.
In a study conducted in Croatia to estimate the reli-
ability of conventional Pap smear in the screening for
both low and high grade intraepithelial cervical lesions
and early invasive cervical cancer29,30, the rate of false
negative findings was 10%, of which screening error ac-
counted for 3.1% and sampling error for the rest of 6.9%.
The rate of false positive findings was 1.4%, of which er-
roneous smear interpretation accounted for 0.6%, and SIL
detected on follow-up and/or repeat biopsy for the rest of
0.8%, switching the categorization of these cases from
»cytologically false positive« to »histologically false nega-
tive« due to error on collecting biopsy specimens. The
sensitivity was 90.0%, specificity 98.6%, PPV 92.3%,
NPV 98.1%, and overall diagnostic accuracy 97.2%.
The main objection to conventional cytology as a
screening test refers to its low sensitivity. However, the
rate of false negative findings can be considerably re-
duced by strictly following professional rules, primarily
careful sampling and smear preparation, fixation and
processing through thorough screening and professional
interpretation, thus upgrading the test sensitivity.
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Conventional Pap test is not only used as a classical
screening test for lesion detection but also as a differen-
tial diagnostic method predicting histological diagnosis.
It is of great importance because the type and severity of
the lesion detected will dictate further diagnostic and
therapeutic procedure. Differential cytology of squamous
intraepithelial lesions, distinguishing three grades of dys-
plasia and carcinoma in situ, has a total sensitivity of
67%, specificity of 87%, PPV of 59%, NPV of 90%, and
overall diagnostical accuracy of 75%; diagnostic accuracy
increases with lesion severity and is directly proportional
to reproducibility of each cytological diagnosis29,31–33.
The small number of glandular intraepithelial lesions
neoplasia relative to squamous ones, and the fact that
their morphological properties have only been inten-
sively investigated and characterized in the last two de-
cades, have resulted in the lack of experience and atten-
tion in the search for these lesions in cytological smears.
Consequentially, diagnostic accuracy in recognizing ab-
normal columnar cells in cytological smears, alone or in
combination with a squamous component, is only 55%33.
The Osijek-Baranja County was taken as a represen-
tative sample to assess the risk population coverage by
opportunistic screening4. Pap smears collected at gyne-
cology clinics and hospital departments in the County
were analyzed at Department of Clinical Cytology, Osijek
University Hospital in Osijek, Croatia. Dur- ing a three-
-year period (2003–2005), 104,062 conventional Pap smears,
77,692 (74.7%) of these primary cases and 26,370 (25.3%)
duplicate cases, were examined. The number of primary
cases corresponded to the total number of women exam-
ined. The target population of women aged 25–64, that
should be examined once in three years, accounted for
60,374 (68%) Pap smears (Table 2).
Opportunistic screening covered 68% of the target
population, i.e. those spontaneously visiting gynecolo-
gical offices for reproductive age physiology/pathology,
while the total number of tests performed should have
included the entire population at risk. Study results ex-
plained the unfavourable pattern observed in the inci-
dence and mortality of cervical carcinoma in Croatia as
compared with other west and south European coun-
tries, pointing to the need of implementing the national
programme of cancer prevention and early detection,
which should include the entire population at risk34.
Liquid-Based Cytology: Alternative
Cytology Method of Higher Sensitivity
New techniques of cervical-endocervical cytology sam-
pling and processing have been developed in the last few
decades, with the introduction of liquid-based cytology
(LBC) as one of the most important achievements in the
field. In contrast to conventional Pap test, in LBC tech-
nique the specimen obtained from uterine cervix is not
applied onto the slide but the instrument is immersed in
a glass containing transport fixation liquid, where it is
thoroughly vortexed for optimal utilization of the entire
cell material35. Using conventional method, up to 80% of
the specimen is lost with the discarded instrument36–38; it
is considered to be one of the main reasons for false nega-
tive Pap tests (6–50%)39–42 and false negative findings in
women with HGSIL and invasive carcinoma (20–50%)42–44.
Cell suspension in fixation liquid is stable at room
temperature for up to several weeks38,45, and is labora-
tory processed by use of semi-automated or automated
commercial devices. Currently, a number of such devices
are available, with those approved by the United States
Food and Drug Administration (FDA) for cervical screening
being best known: ThinPrep processors (Cytic Corpora-
tion, Massachusetts, USA) and AutoCyte-Prep system
(ThiPath Imaging, Inc., North Carolina, USA). Excess
blood and inflammatory exudate is mechanically remov-
ed from suspension specimen, and a small representative
specimen is transferred and uniformly applied in thin
layer onto the slide, in a circle of 13 mm (AutoCyte-
-Prep) or 19 mm (ThinPrep) in diameter.
Most authors point to the advantages of LBC over
conventional smear, which include a reduced rate of in-
adequate samples35,46–48 (by even up to 97%)47 and of
false negative findings49–51, higher rate of abnormal cyto-
logy findings detected52,53, and significantly shorter time
(by up to 60%) needed for analysis of a specimen pre-
pared by the new method48. Another advantage of the
LBC method, also admitted by those who found no differ-
ence when evaluating these two methods of cervical cy-
tology sample preparation54, refers to the fact that the re-
maining cell suspension can be used for more sophi-
sticated diagnostical methods such as Human papillo-
mavirus (HPV) analysis (so- called reflex testing), thus
upgrading the screening test sensitivity and specificity,
in order to prevent unnecessary overtreatment of lesions
that would otherwise undergo spontaneous regression.
In addition, cell suspension can also be used for the diag-
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TABLE 2
NUMBER OF WOMEN AGED 25–64 IN OSIJEK-BARANJA COUNTY (2001 CENSUS) AND NUMBER OF WOMEN COVERED BY CYTOLOGY




25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64
Osijek-Baranja County 10,378 11,188 12,396 12,635 12,045 10,730 9,195 10,655 89,222
With Pap test 10,081 9,180 8,922 9,124 8,761 6,908 4,288 3,110 60,374
% of tested 97 82 72 72 75 64 47 29 68
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nosis of other sexually transmitted diseases (Chlamydia
trachomatis, gonorrhea, etc.), or molecular and cyto-
genetical methods can be employed, thus making »the
impossible possible« in the future55. The more so, the
rest of material can be used for additional preparations
for education and external quality control.
The major hindrance to the introduction of LBC tech-
nique is the high cost of its utilization in organized
screening actions. Yet, according to the report issued by
the Sheffield School of Health and Related Research
(ScHARR)48, the initially high price of the instrumenta-
tion will pay off, primarily through a reduced number of
inadequate specimens, avoiding unnecessary retesting,
and centralization of material processing at only a few
laboratories. Furthermore, the implementation of LBC
requires additional training of cytologists and cytotech-
nologists. Cytological analysis of thick layers may fre-
quently prove quite demanding, along with a lower speci-
ficity as compared with conventional Pap test56.
Conclusion
The tradition of more than half a century, the net-
work of cytology laboratories staffed with cytologists and
properly trained cytotechnologists of enviable skill and
competence, and more than 450,000 Pap tests performed
per year provide strong basis for the success of cytologi-
cal screening as the basic method of secondary preven-
tion for cervical carcinoma in Croatia. Opportunistic
screening in Croatia reflected in the substantial decrease
of cervical cancer incidence from 26 to 15 per 100,000
women-years between 1970 and 1990 remaining almost
constant till then57. However, some modifications appear
to be necessary, which primarily refers to the substitu-
tion of opportunistic screening by a properly designed,
organized and controlled national screening, as all pre-
conditions for it have been fulfilled. In addition, alterna-
tive, high sensitivity methods of sample preparation
should be introduced in the cytology service at the na-
tional level.
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CITOLO[KI PROBIR RAKA VRATA MATERNICE U HRVATSKOJ
– PRO[LOST, SADA[NJOST I BUDU]NOST
S A @ E T A K
Prikazan je segment klini~ke citologije u Hrvatskoj koji se bavi cervikalnom citologijom, kako bi se analizom organi-
zacije, izobrazbe i u~injena rada, uz objektivnu vrijednost identificirale i slabe to~ke oportunisti~kog probira konvencio-
nalnim Papa-testom, te predlo`ile mjere za postizanje njegove najve}e mogu}e u~inkovitosti u cilju smanjena smrti od
raka vrata maternice. U 35 laboratorija koji su ustrojeni u skladu sa standardnim protokolom rada uz kontinuiranu
unutarnju i vanjsku kontrolu kvalitete, u kojima je uposleno 68 specijalista citologa i 91 educirani citoskriner, pregleda
se na godinu preko 450.000 Papa testova. Iako je tim brojem mogu}e jednom u tri godine obuhvatiti sve `ene u rizi~noj
dobi od 25–64 godine, obuhvati se tek 68% onih koje se spontano javljaju ginekologu zbog fiziologije/patologije repro-
duktivne dobi. U Hrvatskoj je pouzdanost citolo{kog probira na zavidnoj razini, {to se mo`e pripisati dugoj tradiciji
sustavne izobrazbe citologa (poslijediplomski studij od 1967. i samostalna specijalizacija od 1974.) i citoskrinera (od
1968.). Osjetljivost Papa-testa je 90,0%, specifi~nost 98,6%, pozitivna prediktivna vrijednost 92,3%, negativna predikti-
vna vrijednost 98,1%, a ukupna dijagnosti~ka to~nost 97,2%. Glavna zamjerka se odnosi na nisku osjetljivost. Tradicija
du`a od pola stolje}a, razvijena mre`a citolo{kih laboratorija sa zavidnim fondom specijalista citologa i educiranih cito-
tehnologa, te broj pregledanih Papa-testova na godinu sna`an su argument mi{ljenju da citolo{ki probir u Hrvatskoj
treba ostati temeljnom metodom sekundarne prevencije raka vrata maternice. Nu`ne su pritom odre|ene promjene, u
prvom redu zamjena oportunisti~kog probira dobro osmi{ljenim, organiziranim i kontroliranim nacionalnim probirom
za koji su ispunjeni svi preduvjeti, te uvo|enje alternativnih metoda pripreme uzorka vi{e osjetljivosti.
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HPV Technologies Advancing Public Health:
Discussion of Recent Evidence
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A B S T R A C T
Effective primary and secondary cancer prevention programmes are key to improve public health. Cervical cancer is
preventable if high quality screening programmes, diagnosis and treatment are offered to female populations at high
coverage. Nevertheless, it continues to be a public health problem, and screening programmes need improvements. Hu-
man papillomavirus (HPV) has been firmely established as the necessary cause of virtually all cervical cancer cases. To
date we count two clinically validated and approved HPV technologies, available to prevent cervical cancer, and other
diseases caused by these carcinogenic viruses: Prophylactic vaccines for primary prevention, and HPV DNA tests for sec-
ondary prevention, to detect life threatening infections by carcinogenic HPV types, allowing timely diagnosis and clinical
management of precancerous lesions. The new technologies will help improve the health of the public if made widely ac-
cessible. Similar to vaccination programmes, systematic and well organized cervical screening programmes, with high
quality validated HPV tests, can save more lives than ever and improve women’s health, in an effective manner.
Key words: Human papilomavirus, screening, vaccine, cervical cancer
Introduction
Public health is the approach to medicine that is con-
cerned with the health of the community as a whole: pub-
lic health is community health. In this context, the mis-
sion of public health professionals is assuring conditions
in which people can be healthy. This can be achieved
through three key public health functions: 1) systematic
assessment and accurate monitoring of the health of
communities and populations at risk, to identify health
problems and their causes; 2) assuring access to appro-
priate and effective interventions, including health care
and disease prevention services, and evaluation of the
cost-effectiveness of such services; and 3) formulation of
public policies designed to solve identified global health
problems in a sustainable manner. These functions can
include the provision of personal health care (services at
the clinic level, district or referral hospital) or be popula-
tion-based such as immunization or screening program-
mes, and may also include legislation (guidelines, man-
datory interventions) and economic incentives such as
subsidies. Public health professionals are concerned with
planning and implementation of activities that fulfil one
of the three functions, leading to measurable outcomes
and improvements in the health of the public, within rea-
sonable time frame. Primary and secondary prevention
programmes have a synergistic effect in improving health.
Cervical cancer is the second most common cancer in
women worldwide with about half million new cases ev-
ery year1. Cervical cancer is preventable and readily
treatable, still it kills one of two women diagnosed with
cancer, and over 250 thousand women die annually. World-
wide, survival rates vary between regions with good
prognosis in some regions, e.g. 73% in the United States2,
and 63% showed in European registries3, where high
quality screening programmes have been implemented
in large scale.
The Human papillomavirus in the Root
of New Technologies for Cancer Prevention
The notion that papillomavirus infection underlies
the development of cancer of the cervix in women was
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first described in 1976 by zur Hausen4. Since then, on the
basis of a variety of scientific assessements, Human pa-
pillomaviruses (HPVs) have been firmely established as
the major cause of virtually all cancers of the uterine
cervix5. This breakthrough in knowedge of cancer etiol-
ogy led to the development of innovative technologies,
that can be used as tools to improve health care and
strategies to accelerate cervical cancer prevention. For
instance, screening to identify precancerous disease sta-
tes, that can be successfully removed without sequelae,
can save lives. Cervical screening programmes have been
recommended to targeting women after the age of 25 in
some countries, although the target age and screening
intervals can be adapted to needs and resources of differ-
ent countries.
HPVs are small DNA viruses wraped by a shell or vi-
ral capsid, composed of two structural proteins expressed
late upon viral replication, known as L1 and L2. HPVs
infect the stratified squamous epithelia of skin and mu-
cous membranes, where they may cause benign lesions,
some of which have the potential to progress to invasive
cancer. Most infections are self-limited and asymptom-
atic, presumably because the host eventually mounts a
successful immune response. There are co-factors that
increase the risk for cancer development in infected sub-
jects.
While there are over 100 different types of HPVs mo-
lecularly characterized6 about 15 types have been evalu-
ated as highly carcinogenic to humans, and two types
among those have consistently been reported as most
common in cervical cancer cases, HPV types 16 and 187.
The genome of these two common types have been iso-
lated by molecular cloning in 19838 and their cloned
DNAs served as basis for producing vaccines by biotech-
nolgy methodology, as well for molecular diagnostic tests
as described bellow.
To date we count two prominent clinically validated
and approved technologies available to prevent cervical
cancer, and some other cancers caused by these carcino-
genic viruses: 1) prophylactic vaccines against HPV the
two most common carcinogenic types, and 2) molecular
HPV DNA tests to detect life threatening infections by
carcinogenic HPV types, and to allow timely diagnosis
and clinical management of precancers. On one hand,
prophylactic HPV vaccines can prevent the infections,
and therefore the associated diseases that the infectious
viruses can cause. Because they cannot influence the
course of already established infections, vaccines may be
most beneficial if administered before any infection oc-
curs. On the other hand, HPV DNA tests can identify al-
ready existing infections and prompt to early clinical
management and treatment, as appropriate, before the
early HPV associated precancerous lesions can progres-
ses to invasive cancer. These two available technologies
are schematically illustrated in Figure 1, and will be dis-
cussed bellow. Understanding the successes and limita-
tions of new technologies will help to make best use of
them for improving the health of the public in general.
HPV Vaccine Technology for Primary
Prevention
The vaccines under consideration here are recombi-
nant protein vaccines comprising L1 proteins that self-
assembly into particles similar to empty shells of the vi-
rus, and are therefore non-infectious and non-oncoge-
nic9.
The aim of vaccination against HPV is to induce im-
munity to neutralize HPV infections and later associated
diseases and cancers. Clinical data originated in several
studies in phase 1, phase 2 and phase 3 have been
published10,11. Although the primary concern is reduction
in cervical cancer cases and deaths, the impact of vacci-
nation on surrogate markers and intermediate diseases
can be assessed sooner, and may have implications for de-
sign and implementation of effective prevention pro-
grammes. This information will also be crucial for plan-
ning succesful health policy initiatives that involve both
screening and vaccination.
Vaccines that have completed controlled efficacy stud-
ies have demonstrated high levels of efficacy against
histologically characterized high grade dysplasias associ-
ated to the viral antigen types included in the vaccines,
namely cervical intraepithelial neoplasias (CIN2-3) or
worse, following administration of a three-dose regimen
among women who had no evidence of previous infection
with HPV13.
The indications for the use of HPV vaccines in the EU
are, so far, for prevention of HPV 16/18 related cervical
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Fig. 1. FDA approved technologies for use in primary and sec-
ondary cancer prevention to date. Two health technologies have
been so far approved by the US FDA and EMEA, as well as other
regulatory authorities, for prevention of neoplasis. For Primary
prevention, a prophylactic recombinant quadrivalent vaccine,
based on proteinaceous Virus Like Particles against two low risk
HPV types, 6 and 11, and two high risk HPV types 16 and 18, is
available for administration to subjects 9–26 years of age. For
secondary prevention a screening test available as two sets of re-
agents to detect 5 low risk HPV types, and 13 high risk types, for
use in laboratory diagnosis of neoplasias at risk to progress to
cancer, and recommended for routine use on women over 30 years.
HPV – Human Papillomavirus, y.o. – years old, FDA – Food and
Drug Administration, EMEA - European Agency for the Evalua-
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cancinomas, high grade cervical dysplasias CIN2 and
CIN3, high grade vulvar dysplasias, VIN2 and VIN3, as
well as prevention of HPV 6/11 related genital warts
(condyloma acuminata), and in children and adolescents
9 through 15 years of age, and women 16 through 26 years
of age14.
One pivotal vaccine trial included over 20.000 females
13–26 years old (median age of 20) enrolled in different
geographical regions. The population for the efficacy
studies included large proportion of women in Europe
(44.1%), mostly from Nordic countries, 25.3% women in
North America, 27% in Latin America and only 3.6% in
Asia (available under Food and Drug Administration
FDA and European Agency for the Evaluation of Medic-
inal Products EMEA websites15–17). It was noted that of
the females in the trial population aged 13–26 years over-
all 12% had an abnormal baseline Pap test with squa-
mous intraepithelial lesions. The majority of these were
low grade SIL and atypical squamous cells of undeter-
mined significance (ASC-US). In addition, 27% of these
subjects had been previously exposed to one or more of
the vaccine HPV types (sero+ and/or PCR+).
Different subpopulations among the randomized fe-
males enrolled in the studies were considered for analy-
ses of efficacy (Table 1)15–17. Per-Protocol Efficacy (PPE)
included subjects who received all 3 vaccinations, were
seronegative to the appropriate HPV type(s) at day 1 and
PCR-negative to the appropriate HPV type(s) day 1 through
month 7, and generally did not deviate from protocol.
Modified Intention-To-Treat (ITT-1) analysis included
subjects who received all 3 vaccinations, were serone-
gative to the appropriate HPV type(s) at day 1 and
PCR-negative to the appropriate HPV type(s) day 1 through
month 7, and included general protocol violators. Mod-
ified ITT-3 included all subjects who received at least 1
vaccination, regardless of initial serology and PCR sta-
tus.
Per Protocol HPV type-specific analyses indicated a
very high level of efficacy in naïve subjects, while the effi-
cacy for all HPV related disease on a population basis, es-
pecially if given to many females who already have an
HPV infection, appear to be lower, as summarized in Ta-
ble 1. For subjects naïve for the relevant vaccine HPV
type(s), the measured vaccine efficacy against HPV 16
and/or 18 related CIN2/3 or worse was 100%, and for all
randomized trial population, the vaccine efficacy was
about 40%, due to the fact that about a quarter of women
had evidence of previously been infected with HPV. Note-
worthy, data was analysed in a HPV type specific man-
ner. Hence, females naïve to the four vaccine HPV types
are expected to benefit most from vaccination.
Furthermore, vaccinated subjects naïve to all four
vaccine HPV types could still develop disease related to
an HPV type not included in the vaccine. In one case sce-
nario, vaccination of naive populations shows that ap-
proximately 50% reduction in cervical cancer mortality
could be achieved by vaccination in over many years12,13.
Combination of vaccination and screening strategies are
likely to offer the most effective prevention to cervical
cancer.
HPV DNA Test Technology for
Secondary Prevention
An independent study conducted by the International
Agency for Research on Cancer (IARC), and a independ-
ent Advisory Group concluded there is sufficient evidence
that screening for cervical cancer by cytological examina-
tion of Pap smear cell samples does prevent death18. The
experts, however, emphasized that in order to achieve
this goal optimally, an organized programme with quality
control of every key step of the entire process is a prereq-
uisite. Tests for the presence of viral DNA in a sample of
epithelial cells have been established as a step toward
S. R. Pagliusi: HPV Technologies Advancing Public Health, Coll. Antropol. 31 (2007) Suppl. 2: 55–60
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TABLE 1
SUMMARY OF STATISTICAL ANALYSES RESULTS FROM CLINICAL TRIALS TO MEASURE THE EFFICACY OF A QUADRIVALENT VACCINE
IN PREVENTING CIN 2–3 ASSOCIATED TO HPV INFECTIONS IN THE TRIAL POPULATION OF FEMALES AGED 15–26 YEARS OLD
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Statistical review and evaluation
GardasilTM
(Merck & Co.)**
any HPV type CIN2–3 or worse in






Clinical trials analysis to measure the efficacy of a quadrivalent vaccine in preventing CIN 2–3 associated to HPV infections in the trial
population of females aged 15–26 years old. Three trial sub-populations considered for analysis are indicated here: the HPV type spe-
cific per-protocol-efficacy analysis, the type specific modified intention to treat analysis, and the modified intention to treat analysis as
to efficacy against CIN2–3 associated to any HPV type. *Data available in the public domain, at package insert Gardasil label http://
www.fda.gov/cber/label/hpvmer060806LB.pdf, and **Interim analysis data adapted from Dr. N. Miller, available at http://www.fda.
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identifying potentially precancerous conditions. In this
context, the IARC expert Group concluded that there is
also sufficient evidence that the HPV test for women
25–65 years can reduce mortality from cervix cancer18. If
high quality screening test is provided to the public it
will likely have an immediate impact on disease burden,
in contrast to prophylactic vaccination, because it is de-
signed to identify and avert cases in the women who al-
ready have some precancer pathology and are at high
risk of progression to invasive cancer.
It is important to understand the difference between
analytical and clinical sensitivity in order to allow effec-
tive use of HPV technology for clinical diagnostics. While
analytical sensitivity relates to the amount of analyte or
genome equivalent or copy number of viral particles
present in a given sample, the clinical sensitivity relates
to the degree of agreement of a positive test result with a
positive disease status. Generally a test with high analyt-
ical sensitivity, detecting down to 10 viral copies per sam-
ple, would give positive results to all infected individuals,
irrespective if this is a transient subclinical infection or
an infection associated to neoplasia. Tests that detect
only higher levels of viral DNA, eg. more than 5000 cop-
ies per sample, give positive results that are more likely
associated to neoplasias at risk to progressing to cancer,
and so are clinically relevant19.
New diagnostic assays must be validated using data
regarding prediction of risk of cancer and CIN3 from
large representative study populations. In addition to
targeting the correct genotypes, HPV tests must have
clinically validated viral load cut points, ie. analytical
sensitivity20. Hybrid Capture 2 (HC2) is FDA-approved,
CE-marked, clinically validated, and commercial HPV
test available worldwide. The test is available with two
sets of reagents, one set to detect five low-risk types HPV,
and another reagents set to detect 13 high-risk types
HPV21. The analytical detection level of HC2 HPV has
been set at 1.0 HPV DNA pg/mL (5000 genomes/assay)
based on multiple clinical trials over a long period of time
with high grade cervical intraepithelial neoplasia (CIN
2+) as the disease endpoint22.
Primary screening with combined cytology and HPV
testing is already an accepted and approved option in
North America. The HPV HC2 test is recommended in
the United States as adjunct to cytology screening for
women over the age 30, or for triage of inconclusive cytol-
ogy results in women under 30-years old23.
In the European guidelines to be released now, evi-
dence for HPV testing is accepted for two clinical applica-
tions: triage of equivocal cytology (ASCUS), and follow-
up of treated lesions to predict failure or success of the
offered therapy24. HPV triage of LSIL is recommended
for women over 30 years of age, where the specificity of
HPV test is higher than in young women25. In Europe a
high level of confidence on primary HPV screening from
randomized trials is awaited to complement the guide-
lines. At present, there are five randomized trials under
way in Europe, to assess the effectiveness of HC2 as pri-
mary screening test for public health programmes. Simi-
larly to endpoints used in vaccine studies, screening
studies considered detect prevalent CIN2–3 in long fol-
low-up periods. In general interim studies results show-
ed that HC2 clinical performance in the field, as mea-
sured by biopsy confirmed cervical histopathology, is
consitently higher than cytology based methods (Table
2)24,26–29. A meta-analysis of the various studies con-
ducted in Europe and in North America involving over
60.000 women over 35-years old, confirmed that HC2
performance in the field to detect women with cervical
premaligant lesions, is higher than cytology. With cytol-
ogy triage, the specificity improves to the level of re-
peated conventional cytology. The studies also showed
that combining HC2 with cytology maximizes the clinical
benefits of large cervical screening programmes22.
S. R. Pagliusi: HPV Technologies Advancing Public Health, Coll. Antropol. 31 (2007) Suppl. 2: 55–60
58
TABLE 2
OVERVIEW OF RESULTS OF SOME EUROPEAN STUDIES COMPARING CYTOLOGY AND MOLECULAR METHODS DETECTION RATES
FOR HIGH GRADE CERVICAL DISEASE
Source
reference
Study site and size (N)
Any HR HPV type
CIN2+ or worse
Number of Cases
Clinical Sensitivity CIN2+ or worse
Endpoint
























513 283 96.1% 53%
*Randomized trial, **The HC2 assaw shows consistenly higher rates of disease detection in large studies, including randomized trials,
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Another advantage of HPV test is that women with a
negative result have an extremely low probability of hav-
ing a CIN in the following 10 years. The longitudinal sen-
sitivity to predict CIN3+ over a period of 10 years is 66%
for HC2 whereas only 35.4% for baseline cytology defined
as ASCUS+, while the positive predictive value of cytol-
ogy remains higher than HC230–31. Importantly, the posi-
tive predictive value of HPV test can be significantly
increased by typing for HPV 16 and 1832. These observa-
tions indicate that HPV testing is safe and could be
cost-effective allowing longer screening intervals, as op-
posed to methods such as Pap smears. In addition it may
decrease significantly psychological anxienty associated
with screening practice. Positive results for HPV 16 and
18 may warrant a shorter follow-up period.
A proposed new paradigm for cervical screening man-
agement is schematically illustrated in Figure 2. If re-
source constrains need to be respected, a HPV test would
be a possible option because it is based on the higher sen-
sitivity consistently demonstrated using HPV test, and
high sensitivity could be achieved using cytology triage,
for example34.
Conclusion
To date, two HPV technologies reviewed and ap-
proved by regulatory authorities in North America and
Europe for use in populations are at hand: HPV vaccina-
tion and HPV testing. Both technologies are derived
from the cancer causing virus, and represent effective in-
terventions to eliminate cervical cancer. Vaccines are
tools for primary prevention strategies, i.e. to prevent
the life treatening infection of establishing, and HPV
tests are tools for secondary prevention strategies, i.e.
prevent infections and neoplasias of progressing to inva-
sive cancer.
There are some limitations that need to be acknowl-
edged: vaccines to date target two out of fifteen carcino-
genic types of HPV, and will likely prevent 70% of poten-
tial cancer cases in vaccinated subjects, so screening will
need to continue in order to prevent those cases not pro-
tected by these vaccines. The vaccines are essentially
prophylactic and have no effect on the course of already
acquired infections, therefore screening needs to con-
tinue ensuring the population that previously acquired
infections will be prevented of developing to cancer. Vac-
cination may have a lag of decades between the interven-
tion and a reduction in cancer incidence at population
level. Nevertheless, these limitations could be surmoun-
ted by vaccines that would be effective against most of
the HPV carcinogenic types.
There are also limitations to HPV testing, as HC2
HPV test detects the 13 carcinogenic types identified,
and has the potential to identify 95% of cases at an early
stage to allow timely treatment. Cases caused by some
HPV types not included in the test may not be detected.
Notably, this can be overcome if the test is combined to
cytology where is has demonstrated to be able to achieve
100% sensitivity. Negative HPV test results may warrant
an assessment for appropriatness of sampling, such as
cellular DNA content.
In an ideal public health service primary and second-
ary prevention strategies implemented in parallel will
have a synergistic effect and solve the public health prob-
lem faster, than each strategy isolated. Noteworthy the
key for success in vaccination programmes lies on the
systematic and well organized approach to vaccinate the
populations at high coverage, in addition to use quality
products. Similarly, only screening programmes conduct-
ed with quality products, implemented in a systematic
and well organized manner at high coverage, while tar-
geting the female population at risk, can save lives and
improve women’s health, and will impact on the health
of their families and communities.
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POMACI U JAVNOM ZDRAVSTVU ZAHVALJUJU]I NOVIM METODAMA VEZANIM UZ HPV:
RASPRAVA O NEDAVNIM DOKAZIMA
S A @ E T A K
U~inkoviti primarni i sekundarni programi prevencije raka vrata maternice su klju~ni u pobolj{anju javnog zdrav-
stva. Rak vrata maternice je mogu}e sprije~iti ukoliko se `enama ponude kontrolirani visoko-kvalitetni programi pro-
bira, dijagnostike i lije~enja. Unato~ tomu, ovaj rak i dalje predstavlja javno-zdravstveni problem, a programe probira
treba pobolj{ati. Humani papilomavirus (HPV) se smatra neophodnim uzro~nikom gotovo svih slu~ajeva raka vrata
maternice. Danas postoje dvije klini~ki potvr|ene i odobrene metode vezane uz HPV, dostupne u prevenciji raka vrata
maternice i drugih bolesti uzrokovanih ovim karcinogenim virusima: profilakti~ka cjepiva za primarnu prevenciju te
HPV-DNK-testovi za sekundarnu prevenciju, detekciju infekcija karcinogenim tipovima HPV-a opasnih po `ivot, {to
omogu}uje pravovremenu dijagnozu te klini~ko lije~enje stadija prije raka. Nove metode }e pomo}i pomacima u javnom
zdravstvu ukoliko budu {iroko dostupne. Sli~no programima cijepljenja, sustavno i dobro organizirani programi probira
raka vrata maternice, sa visoko-kvalitetnim va`e}im HPV-testovima, mogu spasiti vi{e `ivota nego ikad te pobolj{ati
zdravlje `ena na vrlo u~inkovit na~in.
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Quality Assurance of Human
Papillomavirus Testing
Ruth Tachezy and Jana [mahelová
National Reference Laboratory for Papillomaviruses, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
A B S T R A C T
The External Quality Assurance (EQA) in medical microbiology in the Czech Republic is well organized. It is coordi-
nated by the Accreditation Department of the Centre of Epidemiology and Microbiology (AD-CEM) of the National Insti-
tute of Public Health in Prague. Since 1993 when the first samples were sent out the number of programmes and partici-
pating laboratories has been rapidly increasing. EQA for Human papillomavirus (HPV) has been available since 2000.
As has been shown for other programmes, the EQA for HPV has proved to be useful, helping to improve the accuracy of
analyses and contributing to the standardization of methods of HPV DNA testing. EQA for HPV has been well received
by routine laboratories, demonstrated by a high number of these institutions voluntarily participating in EQA.
Key words: external quality assurance (EQA), human papillomavirus (HPV)
Introduction
Today, most diagnostic laboratories are capable of de-
tecting a wide range of infectious agents. The In Vitro Di-
agnostic Industry is committed to bringing an even big-
ger variety of diagnostic assays on the market in the
future. Even though the process of certification of in vi-
tro diagnostics for infectious agents is obligatory, this is
not always a guarantee that the assay is working prop-
erly in the end-user’s laboratory. Especially for very sen-
sitive molecular diagnostic assays, which often straddle
the divide between research and routine, internal and ex-
ternal quality assurance is important. Several institu-
tions worldwide provide panels of reference samples for
the most commonly diagnosed infections. For Human
papillomaviruses (HPV), the first internationally avail-
able panel of samples for quality assurance was offered
by Instand (WHO Collaborating Centre for Quality As-
surance and Standardization in Laboratory Medicine)1 in
2004.
Long Tradition
The system of External Quality Assessment (EQA) in
the Czech Republic was introduced in 1993. The first
programme focused on sera for detection of the hepatitis
B virus and strains of bacteria for identification. From
1993 till 2002 the number of provided surveys increased
from 2 to 34 and the number of participating laboratories
increased from 79 to 440 (Figures 1 and 2). In order to
provide technical support for this programme, a coordi-
nating centre for EQA in medical microbiology was es-
tablished (the Accreditation Department of the Centre of
Epidemiology and Microbiology (AD-CEM), National In-
stitute of Public Health). Since then, AD-CEM has devel-
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Fig. 1. Number of programmes provided by the Accreditation De-
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oped a wide network of national reference laboratories
and some other highly specialized centres, which prepare
samples for EQA2.
AD-CEM distributes the coded samples together with
all required protocols containing detailed instructions.
Each programme has an individual deadline for receiving
the results. AD-CEM sends the protocols with the results
to the contractual laboratory for evaluation. Each partic-
ipating laboratory in this system has a unique identifica-
tion code and the evaluation of results is therefore anon-
ymous. The certificate of participation is issued to all
participants who registered for the programme in the
particular year and those who successfully passed the
EQA also obtain the Certificate of proper diagnostics.
After ten years of its existence, AD-CEM has achieved
some very positive outcomes. First of all, the accuracy of
analyses has increased and methods have become better
standardized. In addition, significant variations have
been detected between different diagnostic sets; as a re-
sult, those sets that have yielded unsatisfactory results
have been eliminated.
Participation in the system of EQA is not compulsory,
but most of the routine laboratories voluntarily take part
since it allows them to compare the performance of a
wide variety of detection techniques and diagnostic sets
with many others laboratories. All results are published
in the journal, »Zprávy CEM« (News of CEM), issued by
the Centre of Epidemiology and Microbiology, National
Institute of Public Health as well as on the websites of
some of the contractual laboratories.
External Quality Assurance for HPV
In 1998, the National Reference Laboratory (NRL)
for Papillomaviruses was established by the National
Public Health Authority on the recommendation of the
Working Group for Virology of the Society for Clinical
Microbiology of the Czech Medical Association JEP to
improve the interpretation of results and disseminate in-
formation concerning the clinical usefulness of HPV
DNA detection among specialists.
Since 2000, 5 EQA sample series have been distrib-
uted annually to each of the participating laboratories
(Figure 3). Since 2003, EQA has also been provided to
laboratories using PCR-based diagnostic kits. EQA is
carried out depending on the diagnostic kit used (i.e. de-
pending on whether the kit detects both low risk [LR]
and high risk [HR] HPV types or HR HPV types only). If
the kit used detects both LR and HR HPV types, the par-
ticipating laboratory is awarded a score of 2 points for
each correct result and loses 1 point when failing to de-
tect either LR or HR HPV types. When an incorrect re-
sult is reported for a sample with a borderline amount of
virus for a detection limit of the given kit (provided the
test is recommended for diagnostic use by the NRL),
NRL requires correct interpretation of any equivocal re-
sult. If possible, NRL informs the participating labora-
tory about the mechanism likely to be responsible for the
error (e.g. low sensitivity of the method, defective kit
batch, improper performance of the test, sample contam-
ination, etc.).
The samples for EQA are prepared to simulate the
cervical smear samples taken to a transport medium. At
the beginning of EQA, the Specimen Transport Medium
(STM, Digene) was used. Later, when PCR-based com-
mercially available sets appeared, samples prepared in
the PreservCyt medium (Cytyc) for PCR-based methods
were used. Recently, we finished a study whose results
show the possibility of using STM medium for both
non-amplification and amplification-based methods. In
each sample, a background of 100,000 HPV negative cells
is included. Each series contains an HPV negative, LR
HPV positive and HR HPV positive sample and also a
sample positive for both LR and HR HPV. Both HPV pos-
itive cell lines and cloned DNA is used for sample prepa-
ration. Different amounts of HPV positive cells and/or
cloned DNA are used to simulate different viral load and
verify the sensitivity of methods used in laboratories. To
illustrate, we include a table showing the results of par-
ticipating laboratories in 2001 and 2006 (Table 1 and 2)3.
At the beginning of EQA for HPV, most of the labora-
tories used Hybrid Capture Tube test (HCT, Digene),
which has been shown to have a limited sensitivity for











































Fig. 2. Number of laboratories registered in the External Quality
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the detection of CIN2+ lesions. Therefore, in the EQA in
2000 we set the cut-off line just above the detection level
for HCT. We recommended that all laboratories plan to
switch to HC2 (Digene) (primarily because at that time
no other commercial sets were available on the Czech
market). The reaction was quite positive and as you can
see from Table 3, the spectrum of diagnostic sets used in
routine laboratories changed. In 2000, 50% (11/21) of
laboratories in EQA used HCT, but this number de-
creased to 3 out of 22 in 2002 and just 1 in 23 laboratories
in 2004. 2004 was the first year when 3 laboratories used
PCR-based HPV DNA tests (HPV INNO-LiPA Innogene-
tics, Amplicor HPV Test Roche, DNA PCR Test Gentech).
Discussion
From the onset of EQA, we regularly detected mis-
takes in using even such robust sets as HC2. However,
over the years, the performance of laboratories in EQA
improved and in the last two years we have had no mis-
takes reported from the laboratories using HC2 or HC2
HR sets. In 2006, we had 6 laboratories using commer-
cially available PCR-based sets. The results of EQA from
laboratories which use PCR-based sets show bigger het-
erogeneity and confirm the need for participation in the
EQA (Table 2)3.
In the absence of an internationally available prog-
ramme for EQA for HPV, we exchanged the samples with
the Laboratory of Clinical and Epidemiological Virology,
Rega Institute for Medical Research, University of Leu-
ven, Belgium in 2002. In 2004 Instand (WHO Collabo-
rating Centre for Quality Assurance and Standardization
in Laboratory Medicine)1 for the first time offered EQA
for HPV and since then, NRL has been successfully par-
ticipating in this programme. In 2004, Instand prepared
samples which had a limited amount of HPV DNA (below
the cut-off for HC2 Digene). Since we used different
R. Tachezy and J. [mahelová: Quality Assurance of HPV Testing, Coll. Antropol. 31 (2007) Suppl. 2: 61–65
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HCT Digene 26 0.25 0.24 0.33* 0.25 0.25 0.26* 0.73* 0.42* 0.26 0.26* 2.0
HCT Digene 118 0.19 0.25 0.48* 0.26 0.25 0.58* 1.44 1.03 0.34 2.75 6.0
HCT Digene 211 0.58 0.26 0.72* 0.30 0.62 0.35* 1.38 0.64* 0.54 0.31* 2.0
HCT Digene 28 0.23 0.24 0.32* 0.20 0.22 0.34* 0.75* 0.40* 0.20 0.24* 0.0
HCT Digene 371 0.28 0.49 0.39* 0.32 0.25 0.35* 0.77* 0.63* 0.25 1.04 4.0
HCT Digene 406 0.89 1.28** ND ND 0.67 2.01 ND ND 3.33** 0.72* 0.0±4.0
HCT Digene 18 3.78** 3.6** 0.53* 0.99 0.31 0.68* 3.84 1.41 0.29 0.26* 0.0
HCT Digene 192 0.37 0.30 0.45* 0.38 0.37 0.38* 1.07 0.64* 0.43 0.43* 2.0
HC2 Digene 165 0.14 0.17 1.18 0.17 0.19 0.87* 7.02 2.60 0.16 16.89 8–9.0
HC2 Digene 373 0.93 0.19 2.44 0.20 1.14** 1.47 1.81 1.82 0.82 17.93 8.0
HC2 Digene 156 0.18 0.14 1.04 0.15 0.16 1.30 3.42 2.21 0.18 18.90 10.0
HC2 Digene 115 0.20 0.50 1.41 0.16 0.29 1.58 6.30 2.36 0.22 16.78 10.0
HC2 Digene 585 0.54 1.34** 1.88 2.00** 2.12** 2.92 4.71 2.21 5.67** 22.21 2.0
HC2 Digene 584 0.20 0.21 1.42 0.20 0.36 1.38 6.79 3.16 0.20 18.99 10.0
HC2 Digene 13 0.34 0.37 1.75 0.40 0.27 1.38 10.51 2.61 0.26 18.84 10.0
HC2 Digene 344 0.24 0.21 1.04 0.50 0.23 1.20 4.16 1.70 0.38 11.89 10.0
HC2 Digene 405 0.59 0.24 1.28 0.47 0.23 1.38 4.53 2.05 0.51 15.77 10.0
HC2 Digene 31 0.34 0.25 1.69 0.36 0.31 2.43 6.36 2.83 0.45 34.82 10.0
HC2 Digene 315 0.40 0.70 1.12 0.40 0.30 1.20 4.50 2.40 0.50 15.20 10.0
HC2 Digene 147 0.56 0.47 1.72 0.28 0.55 1.38 6.67 2.68 0.46 18.40 10.0
HC2 Digene 407 0.57 0.52 1.14 0.77 0.46 1.60 3.86 2.29 0.45 13.97 10.0
HC2 Digene 11 0.15 0.26 1.02 0.20 0.13 1.13 3.51 1.63 0.19 12.85 10.0
HC2 Digene 230 0.23 0.19 1.06 0.18 0.20 1.22 4.09 1.82 0.22 15.56 10.0
HC2 Digene 471 0.16 0.14 1.43 0.15 0.17 1.36 5.67 2.70 0.18 18.75 10.0
HC2 Digene NRL PV 0.35 0.33 1.67 0.23 0.39 1.73 7.27 2.64 0.35 18.63 10.0
EQA – External Quality Assurance, HPV – Human Papillomavirus, * – error caused by the low sensitivity of the detection method, ** –
probable contamination of samples, HCT – Hybrid Capture 1 HPV test (Digene), HC2 – Hybrid Capture 2 HPV test (Digene), LR – low
risk, HR – high risk, RLU/CO – relative light units/cut-off, ND – not done, NRL PV – National reference laboratory for papilloma-
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HC2 Digene 11 24.43 0.15 0.11 3.79 20.76 0.13 0.11 0.11 0.12 6.51 10.0
HC2 Digene 13 24.60 0.25 0.32 4.41 24.18 0.23 0.19 0.15 0.15 6.43 10.0
HC2 Digene 31 29.23 0.15 0.10 4.61 30.53 0.18 0.11 0.13 0.12 7.83 10.0
HC2 Digene 79 30.46 0.12 0.08 4.76 30.74 0.13 0.11 0.09 0.08 7.63 10.0
HC2 Digene 115 27.31 0.16 0.16 4.09 23.01 0.16 0.14 0.15 0.12 7.15 10.0
HC2 Digene 118 28.83 0.15 0.11 4.54 27.00 0.15 0.10 0.09 0.10 6.47 10.0
HC2 Digene 156 29.49 0.16 0.11 4.43 22.56 0.36 0.13 0.13 0.18 5.53 10.0
HC2 Digene 165 29.30 0.26 0.13 4.98 29.80 0.21 0.15 0.20 0.14 6.94 10.0
HC2 Digene 192 28.71 0.10 0.09 4.51 25.35 0.08 0.10 0.08 0.10 6.10 10.0
HC2 Digene 230 18.02 0.79 0.46 2.47 18.91 0.75 0.55 0.46 0.43 4.74 10.0
HC2 Digene 315 26.70 0.10 0.10 3.60 27.90 0.20 0.10 0.10 0.10 5.60 10.0
HC2 Digene 325 30.36 0.19 0.12 4.54 31.74 0.18 0.14 0.14 0.13 8.27 10.0
HC2 Digene 344 27.37 0.35 0.11 3.56 29.95 0.18 0.21 0.15 0.47 6.33 10.0
HC2 Digene 354 20.68 0.10 0.08 3.51 19.98 0.10 0.12 0.06 0.10 2.85 10.0
HC2 Digene 369 18.22 0.54 0.63 2.95 16.47 0.49 0.38 0.54 0.38 4.45 10.0
HC2 Digene 371 28.88 0.16 0.07 4.22 26.02 0.25 0.10 0.11 0.12 6.73 10.0
HC2 Digene 373 3.16 0.16 0.15 4.40 26.60 0.17 0.16 0.17 0.16 6.69 10.0
HC2 Digene 407 25.00 ND ND ND 31.00 ND ND ND ND 6.00 10.0
HC2 Digene 585 27.46 0.26 0.45 4.38 23.70 0.27 0.23 0.24 0.18 7.45 10.0
HC2 Digene 734 29.37 0.16 0.09 4.85 27.72 0.14 0.09 0.13 0.10 7.17 10.0
HC2 HR Digene 584 – 0.19 – 4.45 – 0.14 – 0.12 – 7.38 10.0
HC2 HR Digene 736 – 0.13 – 5.15 – 0.14 – 0.21 – 8.21 10.0
HC2 Digene NRL PV1 28.50 0.13 0.10 4.65 29.50 0.12 0.10 0.13 0.15 7.59 10.0













































16 poz poz neg neg** poz neg neg neg neg poz 9.0
Amplicor HPV
Test Roche
365 – poz – poz – neg – neg – poz 10.0
Amplicor HPV
Test Roche
716 – neg* – poz – neg – neg – poz 10.0
Amplicor HPV
Test Roche
NRL PV – poz – poz – neg – neg – poz 10.0
“in house” PCR
GP5+/6+bio
NRL PV HPV 6 HPV 33 0 HPV 16 HPV 6 0 0 0 0 HPV 16, 39 10.0
EQA – External Quality Assurance, HPV – Human Papillomavirus, * – borderline concentration of HPV DNA, ** – error, LR – low
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methods for assessment of EQA in our laboratory, this
discrepancy was obvious and we sent our comments to
the producers of EQA, which resulted in the change of
the HPV DNA amount in the ECQ in 2005.
Conclusion
EQA in medical microbiology in the Czech Republic is
well organized. It is coordinated by AD-CEM of the Na-
tional Institute of Public Health in Prague. First samples
were sent out in 1993. EQA for HPV has been available
since 2000 and in 2006, 29 laboratories participated in
this programme. As has been shown for other prog-
rammes, the EQA for HPV has proved to be useful, help-
ing to improve the accuracy of analyses and contributing
to the standardization of methods of HPV DNA testing.
EQA for HPV has been well received by routine laborato-
ries, demonstrated by a high number of these institu-
tions voluntarily participating in EQA.
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OSIGURANJE KVALITETE TESTOVA NA HUMANI PAPILOMAVIRUS (HPV)
S A @ E T A K
Vanjska provjera kvalitete (EQA, od engl. External Quality Assurance) je dobro organizirana u medicinskoj mikro-
biologiji u Republici ^e{koj. Koordinirana je od Odjela za akreditaciju centra za epidemiologiju i mikrobiologiju (AD-
-CEM, od engl. Accreditation Department of the Centre of Epidemiology and Microbiology) Nacionalnog instituta javnog
zdravstva u Pragu. Od 1993. godine, kada su prvi uzorci poslani vani, broj programa i uklju~enih laboratorija je naglo
narastao. EQA je za humani papilomavirus (HPV) bila u upotrebi od 2000. godine. Kako je bilo prikazano za druge
programe, EQA se pokazala korisnom za HPV, poma`u}i tako pove}anju to~nosti analiza i doprinose}i standardizaciji
metoda HPV-DNK-testova. EQA je dobro prihva}ena za HPV od strane laboratorija koji vr{e rutinske analize, na {to
ukazuje dobrovoljno sudjelovanje velikog broja ovih institucija u EQA.
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TABLE 3
























2000 22 21 11 10 – – – –
2001 25 24 8 16 – – – –
2002 28 22 3 19 – – – –
2003 27 21 2 18 – 1 – –
2004 25 23 1 19 – 2 – 1
2005 25 23 – 19 – 2 1 1
2006 29 28 – 20 2 3 2 1
EQA – External Quality Assurance, HPV – Human Papillomavirus, HCT – Hybrid Capture 1 HPV test (Digene), HC2 – Hybrid Cap-
ture 2 HPV test (Digene), HR – high risk, HPV INNO-LiPA – Line blot assay (Innogenetics), Amplicor HPV Test – Polymerase chain
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A B S T R A C T
Opportunistic screening based on the Pap smear has been undertaken in Croatia since 1953. However, cervical cancer
remains an important health problem in Croatia when compared to European countries with organised screening pro-
grammes. In Croatia, in addition to screening based on well established cytology, Human papillomavirus (HPV) testing
is widely used as secondary test as a triage to borderline cytology and as a follow-up after treatment of severe cervical
lesions. Many different approaches for HPV testing arose in Croatia over the last decade depending on the needs of each
medical institution involved. Presently, there is an urgent need for better networking between the laboratories, the imple-
mentation of quality assessment and the adaptation of a uniform system of referring to and reporting of HPV testing. In
conclusion, the best possible organisation for HPV testing would be essential for implementation of HPV testing as pri-
mary screening test in Croatia, an thus ultimately and hopefully, the more successful cervical cancer control.
Key words: Cervical cancer, human papillomavirus testing, screening programme, quality assessment
Background
Cervical cancer remains an important health problem
in Croatia where the incidence rate of 14.4/100,000 wo-
men recorded in 20041 is slightly lower than the average
world incidence (16.2/100,000 women-year) but much
higher than rates recorded in European countries with
organised screening programmes.
Cervical cancer is highly amenable to screening be-
cause it has a long pre-clinical phase with precursor le-
sions that can be identified by cervical cytology (Papa-
nicolaou or Pap smears) and that can be easily treated
using simple procedures if they are detected at an early
stage. Opportunistic screening based on the Pap smear
has been undertaken in Croatia since 1953 when the first
laboratory for gynaecological cytology was established in
Zagreb2. Since then, a network of more than 30 laborato-
ries has developed and now provides good coverage of a
large part of the target population. Opportunistic screen-
ing has produced a decrease in cervical cancer incidence
from 26/100,000 to 15/100,000 women-years between
1970 and 1990, although it remained almost stable there-
after1.
The European Code Against Cancer states that all
women from 25 years of age should participate in organ-
ised cervical screening programmes, the Council of the
67
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European Union has recommended that all Member Sta-
tes should implement organised cervical cancer screen-
ing programmes and the new European Guidelines now
state that cervical cancer screening should only be of-
fered within the context of an organised programme3,4.
In 2003, a panel of Croatian experts prepared a proposal
for the implementation of an organised screening pro-
gramme that was submitted to the Croatian Ministry of
Health and Social Welfare5. This proposal recommended
that the programme should start by offering conven-
tional Pap smears to all women from 25 to 64 years of age
(app. 1.2 million women) who should be screened annu-
ally for the first 3 years but with the screening interval
subsequently extended to 3 years for all women who have
had 3 consecutive normal Pap smears. The proposal also
recommended the implementation of liquid-based cytol-
ogy with the extension of the screening interval to 5
years and the addition of HPV testing for women over
the age of 305.
The implementation of an organised cervical screen-
ing programme in Croatia would be facilitated because
many of the necessary elements are already in place:
• high quality cytology; gynaecological cytology is a man-
datory sub-specialisation and cytotechnicians are re-
quired to participate in continuing education since 19672.
Also, gynaecological cytology is regularly reviewed and
updated with the last improvement being a refinement
of cytological classification to »Zagreb 2002« that was
adapted from »Zagreb 1990« and the »National Cancer
Institute Bethesda System 2001«6.
• a well developed network of quality controlled gyna-
ecologic cytology laboratories with extensive expertise
in gynaecologic cytology
• a nationwide network of gynaecologists that currently
offer screening to women,
• well established procedures for the diagnosis and treat-
ment of women with abnormal smears7,
• a tradition of expert colposcopy that has been in place
since 1992,
• a network of laboratories with extensive experience in
HPV testing for diagnostic purposes that has been in
place since 1995, and
• the computerisation of the health system that is now
in the process of being implemented.
However, opportunistic screening in Croatia does not
include the entire target population and this is reflected
in the mortality rate that has shown only a small de-
crease between 1970 and 2002 from 6/100,000 to 5/
100,000 women-years1 and the goal must be to reach the
very low rate of 2–3/100,000 women-year that has been
achieved by the Finnish screening programme8. As such,
there is now an urgent need for the implementation of a
properly organised, population-based screening pro-
gramme that would effectively combine all the new tech-
nologies in a rational approach that would maximise the
cost-effectiveness and equitably serve all the women of
Croatia. Very importantly, this programme would also
have to carefully consider the appropriate management
of women who have been vaccinated against HPV and
who would have a different risk profile from women who
had not been vaccinated9.
HPV Infections and Cervical Cancer
Persistent infection with HPV has now been con-
firmed as a necessary, although not sufficient cause of
cervical cancer10,11. There are more than 130 well charac-
terised HPV types, with approximately 40 types that can
infect the genital mucosa. These have been classified into
high-risk (hr) and low-risk (lr) HPV genotypes according
to their association with cervical cancer and its precursor
lesions; HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
68, 73 and 82 were classified as high-risk or carcinogenic
types, HPV 26, 53 and 66 as probably carcinogenic, while
HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108
were classified as low-risk types12.
The genital HPV types are primarily transmitted by
sexual contact and all women who have had a sexual rela-
tionship are at risk for both HPV infection and cervical
cancer. Host factors as well as behavioural and environ-
mental factors, may facilitate cancer development in
women with a persistent HPV infection and the risk of
cervical cancer increases with immunodeficiency, higher
parity, tobacco smoking, co-infection with other sexually
transmitted agents (human immunodeficiency virus HIV,
herpes simplex virus 2 HSV 2, Chlamydia trachomatis
and Neisseria gonorrhoeae) and long-term (>5 years) use
of oral contraceptives10. However, the association be-
tween hrHPVs and cervical cancer is the strongest ever
found for a human cancer with a relative risks for the de-
velopment of cervical cancer ranging from 50–500 de-
pending on the HPV genotypes, single or multiple HPV
infections and the amount of virus (virus load)10,11. Also,
cervical cancer will not occur in the absence of a persis-
tent infection with one of the oncogenic HPV types13.
Worldwide, HPV 16 is the most common hrHPV type
as it is found in 60% of cervical cancer cases, while HPV
type 18 is found in about 10%, types 45 and 31 in 4%
each, and types 33, 52 and 58 each in another 2%10. HPV
16 and 18 are also associated with about 25% of the low
grade cervical lesions (LSIL) and 50 to 60% of the high
grade cervical lesions (HSIL). HPV 6 and 11 are respon-
sible for about 10% of LSIL and about 90% of genital
warts that do not represent additional risk for cancer
developement10.
HPV infection is very common in young women, but
most infections are transient and resolve spontaneously
in 6 to 24 months. Only a very small percentage of HPV
infections will lead to precursor cervical lesions and only
those that persist long-term pose a risk for the develop-
ment of cancer. Cervical precursor lesions persist longer
and progress more quickly in women with hrHPV infec-
tions than in women with lrHPV infections or those
without HPV. Approximately 60% or more of cases of
mild dysplasia resolve spontaneously and only about 10%
progress to moderate or severe dysplasia within 2 to 4
years. In some cases, moderate or severe dysplasia may
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occur without an earlier detectable mild dysplasia stage.
Less than 50% of cases of severe dysplasia progress to in-
vasive carcinoma, with much lower rates seen in younger
women. Usually it takes 10 to 20 year for precursor le-
sions caused by hrHPV to progress to carcinoma and this
is what makes cervical cancer a relatively easily prevent-
able disease and provides the rationale for screening10.
Pap Smear and HPV Testing
Cervical cancer is rare before the age of 30 years.
Screening younger women detects many lesions that will
regress spontaneously and leads to considerable over-
treatment. Also, screening by Pap smear every three
years is nearly as effective as yearly screening. According
to the WHO recommendation if the resources are lim-
ited, screening every 5–10 years – or even just once be-
tween the ages of 35 and 45 years – will significantly re-
duce deaths from cervical cancer11. On the other hand,
negative HPV test virtually excludes any risk of having
significant prevalent cervical disease and provides the
same degree of protection over 5 years that the accepted
standard of a negative Pap smear provides over 2 years.
Therefore, it is likely that HPV testing could also provide
substantial cost savings for most European countries by
reducing the screening frequency with no increase in risk
for the women being screened14. However, HPV test-
ing-based screening should not begin before 30 years of
age.
Testing for HPV could be a useful cervical cancer
screening tool and its use has been proposed for primary
screening, triage of equivocal Pap smears and for the fol-
low-up of patients after treatment for severe cervical le-
sions. Women who test positive are at high risk of devel-
oping cervical precursor lesions and cancer and they
should be referred to more extensive diagnostic proce-
dures. About 15–30% of women with normal cytology
who are hrHPV positive will develop high-grade precan-
cerous lesions, cervical intraepithelial neoplasia (CIN)
grade 2 or 3 within 4 years of detecting the HPV in-
fection15. In contrast, women who test negative or are
lrHPV positive have almost no risk of developing cervical
precancer or cancer and it is thus justifiable to offer such
women less frequent screening.
HPV testing has been extensively evaluated and ma-
jor international reviews have concluded that it 1) is
more efficient than repeated cytology in the triage of am-
biguous cytological lesions, 2) is at least as efficient as cy-
tology as a primary screening test, and 3) is more effi-
cient than cytology as a test of follow-up for recurrence
after treatment of severe cervical lesions10. HPV testing
as primary screening, at this time, is recommended for
use only in pilot projects or other closely monitored set-
tings. Several large-scale randomised controlled trials for
evaluation of HPV testing for primary screening are at
the moment conducted in Europe9.
A comparative analysis of different studies on HPV
testing for primary screening showed that HPV testing
was substantially more sensitive in detecting CIN2+
than cytology (96.1% vs. 53.0%) but slightly less specific
(90.7% vs. 96.3%). The sensitivity of HPV testing was
uniformly high at all ages, whereas the sensitivity of cy-
tology was substantially better in women over the age of
50 than in younger women (79.3% vs. 59.6%), while the
specificity of both tests increased with age. These results
support the use of HPV testing as the sole primary
screening test, with cytology reserved for women who
test HPV positive16.
A good screening test should be accurate, reproduc-
ible, inexpensive, easy to perform and easy to follow-up,
acceptable and safe. HPV testing meets all of these crite-
ria, except for its high price, and this would probably de-
crease if the test is used on large-scale. At present, there
is only one HPV test approved by the United States Food
and Drug Administration (US FDA) and European Agen-
cy for the Evaluation of Medical Products (EMEA), the
Hybrid Capture 2 test (HC2; Digene Co.), which uses a
cocktail of 13 hrHPV types that are included within the
15 hrHPV types noted above.
Many other tests, commercial or in-house are poly-
merase chain reaction (PCR) based HPV tests, which
uses general (consensus) primers that recognise most hr-
and lrHPV types. The analysis of the PCR amplicon gen-
erated by consensus PCR by different methods (hybrid-
ization with specific probes, restriction fragment length
polymorphism analysis, and sequencing) enables deter-
mination of HPV types as well as direct type-specific
primer directed PCR. These methods of HPV genotyp-
ing, while sensitive and specific are too costly and cum-
bersome to incorporate into large-scale screening pro-
grammes. In the future, clinicians might benefit from
knowing the number and the identification of the specific
types present in order to follow for persistent infections
and/or to test for cure after therapy, and also to monitor
vaccinated women.
HPV Testing in Croatia
Laboratory network
In Croatia, several laboratories for molecular diagnos-
tics offer detection and genotyping of HPVs17–20. These
laboratories are located in Zagreb, Split, Rijeka and Osi-
jek, and belong to public or to private health care system;
only one laboratory is based in research setting. All labo-
ratories are equipped with special clean room to avoid
PCR amplicon contamination, specified equipment and
reagents required for a specific test. The work is per-
formed by highly trained technicians and supervised by
medical doctors, molecular biologists or medical bioche-
mists.
HPV testing methods
At present, there are several HPV testing systems
that are used in the established laboratory services in
Croatia. The first step in HPV testing is to collect an ade-
quate sample for HPV-DNA determination. HPV testing
can be performed using the same specimen collection me-
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dium used for cytological examination (Thin-Prep), or
dedicated collection medium specified by the manufac-
turer (Digene, Roche, and other). It should be noted that
sampling error and processing of the collected sample
could play an important role when using highly sensitive
molecular assays.
PCR was traditionally the first implemented method
for clinical use and is still used widely in most Croatian
laboratories17. HC2 method was the first commercial
method used in clinical laboratories but now, several
other commercial assays (PCR-based methods) are also
used: AMPLICOR HPV Test (Roche Co.) and TaKaRa
PCR Human Papillomavirus Typing Set (TAKARA Mirus
Bio Inc.). In addition, several laboratories offer in-house
consensus and type- specific PCR, HPV detection and
HPV genotyping by line blot assays (LiPA, Innogenetics;
LA HPV genotyping; Roche). Sequencing of PCR am-
plicon is used in only research setting.
Standardization and quality assessment
Standardization, quality assessment and quality con-
trol are important issues in any routine diagnostic test-
ing. They all serve to establish, maintain and guarantee a
high level of quality in the performance of a laboratory to
provide correct diagnoses that has a major influence on
the management of disease. In the past, substantial ef-
forts have been made by public and private organizations
to established and assure a high quality of diagnostic pro-
cedures. Standardization in protocols and methods, to-
gether with regular participation in internal and exter-
nal quality testing is essential for molecular diagnostic
laboratories21,22. The challenge for a laboratory that
wants to introduce this kind of testing is that it is very
demanding because of two major reasons: first, the mo-
lecular diagnostic tests are technically demanding and
require more expertise from the user compared to con-
ventional tests and secondly, because of the extreme sen-
sitivity of PCR and similar tests that can produce false
positive results created by contamination23. Scientific,
commercial or public institutions should provide panels
with negative and positive control specimens which will
be analysed on regular basis in diagnostic laboratories
participating in a quality control scheme. Data process-
ing and statistical analyses should be done by independ-
ent institutions that are responsible for supervising and
licensing procedures.
The HPV test should be performed in clinical labora-
tories with a supervision of specialist of microbiology, cy-
tology, pathology or a molecular biologist. Only tests that
have been validated and standardized tests for use in
clinical practice should be used and the laboratories
should have a validated license to perform the specific
test. Other, not clinically validated, HPV tests should be
done only for research purposes24. Interpretation of the
HPV test result should be done according to the standard
»cut-off« point recommended by the test manufacturer.
The referral order for HPV testing should include, be-
sides the general identification data, the date the sample
was taken, the date of birth, the stage of the menstrual
cycle, previous Pap smear findings and, if present, previ-
ous colposcopy, treatment and histological results.
The report of HPV test result should be composed of:
1) general patient data (name, date of birth), 2) referral
diagnosis (from the referral order: Pap test result, other
relevant colposcopic or histological results, 3) date of
sample taking, 4) referral physician and medical institu-
tion, 5) method of HPV testing, 6) interpretation of HPV
test result, and 7) optionally, recommendation of future
procedures or follow-up. However, the recommendation
should be given only by experts in the field of cervical le-
sions (gynecologic cytologists, pathologists and gynecolo-
gists) considering all clinical, cytological and pathological
data available about a particular patient, respecting the
accepted algorithms of follow-up or treatment of abnor-
mal cytology and histology7.
Conclusion
The higher sensitivity of HPV testing over cytology
offers a number of advantages, including, most impor-
tantly, the potential of reducing cervical cancer rates
while reducing the number of screens in a lifetime neces-
sary to achieve this goal. In Croatia, in addition to
screening based on well established cytology2, HPV test-
ing is widely used as secondary test as a triage to border-
line cytology and as a follow-up after treatment of severe
cervical lesions7. At present, screening is done only with
the conventional Pap test, and HPV testing therefore re-
quires an additional visit to gynaecologist which wastes
both time and money. Moreover, many different ap-
proaches for HPV testing arose in Croatia over the last
decade depending on the needs of each medical institu-
tion involved. Consequently, the implementation of HPV
testing in Croatia is still very heterogeneous and uncon-
trolled. So, there is an urgent need for better networking
between the laboratories, the implementation of quality
assessment and the adaptation of a uniform system of re-
ferring to and reporting of HPV testing. In conclusion,
the best possible organisation for HPV testing would be
essential for implementation of HPV testing as primary
screening test in Croatia, an thus ultimately and hope-
fully, the more successful cervical cancer control.
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HPV TESTIRANJE U PROBIRU RAKA VRATA MATERNICE U HRVATSKOJ – DANAS I SUTRA
S A @ E T A K
Oportunisti~ki probir temeljen na citolo{kom Papa-testu provodi se u Hrvatskoj od 1953. godine. Unato~ tome, u
usporedbi s Europskim dr`avama s organiziranim programima probira, rak vrata maternice u Hrvatskoj jo{ uvijek
predstavlja zna~ajni zdravstveni problem. U Hrvatskoj, uz probir temeljen na priznatoj i dobro uhodanoj citologiji, HPV
testiranje sve se vi{e koristi kao sekundarni test razvrstavanja nakon grani~nog citolo{kog nalaza te kao kontrolni test
nakon lije~enja te`ih promjena vrata maternice. Tijekom posljednjih deset godina u Hrvatskoj se pojavljuju brojni raz-
li~iti pristupi HPV testiranju, ovisno o potrebama i stavovima pojedinih zdravstvenih ustanova koje ga primjenjuju.
Stoga se danas javlja neophodna potreba za boljom povezano{}u laboratorija, uspostavljanjem sustava kontrole kva-
litete i zauzimanjem ujedna~enog stava o indikacijama za HPV testiranje i na~inu izdavanja nalaza HPV testa. U zak-
lju~ku smatramo da }e najbolje mogu}e ure|en sustav HPV testiranja biti preduvjet za uvo|enje HPV testa u primarni
probir u Hrvatskoj, kao i uspje{niju borbu za suzbijanje raka vrata maternice.
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A B S T R A C T
Human papillomavirus (HPV) infection has been identified as major risk factor for cervical intraepithelial neoplasia
(CIN) and invasive cervical cancer. About 40 HPV viral types are commonly found in the genital tract. Most HPV infec-
tions resolve spontaneously, while persistent infection with oncogenic types, namely HPV 16 and 18 is necessary for CIN
to occur and progress to cancer. Cervical screening is presently based on the Pap smear that is designed to diagnose pre-
cancerous lesions and cervical cancer. The aim of this study was to investigate the prevalence of HPV DNA and to deter-
mine HPV types distribution among 361 women attending regular gynecological visit. There were 205 women (29±8
years old) without determined abnormal cervical lesions and 156 women (34±15 years old) with abnormal Pap smear;
low grade squamous intraepitehelial lesions (LSIL, n=69), high grade squamous intraepithelial lesions (HSIL, n=72)
and atypical squamous cells of undetermined significance (ASCUS, n=15). HPV DNA detection and genotyping was
performed by Hybrid Capture 2 assay and additionally by consensus and type-specific primers directed PCR. The overall
prevalence of high-risk HPV (hrHPV) in women with abnormal Pap smears was 67.9% (106/156), of which in ASCUS
33.4% (5/15), LSIL 62.3% (43/69) and HSIL 80.6% (58/72). In HPV positive specimens, HPV 16 was found as predomi-
nant type in 60.4% cases, followed by HPV 31 (8.5%), HPV 33 (6.6%) and HPV 18 (3.7%). In the group of women without
obvious cervical changes the overall hrHPV prevalence was 35.6% with HPV 16 found in 43.8% cases, followed by HPV
31 (17.8%), HPV 33 (9.5%) and HPV 18 (6.8%). In both study groups, women with and without cervical lesions, the prev-
alence of HPV of indeterminate type was 14.2% and 13.7%, respectively. Our results indicate that cervical intraepithelial
lesions are largely associated with HPV type 16, followed by HPV types 31, 33, 18 and HPV of indeterminate type. Al-
though there is a significant difference in hrHPV DNA prevalence among two groups, no significant differences between
particular hrHPV types distribution were observed.
Key words: Cervical intraepithelial lesions, Human papillomavirus(HPV) detection, hybrid capture, HPV preva-
lence, polymerase chain reaction
Introduction
Human papillomavirus (HPV) infection has been iden-
tified as major risk factor for cervical intraepithelial neo-
plasia (CIN) and invasive cervical cancer1,2,. Epidemio-
logical studies indicate a strong association of high-risk
human papillomavirus (hrHPV) genotypes with cervical
carcinoma and malignant transformation of cervical epi-
thelial cells1,2,3.
There are about 40 HPV viral types that are com-
monly found in the genital tract4. The most prevalent
hrHPV genotypes worldwide, which infect uterine cer-
vix, are HPV 16 (~53%), followed by HPV 18 (~15%),
HPV 45 (~9%), HPV 31 (~6%) and HPV 33 (~3%)1. Most
HPV infections resolve spontaneously over 6 to 18
months, while viral persistence is necessary for CIN le-
sions to progress5. According to the Croatian National
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Cancer Registry6, the incidence of cervical cancer in 2004
was 14.4 new cases per 100,000 women. There are only a
few reports describing HPV genotype distribution in ab-
normal cervical Pap smears in Croatia7,8. Initial screen-
ing is presently based on the Pap smear and cytological
examination. Cytology-based cervical cancer screening
using Pap smears and new technologies such as liq-
uid-based cytology have made significant impact on re-
ducing cervical cancer rates worldwide10. Early detection
and appropriate treatment of cervical lesions provide the
best approach to prevent cervical cancer11–13. Treatment
of pre-invasive lesions identified in screening program-
mes is very effective, but care should be taken to avoid
unnecessary over-treatment. HPV testing and prophy-
lactic vaccination will change substantially the use of
cervical cytology, probably in favour to HPV testing as
the primary test in secondary prevention10.
Current studies evaluate the implementation of HPV
testing in screening algorithms for the women with an
increased risk for development of cervical cancer and
those which could undergo unnecessary re-testing14,15.
The aim of this study was to investigate the preva-
lence of HPV DNA and HPV types distribution among
361 women attending regular gynecological visit. Accord-
ing to cytological findings they were separated in the two
study groups: women with normal and women with ab-
normal Pap smears.
Materials and Methods
This study was performed among 361 women attend-
ing regular gynecological examination in Zagreb and
Rijeka County between 2004 and 2006. Informed consent
was sign by all women who participated in the study. Cer-
vical lesions were classified according to »Zagreb 2002«
Uniform Classification of Uterine Cervix Cytological Find-
ings in Croatia9 adapted from the Bethesda system into
normal epithelium, low-grade intraepithelial lesions (LSIL
or CIN1) indicating a low risk of malignant transforma-
tion which may resolve spontaneously, high-grade in-
traepithelial lesions (HSIL, CIN2 or CIN3-carcinoma in
situ) having a potential to progress to invasive cervical
cancer, and finally borderline Pap smears, classified as
atypical squamous cells of undetermined significance
(ASCUS). Cervical smears were obtained from 156 wo-
men (34±15 years old) with LSIL (n=69) and HSIL
(n=72) and ASCUS (n=15). All women from this group
were diagnosed by cytological examination followed by
subsequent HPV detection and genotyping. A second
group of women consisted of 205 women (29±8 years old)
undergoing regular preventive gynecological examina-
tions. Women in this group had normal cytological smears
and were also tested for the presence of HPV DNA, fol-
lowed by subsequent genotyping of HPV DNA positive
cases. All cervical smears were taken with cervical brush
and collected to specimen transport medium (Digene Di-
agnostic, USA) and stored at +4 °C until testing. Samples
were divided into aliquots for hybridization in the liquid
phase and polymerase chain reaction (PCR) tests.
Hybrid capture HPV assay
The Hybrid Capture assay (HC2, Digene Diagnostic,
USA) is based on signal amplification by chemilumines-
cent detection16. Specimens containing the target DNA
hybridize with a specific HPV RNA probe cocktail. The
RNA:DNA hybrids are captured onto the surface of a tube
coated with antibodies specific for hybrids and detected
with a chemiluminescent substrate. The intensity of the
light emitted denotes the amount of target DNA in the
specimen. RNA probe mix for the detection of hrHPV
types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
was used according to the manufacturer’s instructions.
DNA extraction and PCR analysis
DNA was isolated by NucleoSpinTissue kit (Ma-
charey-Nagel, Duren, Germany) according to the manu-
facturer’s instructions. Successful DNA extraction was
confirmed by the presence of b-globin gene sequence17.
Detection of HPV DNA was performed by PCR using E6
and E7 consensus primers pU-1M/pU-2R, which are spe-
cific for HPV 16, 18, 31, 33, 35, 52 and 58 types18 (Human
Papillomavirus Typing Set, Takara Biomedicals, Japan).
HPV typing of HPV 16, 18 and 33 was performed by PCR
with primers chosen within the E6 region (Human Papil-
lomavirus Detection Set, Takara Biomedicals, Japan)19,
while HPV 31 was amplified with primers chosen within
the E7 region of the HPV genome3.
PCR products of 228 to 268 bp for generic amplifica-
tion, and 100 and 140 bp for type-specific amplification
were resolved by electrophoresis on 1.5 to 2% agarose gel.
Statistical analysis
HPV prevalence was expressed as percentage of HPV
positives against all cases tested for HPV. The prevalence
of individual hrHPV genotypes was determined as single
infection. Multiple hrHPV infections were defined as two
hrHPV genotypes. The distribution of non-continuous
cytological variables versus HPV status was analysed
with the Chi-square test (c2). P values of <0.05 were
used as the cut-off for statistical significance.
Results and Discussion
High-risk HPV DNA was detected in 179 and 154 out
of 361 cervical smears by HC2 and PCR, respectively (Ta-
ble 1). It was demonstrated that correlation between
HC2 and PCR was between 85.8% (91/106) to 86.3%
(63/73) This data were additionally confirmed by type-
-specific PCR amplification which failed to detect any
HPV type in 13.7% and 14.2% of cases in the group with
CIN and the group with normal cervical findings, respec-
tively, and was referred as HPV of indeterminate types
(Table 1).
In 25 women, the positive HPV-DNA results obtained
by HC2 test were not confirmed by type-specific PCR am-
plification for HPV types 16, 18, 31 and 33, suggesting a
presence of another HPV type which could be detected by
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the probes of broader HPV type spectrum in the HC2
assay16.
Comparison of the HC2 and PCR with hrHPV prim-
ers demonstrated concordant results in as many as
86.0% (154/179) of HPV-DNA positive samples. There-
fore, PCR method with E7 consensus primers pU-1M/
pU-2R which achieved sensitivity comparable to HC2 is
also a good method for screening assessments. Develop-
ment of methods for simple, rapid and accurate detection
of HPV DNA has a central role in many strategies de-
signed to reduce the risk of cervical cancer20,21.
High-risk HPV infection was present in 73 out of 205
(35.6%) women with normal Pap smear (control group)
and in 106 out of 156 (67.9%) women with abnormal Pap
smear. The hrHPV prevalence is significantly different
between these two groups (c2=37.060, p£0.001) (Table
1). Statistically significant difference in hrHPV preva-
lence was detected in women with LSIL – 62.3% (43/69)
and those with HSIL – 80.6% (58/72) compared to women
with ASCUS – 33.3% (5/15) (c2=14.511, p£0.001 for
trend).
Out of all HPV positive specimens HPV 16 was the
predominant type in all cytological entities detectable in
60.0% of ASCUS, 55.8% of LSIL and 63.8% of HSIL as
well as in 43.8% women with normal Pap smears (Table
1). In most studies HPV 16 was found to be the most
prevalent HPV genotype in cervical cancer, precursors le-
sions and cytologically normal Pap smears5,22. The asso-
ciation of HPV types and histological type of the cancer is
well established; HPV16 being the most frequently found
genotype in squamous cell carcinoma (SCC), while HPV18
in adenocarcinoma23. Our previous study demonstrated
the high overall prevalence of HPV-DNA in cervical neo-
plasia (>90%)24. In CIN3 and SCC, HPV 16 was the most
common hrHPV type, identified in 65% and 52% of cases,
respectively24. Grce et al. have demonstrated that among
Croatian non-pregnant women increase in hrHPV preva-
lence is associated with CIN grade changes from 1 to 3
(35.1%, 64.6% and 81.0%, respectively) with HPV 16 be-
ing predominant type in all cervical lesions7.
HPV 18 was detected in 3.7% (4/106) of women with
intraepithelial lesions and in 6.8% (5/73) specimens of
women with normal smears. HPV 31 and 33 are detected
in 8.5% (9/106) and 6.6% (7/106) cases of CIN, respec-
tively, and in 17.8% (13/73) and 9.5% (7/73) of normal
smears. The high prevalence of HPV 31 (17.8%) was
found in women with normal Pap smears, although the
most relevant studies report average prevalence between
5 and 8%1,3,7,8. Had`isejdi} et al.24 have demonstrated the
unexpected high prevalence of HPV 31 of 10% and 26%
in CIN3 and SCC, but in almost half of these cases as
part of multiple infection.
HPV of indeterminate type was found in 14.2% (15/106)
and 13.7% (10/73) of cases from abnormal and normal
Pap smear groups, respectively. In LSIL cytological group,
the prevalence of indeterminate HPV type 20.9% was the
highest one, although with no statistical significance.
The possible explanation for this finding could be the fact
that HPV of indeterminate type could be low- as well as
high-risk HPV types; there is always a possibility of
cross-hybridization of HC2 RNA probes and in case of
PCR with generic primers amplification of a large num-
ber of different HPV types.
Low prevalence of multiple infections in LSIL and
HSIL as well as in normal Pap smears was found in 6.9%,
5.2% and 8.2% cases, respectively. These data suggest
that single hrHPV infection in LSIL and HSIL (>90%)
are significant for establishing and maintaining prolife-
rative growth of epithelial cells25.
Conclusion
Our results indicate that cervical intraepithelial le-
sions are largely associated with HPV types 16, 31 and 33
followed by HPV 18 and HPV of indeterminate type. A
significant difference between hrHPV prevalence among
the group of women attending regular examination with
normal cytology and the group of women with abnormal
Pap smear was observed. However, no significant differ-
ences between particular hrHPV types distribution were
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TABLE 1













n % n % n % n % n % n % n % n %
ASCUS 15 10 66.7 5 33.3 3 60.0 0 - 1 20.0 0 - 0 - 1 20.0
LSIL 69 26 37.7 43 62.3 24 55.8 1 2.3 3 6.9 3 6.9 9 20.9 3 6.9
HSIL 72 14 19.4 58 80.6 37 63.8 3 5.2 5 8.6 4 6.9 6 10.3 3 5.2
Women with abnormal
Pap smears (34±15 years)
156 50 32.1 106 67.9 64 60.4 4 3.7 9 8.5 7 6.6 15 14.2 7 6.6
Women with normal
Pap smears (29±8 years)
205 132 64.4 73 35.6 32 43.8 5 6.8 13 17.8 7 9.5 10 13.7 6 8.2
hrHPV – high-risk human papillomavirus, *HPV indeterminate: HPV types other than 16, 18, 31, 33, **Multiple HPV infections: posi-
tive for HPV 16/18, 16/31 and 18/31
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observed between the two groups of women. The signifi-
cance of higher prevalence of HPV 31 type in women
with normal Pap smears as well as indeterminate HPV
type in low-grade intraepithelial lesions should be con-
sidered in future epidemiological studies of hrHPV prev-
alence in borderline cervical intraepithelial lesions.
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PREVALENCIJA HPV U CERVIKALNIM BRISEVIMA UZETIM PRIGODOM REDOVITOG
GINEKOLO[KOG PREGLEDA
S A @ E T A K
Infekcija humanim papilomavirusom (HPV) je jedan od glavnih rizi~nih ~imbenika za nastanak cervikalne intra-
epitelijske neoplazije (CIN) i invazivnog karcinoma vrata maternice. Oko 40 HPV tipova je utvr|eno u urogenitalnoj
regiji `ena. Iako u ve}ini slu~ajeva infekcija prolazi spontano, trajna infekcija s HPV tipovima visokog rizika, posebice
HPV-16 i HPV-18 je neophodna za nastanak CIN-a i invazivnog karcinoma. Probiranje na prekancerozne lezije i kar-
cinom vrata maternice danas se temelji na citolo{kom pregledu Papa-razmaza. Cilj i svrha ove studije je bila da se ispita
prevalencija HPV-DNK i odredi raspodjela HPV tipova visokog rizika u skupini `ena (n=361), koje su do{le na redovni
ginekolo{ki pregled i pristale da sudjeluju u studiji. U skupini je bilo 205 `ena `ivotne dobi 29±8 godina s urednim
Papa-nalazom i 156 `ena u dobi 34±8 godina s promjenama u Papa-nalazu; s niskim stupnjem intraepitelijske lezije
(LSIL, engl. Low grade Squamous Intraepithelial Lesions) 68 `ena, s visokim stupnjem intraepitelijske lezije (HSIL,
engl. High grade Squamous Intraepithelial Lesions) 72 `ene i s atipi~nim nalazom plo~astih stanica neodre|enog zna-
~aja (ASCUS, engl. Atypical Squamous Cells of Undetermined Significance) 15 `ena. Odre|ivanje HPV-DNK i tipizacija
provedeni su metodama Hybrid Capture 2 (HC2) i lan~anom reakcijom polimeraze (PCR, engl. Polymerose Chain Reac-
tion) temeljenim na koncenzus i tip-specifi~nim po~etnim oligonukleotidima. Ukupna prevalencija HPV-DNA visokog
rizika u `ena s abnormalnim Papa-razmazom bila je 67,9% (106/156) i to s ASCUS-om 33,4% (5/15), LSIL-om 62,3%
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(43/69) i HSIL-om 80,6% (58/72). Od svih HPV-pozitivnih uzoraka u toj skupini, HPV-16 ja na|en u 60,4% `ena, HPV-
-31 u 8,5%, HPV-33 u 6,6% i HPV-18 u 3,7% `ena. U skupini `ena bez promjena na vratu maternice, ukupna pre-
valencija HPV-DNK visokog rizika je utvr|ena u 35,6% `ena, s udjelom HPV-16 od 43,8%, HPV-31 s 17,8%, HPV-33 s
9,5% i HPV-18 s 6,8%. U obje skupine, prevalencija neodre|enog HPV-tipa bila je 14,2% i 13,7%. Na{i rezultati su
pokazali da su intraepitelijska o{te}enja vrata maternice udru`ene s HPV-tipovima visokog rizika i to 16, 31, 33 i 18 u
vi{e od 85% slu~ajeva, dok preostali dio predstavljaju netipizirani HPV-tipovi.
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A B S T R A C T
Human papillomavirus (HPV) infection is the main cause of cervical cancer, the second most common cancer in
women worldwide. More than 200 types of HPV have been described, and within this range more than 40 types attack ep-
ithelium of genital tract. The types that were most commonly related to the development of cervical cancer are called
high-risk types (HR HPV). There are very few studies about HPV prevalence in Croatia and there is an absolute lack of
data for Split and Dalmatian County. Therefore, during a 6 month period, we routinely screened 570 women for HPV
DNA at the Educational Public Health Institute of Split and Dalmatian County. HR HPV was detected in cervical exfoli-
ated cells, by using Hybrid Capture 2 HPV DNA test. Out of the total number of tested women, 200 (35%) of them were
positive to HR HPV. Polymerase chain reaction (PCR) based assays were employed for HR HPV genotyping in positive
specimens. The following frequency was observed: HPV 16 in 10%, HPV 18 in 6.1%, HPV 31 in 2.6%, HPV 33 in 1.9%,
HPV 52 in 1.4%, HPV 59 in 0.7%, HPV 45 in 0.4% specimens, while 11.9% of tested specimens currently remained
untyped. It is necessary to expand this study to a larger number of women, in order to better evaluate genital HPV types
distribution among women in this region.
Key words: Human papillomavirus (HPV), high-risk genotypes, Split and Dalmatian County, Croatia
Introduction
Cervical cancer is the second most common cancer in
women worldwide. Infection with Human papilloma-
virus (HPV) is the main cause of cervical cancer1. HPV is
the most common sexually transmitted viral disease and
one of the most frequent causal agents of sexually trans-
mitted diseases. Genital HPV infection is rarely reported
(there is no legal obligation). While its prevalence is as-
sumed to be higher than 20 million, the incidence of HPV
infection only in the United States ranges from one mil-
lion to 5.5 million per year2. The prevalence of HPV DNA
in cervical cancer cases is 99.7%3, while in cervical speci-
mens of women without cervical cancer ranges from 5%
to 20%4–6. More than 200 types of HPV are known, and
within this range more than 40 attack epithelium of gen-
ital tract. The types that are most commonly related to
the development of cervical cancer, so called oncogenic or
high-risk types (HR HPV), are: 16, 18, 31, 33, 34, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68 and 702,7. The most common
HPV types in cervical cancer are: HPV type 16 (46% to
63%) and HPV type 18 (10% to 14%)7. There are very few
studies in Croatia about HPV prevalence related only to
cervical specimens of women with abnormal Papani-
colaou (Pap) smear, with the most common types: HPV
type 16 (11.4% to 20.2%) and HPV type 31 (5% to
17.8%)8–10. Concerning the absolute lack of data for Split
and Dalmatian County, we initiated a testing for HPV in
order to evaluate the prevalence in our region.
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Materials and Methods
In the Educational Public Health Institute of Split
and Dalmatian County, during the 6 months period in
2006, HPV screening tests were done in 570 women. The
age range of the study was 18 to 62 years (the average
age 40 years). The study population included all women
referred by their gynecologists for HPV DNA testing to
our laboratory, as a survey of general population (with
unknown cytological diagnosis). HR HPV was detected in
cervical exfoliated cells, by using Hybrid Capture 2 (HC2)
HPV DNA test (Digene Corporation, Gaithersburg, MD
USA). HC2 test was used in screening specimens for high-
risk types of HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68), which had been approved by Food and Drug Ad-
ministration (FDA, USA) for detection of HPV DNA in cer-
vical specimens for diagnostic purpose. This test cannot dif-
ferentiate individual types of HPV within the group2.
Only HR HPV positive specimens analyzed by HC2
test were sent for further genotyping. DNA was ex-
tracted from cervical cells, by using reagents Nucleo Spin
Tissue (Machery-Nagel, Düren, Germany). Genotypes
were distinguished by polymerase chain reaction (PCR)
based assays using primer sequences for HR HPV types:
16, 18, 31, 33, 45, 52, and 59 (Table 1). Positive and nega-
tive controls were included in each reaction. PCR reac-
tions were performed according to the manufacturer in-
struction on PCR system (Applied Biosystems, Foster
City, USA). PCR products were detected using agarose
gel electrophoresis (3% agarose gel). The specific primers
for amplification of the sequence containing E6 region of
HPV types: 16, 18 and 33 were used (TaKaRa, Bio. Inc.,
Japan)11–12. Amplification products yield DNA fragment
of 140 bp for HPV types: 16, 18 and 141 bp for HPV type
33. The presence of HPV types: 31, 45, 52 and 59 was de-
tected by using primers for amplification of the sequence
containing E7 region, described by Walboomers et al.3,
yielding a PCR product of 100 bp.
Results
During routine HPV testing in Split and Dalmatian
County, total of 570 women were tested, and 200 (35%) of
them were positive to HR HPV, when samples were as-
sessed by HC2 test. Only HR HPV positive specimens by
HC2 were further genotyped by PCR based assays. Our
analysis revealed the frequency of HPV 16 in 10%, HPV
18 in 6.1%, HPV 31 in 2.6%, HPV 33 in 1.9%, HPV 52 in
1.4%, HPV 59 in 0.7%, HPV 45 in 0.4% specimens (Table
2). Among HPV positive sample, HPV 16 was the more
abundantly found types in 28.5% cases, followed by HPV
18 (17.5%), 31 (7.5%), 33 (5.5%), 52 (4%), 59 (2%) and 45
(1%), while 68 (34%) specimens remained with unre-
solved genotype (Table 2). Multiple HPV infections were
found in two cases out of 200 (1%): HPV 16 and 33, and
HPV 18 and 31, respectively.
Discussion
Having in mind the absolute lack of data for Split and
Dalmatian County, we screened HPV prevalence in our
region. Our preliminary study included 570 women who
underwent routine screening as a survey of general pop-
ulation with either normal or abnormal Pap smears. Our
results showed that 35% of them were positive for HR
HPV. These positive samples detected by HC2 were fur-
ther genotyped by type-specific primer-directed PCR for
7 most common types of HR HPV (Table 1). In our study,
among HPV positive sample the most commonly found
HPV types were: HPV 16 in 28.5%, HPV 18 in 17.5%, and
HPV 31 in 7.5% specimens, while 68 (34%) specimens
currently remained undetermined (Table 2).
The prevalence of HR HPV in cervical specimens of
women without cervical cancer ranges from 5% to 20%
worldwide, while in healthy women with normal Pap
smears it is approximately 10%4–6. Among European
women with low grade lesions found in Pap smears, HPV
prevalence in exfoliated cells is 67.8%, with the most
common HPV types: HPV type 16 in 19.4% specimens
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HPV – Human Papillomavirus
TABLE 2
HIGH-RISK HPV FOUND IN THE CERVICAL SPECIMENS AMONG








16 57 10.0 28.5
18 35 6.1 17.5
31 15 2.6 7.5
33 11 1.9 5.5
52 8 1.4 4.0
59 4 0.7 2.0
45 2 0.4 1.0
others 68 11.9 34.0
HPV – Human Papillomavirus
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and HPV type 31 in 10.4% specimens. Prevalence of HPV
type 18 in Europe is 5.1%, but ranges from 0% to 31.4%,
compared by region13. Very few studies about HPV prev-
alence in Croatia were conducted. The studies presented
by Grce et al. analyzed only women with abnormal Pap
smears. According to these studies in Croatia, HPV prev-
alence in cervical specimens of women with abnormal
Pap smears ranges from 43% to 64%, with the most com-
mon types: HPV type 16 (11.4% to 20.2%) and HPV type
31 (5% to 17.8%)8–10. In our study, we had unexpectedly
high number of specimen without genotype (34%), in
comparison to studies by Grce et al. that reported from
23.7% to 49% of untyped HPV DNA positive samples9,10.
This result might be due to presence of other rare types
of HPV, insufficient quantity of DNA in the specimen or
due to differences between detection methods (HC2 and
PCR). The integrity of DNA from 68 specimens with un-
resolved HPV genotype was further tested for b-actin by
PCR, and 13 (19.1%) did not yield amplification product.
Our results of HR HPV genotyping are slightly differ-
ent from those found in other studies conducted in Cro-
atia due to several reasons. In previous studies regarding
HPV prevalence in Croatia, mainly women with abnor-
mal Pap smears were tested for the presence of HPV and
typed for a limited number of HPV types (HPV 6/11, 16,
18, 31 and 33)8–10. In our study, population included
women who were referred by their gynecologists for HPV
DNA testing to our laboratory (with unknown cytological
diagnosis). Furthermore, in this study HPV DNA posi-
tive samples by HC2 were further genotyped for more
HR HPV types (HPV 16, 18, 31, 33, 52, 59 and 45) than
those reported in previous studies. The frequency of
HPV types in the study of Grce et al. 20019 conducted on
1,874 cervical specimens collected in the region of Zagreb
and this study are similar for HPV types 16 (12 versus
10%) and 33 (2.7 versus 1.9%), but discordant for HPV
18 (2.4 versus 6.1%) and 31 (5.1 versus 2.6%). The reason
for these discrepancies could be (1) small number of ana-
lyzed sample in this study, (2) the choice of type-specific
primers for DNA amplification, and (3) different distri-
bution of HR HPV types in both Counties. Split and Dal-
matian County is an important tourist region of Croatia
with a high number of tourists passing through. It is also
a maritime centre with the port and significant number
of seamen that are carriers of HPV types gained from all
over the world and spread within this County. Due to
these reasons, it is important to continue this study on
larger number of specimens and to enlarge the spectrum
of genotyping of HR HPV in order to evaluate HPV geni-
tal types distribution among women in this region, espe-
cially in the context of HPV vaccine application.
Conclusion
The data obtained from our study indicate that HPV
16 and 18 are the most common HPV types found in the
cervical specimens among women of Split and Dalmatian
County as in most studies worldwide. However, low abun-
dant HR HPV types differ between regions in Croatia. In
our opinion, it is necessary to expand this study to a
larger number of women in order to obtain a better dis-
tribution of HR HPV types in Split and Dalmatian Co-
unty.
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RASPODJELA POJEDINIH TIPOVA HUMANOGA PAPILLOMA VIRUSA U UZORCIMA
OBRISKA VRATA MATERNICE @ENA SPLITSKO-DALMATINSKE @UPANIJE
S A @ E T A K
Infekcija uzrokovana human papillomavirusom (HPV) je glavni ~imbenik razvoja karcinoma vrata maternice, dru-
goga po u~estalosti me|u karcinomima u `ena u svijetu. Poznato je vi{e od 200 tipova HPV-a, od kojih vi{e od 40 tipova
napada epitel spolnoga sustava. Tipovi koji se naj~e{}e povezuju s razvojem karcinoma vrata maternice nazivaju se
visokorizi~ni tipovi (HR, engl. High Risk HPV). U Hrvatskoj je, do sada, napravljeno svega nekoliko studija o pre-
valenciji HPV-a, a ne postoje nikakvi podatci za Splitsko-dalmatinsku `upaniju. Zbog toga smo, u Nastavnom zavodu za
javno zdravstvo Splitsko-dalmatinske `upanije, napravili probir 570 `ena na HPV DNK, u razdoblju od 6 mjeseci. HR
HPV dokazan je u obriscima vrata maternice, metodom HC2 (Hybrid Capture 2, Digene). Od ukupnoga broja testiranih
`ena njih 200 (35%) je bilo pozitivno na visokorizi~ne tipove HPV-a. Daljnjom genotipizacijom HR HPV pozitivnih uzo-
raka, metodom lan~ane reakcije polimerazom (PCR, engl. Polymerase Chain Reaction), utvr|ena je u~estalost tipa 16 u
10% uzoraka, tipa 18 u 6,1%, tipa 31 u 2,6%, tipa 33 u 1,9%, tipa 52 u 1,4%, tipa 59 u 0,7%, tipa 45 u 0,4% uzoraka, dok
su 11,9% uzorka, za sada, ostala netipizirana. Smatramo da je neophodno pro{iriti studiju na ve}i broj ispitanica, te
nastaviti pra}enje pro{irenosti pojedinih tipova HPV-a u `ena ove regije.
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Genital Human Papillomavirus Infection
in Women from the Zagreb Region
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A B S T R A C T
Human papillomavirus (HPV) infection is the most common sexually transmitted infection, especially among young,
sexually active individuals. As persistent infection with oncogenic types may lead to cervical cancer, HPV testing is a use-
ful tool to screen for women at risk for subsequent development of cervical cancer. The aim of the study was to determine
the prevalence of high-risk HPV (hrHPV) infection in different age groups of cytologically selected women from the
Zagreb region, and to evaluate the frequency and results of repeat hrHPV testing. During a one-year study period (No-
vember 2005 to November 2006), a total of 3,440 cervical samples from women attending gynecological services of public
and private health care systems were received. They were tested for 13 hrHPV genotypes by the polymerase chain reaction
based AMPLICOR HPV test (Roche Molecular Systems). The overall prevalence of hrHPV was 34.6%. Most samples were
obtained from women aged 21–30 years (44.2%), followed by the 31–40 (27.6%), 41–50 (15.7%), 51–60 (5.3%) and ³61
(2.4%) age groups. Out of 3,227 cervical samples obtained from women of known age, 4.9% were obtained from the group
of girls younger than 21, in which the highest prevalence of hrHPV (49.4%) was found. A similar prevalence was ob-
served in women aged 21–30 (45.1%). The prevalence gradually decreased with age. During the study period, repeat
hrHPV testing was performed in samples from 66 women at different intervals. Out of 28 women that were hrHPV nega-
tive on initial testing, only five women turned positive on repeat testing. Out of 38 women that were positive on initial
testing, in one-third hrHPV could not be detected on repeat testing. As expected, hrHPV infection was highly prevalent in
female adolescents and young women. Further investigation on repeat hrHPV testing is needed to assess virus clearance
and rate of newly acquired infection.
Key words: High-risk human papillomavirus (hrHPV), prevalence, AMPLICOR HPV Test, repeat hrHPV testing
Introduction
Human papillomavirus (HPV) infection is the most
common sexually transmitted infection1. Among more
than 100 known HPV genotypes, there are 40 that affect
anogenital mucosa2. According to their potential to in-
crease the risk of cervical cancer, they are divided into
low-risk group, which is usually associated with benign
lesions such as condylomata acuminata, and high-risk
HPV (hrHPV) genotypes, which have a role in cervical
carcinogenesis3. High-risk HPV types are demonstrated
in almost 100% of cervical carcinomas4. The infection is
especially prevalent among sexually active adolescents
and young adults, but usually of short duration in these
age groups5. Only persistent infection, which is more
common in older women, may lead to cervical cancer and
its precursor lesions, cervical intraepithelial neoplasia
2/3 (CIN 2/3). The precise role of HPV in the etiology of
cervical cancer is unknown and the host immune system
is considered to be of crucial importance in HPV clear-
ance or development of persistence after primary in-
fection6,7.
HPV testing has a recognized role in improvement of
cervical-cancer screening programmes, evaluation of wo-
men with unclear or low-grade cytological abnormalities,
and follow-up of patients treated for CIN3,8,9. The only
test currently approved by the U.S. Food and Drug Ad-
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ministration for HPV detection is Hybrid Capture 2 HPV
DNA test (HC2) (Digene Corporation, Gaithersburg, MD,
USA). This signal amplification assay detects 13 high-
-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68)
and five low-risk (6, 11, 42, 43 and 44) HPV types. Al-
though evaluation of its laboratory performance has con-
firmed its reliability and reproducibility, several recent
studies showed a significant analytical inaccuracy, mainly
due to the cross-reactivity of its high-risk probe cock-
tail10–12. In 2003, a newly developed polymerase chain re-
action based AMPLICOR HPV test (F. Hoffmann-La
Roche Ltd., Basel, Switzerland) was marketed. This tar-
get amplification test detects the same 13 hrHPV types
as HC2 assay, with simultaneous detection of human
b-globin gene, which allows assessment of cellular ade-
quacy, extraction and amplification of each processed
specimen. Some recent studies demonstrated the HC2
assay and AMPLICOR HPV test to give comparable re-
sults, both being suitable for routine use13,14. In a recent
study, the AMPLICOR HPV test demonstrated even
higher analytical sensitivity and specificity13. While the
higher analytical specificity of AMPLICOR HPV in com-
parison to that of HC2 can be considered clinically bene-
ficial, the clinical importance of the higher analytical
sensitivity of AMPLICOR HPV is still a matter for exten-
sive professional discussion13,15.
The aim of the study was to determine the prevalence
of hrHPV infection in different age groups of women
from the Zagreb region using AMPLICOR HPV test, and
to evaluate the frequency and results of repeat hrHPV
testing in the same population.
Materials and Methods
Patients and clinical specimens
During the one-year study period (November 2005 to
November 2006), a total of 3,440 cervical cell specimens
for hrHPV testing were received at the Laboratory of
Molecular Microbiology, Zagreb Institute of Public Health.
The specimens were obtained from cytologically selected
women attending gynecological services of public and
private health care systems in the Zagreb region. The
median age of the women was 31 (range, 15–73) years.
For 213 specimens no data on the patients’ age were
available. Cervical samples were collected by 46 gynecol-
ogists using Cervex-Brush (Rovers Medical Devices). Up-
on sampling, the brush was washed in a ThinPrep vial
containing PreservCyt solution (Cytyc Corporation, Box-
borough, MA, USA). During the study period, repeat
hrHPV testing was performed in samples from 66 wo-
men at different time intervals. The indication for repeat
testing was clinical evaluation of the patients.
Specimen preparation
HPV DNA was isolated from the PreservCyt solution
using AmpliLute Liquid Media Extraction kit (AMPLI-
COR HPV test, Roche Molecular Systems) according to
the manufacturer’s instructions. Briefly, HPV DNA was
released by lysing cervical cells under denaturing condi-
tions at elevated temperatures in the presence of pro-
teinase K, chaotropic agent and detergent, isolated and
purified over columns with silica-based membrane using
vacuum pressure, and eluted with elution reagent. Dur-
ing the procedure, the human b-globin gene was concur-
rently isolated, allowing assessment of cellular adequacy,
extraction and amplification of each processed specimen.
Amplification
Polymerase chain reaction (PCR) based AMPLICOR
HPV test (Roche Molecular Systems) is designated to
amplify HPV DNA from 13 high-risk genotypes (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). The test am-
plifies 165 bp long nucleotide sequence within the poly-
morphic L1 region of the HPV genome with a master mix
containing biotin labeled primers. An additional primer
pair is added to allow simultaneous amplification of the
human b-globin gene (268 bp amplicon). PCR was per-
formed with a final reaction volume of 100 mL, contain-
ing 50 mL of AMPLICOR HPV master mix and 50 mL of
isolated DNA, on GeneAmp PCR System 9700 with gold
block (Applied Biosystems, Foster City, CA, USA) using
AMPLICOR defined parameters: 2 min at 50 °C and 9
min at 95 °C, followed by 40 cycles of: 30 s at 95 °C, 45 s at
54 °C and 30 s at 72 °C, with a final extension at 72 °C for
no longer than 1 h.
Hybridization and detection
After amplification, the amplicons were chemically
denatured to form single-stranded DNA. Two separate
96-microwell plates, one coated with HPV high-risk probes
and the other with b-globin specific oligonucleotide prob-
es, were used for HPV and b-globin detection. After add-
ing of AMPLICOR hybridization buffer and denatured
amplicons to appropriate wells of both detection plates,
hybridization reaction occurred. Following hybridization
and washing procedures, bound hybrids were detected
with a biotin avidin-horseradish peroxidase assay. The
absorbance at 450 nm was measured immediately using
an automated microwell plate reader (Anthos 2010,
ASYS Hitech, BIOCHROM Group, Great Britain). Ac-
cording to AMPLICOR instructions, HPV absorbance
reading of ³0.20, accompanied with any value of b-globin
result, was considered positive for the presence of hrHPV.
HPV result of <0.20 and b-globin result of ³0.20 was con-
sidered negative for the presence of hrHPV. Test result
could not be interpreted if both (HPV and b-globin)
absorbance values were <0.20. HPV DNA, if present,
could not be detected because of inadequate cell content
of specimen or inadequate extraction or amplification
procedure. In that case, another aliquot of original speci-
men was retested and, if the same result appeared, new
specimen collection was recommended.
Statistical methods
Proportions were compared by the c2-test. A p value
<0.01 was considered statistically significant. The 95%
confidence interval for a proportion was calculated ac-
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cording the Wilson procedure with a correction for con-
tinuity16. The decrease of hrHPV prevalence with age
was estimated by the c2-goodness of fit to rectangular
distribution using STATISTICA 7.1 (StatSoft Inc., Tulsa,
OK, USA).
Results
Results of this study conducted during the one-year
period in 3,440 cervical samples tested for the presence
of 13 hrHPV types by AMPLICOR HPV test showed the
overall hrHPV prevalence to be 34.6%. Out of 3,227 cer-
vical specimens from women of known age, hrHPV was
detected in 1,120 (34.7%) samples. In four (0.1%) sam-
ples, HPV test results could not be interpreted. Out of
213 cervical samples from women with no age data avail-
able, hrHPV was detected in 70 (32.9%) samples (c2=
0.24, p>0.01).
Out of 3,227 cervical samples obtained from women of
known age, 158 (4.9%) were obtained from the group of
girls younger than 21, in which the highest prevalence of
hrHPV (49.4%) was recorded. Most cervical specimens
were obtained from women aged 21–30 (1,425 samples,
44.2%); in this group hrHPV was detected in 642 (45.1%)
patients. The prevalence of hrHPV gradually decreased
with age (c2=1,531.3, df=5, p<0.01). In the 31–40 age
group (27.6% of study patients), the recorded prevalence
was 28.9%, followed by 19.3% in the 41–50 age group and
13.5% in the 51–60 age group. In women older than 60,
the prevalence of hrHPV was 28.9% (Table 1). There was
a statistically significant difference in the distribution of
hrHPV genotypes according to age groups (c2=183.96,
df=5, p<0.01), which was due to the higher prevalence of
hrHPV in younger women (£30 years).
Out of 3,440 cervical samples tested for hrHPV, 1,168
(34%) of samples were diagnosed as atypical squamous
cells of undetermined significance (ASCUS), 468 (13.6%)
of samples were diagnosed as dysplasia levis or CIN 1,
152 (4.4%) of samples were diagnosed as CIN 2 (n=107),
CIN 3 (n=43) or carcinoma in situ (n=2), and for 1,652
(48%) of samples the informations regarding cervical ab-
normalities were not available. In the ASCUS group
hrHPV was detected in 432 (37%) patients. The preva-
lence of hrHPV increased with the severity of cervical
lesions. In the CIN 1 group hrHPV was detected in 201
(43%) and in the CIN 2/3 group in 111 (73%) patients
(c2=158.1, p<0.01).
During the study period, repeat hrHPV testing was
performed in samples from 66 women at different inter-
vals. Out of 28 women found to be hrHPV negative on
initial testing, only five women turned positive on repeat
testing. Six women underwent retesting within three
months of initial testing, all of them being negative for
hrHPV again. Of twelve women that underwent re-test-
ing within 3–6 months, hrHPV was detected in three
cases. In seven women, repeat testing was performed
within 6–9 months, one of them being positive for hr-
HPV. Three women underwent retesting within 9–12
months, with hrHPV detected in one case.
On repeat testing, hrHPV could not be detected in
one third of 38 women found hrHPV positive on initial
testing. Repeat testing within three months was per-
formed in 11 women, two of them negative; within 3–6
months in 15 women, six of them negative; within 6–9
months in nine women, four of them negative; and with-
in 9–12 months in three women, all of them positive.
Discussion and Conclusion
The present study assessed the prevalence of hrHPV
types among cytologically selected women from a large,
well-defined region in Croatia, tested during the one-
-year period at Zagreb Institute of Public Health. In
3,440 tested women with cytologically abnormal smears,
the prevalence of hrHPV was 34.6%.
The prevalence of hrHPV is known to decrease with
age, from 20% among women aged 20–30 to 5% in women
aged >30, as estimated in previous studies in pregnant
and non-pregnant women with cytomorphologically nor-
mal cervical smears17–19. Although the prevalence of
hrHPV is considerably higher among women with cyto-
logically abnormal smears, a higher rate of hrHPV is still
recorded in women aged <30 than in those from older
age groups irrespective of the grade of cytological abnor-
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TABLE 1
RESULTS OF CERVICAL SAMPLES TESTED FOR 13 HIGH-RISK HPV GENOTYPES BY AMPLICOR





n=4 % n=1,120 % 95%CIc
£20 158 0 0 78 49.4 41.4–57.4
21–30 1,425 2 0.1 642 45.1 42.5–47.7
31–40 889 2 0.2 257 28.9 26.0–32.0
41–50 508 0 0 98 19.3 16.0–23.1
51–60 171 0 0 23 13.5 8.9–19.7
³61 76 0 0 22 28.9 19.4–40.7
HPV – human papillomavirus, aNT – not possible to interpret, bc2=183.96, df=5, p<0.01, cCI – confidence interval
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mality. A recent study of the distribution of HPV types in
ThinPrep Papanicolaou (Pap) tests classified according
to the »Bethesda 2001 terminology« in correlation with
patient age detected one or more of 13 hrHPV types in
53% of samples diagnosed as atypical squamous cells of
undetermined significance (59% of patients aged <30
and 45.5% of patients aged 30), 55.5% of samples diag-
nosed as low-grade squamous intraepithelial lesion (60%
of patients aged <30 and 44% of patients aged 30), 80%
of samples in which the high-grade squamous intraepi-
thelial lesion could not be ruled out; and 87.5% of sam-
ples diagnosed as high-grade squamous intraepithelial
lesion20. In the present retrospective study, most cervical
specimens were obtained from women aged 21–30 (44.2%),
in which group hrHPV was detected in 45.1% of patients.
Limitations of the study included the unavailability of
cytological, clinical and epidemiological data for all pa-
tients, and involvement of a great number of gynecolo-
gists and cytologists, which resulted in variable classifi-
cation of cervical abnormality. Additional prospective
investigation of samples cytologically diagnosed accord-
ing to the »Bethesda 2001 guidelines« is needed.
As expected, hrHPV infection was found to be highly
prevalent in female adolescents and young women from
the Zagreb region. Similar findings were recorded in a
study conducted in 1998 and 1999 in Croatia, when 466
women with minor and moderate cervical abnormalities
were tested. The prevalence of hrHPV was found to be
66% in women aged <20, 57% in women aged 20–29, and
65% in women aged 30–3921. In this study, the decline of
hrHPV prevalence with age was less pronounced because
of the small number of subjects, especially those over age
50. In another study published in 2001, assessing the
prevalence of HPV in cervical specimens obtained from
1,874 women with abnormal Pap smears collected during
the 1996–1998 period, the HPV positivity rate declined
with age22. In a more recent study, the same authors
demonstrated the presence of HPV in cervical samples to
significantly increase with the severity of cervical le-
sions23. The same was observed in the present study
which is valuable because of the great number of women
included, yielding relevant epidemiological data for this
geographical region. However, properly designed, target
studies are necessary to overcome the shortcomings of
the present, retrospective study.
During the one-year study period, only 66 women
were tested on multiple occasions, which cannot be con-
sidered a relevant sample, therefore further investiga-
tion with repeat hrHPV testing is needed to assess virus
clearance and rate of newly acquired infection in correla-
tion with patient age and cytological diagnosis.
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INFEKCIJA GENITALNIM HUMANIM PAPILOMAVIRUSIMA U @ENA
SA ZAGREBA^KOG PODRU^JA
S A @ E T A K
Infekcija humanim papilomavirusima (HPV) naj~e{}a je spolno prenosiva bolest, poglavito u mladih, seksualno ak-
tivnih osoba. Kako ustrajna infekcija mo`e dovesti do raka vrata maternice, testiranje na HPV je korisno sredstvo u
probiranju `ena koje su pod pove}anim rizikom od razvoja karcinoma vrata maternice. Cilj ovoga rada bio je utvrditi
prevalenciju infekcije HPV visokog rizika (hrHPV, engl. high risk HPV) u razli~itim dobnim skupinama citolo{ki odab-
ranih `ena sa zagreba~kog podru~ja, te analizirati u~estalost i rezultate ponovljenih testiranja na hrHPV. U promat-
ranom jednogodi{njem razdoblju (studeni 2005. do studeni 2006.) ukupno je zaprimljeno 3.440 uzoraka obrisaka vrata
maternice `ena iz ginekolo{kih ambulanata domova zdravlja i privatnih ginekolo{kih ordinacija. Uzorci su testirani na
prisutnost 13 genotipova hrHPV testom AMPLICOR HPV (Roche Molecular Systems), koji se temelji na lan~anoj re-
akciji polimerazom. Ukupna prevalencija hrHPV iznosila je 34,6%. Ve}ina uzoraka zaprimljena je od `ena u dobnoj
skupini od 21–30 godina (44,2%), a slijedile su dobne skupine `ena od 31–40 (27,6%), 41–50 (15,7%), 51–60 (5,3%) i ³61
godine (2,4%). Od ukupno 3.227 obrisaka vrata maternice zaprimljenih od `ena poznate dobi 4,9% je otpadalo na po-
pulaciju djevojaka mla|ih od 21 godine. U toj dobnoj skupini utvr|ena je najve}a prevalencija infekcije hrHPV (49,4%).
Sli~na prevalencija uo~ena je u `ena dobne skupine od 21–30 godina (45,1%). U starijim dobnim skupinama preva-
lencija se postupno smanjivala. U promatranom razdoblju testiranje na hrHPV ponovljeno je u razli~itim vremenskim
razmacima na uzorcima dobivenim od 66 `ena. Od 28 `ena koje su na prvom testiranju bile negativne samo ih je pet bilo
pozitivno na ponovnom testiranju. Od 38 `ena koje su na prvom testiranju bile pozitivne u jedne tre}ine se hrHPV se
nije mogao utvrditi kod ponovnog testiranja. Kako se je o~ekivalo, infekcija hrHPV naju~estalija je u adolescentica i
mladih `ena. Potrebna su daljnja istra`ivanja o ponavljanim hrHPV testiranjima kako bi se mogla procijeniti stopa
i{~ezavanja virusa i stopa novo ste~enih infekcija.
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Retrospective Study of the Prevalence of
High-Risk Human Papillomaviruses among
Croatian Women
Nina Milutin-Ga{perov, Ivan Sabol, Gordana Halec, Mihaela Matovina and Magdalena Grce
Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia
A B S T R A C T
The infection with Human papillomavirus (HPV) is the necessary cause for cervical cancer. There are at least 15
High-Risk (HR) HPV types that are significantly associated with progression of cervical intraepithelial neoplasia to cer-
vical cancer. Since previous studies showed that the prevalence of HPV in cervical cancers varies among different geo-
graphic regions, we wanted to investigate the prevalence of HPV types in Croatia, especially low abundant HR HPV
types. By means of consensus primers directed polymerase chain reaction (PCR), we analysed cervical DNA samples of
2,136 Croatian women, mostly with abnormal cervical smears, in order to detect the presence of HPV. Type-specific prim-
ers were then used to determine Low-Risk (LR) HPV types 6/11 and HR HPV types 16, 18, 31, 33, 45, 52 and 58. Out of
2,136 specimens, 1,255 (58.8%) were positive for HPV. More than half of positive samples were typed (64.5%) and 35.5%
still remained untyped. Multiple HPV infections were found in 10.3% of the cases. The most prevalent type, including
both single and multiple infections, was HPV 16 with the prevalence of 15.9%, followed by HPV types 31, 6/11, 33, 18, 52,
45 and 58 with 8.7%, 7.1%, 4.5%, 3.8%, 2.3%, 1.2% and 1.1%, respectively. The significant increase of frequency from
Low-grade Squamous Intraepithelial Lesions (LSIL) to High-grade Squamous Intraepithelial Lesions (HSIL) was ob-
served for HR HPV types 16, 18, 31 and 33 but not 45, 52 and 58. The frequency of unknown HPV types was almost the
same in cervical specimens of women with LSIL and those with HSIL, 19.8% and 21.1%, respectively. The prevalence of
HPV infection rate decreased significantly with patient age from 68.5% (age group 12 to 24 years) to 38.8% (age group 45
to 54 years). But, in women aged 55 or older the overall prevalence increased to 56.6%. Our results indicate that preva-
lence of HR HPV types in Croatia is similar to other countries. We suggest that HPV positive women in Croatia should be
closely monitored by typing for HR HPV types: 16, 18, 31, 33, 45, 52 and 58.
Key words: human papillomavirus (HPV), high-risk (HR) types, Croatia
Introduction
Cervical cancer is the second most common malig-
nancy after breast cancer among women worldwide.
More than 80% of cases occur in developing countries. In
2002, about 493,000 cervical cancer cases (incidence rate
16/100,000) and about 273,000 deaths from cervical can-
cer (mortality rate 8.9/100,000), respectively, were re-
corded worldwide1. The incidence and mortality rates in
Croatia in 2002 represents the intermediate value of the
highest and lowest rates noted in Europe, with 431 cases
(incidence rate 18/100,000) and 209 deaths (mortality
rate 8.7/100,000) from cervical cancer, respectively2,3.
This indicates that cervical cancer represents a major
health concern in Croatia that needs to be improved.
Epidemiological studies have clearly established hu-
man papillomavirus (HPV) infection as the prerequisite
for cervical cancer4. Studies in 22 countries coordinated
by the International Agency for Research on Cancer
(IARC), identified HPV DNA in almost all (99.7%) of
about 1,000 cases of cervical cancer5. To date, more than
200 different HPV types have been recognized on the ba-
sis of DNA sequence data6. More than 100 HPV geno-
types are well characterized7. Over 40 types infect the
human anogenital area, of which some can cause genital
warts and others can lead to precursor cervical lesions,
CIN (cervical intraepithelial neoplasia) and cervical
cancer7. At least 15 HPV types are significantly associ-
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ated with progression of CIN to cervical cancer and are
considered carcinogenic and named High-Risk (HR)
HPV types8. Thus, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73 and 82 were classified as HR or carcino-
genic types, HPV 26, 53 and 66 as probable carcinogenic
types, while HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81
and CP6108 as Low-Risk (LR)8. In contrast to HR HPV
types, LR types are associated with benign genital warts
and only occasionally found in cervical carcinomas. Ac-
cording to the epidemiological and the phylogenetic stud-
ies, most HR HPV types associated with lesions of simi-
lar pathologies are phylogenetically related to either
HPV 16 (31, 33, 35, 52 and 58) or HPV 18 (39, 45, 59 and
68)7.
The prevalence of HPV types in cervical cancers var-
ies among different geographic areas4,9–10. In a worldwide
survey, HPV 16 was found to be the most prevalent type
in cervical cancer (51.0%), followed by HPV 18 (16.2%)
and other types such as HPV 45, 31, 33, 58 and 52 (collec-
tively accounting for 18.3% cases)4. In Europe, beside
HPV 16, types 18, 33, 31 and 45 were the most frequently
found HR HPV types in cervical cancer4. Infection with
HPV 45 was found to be third most frequent in Africa, af-
ter HPV 16 and 18. HPV 52 and 58 are less frequent in
Europe, but not uncommon worldwide, especially in Asia,
being the most frequently found HR HPV types after 16
and 184.
There is limited data regarding the prevalence of low
abundant HR HPV types in Croatia. Therefore, the aim
of this study was to evaluate the prevalence of HR HPV
types 45, 52 and 58 among Croatian women on the archi-
val DNA samples where HPV types 6/11, 16, 18, 31 and
33 were previously determined11,12.
Material and Methods
Study population
Two thousand one hundred and thirty six Croatian
women, mostly with abnormal cervical smears, were en-
rolled in this study. The cervical specimens for HPV detec-
tion and typing were collected in different gynaecological
hospital clinics in Zagreb, Croatia11,12. The cytological
diagnosis13 of the study population consisted of 0.7% (15/2,
136) normal Pap smears, 24.8% (529/2,136) ASCUS (atyp-
ical squamous cells of undetermined significance), 28.8%
(615/2,136) LSIL (Low-grade Squamous Intraepithelial
Lesions) and 40.9% (874/2,136) HSIL (High-grade Squa-
mous Intraepithelial Lesions). Furthermore, there were
4.8% (103/2,136) women with unknown cytological diag-
nosis.
DNA preparation
DNA from cervical cell samples was isolated as de-
scribed previously11,12. Briefly, cervical cell suspensions
were collected and treated with proteinase K (100 µg/ml
in lysis buffer, 10 mM Tris-HCl; pH 7.5, 1 mM EDTA, pH
7.9; 0.5% SDS) overnight at 37°C or 2h at 56°C. Standard
phenol-chloroform extraction and ethanol precipitation
were used for DNA purification. Pelleted DNA was resus-
pended in 50–100 L of deionised sterile water and
stored at –20°C until further analysis14. In order to deter-
mine the quality and the quantity of isolated DNA, each
DNA was analysed by electrophoresis on 1% agarose gels
stained with ethidium bromide and spectrophotomet-
rically14.
HPV detection and typing
Cervical DNA samples were tested for the presence of
HPV DNA by PCR based method as previously des-
cribed11,12–15. Briefly, two sets of consensus primers: MY09/
MY11, degenerated primers, and L1C1/L1C2-1/L1C2-2
primers were used for HPV DNA detection. To internally
control the quality of the target DNA and the absence of
PCR inhibitors, -globin specific primers were used in
the multiplex PCR with MY09/MY11 primers. Type-spe-
cific primers for HPV 6/11, 16, 18, 31 and 33 were also
used in two separate multiplex PCRs, i.e. HPV 6/11 with
31 and HPV 16, 18 with 33. All amplification reactions
were performed on 100 ng of each DNA in a total volume
of 20 l under the optimized conditions as previously
described11,12–15.
In this study, archival DNA samples were additionally
examined for the presence of HPV 45, 52 and 58 with
type-specific primers directed PCR, also 5,16. The reaction
mixtures contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2, 100 M of each dNTP, 0.15 M of each
type-specific primer, 0,12 U AmpliTaq Gold DNA Poly-
merase (Roche) and 100 nm of each DNA in a total vol-
ume of 20 l. The amplification conditions for HPV 52
and 58 consisted of 30 cycles of denaturation at 95°C for
30 sec, annealing at 56°C for 30 sec and extension at 72°C
for 30 sec, while for HPV 45 it consisted of 35 cycles of de-
naturation at 95°C for 40 sec, annealing at 55°C for 40 sec
and extension at 72°C for 45 sec, with in both cases an
initial denaturation at 95°C for 10 min and a final exten-
sion of 7 min.
Aliquots (10 l) of each PCR product were resolved by
electrophoresis in a 2% agarose gel stained with ethi-
dium bromide14. The amplified products were identified
by UV irradiation of the gels, and photographed by Im-
age Master VDS (Pharmacia Biotech).
Statistical analysis
The standard Chi-square (c2) test was used. Two-
-tailed p values were calculated in 2 x 2 tables using the
GraphPad Prism (version 4.00) (GraphPad Software,
San Diego, California). All tests were two sided and the
significance level was set at p  0.0517.
Results
The average age of the study population was 30.6
(ranging from 12 to 75 years of age). The distribution of
patient cytological diagnosis according to patient age is
shown in Figure 1.
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Distribution of different HPV types
All DNA specimens prepared from cervical cell sam-
ples were -globin positive and as such suitable for fur-
ther HPV DNA detection and typing by PCR. Out of
2,136 DNA samples, 1,255 (58.8%) were positive for any
HPV type (Tables 1 and 2).
More than half (64.5%) of HPV positive samples were
typed. In 445 (35.5%) samples HPV type was not deter-
mined (HPV X). Multiple HPV infections with two or more
HPV types were found in 10.3% (129/1,255) of the cases,
mainly among younger women (mean age 26) (Table 2).
LR HPVs (types 6 or 11) appeared as single infections
only in 4.9% (104/2,136) cases. Among HR HPVs, type 16
was the most frequently found as single infection in
11.9% (254/2,136) of the cases, followed by HPV types 31,
33, 18, 52, 45 and 58 found in 5.7% (121/2,136), 2.8%
(60/2,136), 2.6% (55/2,136), 2.2% (46/2,136), 1.0% (22/2,
136), and 0.9% (19/2,136) of the cases, respectively (Ta-
bles 1 and 2).
Out of 129 multiple HPV infections (Table 3), there
were 82 (63.6%) co-infections of two or three HR HPVs
and 47 (36.4%) co-infections of LR HPV (type 6 or 11)
and one or two HR HPV types. The co-infection of HPV
types 16 and 31 or 16 and 6/11 were the most frequent,
present in 25.6% (33/129) and 19.4% (25/129) cases, re-
spectively.
Prevalence of different HPV types
HPV 16 was present in 85 multiple infections and in
254 single infections, which increases the total preva-
lence of HPV 16 in the study population to 15.9% (339/2,
136). HPV 31 was the second most frequent HPV type,
being represented in 65 multiple infections and 121 sin-
gle infections, with a final prevalence of 8.7% (186/2,136)
(Figure 2). The prevalence, including both single and
multiple infections, of HPV types 6/11, 18, 33, 45, 52 and
58 was 7.1% (151/2,136; not shown), 3.8% (82/2,136),
4.5% (95/2,136), 1.2% (25/2,136), 2.3% (49/2,136) and
1.1% (23/2,136), respectively (Figure 2).















Fig. 1. Distribution of patient diagnosis according to patient age.
ASCUS – atypical squamous cells of undetermined significance,
LSIL – low-grade squamous cell intraepithelial lesion, HSIL –
high-grade squamous cell intraepithelial lesion.
TABLE 1





Unknown Normal ASCUS LSIL HSIL
N % N % N % N % N % N %
HPV 6/11 5 4.9 0 0.0 29 5.5 29 4.7 41 4.7 104 4.9
HPV 16 10 9.7 0 0.0 49 9.3 46 7.5 149 17.1 254 11.9
HPV 18 3 2.9 0 0.0 8 1.5 13 2.1 31 3.6 55 2.6
HPV 31 5 4.9 0 0.0 26 4.9 21 3.4 69 7.9 121 5.7
HPV 33 3 2.9 0 0.0 7 1.3 15 2.4 35 4.0 60 2.8
HPV 45 0 0.0 0 0.0 8 1.5 6 1.0 8 0.9 22 1.0
HPV 52 1 1.0 0 0.0 15 2.8 11 1.8 19 2.2 46 2.2
HPV 58 0 0.0 0 0.0 3 0.6 7 1.1 9 1.0 19 0.9
Any HR 22 21.4 0 0.0 116 21.9 119 19.4 320 36.6 577 27.0
HPV X 17 16.5 3 20.0 119 22.5 122 19.8 184 21.1 445 20.8
Multiple 7 6.8 1 6.7 22 4.2 28 4.6 71 8.1 129 6.0
Positive 51 49.5 4 26.7 286 54.1 298 48.5 616 70.5 1,255 58.8
Negative 52 50.5 11 73.3 243 45.9 317 51.5 258 29.5 881 41.3
Total 103 4.8 15 0.7 529 24.8 615 28.8 874 40.9 2,136 100
ASCUS – atypical squamous cells of undetermined significance, LSIL – low grade squamous cell intraepithelial lesion, HSIL – high
grade squamous cell intraepithelial lesion, HPV – human papillomavirus, HR – high-risk, HPV X –unknown HPV type
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Prevalence of HR HPV types in HSIL
When both single and multiple infections are included
HPV 16 was present in 23% (201/874) of HSIL samples
HPV types 31, 33, 18, 52, 58 and 45 were found in 12.0%
(105/874), 6.1% (53/874), 5.0% (44/874), 2.3% (20/874),
1.1% (10/874) and 0.9% (8/874) of the cases, respectively
(Figure 3).
HPV distribution according to patient diagnosis
The prevalence of HPV increased significantly (c2 =
74, d.f. = 1, p < 0.0001) from 48.5% to 70.5% with the se-
verity of cytological findings (Table 1 and Figure 4).
While LR HPV types 6/11 were equally distributed
among LSIL (4.7%) and HSIL (4.7%), HR HPVs were al-
most two times more frequent in HSIL (36.6%) than in
LSIL (19.4%) (for presence of any HR HPV, c2 = 51.75,
d.f. = 1, p < 0.0001). HPV type 16, as a single infection,
was the most frequent, found in 7.5% of cases in LSIL
compared to 17.1% in HSIL (c2 = 29.0, d.f. = 1, p <
0.001). Multiple HPV infections were also two times
more frequent in HSIL than in LSIL, 8.1% and 4.6%, re-
spectively. The frequency of unknown HPV types (HPV
X) was almost the same in cervical specimens of women
with LSIL and those with HSIL, 19.8% and 21.1%, re-
spectively.
HPV distribution according to patient age
The frequency of HPV infections decreased signifi-
cantly (c2 = 94.2, d.f. = 4, p < 0.0001) with patient age
from 68.5% (age group 12 to 24 years) to 38.8% (age
group 45 to 54 years) (Table 2 and Figure 5). But, the
prevalence of HPV in women aged 55 or older increased
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TABLE 2




Unknown 12–24 25–34 35–44 45–54 ³55
N % N % N % N % N % N % N %
HPV 6/11 5 8.6 44 6.4 33 4.2 9 2.4 10 5.6 3 5.7 104 4.8
HPV 16 11 19.0 97 14.0 96 12.3 35 9.4 9 5.1 6 11.3 254 11.9
HPV 18 2 3.5 16 2.3 27 3.5 5 1.3 3 1.7 2 3.8 55 2.6
HPV 31 3 5.2 55 8.0 42 5.4 14 3.7 4 2.3 3 5.7 121 5.7
HPV 33 1 1.7 25 3.6 20 2.6 9 2.4 3 1.7 2 3.8 60 2.8
HPV 45 0 0.0 3 0.4 13 1.7 5 1.3 1 0.6 0 0.0 22 1.0
HPV 52 1 1.7 11 1.6 23 2.9 6 1.6 5 2.8 0 0.0 46 2.2
HPV 58 0 0.0 7 1.0 9 1.2 2 0.5 0 0.0 1 1.9 19 0.9
Any HR 18 31.0 214 30.9 230 29.5 76 20.3 25 14.0 14 26.4 577 27.0
HPV X 13 22.4 153 22.1 164 21.0 72 19.3 31 17.4 12 22.6 445 20.8
Multiple 3 5.2 63 9.1 53 6.8 6 1.6 3 1.7 1 1.9 129 6.0
Positive 39 67.2 474 68.5 480 61.5 163 43.6 69 38.8 30 56.6 1,255 58.8
Negative 19 32.8 218 31.5 301 38.5 211 56.4 109 61.2 23 43.4 881 41.3
Total 58 2.7 692 32.4 781 36.6 374 17.5 178 8.3 53 2.5 2,136 100
HPV – human papillomavirus, HR – high-risk, HPV X – presence of unknown HPV type
TABLE 3
MULTIPLE HPV INFECTIONS
HPV types Cases (N) %
16, 31 33 25.6
6/11, 16 25 19.4
16, 33 14 10.9
18, 31 11 8.5
6/11, 31 7 5.4
31, 33 6 4.7
6/11, 18 5 3.9
6/11, 33 5 3.9
16,18 4 3.1
16, 31, 33 3 2.3
18, 33 2 1.6
45, 52 2 1.6
6/11, 31, 33 2 1.6
16, 18, 31 2 1.6
16, 58 1 0.8
33, 58 1 0.8
45, 58 1 0.8
52, 58 1 0.8
6/11, 16, 18 1 0.8
6/11,16, 31 1 0.8
6/11, 18, 33 1 0.8
16, 18, 33 1 0.8
Total 129 100
HPV – human papillomavirus
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to 56.6%. The observed trend is statistically significant
for HPV 16 (c2 = 10, d.f. = 1, p = 0.0013), HPV 31 (c2 =
10, d.f. = 1, p = 0.0013), presence of any HR HPV (c2 =
22, d.f. = 1, p < 0.0001) and presence of multiple infec-
tion (c2 = 28, d.f. = 1, p < 0.0001).
Discussion
This study was designed to investigate the prevalence
of low abundant HR HPV types 45, 52 and 58 among Cro-
atian women. We analysed archival DNA samples from
2,136 cervical specimens collected from Croatian women
that were previously tested for the presence of LR HPV
types 6 or 11 and HR HPV types 16, 18, 31 and 3311,12,15.
The overall detection of HPV was 58.8%. Out of 1,255
positive samples, 64.5% were typed and in 35.5% of sam-
ples the type was not determined. Those samples gave
positive results with general primers, but they were neg-
ative with type-specific primers used in this study.
The geographic variation of the distribution of differ-
ent HPV types is well established in some regions4,18–20.
Worldwide, in squamous cell carcinoma HPV 16 was the
most prevalent type varying from 46% in Asia to 63% in
Europe, while HPV 18 was the second most common
HPV type. HPV 33, 31 and 45 in Europe and HPV 45 in
Africa were the third HPV types most frequently associ-
ated to cervical squamous cell carcinoma. HR HPV 58 and
52 were found to be less frequent in Europe, but not un-
common worldwide, especially in Asia, where these two
types took the third and fourth place after HPV 16 and 18.
Herein, we found that HPV 16 was the most preva-
lent type among Croatian women, as expected, and it was
present in 15.9% cases of both single and multiple HPV
infections. HPV 31 was the second most prevalent HPV
type appearing in 8.7% both single and multiple HPV in-
fections, followed by HR HPVs 33, 18, 52, 45 and 58 (Fig-
ure 2). The distribution of HR HPV types in the precan-
cerous lesions is slightly different than those in cervical
cancer cases. According to a meta-analysis of Clifford et
al.21 overall HPV prevalence was higher in squamous cell
carcinoma of the cervix (SCC) than in HSIL, 87.6% ver-
sus 84.2%, respectively (SCC : HSIL ratio 1.04). HPV 16
was found to be the most common type in both SCC
(54.3%) and HSIL (45.0%), with a ratio of 1.21. HPV 18
was also more prevalent in SCC (12.6%) than in HSIL
(7.0%), with a ratio of 1.79. Interestingly, HPV 45 was
the third type with a higher ratio (1.85) than those ob-
served with HPV 16 and 18. It was also more frequent in
SCC (4.2%) than in HSIL (2.3%). All other analysed HR
HPVs (including HPV 31, 33, 52 and 58) had ratios less
than 1, i.e. between 0.1 and 0.621. These results suggested


















Fig. 3. Prevalence of specific high-risk human papillomavirus
(HPV) types including single and multiple infections in high-


















Fig. 4. Prevalence of human hapillomavirus (HPV) types including
single and multiple infections according to cytological diagnosis.
Unknown – diagnosis not known, ASCUS – atypical squamous
cells of undetermined significance, LSIL – low-grade squamous





















Fig. 5. Age dependent prevalence of human hapillomavirus (HPV)

















Fig. 2. Prevalence of specific high-risk human hapillomavirus
(HPV) types including single and multiple infections in the whole
study population.
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that HSIL, when associated with HPV 16, 18 or 45 is more
likely to progress to SCC than HSIL associated with other
HR HPV types10,21. This evidence pointed out that women
infected with HPV 16, 18 or 45 may require closer surveil-
lance than women infected with other HR HPV types.
When we compared our prevalence analysis of HR
HPV types in HSIL (including both single and multiple
infections) with a worldwide meta-analysis of Clifford et
al.21, we found some discrepancies (Figure 3). HPV 16
was, as expected, the most frequently found type in HSIL
samples in both studies but with almost twice lower
prevalence in our study than those of Clifford et al., 23%
and 45%, respectively. Similarly in both studies, HPV 31
was on the second place with the prevalence of 12.0% in
our study versus 8.8% in Clifford et al. study. HPV 33, fol-
lowed these two HPV types in both studies with, in this
case, similar prevalence of 6.1% in this study and 7.2% in
Clifford et al. study. Further, we found slightly lower inci-
dence of HPV 18 in HSIL samples, in 5.0% cases versus
7.1%. The major discrepancy was the prevalence of HPV
58. While it was rather frequently found type (6.9%) in
Clifford et al. study, we found much lower incidence
among Croatian women (1.1%). We also noticed unex-
pected low prevalence for HPV 52 (2.3%) and HPV 45
(0.9%) compared to Clifford et al. study (5.2% and 2.3%,
respectively). These discrepancies could be explained by
(1) low number of analysed samples in this study, (2) dif-
ferent determination of cytological diagnosis HSIL13, (3)
the choice of primers sets for type-specific HPV ampli-
fication5,12,16 or (4) our data represent a real picture of HPV
prevalence among Croatian women. However, these obser-
vations clearly point out that further analysis with larger
number of samples and alternative method of typing need
to be carried out in the future to clarify this dilemma.
Herein, we found a strong correlation between the
distribution of HR HPV infections and the severity of
cervical lesions, i.e. the frequency of HR HPVs (type 16,
18, 31 and 33) increased with increasing severity of
squamous intraepithelial lesions-SIL, from 19.4% in
LSIL to 36.6% in HSIL (c2 = 74, d.f. = 1, p < 0.0001).
HPV 16 is the most predictive virus type of SIL and it is
present in 7.5% cases of LSIL and 17.1% cases of HSIL
(c2 = 29, d.f. = 1, p < 0.0001). This result is not surpris-
ing, and matches data found in previous reports22,23–24.
The progression from LSIL to HSIL is strongly associ-
ated with the presence of HR HPVs, while no progression
is associated with the presence of LR HPV types or the
absence of HPV25, which further stresses the importance
of HPV DNA typing.
The frequency of unknown HPV types (HPV X) was
approximately the same in cervical swabs of women with
LSIL and those with HSIL, 19.8% versus 21.1%, respec-
tively. Although type-specific primers that we used in
this study were detecting mainly group of HR HPV types
expected in Europe, we would like to continue our study
and determine the unknown HPV types11,12.
In this study, all 129 multiple HPV infections con-
tained at least one HR HPV type. There were 63.6%
co-infections of two or three HR HPV types, while 36.4%
co-infections of LR and HR HPV types (Table 3). The
co-infection of HPV types 16 and 31 was most frequently
found followed by the co-infection of HPV 16 and 6/11.
The frequency of co-infections follows the frequency of
individual HPV types found in the study population (Fig-
ures 2 and 3). HPV types 45, 52 and 58 were rarely found
in multiple infections.
Herein, multiple infections were two times more fre-
quent in HSIL than in LSIL, 8.1% versus 4.6%, what is
not surprising because multiple HPV infections were
mainly represented by co-infections of two or three HR
HPVs or HR- and LR HPVs. In the similar study popula-
tion in Taiwan, Chang et al.26 found adverse results, i.e.
decreasing frequency of multiple HPV infections with in-
creasing severity of cervical lesions. However, a similar
decrease of multiple infection frequency can be observed
from CIN 2 to CIN 3, if the HSIL category is classified ac-
cordingly to the Croatian classification of cervical sme-
ars13 (data not shown). In both cases, the HPV infections
associated with LSIL still represents transient infec-
tions, while the HPV infections associated with HSIL, es-
pecially CIN 3 most probably persistent infections27.
In this study, the frequency of HPV infections de-
creased significantly (c2 for trend = 72.42, d.f. = 1, p <
0.0001) with patient age. Women under the age of 24
years exhibited the highest rate of HPV infections (68.5%),
while women between 45 and 54 years of age exhibited
the lowest rate of HPV infections (38.8%). Multiple HPV
infections were also found mainly among younger wo-
men (mean age 26). This trend of high prevalence in
young age after the beginning of sexual activity and then
a steady decline in subsequent age group is observed in
other studies27. In this study, an increase of HPV preva-
lence in women aged 55 or older to 56.6% was also ob-
served. This trend of gradual fall and then increase in
older age has been observed for any HR HPV, particularly
HPV 16, HPV 18, 31 and 33 but not 45, 52 and 58, and
multiple HPV infections (Table 2 and Figure 5). Interest-
ingly, HPV 45 and 52 were not found among women ³ 55,
while HPV 58 was found mostly in the age group ³ 55 but
absent in the age group 45–54 years of age; the reason of
that observation could be a small number of analysed
specimens in these age groups. Further analysis with
larger number of samples is needed in these age groups.
In conclusion, the distribution of HPV infections
among Croatian women is similar to most countries with
HPV 16 being the most prevalent type followed by HPV
31 in precancerous lesions. HPV 33, 18 and 52 are all at
the third place of prevalence in this study group, while
HPV 45 and 58 remain low abundant HR HPV types. As
HPV detection of HR types is recommended for women
with equivocal cytology and for follow-up after treatment
of high-grade cervical lesions according to the Croatian di-
agnostic and therapeutic guidelines for management of
women with premalignant cervical lesions28, we suggest to
perform HPV typing for HR HPV types: 16, 18, 31, 33, 45,
52 and 58 in HPV positive women in order to improve the
monitoring process and prevent the cancer development.
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RETROSPEKTIVNA ANALIZA U^ESTALOSTI VISOKORIZI^NIH TIPOVA HUMANOG
PAPILOMAVIRUSA (HPV) KOD @ENA U HRVATSKOJ
S A @ E T A K
Infekcija humanim papilomavirusom (HPV) glavni je uzrok raka vrata maternice. Postoji najmanje 15 visokori-
zi~nih tipova HPV-a koji su zna~ajno povezani s napredovanjem cervikalne intraepitelne neoplazije (CIN) prema raku
vrata maternice. Budu}i da su prija{nje studije pokazale da je u~estalost HPV-a razli~ita me|u razli~itim zemljopisnim
podru~jima, na{ cilj je bio ispitati u~estalost tipova HPV-a u Hrvatskoj, posebno rijetkih visokorizi~nih tipova HPV-a.
Metodom lan~ane reakcije polimerazom (PCR), pomo}u konsenzus po~etnica, a kako bismo ustanovili prisutnost in-
fekcije HPV-om, analizirali smo uzorke DNK 2.136 `ena u Hrvatskoj, uglavnom s abnormalnim nalazom brisa vrata
maternice. Tip-specifi~ne po~etnice kori{tene su za detekciju sljede}ih tipova HPV-a: niskorizi~nih 6/11 te visokori-
zi~nih 16, 18, 31, 33, 45, 52 i 58. Od ukupno 2.136 uzoraka, 1.255 (58,8%) je bilo pozitivno, a 881 (41,3%) uzorak je bio
negativan na prisutnost nekog tipa HPV-a. Vi{e od polovine pozitivnih uzoraka bilo je tipizirano (64,5%), dok kod 35,5%
nije utvr|en tip HPV-a. Vi{estruke infekcije HPV-om su prona|ene u 10,3% slu~ajeva. Utvr|eno je da je naju~estaliji tip
HPV 16 s u~estalo{}u od 15,9%, uklju~uju}i jednostruke i vi{estruke infekcije. Slijedili su ga tipovi HPV-a: 31, 6/11, 33,
18, 52, 45 te 58 s 8,7%, 7,1%, 4,5%, 3,8%, 2,3%, 1,8% te 1,1% u~estalosti. Uo~eno je zna~ajno pove}anje u~estalosti od
blagih (LSIL, engl. Low-grade Squamous Intraepithelial Lesions) do te`ih (HSIL, High-grade Squamous Intraepithelial
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Lesions) promjena vrata maternice za visokorizi~ne tipove HPV-a 16, 18, 31 i 33, ali ne i za HPV 45, 52 i 58. U~estalost
nepoznatih tipova HPV-a (HPV X) bila je gotovo jednaka u uzorcima vrata maternice `ena sa citolo{kom dijagnozom
LSIL i HSIL, 19,8% i 21,1%. Uo~eno je zna~ajno smanjenje broja HPV-a s porastom dobi ispitanica, od 68,5% (dobna
skupina od 12 do 24 godine) prema 38,8% (dobna skupina od 45 to 54 godine). Me|utim, kod `ena od 55 godina i starijih
ukupna u~estalost infekcija HPV-om je porasla na 56,6%. Ovi rezultati u~estalosti visokorizi~nih tipova HPV-a u Hr-
vatskoj se podudaraju s onima zabilje`enim u drugim zemljama. Smatramo va`nim HPV-pozitivne `ene u Hrvatskoj
tipizirati barem na prisustvo visokorizi~nih tipova HPV-a: 16, 18, 31, 33, 45, 52 i 58 kako bi im se pru`ila maksimalna
pozornost.
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A B S T R A C T
Little information is available regarding distribution of HPV types in different histological subtypes of adenocar-
cinoma (AC). Thus, in this study we examined the frequency of high-risk (hr) HPV types in AC, adenocarcinoma in situ
(AIS) and adenosquamous carcinoma (ADSQ). A total of 102 cases of primary cervical adenocarcinoma (26 AIS and 76
invasive AC) obtained from pathology files from 1995–2006 were histologically subtyped. Our results demonstrated that
endocervical type occupied the major subtype of AC (22/66) followed by ADSQ (17/66) where as in the group of AIS
endocervical type (12/23) was followed by intestinal type of AIS (7/23). Successful DNA extraction was obtained in 89
samples; 81 out of 89 (91.0%) tested positive for HPV DNA. The prevalence of HPV DNA in AIS, AC and ADSQ was
91.3% (21/23), 90.9% (60/66) and 94.1% (16/17), respectively. We found HPV 18 type to be the most predominant type in
AIS (11/21) and AC (17/60) followed by HPV of undeternmined type in AIS (3/21) and HPV 16 in AC (9/60) as the sole vi-
ral type. HPV 18 was most frequently detected type in all histological subtypes of AIS and AC. We have detected HPV
DNA in all 5 samples of clear cell carcinoma (CCC), although other studies have reported a highly variable prevalence of
HPV DNA in CCC. The most prevalent HPV type in ADSQ was HPV-16 followed by HPV 33 as single type. The observed
overall predominance of HPV 18 in AIS (2 = 6.109, p£ 0.025) and AC (2 = 8.927, p£0.01) as well as of HPV 16 in ADSQ
(2 = 10.164, p £ 0.01) was statistically significant. Our data revealed statistically significant predominance of single
hrHPV infections in AIS (16/21; 2 = 11.523, p £ 0.001) and AC (37/60; 2 = 6.533, p £ 0.025) whereas multiple hrHPV
infections were more abundant in AC comparing to AIS (23/81and 5/81, respectively; 2 = 13.989, p £ 0.001).
Key words: cervical adenocarcinoma, adenocarcinoma in situ, histological subtypes, HPV prevalence frequency and typing
Introduction
There are two major histological types of invasive cer-
vical cancer: squamous cell carcinoma (SCC) and ade-
nocarcinoma (AC). Incidence rate of SCC has been de-
clining in recent years1 but unfortunately incidence of
cervical AC is increasing in developed countries, despite
their widespread screening programmes. Recent reports
indicated that AC accounts for approximately 20–25% of
uterine cervical cancer compared with only 5–15% in the
past2. Many countries report steady increase in incidence
rates especially among younger women, since early 1970s2–6.
Although effective screening programmes contribute to
decreasing incidence rates of SCC but neither improved
surveillance or classification of ACs appears to account
for all of the increase in ACs. There are more than 40
HPV types known to infect female genital tract, and a
subset of at least 15 of these are known to have a strong
oncogenic potential11. Therefore, HPV types have been
classified according to their association with cervical can-
cer and precursor lesions into oncogenic or high-risk (hr)
and low-risk (lr) HPV types12. Cervical squamous neopla-
sia has shown to be strongly associated with hrHPV in-
fection with studies showing more than 90% of cancers
containing HPV DNA13,14. Although, association of hrHPV
with cervical AC has been studied less extensively, re-
ports in the past decade indicate similar association, sug-
gesting causal relationship between hrHPV and cervical
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AC15,16. Major limitation is that number of patients with
cervical ACs involved in these studies was small. Another
reason why causal relationship between HPV infection
and cervical AC is further complicated is the fact that AC
encompasses several heterogeneous histological subtyp-
es. The majority of tumours are mucionus AC including
endocervical and intestinal type, while minor component
of cervical AC includes variety of histological subtypes
such as endometrioid, clear cell serous, villoglandular,
minimal deviation, mesonephric adenocarcinoma and mix-
ture of those subtypes. Specific histological subtype is
clear cell carcinoma (CCC) which accounts for 2–7% of
cervical AC and if presenting in young patients usually
involves association with diethylstilbestrol (DES) expo-
sure in utero17,18 and HPV DNA negativity. Other pa-
tients with CCC have no known risk factors and occur in
an older age group18.
While hrHPV infection appears to be required for the
development of both SCC and AC, the distribution of
hrHPV types seen in these two forms of disease varies
from study to study. Whereas HPV 16 is the most fre-
quently involved in the development of SCC, HPV 18
alone or in combination with HPV 16 is reported to be a
predominant type in AC19 and adenocarcinoma in situ
(AIS). Little information is available regarding geogra-
phic variation of HPV types in different histological sub-
types of AC. Herein we conducted a retrospective study
in order to evaluate the frequency of HPV types in
adenocarcinoma in situ (AIS), AC and adenosquamous
carcinoma (ADSQ).
Materials and Methods
Case selection and histological subtyping
A total of 102 specimens of primary cervical adeno-
carcinoma were (26 AIS and 76 invasive AC) obtained
from the Department of Pathology, University of Rijeka,
Croatia, which were collected from 1995 to 2006. Paraf-
fin embedded sections of cone or hysterectomy specimens
were reviewed by two pathologists. Each case was his-
tologically subtyped according to the standard histo-
logical criteria20 and associated lesions of the squamous
epithelium were recorded as well. Endocervical type was
the most common invasive adenocarcinoma, found in 22
cases, followed by adenosquamous carcinoma (17 cases),
intestinal (12 cases), and endometrioid type (8 cases).
Five cases were diagnosed as clear cell carcinoma, 3 cases
were signet-ring carcinoma, 3 cases as serous and one
case as villoglandular and glassy cell carcinoma. Mixed
mucinous adenocarcinoma was found in 4 cases. Associ-
ated CIN I–III lesions were found in 11 cases. According
to morphological criteria 15 AIS were suptyped as endo-
cervical, 7 cases as intestinal, 2 cases as endometrioid
and one as adenoaquamous and mixed type. Depending
on tissue availability, successful DNA extraction, defined
by presence of -globin gene sequence, was found in 89
samples, 3 cases of AIS and 10 cases of AC were excluded
from further analysis.
DNA extraction and PCR analysis
Total DNA was isolated from formalin fixed, paraffin
embedded samples. Great care was taken on sample sec-
tioning to avoid any contamination between the samples.
Depending on the amount of biopsy material embedded
in paraffin, 4–10 sections (5 m thick) were placed in a
microcentrifuge tube. The sections were deparaffinized
by adding 1 mL of xylene and heating at 55°C for 30 min-
utes, followed by centrifugation and subsequent removal
of the supernatant. Upon dewaxing with three washes of
xylene, 1 mL of 100% ethanol was added to remove resid-
ual xylene. The tissues were dried at 37°C for 30 minutes
and DNA was isolated using NucleoSpinTissue kit (Ma-
charey-Nagel, Duren, Germany) according to the manu-
facturer’s instructions.
Detection of HPV DNA was performed using E6 and
E7 consensus primers (Human Papillomavirus Typing
Set, Takara Biomedicals, Japan). The HPV types in posi-
tive samples were further characterized by using type
specific primers amplifying sequences of HPV 16, 18 and
33 within E6 and E7 open reading frame (ORF) (Human
Papillomavirus Detection Set, Takara Biomedicals, Ja-
pan) and HPV 31, 45, 52, 59 and 68 in the E7 ORF14.
Statistical analysis
HPV prevalence was expressed as percentage of all
cases tested for HPV in different histological groups of
AC (accounted only once). The overall prevalence of indi-
vidual hrHPV types was determined as they appeared as
either single or within multiple infections. Multiple hrHPV
infection was defined as two or more hrHPV types. The
differences of the means of the continuous variables were
analyzed with the Student’s t-test and the distribution of
non-continuous histological variables versus HPV status
was analyzed with the Chi-square test (	2). P values of
<0.05 were used as the cut-off for statistical significance.
Results
As shown in Table 1. endocervical type represented
the major subtype of AC (22/66) followed by ADSQ (17/66)
where as in the group of AIS endocervical type (12/23)
was followed by intestinal type of AIS (7/23). The average
age of patients with AIS, AC and ADSQ was 41.82, 48.9
and 44, respectively. Statistical analysis revealed that av-
erage age of the patients with AIS and AC (41.82 years
versus 48.9 years) was significantly different (Student’s
t-test; t=2.55, degrees of freedom 87, p£0.05). Looking at
different histological subtypes the average age of pa-
tients with intestinal AC and AIS was the youngest (35.8
and 39.28 years respectively). Cervical intraepithelial
neoplasia (CIN), ranging from CIN I to CIN III accompa-
nied AIS and AC in 27 cases (16/23 and 11/66, respec-
tively).
We were able to successfully extract DNA from 89
samples and 81 (91.0%) tested positive for HPV DNA.
HPV DNA prevalence according to different histological
subtypes of AC, AIS and ADSQ is presented in Table 1.
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The prevalence of HPV DNA in AIS, AC and ADSQ was
91.3% (21/23), 90.9% (60/66) and 94.1% (16/17), respec-
tively. We have detected HPV DNA in all 5 samples of
CCC although other studies have reported a highly vari-
able prevalence of HPV DNA in CCC17,18,21. Also, patients
with CCC belong to oldest age group (63.8 years) com-
pared to all other histological subtypes of AC (Table 1).
While HPV types 16, 18, 31 and 33 were detected in
single or multiple infections we did not detect HPV types
45, 52, 59 and 68 in any tested samples. All samples that
were HPV DNA positive but were not typed as HPV 16,
18, 31, 33, 45, 52, 59 or 68 were marked as HPV X. We
found HPV 18 type to be the most predominant type in
AIS (11/21) and AC (17/60) followed by HPV X in AIS
(3/21) and HPV 16 in AC (9/60) as the sole viral type (Ta-
ble 2). Also, HPV 18 was most frequently detected type in
all histological subtypes of AIS and AC. On the other
hand the most prevalent HPV type in ADSQ was HPV 16
followed by HPV 33 as single type. The observed overall
predominance of HPV 18 in AIS (	2= 6.109, p£ 0.025)
and AC (	2=8.927, p£0.01) and of HPV 16 in ADSQ
(	2=10.164, p£0.01) was statistically significant (Table 3).
When we analysed the distribution of HPV 16 and 18
in endocervical AIS and AC together we found statisti-
cally significant prevalence of HPV 18 (21/31; 	2=6.458,
p£0.025). Also, prevalence of HPV 18 in intestinal AIS
and AC was statistically significant (9/11; 	2=4.701, p£
0.05) (Table 3). However, there is no statistically signifi-
cant prevalence of HPV 18 in remaining histological sub-
types of AIS and AC.
Combining together single and multiple HPV infec-
tions, HPV 18 was detected in 68.2% of AC (30/44) and
66.7% of all AIS (14/21) cases whereas HPV 16 in 36.4%
(16/44) and 28.6% (6/21), respectively. Single HPV type
infections were statistically significant in AIS (16/21;
	
2=11.523, p£0.001) and AC (37/60; 	2=6.533, p£0.025)
while equal number of single and multiple HPV infec-
tions was detected in ADSQ (8/16). However we found
statistically significant higher number of multiple infec-
tions in AC compared to AIS (23/81and 5/81, respec-
tively; 	2=13.989, p£0.001).
Discussion
When we examined the number of AC cases diagnosed
at our Department of pathology (which covers large re-
gion of Rijeka county), we noticed increasing trend of
glandular cervical carcinomas during 1995–2006 period
of time with predominant number of cases in women
29–49 years of age (data not shown). These data are in
accordance with increasing trend of this neoplasia seen
in developed countries2,6.
It is well established that hrHPV is causal factor in
development of SCC and its precursor lesions22 with
studies reporting almost 100% prevalence of HPV in
SCC11,13,23. However, causal linkage of HPV infection to
the cervical AC has not been considered as strong as it is
for SCC due to more variable and generally lower HPV
prevalence rates (60%–96%)18,19,22,24–26. Recent more sen-
sitive extraction and detection techniques have made it
possible to identify the higher rate of HPV infection in
I. Had`isejdi} et al.: HPV in Different Histological Subtypes of Cervical Adenocarcinoma, Coll. Antropol. 31 (2007) Suppl. 2: 97–102
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Endocervical 22 26–74 48.59 6 27.3 2 9.1 20 90.9 15 75 5 25
Intestinal 5 30–40 35.8 1 20 1 20 4 80 2 50 2 50
Endometrioid 8 29–82 54.37 – – – – 8 100 4 50 4 50
Clear cell 5 42–73 63.8 – – – – 5 100 4 80 1 20
Serous 3 38–78 55.67 1 33.3 2 66.7 1 33.3 1 100 – –
Villoglandular 1 40 40 – – – – 1 100 1 100 – –
Mixed 4 37–69 48.75 1 25 – – 4 100 2 50 2 50
Glassy cell 1 65 65 – – – – 1 100 – – 1 100
Adenosqumaous 17 21–73 44 2 11.8 1 5.9 16 94.1 8 50 8 50
All invasive adenocarcinoma 66 21–82 48.9 1 116.7 6 9.1 60 90.9 37 61.7 23 38.3
Endocervical 12 26–56 45.5 10 83.3 1 8.3 11 91.7 7 58.3 4 33.3
Intestinal 7 30–46 39.28 5 71.4 – – 7 100 6 85.7 1 14.3
Mixed 1 40 40 1 100 – – 1 100 1 100 – –
Adenosqumaous 1 47 47 – – – – 1 100 1 100 – –
Endometrioid 2 43 43 – – 1 16.7 1 50 1 100 – –
All adenocarcinoma in situ 23 26–56 41.82 16 69.6 2 8.7 21 91.3 16 76.2 5 23.8
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AC with frequencies reaching 85% or more18,27. Although
DNA extractions from older (>10 years) paraffin embed-
ded tissue blocks can be sometimes cumbersome we were
able to detect HPV DNA in large majority of cases (91%)
consistent with previous findings18,28. We screened our
samples for only 8 hrHPV types because combined to-
gether, as we showed previously29, they cover almost 90%
of overall HPV type found in cervical carcinoma.
I. Had`isejdi} et al.: HPV in Different Histological Subtypes of Cervical Adenocarcinoma, Coll. Antropol. 31 (2007) Suppl. 2: 97–102
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Endocervical 20 3 15 10 50 1 5 – – 1 5 2 10 1 5 – – – – – – 2 10
Intestinal 4 – 2 50 – – – – – – 2 50 – – – – – – – – – –
Endometrioid 8 – 2 25 – – – – 2 25 1 12.5 1 12.5 – – – – – – 2 25
Clear cell 5 – 2 40 – – 1 20 1 20 – – – – – – – – – – 1 20
Serous 1 – – – 1 100 – – – – – – – – – – – – – – – –
Villoglandular 1 – 1 100 – – – – – – – – – – – – – – – – – –
Mixed 4 1 25 – – – – – – 1 25 1 25 – – – – – – – – 1 25
Glassy cell 1 – – – – – – – – – – – – – 1 100 – – – – – –
Adenosqumaous 16 5 31.3 – – – – 3 18.7 – – 1 6.3 – – – – 1 6.3 3 18.7 3 18.7
All invasiveadeno-
carcinoma
60 9 15 17 28.3 2 3.3 4 6.7 5 8.3 7 11.7 2 3.3 1 1.7 1 1.7 3 5 9 15
Endocervical 11 1 9.1 4 36.3 – – – – 2 18.2 1 9.1 1 9.1 – – 1 9.1 – – 1 9.1
Intestinal 7 1 14.3 4 57.1 – – – – 1 14.3 – – – – – – – – – – 1 14.3
Mixed 1 – 1 100 – – – – – – – – – – – – – – – – – –
Adenosqumaous 1 – 1 100 – – – – – – – – – – – – – – – – – –
Endometrioid 1 – 1 100 – – – – – – – – – – – – – – – – – –
All adenocarcinoma
in situ
21 2 9.5 11 52.3 – – – – 3 14.3 1 4.8 1 4.8 – – 1 4.8 – – 2 9.5
HPV – human papillomavirus, *Includes HPV types other than 16, 18, 31, 33, 45, 52, 59, 68; **Includes multiple high risk HPV infec-
tions (HPV 18, 16 &31, HPV 18, 16 & 33, HPV 16, 31 &33, HPV 16, 18, 31 &33)
TABLE 3














Endocervical 20 7 35 15 75 3 15 2 10 1 5
Intestinal 4 2 50 4 100 – – – – – –
Endometrioid 8 3 37.5 5 62.5 3 37.5 2 25 2 25
Clear cell 5 1 20 3 60 – – 2 40 1 20
Serous 1 – – – – 1 100 – – – –
Villoglandular 1 – – 1 100 – – – – – –
Mixed 4 3 75 1 25 1 25 1 25 1 25
Glassy cell 1 – – 1 100 – – 1 100 – –
All invasive adenocarcinoma 44 16 36.4 30 68.2 8 18.2 8 18.2 5 11.4
Adenosquamous 16 13 81.3 4 25 3 18.7 8 50 – –
Endocervical 11 4 36.4 6 54.5 2 18.2 1 9.1 2 18.2
Intestinal 7 2 28.6 5 71.4 1 14.3 1 14.3 1 14.3
Mixed 1 – – 1 100 – – – – – –
Adenosquamous 1 – – 1 100 – – – – – –
Endometrioid 1 – – 1 100 – – – – – –
All adenocarcinoma in situ 21 6 28.6 14 66.7 3 14.3 2 9.5 3 14.3
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HPV infection is required for the development of both
SCC and AC, however, distribution of HPV types seen in
these two forms of the diseases differ. HPV 16 type is the
most frequently involved in the development of SCC30 of
the cervix where as studies describing HPV type preva-
lence in AC are in disagreement. Some report HPV 16
and HPV 18 type to have equal prevalence30,18, while oth-
ers show predominance of HPV 18 in AC26. In this study
we found that, in overall, HPV 18 statistically signifi-
cantly prevails in AIS and AC, while in ADSQ HPV 16 is
the most frequent type. We found HPV 18 predominantly
in endocervical and intestinal AIS and AC, however there
is no statistically significant prevalence of HPV 18 in re-
maining histological subtypes of AIS and AC. Large
meta-analysis study16 showed that the highest risks of
developing AC were associated with HPV 18 (OR=410)
followed by HPV 16 (OD=164). In context of these find-
ings our results support the hypothesis of HPV 18 being
the most important risk factor in developing of cervical
AC. Existing data on the HPV DNA detection in cervical
CCCs are opposing, with some studies indicating HPV
DNA presence17,21,28, while others were unable to identify
HPV DNA18,31. In our study we found all 5 CCC cases to
be HPV DNA positive. Therefore our results are in line
with those that reported positive findings but exact cause
for the discrepancy in the HPV DNA detection from
CCCs is still unclear.
Our data revealed statistically significant predomi-
nance of single hrHPV infections in AIS and AC, how-
ever, other studies showed similar results only for AC18,27.
Presented results support hypothesis of Zielinski et al.27
that invasive growth of glandular epithelial cells is trig-
gered by the action of a single HPV type rather than a po-
tentially synergistic action of multiple HPVs. However,
in our study we found rather high prevalence of multiple
HPV infections in AIS and invasive AC, 23.8% and 38.2%
cases respectively (Table 1), that can not be overlooked.
The fact that multiple infections are even more abun-
dant in invasive AC than in the precursor lesion, might
indicate that multiple infection could contribute to can-
cer development in a more aggressive way than a single
infection with hrHPV.
Conclusion
Our study revealed that the most prevalent hrHPV
type in AIS and AC is HPV 18 while HPV 16 is predomi-
nant type in ADSQ. Analysis of various histological sub-
types of AIS and AC demonstrate that in endocervical
and intestinal carcinoma HPV 18 is predominant type,
whereas in remaining histological subtypes such pre-
dominance was not detected. We have detected HPV
DNA in all 5 samples of CCC although other studies have
reported a highly variable prevalence of HPV DNA in
CCC. Our data revealed statistically significant predomi-
nance of single hrHPV infections in AIS and AC whereas
multiple hrHPV infections were more abundant in AC
comparing to AIS.
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RASPODJELA TIPOVA HUMANOG PAPILOMAVIRUSA U RAZLI^ITIM HISTOLO[KIM
SUPTIPOVIM ADENOKARCINOMA VRATA MATERNICE
S A @ E T A K
Budu}i da su podaci u svijetu o prevalenciji HPV tipova u razli~itim histolo{kim suptipovma adenokarcinoma (AC)
vrlo oskudni, proveli smo ovu studiju s ciljem da ispitamo prevalencije HPV tipova u AC, adenokarcinomu in situ (AIS) i
adenoskvamoznom karcinomu (ADSQ) u Hrvatskoj. Ukupno 102 arhivska uzoraka primarnog adenokarcinoma vrata
maternice (26 AIS i 76 AC), prikupljeno je na patologiji tijekom 1995–2006, i histolo{ki suptipizirano. Dobiveni podaci
su pokazali da je najzastupljeniji suptip AC endocervikalni (22/66), zatim ADSQ (17/66), dok je u AIS-u endocervikalni
suptip utvr|en u 12/23, a intestinalni u 7/23 AIS-a. DNK je uspje{no izolirana iz 89 uzoraka. U 81 uzorku (91%) do-
kazana je HPV DNK. Utvr|ena je HPV DNK prevalencija u AIS-u 91,3%, u AC 90,9 % i ADSQ 94,1%. U slu~ajevima
infekcije samo jednim tipom utvrdili smo da je HPV 18 naju~estaliji u AIS-u (11/21) i AC (17/60), a slijede ih grupa
neodre|enog tipa HPV-a u AIS-u (3/21) te HPV 16 u AC (9/60). HPV 18 je i naju~estaliji genotip u svim histolo{kim
suptipovima AIS-a i AC. Tako|er smo dokazali HPV DNK u svih 5 uzoraka karcinoma svjetlih stanica (CCC) iako su
druge studije pokazale razli~ite podatke o prevalenciji HPV DNK u CCC. Naju~estaliji pojedina~ni HPV tipovi u ADSQ
su HPV 16 i HPV 33. Dokazano je da je ukupna prevalencija HPV 18 u AIS-u i AC, te HPV 16 u ADSQ statisti~ki
zna~ajna; HPV 18 u AIS-u (	2 = 6.109, p £ 0.025) i AC (	2 = 8.927, p£0.01) i HPV 16 u ADSQ (	2 = 10.164, p £ 0.01).
Infekcija s jednim HPV tipom je statisti~ki zna~ajno u~estalija u AIS-u (16/21; 	2 = 11.523, p £ 0.001) i AC (37/60; 	2 =
6.533, p £ 0.025), dok je vi{estruka HPV infekcija u~estalija u AC-u u odnosu na AIS (23/81 i 5/81, 	2 = 13.989, p £
0.001).
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Combined Analysis of HPV DNA and p16INK4a
Expression to Predict Prognosis in ASCUS and
LSIL Pap Smears
Francesca Maria Carozzi
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A B S T R A C T
Human papillomavirus (HPV) is known to play an important etiological role in the genesis of cervical cancer, but only
a very small proportion of infected women develop invasive cervical cancer. The purpose of cervical cancer prevention is
early diagnosis of its precursors. The molecular detection of HPV DNA as a diagnostic test to cervical carcinogenesis
gave a low positive predictive value as compared to the use of biomarkers. p16INK4a has been proposed as putative surro-
gate biomarkers that would allow identification of dysplastic cervical epithelia. Serial consecutive cervical smears were
test for high-risk HPV, stained with immunocytochemistry for p16INK4a and followed-up for 36 months. The aim of the
study was to evaluate the immunohistochemical expression of p16INK4a as a marker of progression risk in low-grade
dysplastic lesions of the cervix uteri. In the present series, significant p16 overexpression was observed in the group that prog-
ressed from low to high-grade squamous intraepithelial lesion when compared with the group that did not progress. In con-
clusion, overexpression of p16INK4a acts as potential biomarkers for cervical cancer progression from premalignant lesions.
Keywords: cervical intraepithelial neoplasia, cervical cancer, human papillomavirus, p16INK4a
Introduction
Epidemiological and molecular studies over the past
two decades have demonstrated that high-risk human
papillomavirus (HR-HPV) types are etiologically related
to the progression to cervical cancer. Although more that
85 types of HPV have been detected in the genital mu-
cosa, in the majority of HPV-infected individuals, the vi-
rus is eliminated. A substantial proportion of HPV lesion
regresses spontaneously over 6–18 months period. Sev-
eral studies have shown that viral persistence is neces-
sary for cervical intraepithelial neoplasia (CIN) lesions to
progress or in fact be maintained.
Although HPV testing has been successfully used and
proposed for triaging to colposcopy those patients with
minor cytologic abnormalities, its positive predictive va-
lue (PPV) is suboptimal and a substantial proportion of
patients are still referred unnecessarily to colposcopy. In
the ALTS study1 the PPV for CIN3 of a positive HR-HPV
test in a patient with and atypical squamous cells of un-
determined significance (ASCUS) Pap was only 10%.
Identifying other molecular events associated with
progression from low (L)- to high (H)-grade squamous
intraepilelial lesions (SIL) is a crucial area of research, as
it may further improve selection of HPV-positive pa-
tients really worthy of assessment and treatment.
The use of modulators involved in the cell cycle as
biomarkers of HR-HPV infected cells may be an impor-
tant tool in the future to identifying those smears con-
taining HSIL of patients that might progress and develop
to cervical carcinoma.
The p16INK4 is a tumour suppressor protein that in-
hibits the function of cdk4 and cdk6, which in turn regu-
late the G1 checkpoint. CDK/cyclin-D phosphorylate the
retinoblastoma protein (pRb), resulting in a conforma-
tional change, with the release of E2F from Rb. Thus, in-
activation of either p16 or Rb function allows the cell to
enter the S phase after only a brief pause as the G1
checkpoint. In addition, the E6 HPV oncoprotein has the
ability to bind p53, resulting in its degradation, and the
E7 gene product inactivates the pRb pathway.
103









 $  
Pathogenic activity of HR-HPV indicated by p16 ex-
pressions on smears could be a strategy to identify pa-
tients at major risk to develop cervical lesions.
The p16INK4a immunostaining has been suggested as a
tool for triaging women with low-grade or borderline cy-
tology; p16 could be particularly interesting among wo-
men with LSIL cytology, where triage by HPV is ineffi-
cient. Several studies2,3 reported a differential expression
of p16 in HSIL, LSIL and normal cervical epithelial cells.
The p16INK4a has been shown to be associated with
HPV-infected high grade lesions but its PPV and sensi-
tivity in prospective follow-up for relevant outcomes (>
CIN2) has yet to be determined.
In our previous report4 we assessed the accuracy of
p16 and HR-HPV testing in identifying high-grade cervi-
cal lesions in 283 cervical samples (ThinPrep) on a con-
secutive series of women referred to colposcopy for ab-
normal cytology (ASCUS). In this follow-up study we
analyzed the role of immunocytochemical expression of
p16 in HPV infected women as prognostic markers of the
progression of SIL.
Subjects, Material and Methods
Initially we assessed p16INK4a immunostaining and
HR-HPV in 283 patients consecutively referred to colpo-
scopy for cytologic evidence of LSIL or ASCUS within the
Florence (Italy) District screening programme for cervi-
cal cancer.
HPV and p16 testing were performed in the whole se-
ries prior to colposcopy assessment: cervical material
was collected using ThinPrep® (Cytic Corp., Boxborough,
MA), allowing for multiple slide preparation and residual
fluid. Laboratory operators performing the testing were
blinded to the colposcopy assessment outcome. The pa-
tients without CIN2 or more were invited regularly for
follow-up cytology; if cytology was ASCUS or more col-
poscopy was performed.
The 238 out of 252 patients were followed for 36
month period and then stratified according the cytology
results and final outcome. Final outcome was defined ac-
cording to colposcopy-directed biopsy result (<CIN2 or
>CIN2) and was assumed to be negative in the presence
of negative colposcopy, indicating no biopsy. Observed
differences were tested by the Chi-square test, with sta-
tistical significance set at p <0.05.
HPV and p16 testing were performed in the whole se-
ries prior to colposcopy assessment: cervical material
was collected using ThinPrep® (Cytic Corp., Boxborough,
MA), allowing for multiple slide preparation and residual
fluid. Laboratory operators performing the testing were
blinded to the colposcopy assessment outcome.
HPV Testing
From each specimen, 2 mL of residual ThinPrep fluid
was used, and DNA extraction was carried out using a
QIAmp DNA Mini Kit (Qiagen Corporation, Venlo, the
Netherlands) according to the manufacturer’s protocol.
Polymerase chain reaction (PCR) analysis was performed
according to a previously described protocol5 using prim-
ers for the E6/E7 region of HR HPV types (HPV 16, 18,
31, 33, 35, 45, 52 and 58). For a quality control of DNA
extraction, the primer set PC04 and Gh20 was employed
to amplify a 268-base pair (bp) fragment of the human
beta globin gene in all specimens. In each PCR reaction,
negative and positive controls were introduced.
p16INK4a Testing
From each specimen, 2 mL of residual ThinPrep fluid
was used for a cytospin preparation; after cytocentri-
fugation (5 min at 1000 rpm), slides were air dried for 10
minutes, then treated with spray fixation reagent, con-
taining polyethylene glycol, and immunostained within
24 hours. Before they were immunostained, all spray-
fixed specimens were incubated in 50% volume/volume
alcohol, followed by one washing step in deionized water.
For immunostaining, CINtectm p16 Cytology kit (Dako
Cytomation, now Dako A S, Glostrup, Denmark) was
used, according to the manufacter’s protocol. In brief,
smears were treated with 3% hydrogen peroxide and
then submitted for epitope retrieval at 95–99 °C for
40(±1) minutes; after cooling, the p16INK4a antibodies
were applied for 30 (±1) minutes and then a reagent for
observation and substrate-chromogen solutions were ad-
ded. Hematoxylin was used as counter stain. The method-
ology differs from other studies on p166,7, but we used the
same monoclonal antibody and believe that the results are
comparable. The choice of cytospin preparation was es-
sentially aimed at a more efficient use of the residual
ThinPrep fluid. Before the study, we made a comparison
of p16INK4a testing on cytospin and ThinPrep preparations
on limited numbers of negative and positive samples (data
not shown), and we observed no differences.
Slides were read by two investigators blinded to final
outcome, and a minimum of 500 cells in different fields
were analyzed. A negative result was defined if no cells
immunoreactive to the p16INK4a antibody were in evi-
dence. Slides showing positive staining for p16 were cate-
gorized on the basis of the percentage of positive cells as:
<5%, 5–10% or >10%. The cellular staining site was also
evaluated and categorized as 1) nuclear, 2) cytoplasmic,
or 3) nuclear plus cytoplasmic.
Results
At recruitment4 we assessed the accuracy of p16 and
HR-HPV testing in identifying high-grade cervical lesions
in 283 cervical samples (ThinPrep) on a consecutive series
of women referred to colposcopy for abnormal cytology
(ASCUS). The results were compared with colposcopy
and biopsy findings. HPV positivity rate was 44.2% among
<CIN1, and 89.2% among CIN2 patients (Chi-square for
trend <10–6). The sensitivity, specificity, and PPV of HPV
testing for CIN2 were 89.2% (25 of 28), 47.8 (122of 255)
and 15.8% (28 of 158), respectively. P16 positivity rate was
25.3% among <CIN1, 57.4% among CIN1 and 88.0%
among >CIN2 patients (square for trend <10–6). Sensitiv-
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ity for CIN2 was 88% (22 of 25), specificity was 61.2% (79
of 129) and PPV was 30.5% (22 of 72).
The patients with cytological abnormalities but with-
out CIN2/3 lesions were followed-up, for 36 months by
cytology and colposcopy was performed if cytology was
ASCUS or worse.
Between 252 patients, 215 women have had a follow-
up procedure: 108/122 (88%) with a negative result for
HR-HPV and 107/130 with a positive result for HR-HPV.
After 36 months (Table1), 8 (7.4%) women with a neg-
ative result for HR-HPV at recruitment, still displayed
abnormal smears (3 ASCUS, 3 LSIL and 2 HSIL). Final
outcome of these cases was: 2 CIN2 (1.8%), 3 CIN1
(2.8%) and 3 Negative (2.8%).
Between women with a positive result for HR-HPV at
enrolment (Table1), after 36 months of follow-up, 18 (16.8%)
women still displayed abnormal smears (2 ASCUS, 10 LSIL
and 6 HSIL). Final outcome of these cases was: 9 CIN2+
(8.4%), 3 CIN1 (2.8%) and 6 Negative (5.6%), (p <0.05).
Considering p16 immunostaing, 66/79 (84%) p16 neg-
ative and 40/50 (80%) p16 positive have had follow-up
(Table 2). During the follow-up of p16 negative women 3
(3/66=4.5%) CIN2 were founded, while 6 CIN2 (6/40=
15%) were founded in p16 positive women (p<0.05).
At the enrolment the number of p16 positive cells did
not correlate with the probability of CIN2 (<5% =
36.3%, 5–10% = 27.2%, >10% = 36.3) and was no fur-
ther considered a relevant variable. No evident differen-
ces in pattern or intensity of p16 expression were ob-
served between the specimens with high grade lesions
and without high lesions at follow-up.
Discussion
HPV DNA testing appears useful in the triage of
equivocal Pap-smears; however studies could not demon-
strate a high level of specificity of HPV DNA testing for
clinically significant cervical disease. The p16 immuno-
staining has been suggested as a tool for triaging women
with low-grade or borderline cytology; p16 could be par-
ticularly interesting among women with LSIL cytology,
where triage by HPV is inefficient. Moreover, an obvious
problem in using HPV testing as a screening tool is that a
sizable proportion of normal women are HPV positive;
however a report8 suggested that about 15% of women in
annual screening programme who concurrently have a
negative Pap test and a positive oncogenic HPV test will
have a subsequent abnormal Pap test within 5 years.
Nevertheless, HPV testing also identified many tran-
sient HPV infections that are not associated with high-
grade CIN. Several studies based on molecular markers
associated with HPV infection could facilate and optimise
diagnosis in a screening setting. It may be possible to de-
tect clinically important disease with risk of progression
towards dysplasia and carcinoma, and consequently, im-
prove patient care by combining test results from molecu-
lar markers with either cytology or HPV or both.
Several studies2–4 reported a differential expression of
p16 in HSIL, LSIL and normal cervical epithelial cells.
In this study, we evaluated the potential of p16 immu-
nocytochemical expression to predict the course of cytologi-
cal cervical abnormalities associated with HR-HPV types.
In the present series, significant p16 overexpression
was observed in the group that progressed from LSIL to
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TABLE 1
HPV TEST AT RECRUITMENT ACCORDING TO THE CYTOLOGICAL DIAGNOSIS DURING THE FOLLOW-UP
N (%) of HR-HPV negative N (%) of HR-HPV positive Total – N (%)
Normal 100 (92.6) 89 (83.2) 189 (87.9%)
ASCUS 3 (2.8) 2 (1.9) 5 (2.3%)
LSIL 3 (2.8) 10 (9.3) 13 (6.04%)
HSIL 2 (1.8) 6 (5.6) 8 (3.7%)
Total 108 (50.2%) 107 (49.8%) 215
HR – high-risk, HPV – human papillomavirus, ASCUS – atypical squamous cells of undetermined significance, LSIL – low-grade
squamous intraepilelial lesions, HSIL – high-grade squamous intraepilelial lesions
TABLE 2
P16 AT RECRUITMENT ACCORDING TO THE CYTOLOGICAL DIAGNOSIS DURING THE FOLLOW-UP
N (%) of p16INK4a negative N (%) of p16INK4a positive Total – N (%)
Normal 58 (87.9) 31 (77.5) 89 (84.0)
ASCUS 1 (1.5) 1 (2.5) 2 (1.9)
LSIL 6 (9.1) 4 (10) 10 (9.4)
HSIL 1 (1.5) 4 (10) 5 (4.7)
Total 66 (62.3) 40 (37.7) 106
HR – high-risk, HPV – human papillomavirus, ASCUS – atypical squamous cells of undetermined significance, LSIL – low-grade
squamous intraepilelial lesions, HSIL – high-grade squamous intraepilelial lesions
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HSIL when compared with the group that did not prog-
ress. To our knowledge, there are a few studies with a
prospective follow-up design carry out to evaluate SIL
progression and the association of p16 overexpression in
cervical specimens in a screening setting for cervical cancer.
Although p16 protein and HPV infection may be de-
tected in low-grade lesions or reactive changes that un-
dergo spontaneous regressions, Wang9 et al. found that
the risk for CIN progression or HPV persistent is higher
for women with diffuse staining for p16 protein com-
pared with those without diffuse staining in tissue sam-
ples. Negri10 also found that CIN1 cases with diffused
p16 staining had significant higher tendency to progress
to a high-grade lesion that p16 protein negative cases.
Conclusion
This study suggest that the combined use of p16 pro-
tein and HPV testing may be useful in identifying cervi-
cal cells with minor abnormalities and a high risk of pro-
gressing to cervical neoplasia, and also defining cases
requiring early management, or at least close surveil-
lance. Our study demonstrated that p16 evaluation on
ThinPrep samples could be useful as a biomarker for pro-
gressive malignancy in HPV-related cytological abnor-
malities. Patients with ASCUS or LSIL and HR-HPV and
p16 positive test were a major risk to develop high grade
lesion compared with patients HR-HPV negative or HR-
HPV positive but with p16 negative.
These findings suggest that among HPV positive pa-
tients, there is a subgroup that may be at increased risk of
progression to invasive cancer and should be followed-up
more closely. Theoretically, all HR HPV-associated lesions
should express p16INK4a. It is unclear why some CIN2 sam-
ples that are HPV DNA positive were also p16INK4a nega-
tive. We might assume that there are other mechanisms of
p16INK4a regulation besides HPV infection, such as pro-
moter methylation, that could occur in cervical cancer.
However, according to previous report in the literature,
pRb inactivation via the p16/cdk-cyclin/ RB pathway and
increase in p16 expression in HPV- transformed cells is an
important mechanism for cervical carcinogenesis.
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KOMBINIRANA ANALIZA DNA HPV-A I EKSPRESIJE P16 U PREDVI\ANJU
PROGNOZE PAPA-NALAZA ASCUS I LSIL
S A @ E T A K
Poznato je da humani papilomavirus (HPV) igra va`nu etiolo{ku ulogu u nastanku raka vrata maternice, no samo
mali udio inficiranih `ena zaista i razvije invazivni rak vrata maternice. Cilj prevencije raka vrata maternice je rana
dijagnoza njegovih prekursora. Molekularna detekcija DNK HPV-a kao dijagnosti~ki test za karcinogenezu raka vrata
maternice je dala slabo pozitivne prediktivne vrijednosti u usporedbi s upotrebom biolo{kih biljega. p16INK4a je pred-
lo`en kao osnovni biljeg koji bi omogu}io identifikaciju promjena epitela vrata maternice. Grupa uzastopnih obrisaka
vrata maternice je testirana na visokorizi~ne HPV, obojana imunocitokemijski za detekciju p16INK4a i pra}ena 36 mjese-
ci. Cilj studije je bio procijeniti imunohistokemijsku ekspresiju p16INK4a kao biljega rizika progresije u o{te}enjima nis-
kog stupnja stanica vrata maternice. U toj grupi je zabilje`ena znatno pove}ana ekspresija p16 za skupinu koja je pre{la
iz o{te}enja niskog stupnja u o{te}enja stanica vrata maternice visokog stupnja u usporedbi sa skupinom kod koje nije
do{lo do progresije. Zaklju~ili smo da pove}ana ekspresija p16INK4A djeluje kao mogu}i biolo{ki biljeg koji ukazuje na
progresiju o{te}enja vrata maternice u premaligni i maligni stadij.
F. M. Carozzi: Analysis of HPV DNA and p16INK4a Expression, Coll. Antropol. 31 (2007) Suppl. 2: 103–106
106
U:\coll-antropolo\coll-antro-suppl-2-2007\14-Carozzi.vp
4. travanj 2007 10:46:33
Color profile: Disabled
Composite  150 lpi at 45 degrees
Coll. Antropol. 31 (2007) Suppl. 2: 107–111
Short communication
Evaluation of p16INK4a in Cervical Lesion of
Premenopausal and Postmenopausal Women
Ines Krivak Bolan~a1 and Sre~ko Ciglar2
1 Laboratory for Cytology and Clinical Genetics, Department of Gynaecology and Obstetrics, Merkur University Hospital,
Zagreb, Croatia
2 Department of Gynaecology and Obstetrics, Merkur University Hospital, Zagreb, Croatia
A B S T R A C T
Pap smears of postmenopausal women are often misdiagnosed because of the difficulty in distinguishing atrophic ep-
ithelial cells groups only by morphological criteria. In this study we investigated the diagnostic application of immuno-
cytochemical staining of p16INK4a on conventional Pap smear. A total of 137 cervical specimens were enrolled in this
study, of which 77 and 60 cervical smears were taken from premenopausal and postmenopausal women, respectively.
Two cervical smears were taken simultaneously in 68 women, one for conventional cytology and the other for immuno-
staining. Additional 69 cervical smears were taken from the archive, decolorized and then used for immunostaining. In
premenopausal women 1 out of 14 (7.1%) with negative cytology, 7 out of 24 (29.2%) with low grade squamous intra-
epithelial lesion (LSIL), all 35 (100%) with high grade squamous intraepithelial lesion (HSIL) and all 4 (100%) with
squamous cell carcinoma (confirmed by histopathology) had positive staining to p16INK4a. In postmenopausal women
p16INK4a positivity was observed in 4 out of 7 (57.1%) cases of LSIL, 12 out of 14 (85.7%) cases of HSIL and all 4 out of 5
(80%) different cases of carcinoma (1 cervical adenosquamous carcinoma and 3 cervical squamous cell carcinoma in situ
confirmed by histopathology), but none of 34 smears with normal cytology. Twenty smears with normal cytology chosen
for the negative control in this study were from the group of postmenopausal women and were as expected negative for
p16INK4a immunostaining. In the group of postmenopausal women, 16 out of 60 (26.7%) cases the cytological diagnosis
was established on the basis of p16INK4a immunostaining as being HSIL. From our preliminary study on a limited num-
ber of samples, we can however conclude that p16INK4a immunostaining is a very useful tool for cytological diagnosis en-
abling to distinguish HSIL from normal, reactive or inflammatory changes.
Key words: postmenopausal, cervical, dysplasia, immunostaining, p16INK4a
Introduction
It is well established that persistant infection with
oncogenic Human papillomavirus (HPV) causes preneo-
plastic and neoplastic changes of the cervical epithelium,
leading towards carcinoma, especially in middle aged
women1. In postmenopausal age, women have received
little attention concerning this problem. Improvements
in life standards and better health care have led to in-
creasing population of elderly women who come to their
regular gynaecological exam and their Papanicolaou (Pap)
smears2–3. In spite of the fact that there is almost 20% of
women infected with HPV4, only a few of them develop
preneoplastic lesion, and even fewer develop cancer.
Smith and al.5 found that 16% of persistent HPV infec-
tions exist in the elderly group of women, suggesting that
one can predict development of a preneoplastic lesion
that can progress toward cancer. However, problems in
diagnosis such as aging-related changes, reparative chan-
ges and interpretation difficulties may lead towards an
incorrect diagnosis. Pap smears of postmenopausal wo-
men are often misdiagnosed because of the difficulty in
distinguishing atrophic epithelial cell groups only by the
morphological criteria. Those criteria are more viable
when premenopausal women are concerned, referred to
better oestrogen effect, hence better maturation. In this
study we investigated whether immunocytochemical sta-
ining of p16INK4a, performed on conventional Pap smear
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could be of any diagnostic help in solving this dilemma.
Thus, we performed p16INK4a immunostaining on speci-
mens taken from premenopausal and postmenopausal
women in order to make an accurate diagnosis in those
cases, which were impossible for us to distinguish on the
basis of cytomorphological criteria, i.e. to distinguish a
high grade cervical lesion from atrophy or reactive chan-
ges.
Examinees, Materials and the Methods
We analysed 137 cervical smears, which consisted in
69 archival Pap slides and 68 cervical specimens collected
from women who attended our clinic in 2006 for their
regular check-up. They were divided into two age groups.
Seventy-seven premenopausal women were in group I
(median age 34.5) and 60 postmenopausal women (me-
dian age 63) in group II, of which 20 women with normal
cervical smears were used as a control group.
Two simultaneous cervical smears were taken by a
cytobrush and a wooden spatula, one for conventional cy-
tology and the other for immunostaining. Archival Pap
slides were decolorized in 0.5% HCl, rinsed with distilled
water and then immunocytochemically stained with
CINtec™ p16INK4a Kit (DAKOCytomation, Denmark) ac-
cording to the manufacturer instructions. There were no
differences in staining reaction or intensity of reaction
between decolorized and freshly taken smears. Accord-
ing to DAKO instructions at least 1% of cells should be
stained for the reaction to be considered positive. Cells
are regarded as stained if brownish-like granules were
found in nuclei and/or in a cytoplasm.
Pap smears were classified by the »Bethesda system«6
into a normal epithelium, low (LSIL) and high grade
intraepithelial cervical lesion (HSIL) and squamous cell
carcinoma (SCC). Among postmenopausal women, there
was one case of recurrent adenosquamous carcinoma and
metastatic transitional cell carcinoma. In 16 postme-
nopausal women we could not diagnose based on the
morphological criteria; in those women diagnosis was es-
tablished after the p16INK4a immunostaining.
In total, fifty-five women underwent colposcopy and
biopsy, and a consequent cold knife conisation or hyster-
ectomy was performed; in each case histological verifica-
tion was made. Unfortunately, the patient with meta-
static transitional cell carcinoma died.
The distribution of positivity rate versus diagnosis
was analyzed with the standard Chi–square (c2) test. The
statistical significant differences was set at p<0.025.
Results
The distribution of cytological diagnoses and p16INK4a
immunostaining in premenopausal women is as follows:
18.2% (14/77), 31.2% (24/77), 45.5% (35/77) and 5.2%
(4/77) women had a negative cytology, LSIL, HSIL, SCC,
respectively (Table 1). P16INK4a immunostaining was ob-
served in 7.1% (1/14), 29.2% (7/24) and 100% (35/35 and
4/4) of premenopausal women with negative cytology,
LSIL, HSIL and SCC, respectively. The observed frequ-
encies were significantly different (c2=52.24, p<0.0001).
The positive p16INK4a immunostaining of one of the 4
SCC later histologically confirmed, and of normal me-
taplastic cells is shown in Figure 1 and 2. In this age
group we succeed to diagnose all smears according to via-
ble morphological signs and well established criteria for
every grade of intraepithelial lesion.
The distribution of cytological diagnoses and p16INK4a
immunostaining in postmenopausal women is as follows:
52.3% (34/60), 10.8% (7/60), 21.5% (14/60) and 7.7%
(5/60) women had a negative cytology, LSIL, HSIL, SCC,
respectively (Table 2). P16INK4a immunostaining was ob-
served in 57.1% (4/7), 85.7% (12/14) and 80% (4/5) of
postmenopausal women with LSIL, HSIL and SCC, re-
spectively, while none with those with normal cytology.
The observed frequencies were significantlly different
(c2=40.97, p<0.0001).
In 16 postmenopausal women we had difficulties for
classifying a certain cell groups as neoplastic because of
their resemblance to mucosal atrophy or because of the
presence of strong degenerative, inflammatory or reac-
tive changes. In 8 women, after p16INK4a immunostaining
we were able to distinguish HSIL from reactive changes
(Figure 3). Among these women one case of previously
diagnosed adenosquamous carcinoma, was p16INK4a posi-
tive, indicating the possibility of recurrent carcinoma.
Discussion
In spite of good screening methods based on Pap
smear and well organized screening programmes in
many countries, women all around the world continue to
develop cervical disease. The incidence rate of cervical
cancer in developing countries is increasing due to the
aging population, while in Western Europe first peak is
between 30 and 40 years of age and the second peak oc-
curs around 60 years of age7. Genital infection with
oncogenic or high-risk (hr) HPV is established as one of
the main events in pathogenesis of cervical and other
genital tumours1. After the first contact with the virus,
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TABLE 1
P16INK4a FINDINGS ACCORDING TO DIAGNOSIS
OF PREMENOPAUSAL WOMEN
p16INK4a





Negative 13 (92.9) 17 (70.8) 0 0 30 (39)
Positive 1 (7.1) 7 (29.2) 35 (100) 4 (100) 44 (61)
Total 14 (18.2) 24 (31.2) 35 (45.5) 4 (5.2) 77 (100)
LSIL – low grade squamous intraepithelial lesion, HSIL – high
grade squamous intraepithelial lesion, *cervical squamous cell
carcinoma in situ confirmed by histopathology, c2 = 52.24, p <
0.0001
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viral replication is limited to superficial layers of the cer-
vical epithelium that represents the acute, transitory
phase. If viral E6 and E7 oncogene products are over-ex-
pressed in a basal or parabasal layers, they will interfere
with the regulation of the host cell cycle, inducing ge-
netic instability. The probability of progression of cervi-
cal precancerogenic lesions is considered greater with the
longer persistence of papillomavirus infection. Almost
100% of all cervical cancers can be attributed to certain
hrHPV types8. The highest proportion of cervical squa-
mous cancers is associated with HPV type 16, followed by
type 18 which is more common in adenocarcinomas, than
HPV types 31, 33, 45, 52, 58 and others1,7.
There are lots of regulating proteins involved in the
cell cycle control. One of them, p16INK4a, has been shown
to be over-expressed after the cell has been infected by
hrHPV types. Expression of the viral E7 oncogene leads
to functional inactivation of tumour suppressor retino-
blastoma protein (pRB), which in turn, results in strong
over-expression of the cyclin-dependent kinase inhibitor
p16INK4a. This indicates that an active expression of the
viral E7 oncogene is present in dysplastic cells4.
There are a lot of data about HPV prevalence in youn-
ger women, but not much about elderly population. Smith
et al.5 showed that, opposite to a common belief, the prev-
alence rate of HPV in postmenopausal women was al-
most as high as in younger women and the association
between hrHPV and consecutive abnormal Pap smear
was 36%. Bosch and Harper7 on the other hand summa-
rised the results from cohort studies and found that
hrHPV infection persisted in 50% cases. Bruner and
Davey9 had similar results in their group of women aged
60 years and over in contrast with 20% of hrHPV positive
infection in younger groups (40 and 50 year old women).
That leads towards conclusion of Massad et al.10 that
older women more frequently have a higher abnormality
grade, while younger women had more lesions connected
with transient infection.
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Fig 3. p16INK4a staining of high grade squamous intraepithelial
lesion (HSIL) found in a smear of a postmenopausal woman
Fig 2. p16INK4a staining of normal metaplastic cells found in a
smear of a premenopausal woman
TABLE 2
P16INK4a FINDINGS ACCORDING TO DIAGNOSIS OF
POSTMENOPAUSAL WOMEN
p16INK4a
N (%) of cytological diagnosis
Normal LSIL HSIL Carcinoma Total
Negative 34 (100)* 3 (42.9) 2 (14.3) 1** (20.0) 40 (66.7)
Positive 0 4 (57.1) 12 (85.7) 4*** (80.0) 20 (33.3)
Total 34 (52.3) 7 (10.8) 14 (21.5) 5 (7.7) 60 (100)
LSIL – low grade squamous intraepithelial lesion, HSIL – high
grade squamous intraepithelial lesion, *include 20 women as
control group, **transitional cell carcinoma confirmed by his-
topathology, ***1 case of cervical adenosquamous carcinoma and
3 cases of cervical squamous cell carcinoma in situ confirmed by
histopathology, c2=40.97, p<0.0001
Fig 1. p16INK4a staining of malignant squamous cells found in a
smear of a premenopausal woman
U:\coll-antropolo\coll-antro-suppl-2-2007\15-Bolanca.vp
4. travanj 2007 10:48:42
Color profile: Disabled
Composite  150 lpi at 45 degrees
In our study, following »Bethesda recommendations«
we classified lesions as normal including inflammatory
and reactive changes, as LSIL presented with or without
koilocytotic changes, as HSIL and as carcinoma. Among
premenopausal women with normal cervical smears p16-
-positive metaplastic cells were noted in one patient. It is
known that some metaplastic and endocervical normal
cells could be positively stained due to unfinished differ-
entiation of the cells. Staining intensities of the normal,
metaplastic cell are weaker than in dysplastic10,12, and
staining was observed only in the cytoplasm, while the
nucleus showed no staining reaction. After p16INK4a im-
munostaining, most (70.8%) of dysplastic cells in LSIL
were stained negative in a group of premenopausal wo-
men. There were only 7 (29.2%) LSIL smears with a
stained reaction in the nucleus and cytoplasm of the cells
(Figure 1). All of these premenopausal women with HSIL
were hrHPV positive (data not shown). Our results
showed p16INK4a overall positivity of 61% that is similar
to the results of Bose et al.13, although higher percentage
up to 78% were reported previously14,15. We agree with
the statement of Bose that p16INK4a does not have a role
in the diagnosis of LSIL but it might be useful for con-
firming the diagnosis of HSIL since our study showed
positive staining in all HSIL. The role of p16INK4a as a
predictive and prognostic factor is to be confirmed by ad-
ditional large scale studies.
Correct cytological diagnosis of cervical abnormalities
in older women is a much greater problem because of the
morphological similarities between atrophic epithelial
cells and cells from high-grade squamous lesion. There-
fore one should keep in mind several cytomorphologic
findings such as: clean smear background, maturation
index, nuclear/cytoplasmatic ratio, presence of hyper-
chromasia and then incorporate that in physiologic and
pathologic changes of women’s genital tract. Saad et al.16
divided impact factor analysis to individual (degree of
cell maturation, patient age, and smear background) and
the other ones that dramatically influenced accurate di-
agnosis. The following factors were suggested: nuclear
membrane features, hyperchromasia with nuclear/cyto-
plasmatic ratio favouring nucleus and abnormal single
cell arrangement. These cytomorphologic findings lead
us to an »uncertain« cytological diagnosis in postmeno-
pausal smears with profound inflammatory or degenera-
tive changes. By performing p16INK4a immunostaining, in
case that it is positive in the nucleus and cytoplasm, we
will be able to classify some of these »uncertain« lesions
as likely to be HSIL, which could be further confirmed by
histology. In cytologically negative smears of postmeno-
pausal women, p16INK4a staining was negative as well.
Conclusion
From our preliminary study on a limited number of
samples, it appears that although p16INK4a is not helpful
in the diagnosis of LSIL in younger women, in post-
menopausal women it may be useful for confirming cer-
vical lesion even if cytological diagnosis was mild dys-
plasia. To avoid »uncertain« diagnosis when the rate of
possible false-negative diagnoses as well as false-positive
cytology is high, we think that the use of p16INK4a stain-
ing would be helpful for identification of adequate diag-
nosis.
For elderly women with squamous atypia an oestro-
gen treatment is often suggested, maturation effect can
make an abnormal cell more viable and abnormal reac-
tive changes disappear. That involves repeated patient’s
discomfort of physical exam as well as a certain dose of
stress. To minimize that we suggest taking two simulta-
neous smears during Pap sampling; it will allow to per-
form normal Pap and p16INK4a immunostaining. In this
way, we will be able to distinguish more accurately nor-
mal, non-specific reactive or inflammatory changes from
neoplastic changes in postmenopausal women Further-
more, p16INK4a immunostaining would be useful in a rou-
tine laboratory practice for analysis and follow-up of abnor-
mal cervical smears in general. Further population-based
studies will be necessary to analyse predictive value of
p16INK4a protein in cervical smears in both groups of
women.
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PROCJENA P16INK4a U LEZIJAMA VRATA MATERNICE KOD @ENA
U GENERATIVNOJ DOBI I POSTMENOPAUZI
S A @ E T A K
^este su pogre{ne citolo{ke dijagnoze cervikalnih razmaza `ena u postmenopauzi zbog sli~nosti u morfolo{kom
izgledu stanica dubljih slojeva epitela i neoplasti~no promijenjenih stanica. U na{oj studiji istra`ili smo primjenu imu-
nocitokemijskog bojanja sa p16INK4a na cervikalnim razmazima u svrhu rje{avanja tog problema. Imunocitokemijski
smo obojali uzorke 77 `ena u generativnoj dobi i 60 uzoraka `ena u postmenopauzi. Kontrolnu skupinu su sa~injavali
20 urednih citolo{kih razmaza bez izra`enih upalnih ili degenerativnih promjena iz skupine `ena u postmenopauzi.
Kod 68 pacijentica prilikom uzimanja uzoraka u~inili smo 2 razmaza: jedan za citolo{ku analizu a drugi za imuno-
citokemijsko bojanje. [ezdesetdevet predhodno uzetih uzoraka smo odbojali i pripremili za imunoreakciju. Kod `ena
generativne dobi 14 pacijentica je imalo uredan Papa-test i opa`en je p16INK4a pozitivitet kod jednog uzorka (7,1%); 24
uzoraka je ocijenjeno kao SIL (skvamozna intraepitelna lezija) niskog stupnja i me|u njima je bilo 7 (29,2%) p16INK4a
pozitivno obojenih uzoraka. Svih 39 uzoraka SIL visokog stupnja, od kojih 4 karcinoma plo~astih stanica in situ nak-
nadno histolo{ki utvr|enih, pozitivno se obojilo. Pozitivitet p16INK4a kod razmaza starijih `ena je rastao u slijede}em
nizu: 0%, 57,1%, 85,7% i 80% kod 34 urednih razmaza, 4 razmaza niskog i 12 visokog SIL te 4 karcinoma naknadno
histolo{ki utvr|enih (1 adenokarcinom, 3 karcinoma plo~astih stanica in situ). U skupini od 16 pacijentica, to~na cito-
lo{ka dijagnoza SIL-a visokog stupnja postavljena je tek nakon imunocitokemijske reakcije. Na temelju na{eg preli-
minarnog istra`ivanja na malom broju uzoraka, mo`emo zaklju~iti da uklju~ivanje p16INK4a imunocitokemijskog bojanja u
redovitu laboratorijsku praksu mo`e pomo}i u razlikovanju reaktivnih ili degenerativnih promjena od neoplasti~nih
lezija cervikalnog epitela.
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Review
Development of Prophylactic HPV Vaccines
Lutz Gissmann1 and Martin Müller1
1 Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany
A B S T R A C T
Since several years it has been accepted that persistent infection with certain (so called-high risk: HR) types of Human
papillomaviruses (HPV) represents a strong risk factor for cervical cancer. The most frequent HR HPV types 16 and 18
account for about 70% of this tumour, which is the second most frequent malignancy in women worldwide. Several stud-
ies in animal papillomavirus models revealed that protection against infection is conferred by neutralizing antibodies
directed against conformational epitopes of the major structural protein L1. Such antibodies can most efficiently be in-
duced by immunization with virus-like particles (VLP) that assemble spontaneously following expression of L1 in recom-
binant vectors. Large-scale production of HPV 16 and 18 VLPs proved to be successful facilitating, a few years ago, first
clinical trials on safety and immunogenicity. In the meantime more than 25,000 women have been included into several
efficacy trials which demonstrated protection against persistent infection with HPV 16 and 18 and against the develop-
ment of precursor lesions to cervical cancer. Although the ultimate proof of success, i.e. reduction of cancer incidence still
requires the immunization of large populations and many years of follow-up, the existing data are so persuasive that the
responsible agencies in several countries permitted the licensing of the first HPV vaccine in 2006. Several questions such
as the duration of protection, the need development of for post-exposure vaccination strategies and availability of such
vaccine in low-budget countries are open and will be discussed.
Key words: human papillomavirus (HPV) vaccines, cervical cancer
Preventive vaccines are based on the induction of vi-
rus-neutralizing antibodies. For the papillomaviruses
this has first been achieved by immunization with forma-
lin-fixed wart extracts and subsequently by inactivated
purified viruses1. In demand of an appropriate infection
model, it was difficult to determine the neutralizing ac-
tivity of serum antibodies. The first in vitro assay for vi-
rus neutralization was the inhibition of focus formation
of mouse cells in culture by BPV virions2. A more sophis-
ticated neutralization assay was introduced by Kreider
and coworkers who grafted normal human tissue in-
fected in vitro with HPV 11 or HPV 16 under the renal
capsule of immuno-deficient mice where typical lesions
develop3. Infection is then monitored by phenotypic anal-
ysis and by HPV-specific RT-PCR. Only very recently, a
potentially high throughput neutralization assay on the
basis of pseudovirions containing a reported gene be-
came available which allows detection of neutralizing an-
tibodies in an in vitro setting4. Neutralizing antibodies
are directed against the major structural protein L1 and,
to a much lesser degree, against the minor capsid protein
L2. For induction of neutralizing antibodies, the L1 pro-
tein is required to be presented in a correctly folded
conformation. This became only possible with the pro-
duction of L1 virus-like particles (VLPs). In 1986 it had
already been shown that purified VP1 of mouse poly-
omavirus spontaneously assembles into virus-like parti-
cles5. This inspired in the early 1990s the production of
papillomavirus-like particles by different researchers. Zhou
and colleagues used a vaccinia virus expression system to
produce HPV 16 L1 VLPs, however the yield of this sys-
tem was extremely low and did not allow further charac-
terization of the antigen e.g. by immunological studies6.
Shortly after, it was demonstrated that HPV 1, BPV 1
and HPV 11 VLPs can be produced much more efficiently
compared to HPV 16 VLPs leading to the speculation
whether this might be due to intrinsic properties of the
L1 protein of different PV types7,8,9. After a report by
Kirnbauer and colleagues it became clear, however, that
the HPV 16 L1 gene of the original isolate by Dürst et al.
harboured a point mutation rendering its encoded L1
protein virtually assembly defective10. The HPV 16 pro-
totype genome, used by numerous researchers worldwide
113
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was derived from a tumour biopsy, in which the HPV 16
genome was integrated into the cellular genome and thus
had been without any selection pressure for the mainte-
nance of intact structural genes. When HPV 16 genomes
obtained from virus-producing lesions were analyzed,
the respective L1 proteins assembled with much greater
efficiency into VLPs. Sequence analysis revealed that
this difference was based on a single histidine to aspartic
acid exchange at position 202 of the HPV 16 L1 protein.
VLPs were subsequently produced successfully in insect
cells, later also in yeast, in plants and even in cell free
systems. Meanwhile, VLPs of several animal and human
papillomaviruses have been produced, i.e. cottontail rab-
bit papillomavirus, rabbit oral papillomavirus, BPV 1
and 4, canine oral papillomavirus and HPV types 1, 2, 6,
8, 11, 13, 16, 18, 31, 33, 39, 45, 58 and 5911,12,13–15, for re-
view see16. The production of VLPs in larger quantities
made structural and immunological studies possible.
The data obtained from several animal models fos-
tered the concept of prophylactic vaccines against HPV
infections. Virus-like particles proved to be prime candi-
dates for prophylactic vaccination since they induce high-
-titer conformational antibodies of neutralizing capacity
both in non-human primates and in man2,17–25. By pas-
sive transfer of IgG from immunized animals it was
shown that they confer protection against experimental
challenge26.
The first clinical trial with VLPs (of HPV 11) involv-
ing human subjects was initiated in 1996 (for reference
see Inglis et al.27). HPV 11 VLPs used in this study were
produced in insect cells. The success of this trial initiated
further HPV vaccine development. In several phase I
clinical trials safety and immunogenicity of HPV 11, 16
and 18-specific VLPs generated by expression of the L1
protein in yeast or in insect cells were demonstrat-
ed17,19,20–22. Three VLP-based vaccines (HPV 16, HPV 16
+ 18, HPV 6 + 11 + 16 + 18) were brought into clinical
efficacy trials. The so far only licensed vaccine provided
by Merck & Co (Gardasil
TM
) contains in addition to the
most relevant cancer-associated HPV types 16 and 18
also VLPs of the low-risk HPV types 6 and 11 aiming for
protection against genital warts whereas the product de-
veloped by GlaxoSmithKline has only the two high-risk
HPVs. The data obtained from immunization of about
25,000 young women receiving either vaccine or placebo
demonstrated after more than 4 years of follow-up pro-
tection against incident and persistent infection with
HPV 6/11, and/or HPV 16 an 18 and the lesions associ-
ated therewith (external genital lesions, high grade CIN,
adenocarcinoma in situ)28–32. Longer follow-up and large
scale population-based efficacy trials will be required to
evaluate the potential of these vaccines to reduce the in-
cidence of cervical cancer33,34. Based on the existing data,
however, the regulatory agencies in different countries
have approved. It will be more difficult to evaluate the ef-
ficacy towards genital warts since the information about
the incidence of this disease is rather scarce (http://
wrongdiagnosis.com/g/genital warts). The second prod-
uct manufactured by GlaxoSmithKline (consisting of HPV
16 + HPV 18 VLPs) is expected to enter the market soon.
After introduction of the vaccines there are several
open questions that can be solved only after wide applica-
tion in different countries and longer time of follow-up.
The critical issues include the acceptance of the HPV-
-specific vaccines within different cultures35,36 including
the question whether the vaccine will be marketed as
preventive measures against a sexually transmitted dis-
ease or as anti-cancer prophylaxis37. Other issues are the
duration of immune protection and the participation of
vaccinated women in Pap-screening programs since HPV
16 and 18 accounts for about 70% of cervical cancer
cases38 hence the risk for this disease by other high-risk
HPV types is not negligible. Therefore, vaccinated wo-
men need to be educated about the necessity to keep up
with the screening program although the intervals of the
visits can possibly be extended39. Obviously prophylactic
vaccination will be highly desirable in areas where scre-
ening programs are not offered to the general population
and where cervical cancer is a major public health prob-
lem. The high price clearly is prohibitive and joint efforts
of scientists (developing more cost effective protocols),
providers and politicians (discussing multi-tiered pric-
ing) and public and philanthropic foundations (providing
large amounts of money) are needed to make the vac-
cines available to the populations of highest need.
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RAZVOJ PROFILAKTI^KOG CJEPIVA PROTIV HPV-a
S A @ E T A K
Od prije nekoliko godina je prihva}ena tvrdnja da trajna infekcija s odre|enim (tzv. visokorizi~nim; HR od engl. high
risk) tipovima humanog papilomavirusa (HPV) predstavlja jaki faktor rizika za razvoj raka vrata maternice. Naj~e{}i
HR HPV-i su tipovi 16 i 18, povezani s oko 70% ovog tumora, koji je na drugom mjestu naj~e{}ih oboljenja kod `ena u
svijetu. Nekoliko studija na modelima animalnih papilomavirusa je pokazalo da je za{tita protiv ove infekcije neu-
traliziraju~ih antitijela protiv konformacijskih epitopa glavnog strukturnog proteina L1. Ta antitijela mogu biti vrlo
u~inkovito inducirana imunizacijom sa ~esticama sli~nim virusima (VLP, engl. Virus-Like Particles) koje se spontano
nakupljaju nakon ekspresije L1 u rekombinantnim vektorima. Velika skala proizvodnje VLP-ova od strane HPV 16 i 18
se pokazala uspje{nom, olak{avaju}i tako, prije nekoliko godina, prve klini~ke pokuse o sigurnosti i imunogenosti. U
me|uvremenu, vi{e od 25.000 `ena je bilo uklju~eno u nekoliko klini~kih pokusa o za{titi protiv trajne infekcije ti-
povima HPV-a 16 i 18 te o sprje~avanju razvoja o{te}enja koja prethode raku vrata maternice. Iako je krajnji dokaz
uspjeha smanjenje stope pojavnosti raka, potrebno je jo{ cijepiti velike skupine te ih godinama pratiti. Ipak, sada{nji
podaci su toliko uvjerljivi da su zadu`ene agencije u nekoliko zemalja dopustile uvo|enje prvog cjepiva protiv HPV-a u
2006. g. Neka pitanja, kao {to je trajanje za{tite, potreba za razvojem strategija nakon cijepljenja i dostupnost ovog
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A B S T R A C T
In this paper legal prerequisites for vaccine licensure in Croatia are discussed. The Croatian legislation concerning
vaccine licensing, marketing authorisation and utilization is reviewed. The procedures for including a vaccine into the
Mandatory Childhood Vaccination Programme are also discussed with focus on Human papillomavirus (HPV) vaccines.
Non-obligatory vaccination recommendations are given when according to professional opinion; vaccination is benefi-
cial for the vaccinee. There is little doubt that HPV vaccines should be recommended for preadolescent girls in Croatia.
However, reaching a decision on its possible introduction into the Childhood Vaccination Programme will require care-
ful consideration of the larger picture and a comparison of the cost-effectiveness of a mandatory vaccination against
other competing public health priorities.
Key words: vaccination, regulations
Introduction
The first prerequisite for a vaccine to be legally used
in Croatia is licensure. The Agency for Medicinal Prod-
ucts and Medical Devices (AMPMD) is responsible for
the licensing procedure and for marketing authorization
of vaccines1. However, it is very important to understand
that licensing and marketing authorization only guaran-
tee the quality, safety and efficacy of vaccines but this
does not determine the way a vaccine will be used.
Each lot of vaccine regardless of the manufacturer is
subject to quality control performed by the AMPMD, Di-
vision for Immunological Medicinal Products. Further,
the AMPMD undertakes a variety of other tasks includ-
ing postmarketing surveillance and this is done in collab-
oration with the Croatian National Institute of Public
Health which is responsible for surveillance of adverse
events following immunization. Based on this surveil-
lance, the AMPMD can request that the manufacturer
review and change the summary of product characteris-
tics, as well as the prescribing information.
The way a vaccine will be used depends on a number
of epidemiological, regulatory and financial factors. Vac-
cines may be mandatory for the entire eligible population
such as specific birth cohorts according to the Childhood
Vaccination Programme2, or for specific at-risk groups
such as hepatitis B vaccination for health care workers.
Then, there are vaccines that are recommended for spe-
cific groups such as typhoid fever vaccination for travel-
lers to endemic areas and influenza vaccination for the
elderly, health care workers and chronically-ill patients.
Mandatory Vaccinations
Each year, the Minister of Health announces the
Childhood Vaccination Programme (»the Programme«)
based on the recommendation from the Croatian Insti-
tute of Public Health (CIPH). The declaration of manda-
tory vaccination or the provision of free-of-charge vac-
cines is regulated by health care legislation, primarily
the Act on the Protection of the Population from Infec-
tious Diseases, which is further elaborated by the imple-
menting provisions that are issued by the Minister of
Health3,4. Mandatory vaccinations that are covered by
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the Childhood Vaccination Programme are obligatory for
all in the defined target population because it is in the in-
terest of the community to have all its members / citizens
vaccinated, as well as being in the interest of the individ-
ual vaccinee. All mandatory vaccinations according to
the Programme are free of charge for the vaccinee, be-
cause the vaccines are purchased and vaccination is re-
imbursed to primary health care physicians by the Cro-
atian Health Insurance Institute. The current Childhood
Vaccination Programme is presented in Table 1.
Mandatory vaccination carries with it the responsibil-
ity of the government to secure safe and effective vac-
cines and to organise the health care system in such a
way that it makes vaccination accessible to all within the
designated target population. This is also regulated by
law, primarily the Health Care Act, the Act on the Pro-
tection of the Population from Infectious Diseases (noted
above), as well as various bylaws and ordinances arising
from these acts5. According to these documents, it is the
duty of primary health care providers to vaccinate pre-
school children according to the Programme. Newborns
are vaccinated in the maternity wards, while elementary
school pupils are vaccinated at school by the school medi-
cal service that is affiliated to the County Institutes of
Public Health.
As you will see, mandatory vaccination involves an
enormous commitment on the part of the community, in-
stitutions and individuals so the decision to include a vac-
cine into the Programme or not must be based on solid sci-
entific evidence and the highest professional expertise.
The Croatian Institute of Public Health (CIPH) is the
institution responsible for designing the Childhood Vacci-
nation Programme in Croatia. In collaboration with the
relevant partners (representatives of paediatric associati-
ons, school health associations, epidemiologist associations,
family doctors, etc.), the CIPH analyses the epidemiolo-
gical situation regarding vaccine-preventable diseases,
the performance of the proposed vaccination programme
and all suggestions relevant to the Programme to de-
velop and present a recommendation to the Minister. In
certain instances, public opinion is taken into account in
the decision-making process even if it is at odds with the
scientific evidence and professional knowledge.
There are also a number of vaccinations which are man-
datory for specific groups, e.g. hepatitis B (HBV) vaccina-
tion for health-care workers and for sexual partners of
HBV carriers, then prophylaxis for persons exposed to ra-
bies; these vaccines are free of charge for individuals and
reimbursed by the Croatian Health Insurance Institute.
Recommended Vaccination
Non-obligatory vaccination recommendations are those
considered to be of interest for the individual but not to
the whole community, and these can be either paid for by
public Health Insurance or the individual. For example,
influenza vaccination for health-care workers, the el-
derly and chronically-ill patients, pneumococcal vaccina-
tion for asplenic patients and the elderly in nursery
homes, etc. are examples of vaccinations that are recom-
mended and paid for by public Health Insurance. Then,
all vaccinations recommended to travellers to prevent
diseases that are endemic in the countries they are going
to such as cholera, meningococcal meningitis, yellow fe-
ver or hepatitis A are paid for by the vaccinee. The same
applies to tick-borne encephalitis vaccine, which is rec-
ommended for persons exposed to ticks in endemic areas,
either professionally or recreationally.
HPV Vaccination
As far as Human papillomavirus (HPV) vaccine is
concerned, as soon as the vaccine is licensed and the
batch control is finished, the vaccine will receive market-
ing authorization and can be used in Croatia. Then, rec-
ommendations for the use of vaccination will be issued by
professional medical associations, e.g. gynaecology, pae-
diatrics or epidemiology associations, or other non-gov-
ernmental associations. Whether it will be reimbursed or
not depends on the Health Insurance Institute. Any of
the associations which issue recommendations can sug-
gest the reimbursement of vaccination by the Health In-
surance Institute or request the Ministry of Health to
initiate the process for covering expenses by the Health
B. Kai} et al.: Vaccine Regulations in Croatia, Coll. Antropol. 31 (2007) Suppl. 2: 117–120
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TABLE 1
CHILDHOOD VACCINATION PROGRAMME IN CROATIA
FOR YEAR 2007
Age Vaccine
Birth* BCG, Hepatitis B
2 months Hib, Hepatitis B
3 months DTP, IPV
4 months DTP, OPV, Hib
6 months DTP, OPV, Hib, Hepatitis B
12–18 months MMR, DTP, OPV, Hib
3 years DTP
6 years MMR, Td, OPV
12 years Hepatitis B **
13 years PPD, BCG***
14 years Td, OPV
19 years TT
60 years TT
BCG – Bacillus Calmette-Guerin, Hib – Haemophilus influenzae
type B, DTP – Diphtheria, tetanus, pertusis, IPV – Inactivated
polio vaccine, OPV – Oral polio vaccine, MMR – Measles, mumps,
rubella, PPD – Purified protein derivative testing, Td – Tetanus,
diphtheria, adult formulation, TT – Tetanus toxoid, * Newborns
to HBsAg positive mothers receive HBIG at birth together with
the first dose of hepatitis B vaccine, which is continued accord-
ing to a 0, 1, 2, 12 scheme, ** Three doses of hepatitis B vaccine
according to a 0, 1, 6 scheme. Vaccination at the age of 12 will be
discontinued when children vaccinated as newborns reach this
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Insurance Institute. In both cases, the Health Insurance
Institute establishes a committee of the relevant medical
experts and eventually decides whether the Health In-
surance Institute will cover the expenses or not.
The vaccination strategy that is anticipated to have
the greatest impact on the incidence of cervical carci-
noma in the future would involve at least universal vacci-
nation of preadolescent girls6. In Croatia, this means in-
troducing the vaccine into the mandatory Childhood
Vaccination Programme.
Although the public health burden of cervical carci-
noma in Croatia is well-known, together with the general
epidemiology of HPV infection and the general charac-
teristics of available vaccines, there are still uncertain-
ties which must be clarified before considering the intro-
duction of HPV vaccine into the Programme.
The reduction of precancerous and invasive cervical
lesions achieved by vaccination with reasonably high cov-
erage rates is anticipated to be substantial, but not
enough to eliminate the need for cervical screening6,7. In
order to calculate how substantial this reduction of pre-
cancerous lesions and cancer will be, a systematic review
of available information on the prevalence of HPV types
in our population is necessary. Then, this will need to be
compared to the impact that could be achieved through
improvements to the cervical screening system. Never-
theless, the potential of HPV vaccines to prevent precan-
cerous lesions caused by HPV types included in the vaccine
would appear to favour vaccine introduction regardless
of the reductions in cancer that could be achieved by im-
provements to screening.
A characteristic of the HPV vaccine that could be an
obstacle to the wide acceptance of the vaccine in public as
well as in the professional community is the fact that a
significant impact on the burden of disease can not be ex-
pected within 20–30 years of the introduction of the vac-
cination into the Programme, provided always that high
coverage rates would be achieved and maintained contin-
uously. And finally, the price of introducing this vaccine
into the Programme is an important issue. In case it
would be established that vaccination would achieve
better results in reducing cervical cancerous lesions than
alternative interventions (e.g. enhanced screening), the
cost-effectiveness would have to be assessed against
other interventions in the health care system, waiting to
be implemented or improved. Since the health budget is
a single source, money for screening programmes, paper
towels or antibiotics all comes from the same source as
the funds for vaccination, there are numerous needs
competing with each other for the funds.
So far, the introduction of vaccines into the Pro-
gramme was never limited by the health care budget,
mostly due to the fact that it was clear the vaccines (at
their given prices) were the most cost-effective interven-
tions. However, it is expected that one dose of HPV vac-
cine would cost about 100 Euros and therefore, introduc-
ing this vaccine into the Programme to vaccinate only
one birth cohort of girls (e.g. 11-year-old girls) would
raise the annual cost of the Programme by 130% (the
HPV vaccine would cost about 6.7 million Euros which is
30% more than all the other vaccines used in the Pro-
gramme at the moment 5.1 million Euros8).
Conclusion
The HPV vaccine will soon be licensed in Croatia and
will have an important role in the prevention of cervical
cancer in this country. Immediately after licensure physi-
cians will be able to use it on individual, patient-pay ba-
sis. In order to ensure reimbursement of the vaccine by
the Croatian Health Insurance Institute, a request would
need to be issued and an expert committee would then
decide if the request should be accepted.
Regardless of the reimbursement policy for recom-
mended vaccinations, no effect on the public health bur-
den of cervical cancer can be expected unless vaccination
is implemented to the whole target population within a
well designed vaccination programme. This could be
achieved by introducing HPV vaccination into the man-
datory Childhood Vaccination Programme.
Still, much information must be gathered in order to
assess the potential public health benefit of this vaccine
in Croatia (type specific epidemiology of HPV in Croatia,
potential of improved screening for cervical cancer in
Croatia, etc.). From the perspective of an institution re-
sponsible for the introduction of new vaccines into the
Childhood Vaccination Programme and the allocation of
considerable amounts of public funding into one specific
intervention, we believe that these associations advocat-
ing introduction of a new vaccine should make every ef-
fort to demonstrate this is the best available option.
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ZAKONSKA REGULATIVA VEZANO UZ CJEPIVA U HRVATSKOJ
S A @ E T A K
U ovom ~lanku raspravlja se o legislativi koja mora biti udovoljena da bi se cjepiva koristila u Hrvatskoj. Kori{teni su
zakoni i pravilnici kojima se regulira registracija, pu{tanje lijeka u promet, te na~in kori{tenja cjepiva. Postupci za
uklju~ivanje cjepiva u Program obveznih cijepljenja su tako|er prodiskutirani, s naglaskom na cjepivo protiv humanog
papilomavirusa (HPV). Preporuke za cijepljenja koja nisu obvezna se izdaju na temelju stru~nog stava da je cijepljenje
korisno za pojedinca. Nema sumnje da se cijepljenje protiv HPV-a mo`e preporu~iti djevoj~icama u preadolescentnoj
dobi. Me|utim, da bi se donijela odluka o uvo|enju cjepiva u Program obveznih cijepljenja potrebno je sa razli~itih
medicinskih stajali{ta razmotriti uvo|enje cijepljenja u odnosu na druge javnozdravstvene prioritete koji se nadme}u za
ista sredstva.










 $  
Coll. Antropol. 31 (2007) Suppl. 2: 121–130
Original scientific paper
Early Sexual Intercourse and Risk Factors
in Croatian Adolescents
Marina Kuzman, Ivana Pavi} [imetin and Iva Pejnovi} Franeli}
School Medicine Service, Croatian National Institute of Public Health, Zagreb, Croatia
A B S T R A C T
Sexual behaviour in adolescence is a sensitive issue and has possible immediate and long term medical and psychical
consequences. The aim of the study was to examine whether early sexual intercourse varies by gender and how is associated
with unhealthy behaviour and factors of psycho-social well-being. 773 boys and 857 girls of 15.5 years old, included in a
representative national school-based survey, conducted in Croatia in 2006, were invited to fill in anonymous question-
naires. Sexual experience before the age of 16 years was reported by 28.6% of the boys and 16.5% of the girls. Early sexual
experience in boys was associated with smoking, drinking of alcohol, marijuana taking, physical fighting, and bullying
other. The odds ratio was highest for smoking. (OR:8.1; CI:5.4–12.1). For girls the same variables were associated with the
early sexual intercourse, marijuana use being the strongest independent predictor (OR:8.0; CI:5.0–12.6). While controlled
for other behaviours, daily smoking remained the strongest predictor for both genders. Girls who had early sexual experi-
ence were more prone to be dissatisfied with their health (OR:2.9; CI:2.0–4.2), with their life (OR:2.1; CI:1.4–3.0), commu-
nication with father and mother (OR:1.9; CI:1.2–2.8 and OR:1.7; CI:1.1–2.6) and reported more psychosomatic symptoms
(OR:2.9; CI:2.0–4.3). For both genders odds were higher if they had good communication with the friend of the opposite
gender. Evenings spent out with friends were associated to early sexual experience in boys and girls as well as poorer school
achievement. Early menarche was associated with the probability of being engaged in the early sexual intercourse and with
smoking, marijuana use and psychosomatic symptoms. Early sexual intercourse is associated with unhealthy behaviour
such as smoking, substance abuse, aggressiveness and lower psychosocial well-being. Preventive educational programmes
should follow multi-facet approaches and recognize differences between boys and girls. Human papillomavirus (HPV) vac-
cination could be part of a comprehensive approach and is not to be viewed as an isolated activity.
Key words: early sexual intercourse, risk factors, menarche, Croatia
Introduction
Human sexuality includes complexity of physical cha-
racteristics and capacities for specific sex behaviours, de-
termined by psychosocial values, norms, attitudes, and
contextual factors that influence these behaviours. The
major risks associated with teenage sexual behaviour in-
clude pregnancy, with physical and psychological conse-
quences; cervical dysplasia, in which early onset of sexual
activity is an important risk factor; and sexually trans-
mitted disease, where rates, when adjusted for sexual ac-
tivity, are greater for adolescents than for any other
group1. Adolescent sexuality is a sensitive issue, teenage
sexual health outgrows the previously mentioned health
risks and the factors influencing risk sexual behaviour,
particularly sexual intercourse and its consequences are
the matter of the permanent adults’ concern2. Sexual be-
haviour in adolescence can pose the immediate health
risk but is also an important factor of reproductive
health in later life3. Major concerns related to teenage
sexual activity as listed above are far more important
from female prospective. However, sexual behaviour of
teenage boys shouldn’t be neglect, as teenage boys are
not only more susceptible to initiating intercourse4, but
also are becoming fully sexually active at a younger age
than the girls5,6,7, and are taking risks in doing so8.
Different researchers show that sexual activity in ad-
olescents is not an isolated experience and is connected
to other risk behaviours, leading to variety of short term
and long term consequences. Thus, it was shown that al-
cohol misuse and use of other substances may place teen-
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agers at greater risk of initiating early and unprotected
sexual intercourse9,10. In addition to early (< age 13) ex-
perimentation with cigarettes and alcohol, and being in-
volved in fighting was associated with early initiation of
sexual activity independent of race or gender11. In other
study health compromising behaviours (early initiation
of sexual intercourse, cigarette smoking, alcohol and
marijuana use, involvement in violence and delinquency)
clustered among young people with associations being
stronger for females12. That having tried smoking was as-
sociated with early sexual activity in both genders, while
having tried drinking was associated with early sexual ac-
tivity only for girls, was found for Canadian students13.
Sexual behaviour of the young person is not only re-
flection of his or her personal characteristics, but is also
determined by the broader surroundings in which young
person lives, emphasising importance of family, peers,
and school14. It was argued that decisions about initia-
tion were strongly bound to social context with peers
playing an important role in creating a sense of norma-
tive behavior15. Furthermore, among identified predic-
tors for intimate sexual behaviours were time alone with
groups of peers, and time alone with a member of the op-
posite sex16. Earlier age at first intercourse and deviant
activities of peers each predicted a significantly higher
risk of subsequently developing of substance use dis-
orders17. Identified protective factors for early initiation
of sexual activity included family and school connect-
edness18. The adolescents’ relationship with their moth-
ers was underlined, as well19. Reporting high academic
achievement was significantly correlated with virginity
and appeared to be protective for boys20. In another
study, higher school achievement was associated with not
having sexual intercourse for both sexes21. Several stud-
ies focused on early maturation in girls, showing that
early menarche was associated to early initiation of the
sexual intercourse22,23,13. Mellanby found that teenagers
who start with sexual activity before the age of 16 take
more risks than those do who wait until after that age24.
Although sexual risk-taking behaviours during ado-
lescence embrace different risks as well (multiple part-
ners, unprotected intercourse, intercourse under the in-
fluence of drugs6), in this article we concentrated on
early onset of sexual activity and associated factors. The
early onset of sexual activity was defined as having had
the sexual intercourse at the age of 16 or earlier. In
Croatia, according to available data, the mean age of first
sexual intercourse has been 175,25,26, and at the age be-
fore 16 minority of young people has been found as sexu-
ally active (9.7% of girls, and 23.2% of boys)27.
The aim of the study was to examine whether selected
risk factors are gender specific for the early sexual inter-
course and to emphasize the implications for prevention.
Subjects, Material and Methods
Study Sample
In the article the results of the Health Behaviour in
School-aged Children survey carried out in Croatia in
2006 were used. The survey involved students aged 11.5,
13.5 and 15.5 years, which in Croatia means fifth and
seventh grades in the primary and the first grades in the
secondary schools. In total 4,968 of the respondents were
embraced, out of the 2,442 boys and 2,526 girls. In the
sampling procedure the sampling unit was class, using
the list of classes at the national level classes were ran-
domly selected. For the first grades of secondary schools
stratification was done, so to preserve the structure of
the secondary schooling (gymnasiums, 4-year technical
and 3-year vocational schools). For this specific article
only the answers from the 15 years old students were
used, as only for the questions about sexual experience
were asked. The used sub-sample consists of 1,601 stu-
dents, 773 boys and 857 girls.
Data collection
Participating students completed anonymous, struc-
tured questionnaire in a regularly scheduled classroom
period under the supervision of a school counsellor. The
participation was voluntary, confidentiality guaranteed
completely. All filled-in questionnaires were put in the
sealed envelopes, packed together and delivered to the
Croatian National Institute of Public Health.
Measurement Instrument
The questionnaire had 53 questions in total. For this
analysis 17 questions were used. The sexual experience
was assessed as the »yes« answer to the question »Have
you ever had sexual intercourse«. For the girls additional
question about menstruation and the age of the menar-
che was asked. As the other risk behaviours the experi-
mentation with the other substances and aggressive be-
haviour was assessed. For smoking the measurement
was daily smoking, risky drinking was rated as drinking
any sort of alcoholic beverage every week and drunken-
ness as being drunk twice or more. Marijuana use was
measured as any use in the lifetime. Being involved in
physical fight in the past 12 months, being bullied or bul-
lied others in the past couple of months was rated as »no«
or »yes« regardless the frequency in the respected period.
Life satisfaction measured at the Cantril ladder was
rated as positive if scored 6 or more. Satisfaction with
own health measured at the 4-point scale was rated as
satisfying for the »excellent« and »very good categories«.
Psychosomatic symptoms were assessed using 5 point
scale for 8 symptoms (headache, stomach-ache, back-
-ache, feeling low, being irritated or in bad temper, being
nervous, difficulties in getting to sleep and dizziness), as
two or more symptoms being present more that once a
week. Communication was rated using 5 point scale and
answers to question »How easy is for you to talk about
the things that really bother you« to mother, father, best
friend, friend of the same/opposite gender, and answers
»easy/very easy« were used as a good communication
measure. Number of close friends was subdivided as hav-
ing up to three and three or more close friends. Number
of evenings spent out with friends was used as a mean
value of the evenings in the week. School environment
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was assessed using answers to the question »How do you
feel about school« and likeness as answers »I like it a
lot/a bit«. The academic achievement was measured as
answer to the question »In your opinion, what does your
class teacher think about you school performance com-
pared to your classmates«, at the four-point scale and the
answers »very good/good« were rated as good school
achievement.
Statistical analysis
Binary logistic regression analysis was used to pro-
duce unadjusted and adjusted odds ratios with 95% confi-
dence intervals and asymptotic, two-sided, statistical sig-
nificance, which indicate the likelihood of having early
sexual experience for boys and girls who reported other
risk behaviours like smoking, drinking, etc. Through the
article statistical significance was defined by the conven-
tional level of p<0.05. Two-by-two contingency tables
were analysed by Fisher’s Exact test. Three by two and
larger contingency tables like in analysis of prevalence of
early sexual experience by the age of first menarche were
analysed by c2 test with Monte Carlo testing of statistical
significance. Correlation of early sexual experience and
the average number of evenings spent with friends were
analysed by Man-Whitney U test and Monte Carlo test of
statistical significance. Homogeneity of variance was as-
sessed by Levene’s test. Association of ordinal variables
like academic achievement and nominal variables like
gender, when ordinal was treated as dependent, was ana-
lysed by Somers’ d test. All the analyses were carried out
using SPSS 13.0 (SPSS Inc., Chicago, IL, USA) statistical
software package.
Results
Early sexual experience reported 28.6% of the boys
and 16.5% of the girls with statistically significant gen-
der difference (OR:0.5, CI:.3–0.6). Boys were more often
engaged in the experimentation with alcohol and in the
aggressive behaviour. Although girls smoke more and
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TABLE 1
EARLY SEXUAL EXPERIENCE, RISK BEHAVIOUR, SATISFACTION WITH HEALTH,







Total 744 (100.0) 852 (100.0)
Early sexual experience (< 16 years) 213 (28.6) 141 (16.5) 0.5 (0.3–0.6) **
Other risk behaviour
Smoking daily 138 (18.5) 181 (21.2) 1.2 (0.9–1.5)
Drinking weekly 324 (43.4) 236 (27.7) 0.5 (0.4–0.6) **
Been drunk two times or more 354 (47.5) 247 (29.0) 0.5 (0.4–0.6)**
Marijuana in the lifetime 124 (16.7) 94 (11.1) 0.6 (0.5–0.8)*
Physical fight in the last year 385 (51.7) 183 (21.5) 0.3 (0.2–0.3)**
Being bullied in the last couple of months 109 (14.7) 104 (12.3) 0.8 (0.6–1.1)
Bullied others in the last couple of months 221 (29.7) 124 (14.6) 0.4 (0.3–0.5) **
Health
Satisfied with own health 666 (89.5) 644 (75.8) 0.4 (0.3–0.5)**
Satisfied with life 604 (81.4) 604 (70.9) 0.6 (0.4–0.7) **
Psychosomatic symptoms 185 (25.5) 388 (46.0) 2.5 (2.0–3.1)**
Family
Easy talk to father 456 (68.3) 376 (48.5) 0.4 (0.4–0.5)**
Easy talk to mother 585 (81.9) 669 (81.3) 1.0 (0.7–1.2)
Friends
Three or more close male friends 644 (86.7) 444 (52.2) 0.2 (0.1–0.2)**
Three or more close female friends 515 (70.2) 620 (73.1) 1.2 (0.9–1.4)
Easy talk to the best friend 572 (85.4) 786 (94.9) 3.2 (2.2–4.7) **
Easy talk to the friend of the opposite gender 445 (66.7) 491 (60.5) 0.8 (0.6–0.9)
Easy talk to the friend of the same gender 525 (77.5) 731 (88.6) 2.3 (1.7–3.0)**
Four or more evenings spent out with friends 209 (28.1) 184 (21.6) 0.7 (0.6–0.9)
School
Liking school 345 (46.2) 428 (49.8) 1.1 (1.0–1.4)
Good academic achievement 537 (72.0) 627 (73.7) 1.1 (0.9–1.4)
OR – odds ratio for girls; CI – confidence interval; p – asymptotic 2-sided statistical significance, ** p<0.001, *p<0.05
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boys have more experience with marijuana, the differ-
ences are not statistically significant (Table 1).
Girls rated their life satisfaction lower (OR:0.6, CI:
0.4–0.7), were less satisfied with their health (OR:0.4,
CI:0.3–0.5), and were more inclined to report psychoso-
matic symptoms (two or more symptoms more than once
a week; OR:2.5, CI:2.0–3.1). Girls expressed more diffi-
culties in talking to the father (OR:0.4, CI:0.4–0.5). Al-
though girls as well as boys had more friends of the same
gender, the probability for girls to have better communi-
cation to the best friend was three times as high as for
the boys (OR:3.2, CI:2.2–4.7).
Risk behaviours
Independent associations of other risk behaviours
with the early onset of sexual life were assessed by binary
logistic regression for the boys and for the girls sepa-
rately. Odds of having early sexual experience were in
boys statistically significantly higher in case of smoking,
drinking, marijuana taking, and engagement in the phy-
sical fight and bullying others, while no statistically sig-
nificant independent influence was noticed for being bul-
lied (Table 2). The highest probability, independent from
the other included indicators, was detected for smoking.
Odds to have an early sexual experience are eight times
higher (OR: 8.1, CI: 5.4–12.1) for daily smokers than for
the pupils who smoke less often or who do not smoke at
all. On this particular sample level, smoking is followed
by marijuana use and weekly drinking. Boys who have
engaged into such activity have four times larger odds
(OR:4.8 and 4.6, CI:3.2–7.2 and 3.2–6.5) for having had
an early sexual experience than boys who didn’t report
these behaviours.
Multivariate analysis revealed that even controlled
for the other risk behaviour daily smoking remains the
most influencing factor – boys who were daily smokers
had three times higher probability to have early sexual
experience (OR:3.8; CI:2.4–6.1). Next to daily smoking is
weekly drinking followed by the involvement in the phys-
ical fight in the last year. Getting drunk and taking mari-
juana in the lifetime had no significant influence on odds
of having early sexual intercourse while other behav-
iours have been taken into account.
Girls who used marijuana had eight times higher
probability to experience early sexual intercourse than
their peers who did not try marijuana at the time of be-
ing questioned (OR:8.0; CI:5.0–12.6). In the independent
analysis girls who were daily smokers had 7.9 times
higher probability of being engaged in the early sexual
intercourse, and higher probability if they reported drunk-
enness, weekly drinking, involvement in the physical
fight or bullying others (5.5 time, 3.9 times, 3.2 times and
2.5 times respectively). Being bullied in the past couple of
months did not show statistically significant influence on
the early sexual behaviour (Table 3). While controlled for
other behaviours, daily smoking had the strongest influ-
ence to odds of early sexual experience – girls who smoke
every day had three times higher probability for having
had early sexual intercourse (OR:3.6; CI:2.2–5.8). The
probability was higher for drunkenness and marijuana
use (2.2 and 2.0 times)
Psychosocial factors
The probability for the early sexual intercourse was
higher for those boys with lower academic achievement
(OR:2.2; CI:1.6–3.1), for those who had more female
friends (OR:1.5; CI:1.0–2.1) and had better communica-
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TABLE 2
ASSOCIATION BETWEEN EARLY SEXUAL EXPERIENCE AND OTHER RISK BEHAVIOR IN BOYS
Early sexual experience
N (%) of pupils
OR (95% CI) p*
no yes Univariate Multivariate
Smoking daily no 487 (80.1) 121 (19.9) 1 1
yes 46 (33.3) 92 (66.7) 8.1 (5.4–12.1) ** 3.8 (2.4–6.1) **
Drinking weekly no 357 (84.6) 65 (15.4) 1 1
yes 176 (54.3) 148 (45.7) 4.6 (3.2–6.5) **1 2.6 (1.7–4.0) **
Been drunk two times or more no 326 (83.4) 65 (16.6) 1 1
yes 207 (58.5) 147 (41.5) 3.6 (2.5–5.0) ** 1.1 (0.7–1.7)
Marijuana in the lifetime no 480 (77.7) 138 (22.3) 1 1
yes 52 (41.9) 72 (58.1) 4.8 (3.2–7.2)** 1.8 (1.1–2.9) *
Physical fight in the last year no 303 (84.4) 56 (15.6) 1 1
yes 228 (59.2) 157 (40.8) 3.7 (2.6–5.2)** 2.5 (1.6–3.6)**
Being bullied in the past couple of months no 456 (72.4) 174 (27.6) 1
yes 73 (67.0) 36 (33.0) 1.3 (0.8–2.0)
Bullied others in the past couple of months no 399 (76.3) 124 (23.7) 1 1
yes 132 (59.7) 89 (40.3) 2.1 (1.6–3.0) ** 1.9 (1.3–2.7) *
OR – odds ratio for girls, CI – confidence interval, p – asymptotic 2-sided statistical significance, ** p<0.001, *p<0.05
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tion with the friend of the opposite gender (OR:2.1;
CI:1.4–3.1). For the boys who liked school more the prob-
ability of being engaged in early sexual intercourse was
lower (OR:0.7; CI:0.5–1.0) (Table 4). The same variables
remained statistically significant while controlled in mul-
tivariate analysis, the easy talk to friend of the opposite
gender being the strongest predictor (OR2.1; CI:1.4–3.2).
The independent analysis revealed that girls who had
early sexual experience were more prone to be dissatis-
fied with their health (OR:2.9; CI:2.0–4.2), with their life
(OR:2.1; CI:1.4–3.0) and reported more psychosomatic
symptoms (OR:2.9; CI:2.0–4.2). For the girls who had
poorer communication with father and mother the prob-
ability of having had early sexual intercourse was higher
(OR:1.9; CI:1.2–2.8 and OR:1.7; CI:1.1–2.6), as well as for
those with lower academic achievement (OR:2.4; CI:
1.6–3.5). Girls who had good communication with friend
of the opposite gender had higher probability of being en-
gaged in the early sexual experience (OR:3.0; CI:1.9–4.7)
(Table 5).
While controlled for the other psychosocial factors,
communication to friend of the opposite gender was the
strongest predictor (OR:2.7; CI:1.6–4.4), and other fac-
tors increasing probability for early sexual intercourse
were poor academic achievement (OR:2.1; CI:1.4–3.4),
health dissatisfaction (OR:1.9; CI:1.1–3.1) and psychoso-
matic symptoms (OR:1.7; CI:1.1–2.8).
In analysing the evenings spent out with friends and
early sexual experience the mean values were used, while
the gender differences in going out were too high for de-
termine exact common cut-offs. Mean number of evenings
spent out with friend was 2.82 for boys and 2.48 for girls,
with statistically significant gender difference (p<0.001).
As Levene’s test indicated statistically significantly
heterogeneous variances, mean number of nights was
analysed by non-parametric Man-Whitney U test and
Monte Carlo test of statistical significance. Mean num-
ber of nights spent with friends was statistically signifi-
cantly higher for students who had early sexual experi-
ence (p<0.001) (Table 6). When evenings spent out with
friends were treated as interval scale variable, the odds
for both genders were higher for those students who
spent out more evenings (boys: OR:1.3; CI:1.3–1.4; girls
OR:1.3; CI:1.2–1.5).
No statistically significant confounding effect of gen-
der on early sexual experience correlation with number
of evenings spent with friends was found. This research
has not found the indication that the relationship of
number of evenings spent with friends and early sexual
experience are affected by gender.
Maturity and menarche
Odds that 15 years old girls who had the first men-
struation on time (Table 7) will engage in early sexual in-
tercourse are 50% (OR:0.5; CI: 0.3–0.9) less than the
odds for the same behaviour for girls who had the first
menstruation early that is at the age of 11 or earlier.
These with late first menstruation have 70% smaller
odds (OR:0.3; CI: 0.2–0.6) for early sexual experience
than these with the early first menstruation.
For the girls who had their first menstruation early
(£11 yrs.) marijuana trial (OR:6.4;CI:1.5–28.4) and daily
smoking (OR:3.8; CI:1.2–12.2) were statistically signifi-
cant predictors of early sexual experience. For the girls
who had their first menstruation on time, the strongest
predictors were daily smoking (OR:4.5; CI:2.5–8.2),
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TABLE 3
EARLY SEXUAL EXPERIENCE IN GIRLS REPORTING OTHER RISK BEHAVIOR
Early sexual experience
N (%) of pupils
OR (95% CI) p*
no yes Univariate Multivariate
Smoking daily no 610 (90.9) 61 (9.1) 1 1
yes 101 (55.8) 80 (44.2) 7.9 (5.3–11.8) ** 3.6 (2.2–5.8) **
Drinking weekly no 550 (89.3) 66 (10.7) 1 1
yes 161 (68.2) 75 (31.8) 3.9 (2.7–5.6)** 1.5 (0.9–2.4) *
Been drunk two times or more no 551 (91.1) 54 (8.9) 1 1
yes 160 (64.8) 87 (35.2) 5.5 (3.8–8.1) ** 2.2 (1.4–3.6)*
Marijuana in the lifetime no 664 (87.9) 91 (12.1) 1 1
yes 45 (47.9) 49 (52.1) 8.0 (5.0–12.6) ** 2.0 (1.1–3.6) *
Physical fight in the last year no 584 (87.6) 83 (12.4) 1 1
yes 126 (68.9) 57 (31.1) 3.2 (2.2–4.7) ** 1.4 (0.9–2.3)
Being bullied in the past couple of months no 626 (84.4) 116 (15.6) 1
yes 81 (77.9) 23 (22.1) 1.5 (0.9–2.5)
Bullied others in the past couple of months no 623 (85.7) 104 (14.3) 1 1
yes 87 (70.2) 37 (29.8) 2.5 (1.6–3.9) ** 1.6 (0.9–2.7)
OR – odds ratio for girls, CI – confidence interval, p – asymptotic 2-sided statistical significance, ** p<0.001, *p<0.05
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drunkenness two times or more (OR:2.2; CI:1.2–3.9) and
bullying others in the past couple of months (OR:2.1;
CI:1.1–4.2). For the girls who had their first menstrua-
tion late, that is in the age of 14 or later, the strongest
predictor of an early sexual experience was being drunk
two times or more (OR:4.6; CI:1.3–16.7).
Regarding psychosocial factors the only statistically
significant predictor for the early sexual intercourse among
early menstruating girls (£11 yrs.), was having had more
psychosomatic symptoms (OR:4.4; CI:1.6–12.3). Within
the sample of those with the first menstruation on time
(12–13 yrs.) dissatisfaction with health (OR:2.7,
CI:1.5–4.9), psychosomatic symptoms (OR:3.0, CI:1.9–
4–8), and easy talk to the friend of the opposite gender
(OR:3.4, CI:1.9–6.0) contributed statistically significant-
ly to the prediction of early sexual intercourse. In the
sample of girls with late onset of menstruation (14+ yrs.)
statistically significant predictor of early sexual behav-
iour was difficult communication with father (OR:8.3,
CI:1.5–47.3).
Discussion
The percentage of 15 year old students who reported
to have had sexual experience had increased in Croatia
between 2002 and 2006 for the boys 23.8% and for the
girls 73.1%, indicating that the possibility of having an
early sexual intercourse became higher for the girls28.
The age of 15 was still for Croatia below the average age
of the first sexual intercourse, which was found in major-
ity of studies to be 17 for both genders3,25,26, or for the
boys a year earlier5,6,7. The prevalence of smoking, alco-
hol and marijuana use, physical fight and being bullied
have been more frequent than in 2002, and the only vari-
able decreased in the 4 year period was bullying others28.
The other recent studies indicated that risk behaviours
like smoking, alcohol drinking and marijuana use show
quicker trends for girls than for boys, thus suggesting
that girls are at a greater risk for being engaged in the
clustered risk behaviour29. The gender differences indi-
cated that girls were less satisfied with the health, life
and more prone to the psychosomatic symptoms. In the
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TABLE 4
EARLY SEXUAL EXPERIENCE IN BOYS ACCORDING TO PSYCHOSOCIAL FACTORS
Early sexual experience
N (%) of pupils
OR (95% CI) p*
no yes Univariate Multivariate
Health satisfaction yes 477 (71.6) 189 (28.4) 1
no 55 (70.5) 23 (29.5) 1.1 (0.6–1.8)
Life satisfaction high 434 (71.9) 170 (28.1) 1
low 95 (68.8) 43 (31.2) 1.2 (0.8–1.7)
Psychosomatic symptoms* no 394 (73.0) 146 (27.0) 1
yes 127 (68.6) 58 (31.4) 1.2 (0.9–1.8)
Talk to father‡ easy 326 (71.5) 130 (28.5) 1
difficult 153 (72.2) 59 (27.8) 1.0 (0.7–1.4)
Talk to mother easy 416 (71.1) 169 (28.9) 1
difficult 94 (72.9) 35 (27.1) 0.9 (0.6–1.4)
Talk to best friend easy 410 (71.7) 162 (28.3) 1
difficult 73 (74.5) 25 (25.5) 0.9 (0.5–1.4)
Talk to friend of the same gender easy 374 (71.2) 151 (28.8) 1
difficult 114 (75.0) 38 (25.0) 0.8 (0.6–1.2)
Talk to friend of the opposite gender difficult 180 (81.1) 42 (18.9) 1 1
easy 297 (66.7) 148 (33.3) 2.1 (1.4–3.1)** 2.1 (1.4–3.2) **
Close male friends none to two 68 (68.7) 31 (31.3) 1 1
three or more 465 (72.2) 179 (27.8) 0.8 (0.5–1.3) 0.8 (0.4–1.2)
Close female friends none to two 168 (76.7) 51 (23.3) 1 1
three or more 357 (69.3) 158 (30.7) 1.5 (1.0–2.1) * 1.5 (0.9–2.3)
Liking school dislike 273 (68.1) 128 (31.9) 1 1
like 260 (75.4) 85 (24.6) 0.7 (0.5–1) * 0.8 (0.5–1.1) *
Academic achievement good 409 (76.2) 128 (23.8) 1 1
not good 124 (59.3) 85 (40.7) 2.2 (1.6–3.1)** 2.3 (1.6–3.4)**
OR – odds ratio for girls, CI – confidence interval, p – asymptotic 2-sided statistical significance, ** p<0.001, *p<0.05, ‡ Independent
variables that were not shown univariate statistically significant influence were omitted from multivariate analysis
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family communication girls are less satisfied with the
communication to the father, which is a finding sup-
ported by other research30 and could be considered as a
risk factor for substance abuse and being bullied. Young
people had more friends of the same gender, girls being
more communicative and close to their best friends and
to the friends of the same gender.
Dickson31 found that many women regretted having
sexual intercourse before age of 16 and that first inter-
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TABLE 5
EARLY SEXUAL EXPERIENCE IN GIRLS ACCORDING TO PSYCHOSOCIAL FACTORS
Early sexual experience
N (%) of pupils
OR (95% CI) p*
no yes Univariate Multivariate
Health satisfaction yes 564 (87.6) 80 (12.4) 1 1
no 146 (70.9) 60 (29.1) 2.9 (2.0–4.2)** 1.9 (1.1–3.1)*
Life satisfaction high 523 (86.6) 81 (13.4) 1 1
low 188 (75.8) 60 (24.2) 2.1 (1.4–3.0)** 1.3 (0.8–2.1)
Psychosomatic symptoms* no 410 (90.1) 45 (9.9) 1 1
yes 294 (75.8) 94 (24.2) 2.9 (2.0–4.3)** 1.7 (1.1–2.8)*
Talk to father† easy 333 (88.6) 43 (11.4) 1 1
difficult 323 (80.8) 77 (19.3) 1.9 (1.2–2.8) * 1.3(0.8–2.1)
Talk to mother easy 573 (85.7) 96 (14.3) 1 1
difficult 120 (77.9) 34 (21.2) 1.7 (1.1–2.6)* 1.10 (0.6–1.8)
Talk to best friend easy 657 (83.6) 129 (16.4) 1
difficult 37 (88.1) 5 (11.9) 0.7 (0.3–1.8)
Talk to friend of the same gender easy 612 (83.7) 119 (16.3) 1
difficult 79 (84.0) 15 (16.0) 1.0 (0.6–1.8)
Talk to friend of the opposite gender difficult 293 (91.6) 27 (8.4) 1 1
easy 384 (78.2) 107 (21.8) 3.0 (1.9–4.7)** 2.7(1.6–4.4)**
Close male friends none to two 343 (85.5) 58 (14.5) 1
three or more 362 (81.5) 82 (18.5) 1.3 (0.9–1.9)
Close female friends none to two 188 (82.5) 40 (17.5) 1
three or more 520 (83.9) 100 (16.1) 0.9 (0.6–1.4)
Liking school dislike 344 (81.1) 80 (18.9) 1
like 367 (85.7) 61 (14.3) 0.7 (0.5–1.0)
Academic achievement good 545 (86.9) 82 (13.1) 1 1
not good 165 (73.7) 59 (26.3) 2.4 (1.6–3.5)** 2.1 (1.4–3.4)**
OR – odds ratio for girls, CI – confidence interval, p – asymptotic 2-sided statistical significance, ** p<0.001, *p<0.05, ‡ Independent
variables that were not shown univariate statistically significant influence were omitted from multivariate analysis
TABLE 6
AVERAGE NUMBER OF EVENINGS SPENT OUT WITH FRIENDS













No 1241 2.37 2.27 2.47 0 7
Yes 354 3.59 3.37 3.82 0 7
TABLE 7
PREVALENCE OF EARLY SEXUAL EXPERIENCE BY THE AGE OF FIRST MENSTRUATION
Early sexual experience
N (%) of pupils Total OR (95% CI) p*
no yes
Early (£11 yrs.) 68 (72.3) 26 (27.7) 94 (100.0) 1
On time (12–13 yrs.) 467 (83.1) 95 (16.9) 562 (100.0) 0.5 (0.3–0.9) *
Late (14+ yrs.) 170 (89.5) 20 (10.5) 190 (100.0) 0.3 (0.2–0.6) **
Total 705 (83.3) 141 (16.7) 846 (100.0)
Abbreviations: OR – odds ratio for girls; CI – confidence interval, 	2, p=0.001, *p<0.05, ** p<0.001
U:\coll-antropolo\coll-antro-suppl-2-2007\18-Kuzman.vp
3. travanj 2007 15:50:34
Color profile: Disabled
Composite  150 lpi at 45 degrees
course at a younger age was associated with risks that
are shared equally between men and women. Coker11 in-
vestigated the circumstances of the first sexual inter-
course and later regrets, finding that at the age of 13
more black than white adolescents of both genders were
sexually active, fighting, cigarette smoking and alcohol
being connected with the early initiation of the sexual ac-
tivity. Burack found that 20% of 13 years old reported
that they already had either full or oral sexual inter-
course8. In Swedish study 16% of the surveyed national
sample reported to have had sexual intercourse before
the age of 15, with more risky sexual behaviour in early
than later starters (pregnancy, number of partners, oral
or anal sex)23. In HBSC2002 Croatian adolescents were
among the less sexually active 15 year old students being
34th out of 35 countries, but substantial increase in the
proportion of female students already experienced early
sexual intercourse indicated that the behaviour has been
changing rapidly.
Risk behaviours
Daily smoking, weekly drinking of any alcohol bever-
age, getting drunk two times or more, taking marijuana,
being involved in the physical fight and being bullied or
bullied others were analysed for both genders. All vari-
ables increased odds for having had early sexual behav-
iour, smoking being the strongest predictor in univariate
analysis for boys and marijuana use for girls. As girls in
Croatia smoke generally more at that age than boys, and
boys more often use marijuana the early sexual inter-
course is strongly connected to the behaviour which is
less socially common for the respective gender. When
controlled for other behaviours, in boys daily smoking,
weekly drinking and aggressive behaviour as being in-
volved in physical fight remained statistically significant.
In multivariate analysis for girls daily smoking was the
strongest predictor, followed by drunkenness and mari-
juana use at the lower level of significance. When ana-
lysed separately, all risk behaviours were connected to
early sexual experience, but in complex situation in the
adolescent maturation the interception of the factors
were different according to gender. Smoking, alcohol and
drug misuse was found to be important for early sexual
intercourse by other authors as well. Fergusson found
that adolescents who reported misusing alcohol had odds
of early onset sexual activity, multiple partners, and un-
protected intercourse that were 6.1 to 23.0 times higher
than for young people who did not misuse alcohol9. Alco-
hol and khat consumption was significantly and inde-
pendently associated with risky sexual behaviour among
Ethiopian youts10 and Robinson found that for six-grad-
ers smoking was the highest predictor of engaging in sex-
ual intercourse for all categories of race and gender32.
Cornelius, using a prospective longitudinal study design,
argued that early sexual intercourse predicts the devel-
opment of substance abuse disorder17. Garriguet in a lon-
gitudinal study analysed characteristics of the 12 and 13
year olds, who at the age of 14 or 15 have been engaged in
the sexual activity, stating that having tried smoking and
drinking for the girls and smoking for the boys were sig-
nificantly associated with early sexual intercourse13.
Valois found that substance abuse and physical fighting
were the strongest predictors for risk sexual behaviour
for boys and girls respectively33, and in Shrier’s study
students reporting they had ever used alcohol or mari-
juana and those reporting recent fighting were 2.7 and
1.6 times more likely to report sexual experience27.
Health, family, friends and school
Health satisfaction, family and friend communication
variables revealed that differences between genders in
the respective behaviours remained significant when
analysed in accordance to the early sexual intercourse.
While girls were generally less satisfied with the life,
health and reporting more psychosomatic symptoms,
these factors in the independent analysis were found to
be significant predictors for the early sexual experience
for the girls, but not for the boys. In addition to that, in
the univariate analysis difficult communication to father
and mother and easy talk to the friend of the opposite
gender were for the girls the additional factors relevant
for the early sexual experience, while for the boys easy
talk to the friend of the opposite gender was the only fac-
tor influencing probability for the higher odds. In mul-
tivariate analysis easy talk to the friend of the opposite
gender remained the only significant factor for the both
genders. Girls are in most European countries less satis-
fied with their life, health and reported more psychoso-
matic symptoms, so these variables could be considered
as gender specific. Nevertheless, the feeling of dissatis-
faction and psychosomatic symptoms seems to influence
early sexual experience in girls. Thus, although not sig-
nificant if controlled for other variables regarding com-
munication in family and friends the gender differences
and girls’ susceptibility to psychosocial influences should
be taken into account in planning the preventive pro-
grammes and activities. Poor communication with father
had been found as a risk factor for girls’ substance abuse
and bullying30,34,35. That adolescents who were suscepti-
ble to early sexual intercourse had fewer positive connec-
tions with parents found L’Engle4. For girls association
was found for having weak self concept (Guarriguet) and
lacking a family member as a confidant (Liu)13,36. Boys
and girls respectively who can easily talk to the friend of
the opposite gender have after controlling for satisfac-
tion, symptoms and family communication 2.1 and 2.7
times higher probability to be involved in the early sex-
ual intercourse. The popularity self-concept was found
by Dilorio as statistically significant predictor for inti-
mate sexual behaviour16. The good communication with
peers might reflect popularity but is also important be-
cause decisions about initiation are strongly bound to so-
cial context with peers playing an important role in cre-
ating sense of normative behaviour15. The number of
evenings spent out with friends was the predictor of initi-
ation of the sexual intercourse for boys and for girls re-
spectively. Although boys go out more often, the same
pattern was observed, meaning that more evenings spent
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out meant higher probability of being engaged in the
early intercourse, the very exact number of evenings de-
pending on gender and on cultural norms. That time
alone spent with group of peers was significantly associ-
ated with early sexual intercourse was found in Dilorio’s
study16.
Liking school was not associated with the early sexual
experience for girls, but boys who were engaged in the
early sexual experience liked school less. Poorer aca-
demic achievement was a strong predictor of the proba-
bility for early sexual intercourse for both genders. That
students engaged in the early sexual intercourse had
lower school achievement was found by Kipke for the
Croatian students11, and relationships between intelli-
gence and the coital status was demonstrated by Hal-
pern37.
Menarche
The early maturation poses the important health risk
for female adolescent and predicts deleterious outcomes
for young girls, including substance abuse, risky sexual
behaviour and pregnancy7. Girls who mature early are
more likely not to be engaged only in the early sexual in-
tercourse, but to be exposed to other risk behaviours. In
our sample marijuana tral and daily smoking were for
early maturing girls the strongest predictors for early
sexual intercourse, meaning that early maturation is an
added risk for earlier observed risk behaviour. For the
girls who had their menarche late getting drunk was
strongly associated with the early sexual intercourse,
which suggesting that pattern of substance abuse might
be influenced by the physical maturity. Girls who had
menarche on the average age were regarding satisfac-
tion, communication with family and friends closest to
the pattern in the whole sample. Early maturing girls ex-
pressed more psychosomatic symptoms which might be
of a great importance for parents and professionals, be-
cause it might reflect the uncertainty and seeking for
help or advice without being able to express it. In the late
maturing girls difficult talk to father was the only predic-
tor associated with the early sexual intercourse, which
might reflect that poor communication has no connec-
tion to the physical maturity but to the age and stage of
adolescence. In Croatian adolescents D`epina found that
the average period between menarche and first sexual in-
tercourse was four years, meaning that earlier menarche
might influence earlier sexual experience38. That coi-
tarche before the age of 15 is related to early menarche
and that early starters reported menarche at the age of
11 or earlier more often stated Edghardh23, and that on-
set of puberty was significantly associated with early sex-
ual activity found Guarriguet13. It is important that
health workers as well as school counsellors are sensitive
to the risk associated with the early maturation among
young girls adapting education and counselling related to
other risk behaviour and self concept for this group. In
should be taken into account that with now available Hu-
man papillomavirus (HPV) vaccine39 one of consequ-
ences could be prevented especially when applied in girls
who had not been sexually active and that with the pre-
vention of the early onset of sexual intercourse the possi-
bilities of medical prevention will definitely have a better
compliance and outcomes.
Conclusion
Early sexual intercourse at the age of 16 or younger is
associated with the complex risk and contextual factors,
some of them being gender specific. Preventing early sex-
ual intercourse means to prevent not only possible medi-
cal consequences, like adolescent pregnancy, sexual trans-
mitted diseases or cervical dysplasia, but to prevent
psychosocial consequences originated from feeling guilty,
unsatisfied or regretful. Effective preventive activities
need to be multi-faceted and take into consideration
other components of the risk behaviour among youth.
The possibility of the prevention of the long-term conse-
quences being offered by the HPV vaccine has to be con-
sidered taking into account optimal schedule, gender dif-
ferences, costs and efficiency. It was argued that the most
successful vaccination programme have to be commu-
nity-wide and avoid any stigma as associated with single
sex vaccination. The costs may, however, restrict HPV
vaccination to the girls, especially since clinical data on
efficacy in boys are still being gathered40. Routine vacci-
nation before sexual debut or shortly thereafter is impor-
tant to achieve optimal effectiveness41. However, vaccina-
tion should not be isolated activity. From a public health
perspective the first stage is education. Promoting the
vaccine and, at the same time, making it clear that HPV
is a sexually transmitted infection will require joint ef-
forts in the wording of policy, education and publicity
materials. Comprehensive health-promoting approach
including family and peers should aim at preventing
complex risk behaviour rather than early sexual inter-
course as an isolated event at the early age.
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RANI SEKSUALNI ODNOSI I RIZI^NI ^IMBENICI U HRVATSKIH ADOLESCENATA
S A @ E T A K
Seksualno pona{anje adolescenata je zbog mogu}ih neposrednih i dugoro~nih medicinskih i psiholo{kih posljedica
vrlo osjetljivo podru~je. Svrha istra`ivanja bila je utvrditi jesu li rani seksualni odnosi spolno specifi~no povezani s
rizi~nim pona{anjima i psihococijalnim ~imbenicima. U nacionalno reprezentativno istra`ivanje u {kolama kori{tenjem
anonimnog upitnika bilo je uklju~eno 773 dje~aka i 857 djevoj~ica dobi 15,5 godina. Spolno iskustvo u dobi do 16 godina
imalo je 28.6% dje~aka i 16.5% djevoj~ica. Vjerojatnost zapo~imanja ranih spolnih odnosa bila je statisti~ki zna~ajno
ve}a u dje~aka koji vi{e pu{e, piju, opijaju se, uzimaju marihuanu, sudjeluju u tu~njavama i zlostavljanju drugih, najve}i
utjecaj registriran je za svakodnevno pu{enje (OR:8.1, CI:5.4–12.1). Iste su varijable s ranim seksualnim iskustvom bile
povezane i u djevojaka, a najve}i je nezavisni utjecaj imalo uzimanje marihuane (OR:8.0; CI:5.0–12.6). Multivarijatna
analiza pokazala je da je najutjecajniji faktor za oba spola redovito pu{enje. Za djevoj~ice koje su nezadovoljnije zdrav-
ljem (OR:2.9; CI:2.0–4.2), `ivotom (OR:2.1; CI:1.4–3.0), odnosima s ocem i majkom (OR:1.9; CI:1.2–2.8 i OR:1.7; CI:
1.1–2.6) ili imaju vi{e psihosomatskih simptoma (OR:2.9; CI:2.0–4.2) ve}a je vjerojatnost stupanja u rane seksualne
odnose. Vjerojatnost ranog seksualnog iskustva ve}a je i u dje~aka i u djevoj~ica za one koji imaju bolju komunikaciju s
prijateljem suprotnog spola. S ranim seksualnim odnosima povezan je i ve}i broj ve~eri provo|en vani s prijateljima te
lo{iji {kolski uspjeh za oba spola. Ranija dob menarhe je povezana s ve}om vjerojatno{}u ranijeg zapo~imanja sek-
sualnih odnosa te s pu{enjem, uzimanjem marihuane i vi{e psihosomatskih simptoma. Rano seksualno iskustvo po-
vezano je s rizi~nim pona{anjima kao pu{enje, pijenje alkohola, uzimanje marihuane, agresivno{}u te psihosocijalnim
~imbenicima. Preventivni programi stoga trebaju slijediti sveobuhvatni pristup uzimaju}i u obzir spolne specifi~nosti.
Cijepljenje protiv humanog papilomavirusa (HPV-a) treba biti dio cjelokupnog preventivnog programa i ne bi se smjelo
smatrati samo izoliranom aktivno{}u.
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Review
How Can the European Federation
for Colposcopy Promote High Quality
Colposcopy Throughout Europe?
Charles Redman1and Joseph Jordan2
1 University Hospital of North Staffordshire, Stoke-on-Trent, UK
2 Birmingham Hospital for Women, Birmingham, UK
A B S T R A C T
Since its inception in 1998, the European Federation for Colposcopy (EFC) now comprises 26 member societies. Its
principle aim is to promote high quality colposcopy throughout Europe with special emphasis on training, education and
treatment. This review summarises EFC’s activities and achievements to date.
Key words: colposcopy, training, education
Introduction
Colposcopic diagnostic performance depends upon a
practitioner’s proficiency as well as the clinical context in
which it is used. It is subjective and the related manage-
ment decisions require problem solving skills and experi-
ence. Both diagnosis and subsequent management re-
quire not only adequate training but also a sufficient
workload to maintain those skills.
There is increasing concern that patients should re-
ceive high quality and cost-effective care throughout Eu-
rope. The need to protect against inadequate practise is
particularly relevant to colposcopy because it is subjec-
tive and because most women who are examined are
well. Performed correctly colposcopy minimises damage
but if performed badly the scope for needless damage is
great. Whereas the indications for colposcopy may vary
throughout Europe, its objective is the same, namely to
detect cervical disease, particularly pre-invasive changes.
It is against this background that the need for shared
standards throughout Europe has become increasingly
recognised. These standards are needed in two key areas,
namely training and treatment.
The European Federation for Colposcopy
From its inception in Dublin in 1998, it was agreed
that a priority for the European Federation for Colpo-
scopy (EFC)1 should be to work towards standardisation
of training for colposcopy and agreement on audit meth-
ods and outcomes of treatment.
The EFC is a federation of colposcopic societies which
now comprises 26 member societies throughout Europe.
During its short history two large and successful trien-
nial conferences have taken place in Greece (Rhodes,
2001) and France (Paris, 2004) as well as a third meeting
to be held in Serbia (Belgrade) this year. The Federa-
tion’s main educational aim has been to create a frame-
work that should promote high quality and uniform
training throughout Europe and a principle goal has
been for all member societies to be able to offer a training
programme that shares common aims and objectives.
Core Curriculum
The primary aim of the training programme was to
produce competent diagnostic colposcopists because di-
agnosis is the foundation for clinical management. De-
spite the fact the colposcopy can be performed in differ-
ent settings and for different indications throughout
Europe, nonetheless, a common set of competences is re-
quired. It was decided to identify and use these necessary
core competences as the basis for curriculum design.
Each identified competence would then act as a learning
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objective for the programme. In other words the training
programme was more concerned with what a competent
trained colposcopist should be able to do rather than pro-
ducing a list of things they need to know2.
In 2001 a consensus exercise was done to identify
what these essential core competencies were, using a
consultative technique called the Delphi technique, which
sought the views of a number of expert colposcopists
throughout Europe3. In all, 28 participants from 21 coun-
tries took part. The list of identified core competencies
was presented to the EFC at its scientific meeting in
Rhodes in 2001 and they were accepted as the basis for
designing colposcopy-training programmes in each of the
member societies. Already a number of societies (UK,
Germany and Spain) have now incorporated this core
curriculum into their training programmes.
Programme Structure
In addition to deciding what needs to be taught, some
agreement is necessary on how the training should occur.
In part, this concerns the structure of European col-
poscopy training programmes and in 2004 a consensus
agreement was been reached on what the recommenda-
tions should be. It is recognised that training must in-
volve actual colposcopic experience that is supervised by
a trainer in a recognised centre. The trainer and the ex-
perience received must meet certain standards in terms
of workload and case-mix. It has been agreed that in
EFC-recognised training programmes trainees would see
a minimum of 100 patients, half of which should be new
presentations and at least a third should have confirmed
histological abnormality.
Treatment Standards
In conjunction with the work on training, in 2004
EFC initiated a modified Delphi survey concerning treat-
ment3. The term 'treatment’ encompasses a wide range
of considerations but we initially focused solely on treat-
ment itself. Identifying standards is an important initial
step in quality assurance which has again involved using
a modified Delphi survey. The agreed standards can then
be used as the basis for audit of treatment throughout
Europe. It is possible that successful participation in this
audit will be one of the criteria required for recognition
as a training centre.
Education
Since 2006 the EFC has convened a number of educa-
tional meetings and courses on colposcopy in order to
promote the principles embedded in the training and
treatment initiatives. Courses were held in Italy (April
2006 in Turin as part of the EBCOG conference) and
Greece (June 2006 in Athens). This year, further courses
are planned in Croatia (April 2007 as part of the Interna-
tional Workshop on Human Papillomavirus and Consen-
sus Recommendations for Cervical Cancer Prevention &
Colposcopy Training), Romania and Serbia. The educa-
tional emphasis is on interactive teaching, focusing on
image recognition and case discussion.
Where do We Go From Here?
The work to date has started to lay down a foundation
on which to build a quality assurance structure. There is
now an agreed core curriculum and training structure
and quality standards for practise are now being devel-
oped. These are early but important steps. So far this
partnership has been fruitful but continued success lar-
gely depends on how far each member state is prepared
to realise the shared objectives of the EFC. It is clear that
the role of the EFC is to co-ordinate the activities of its
member societies and its goals will only be realised by the
achievements of those societies.
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KAKO DA EUROPSKA UDRUGA ZA KOLPOSKOPIJU PROMOVIRA VISOKO-KVALITETNU
KOLPOSKOPIJU DILJEM EUROPE?
S A @ E T A K
Od samih po~etaka, u 1998. g., Europska udruga za kolposkopiju (EFC) obuhva}a 26 dru{tava ~lanova. Njezin klju~ni
cilj je promovirati visoko-kvalitetnu kolposkopiju diljem Europe s posebnim naglaskom na usavr{avanje, obrazovanju i
lije~enja. Ovaj ~lanak sa`ima aktivnosti i postignute uspjehe EFC-e.
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Limitations of Colposcopy in Early Invasive
Cervical Cancer Detection
Goran Grubi{i}
Clinic of Obstetrics and Gynecology, University Hospital »Sestre milosrdnice«, Zagreb, Croatia
A B S T R A C T
Colposcopy is a key element in the diagnostic chain required to reduce cervical cancer mortality but it has limitations
in the diagnosis of malignant disease. In the Republic of Croatia the Croatian Society for Colposcopy and Cervical Pa-
thology started constructing guidelines for early detection, therapy and follow-up of patients with early invasive cervical
cancer in order to achieve the best possible results in diagnosis, therapy and follow-up. From 2001 to 2006 Croatian soci-
ety for colposcopy and cervical pathology organised six courses »Role of colposcopy in early diagnosis and prevention of
premalignant lesions of the uterine cervix« in cooperation with Medical faculty, University of Zagreb and the Croatian
medical chamber. Leading presentations were focused on the epidemiology of cervical cancer, cytologic, colposcopic and
pathohistologic classification, HPV testing and role of male partner. After the theoretical part, a series of colposcopic pic-
tures were presented as a practical part of the course where attendees participated in colposcopic images description and
estimation of what could be the underlying pathological process. Such, courses are needed for continued medical educa-
tion and quality practice of colposcopy.
Key words: early invasive cervical cancer, role of colposcopy
Introduction
Worldwide, invasive cervical cancer is one of the most
frequent causes of death from gynaecological malign dis-
eases, with almost 500,000 new cases per year1. Half of
cancer cases have a fatal outcome in the first five years
following diagnosis. Its incidence is much higher in de-
veloping countries; it seems that both the incidence and
the mortality rate are rather underestimated in these
countries.
In Croatia, according to the 2003 yearbook, 316 new
cases of invasive cervical cancer (IC) (13.7/100 000) and
493 cases of carcinoma in situ (CIS) were diagnosed. Al-
though the cervical cancer mortality rate is decreasing,
100 women die from this disease every year2.
Colposcopy is a key element in the diagnostic chain
required to reduce cervical cancer mortality but it has
limitations in the diagnosis of malignant disease. Herein,
these limitations and the way of improvement of col-
poscopy are presented.
Limitations of Colposcopy
Colposcopy is necessary if the gynaecologist finds no
unusual features of the cervix in the patient with symp-
toms or an abnormal Pap smear (Figure 1 and 2). Col-
poscopic detection of microinvasive cancer depends on its
size and location (Figure 3). Smaller lesions can be mis-
sed, but the probability of stromal invasion increases
with the size of lesion on the surface of the cervix.
Microinvasive cancers on the ectocervix are character-
ised by atypical blood vessels that are prone to bleeding.
These atypical blood vessels are located unusually, dis-
tributed randomly, vary in diameter, and often change di-
rection forming sharp angles. The intercapillary distance
is also larger than normal and variable.
Invasive carcinomas are visible to the naked eye (Fig-
ure 4), but the colposcope enlarges the image showing
the surface and the atypical blood vessels more clearly.
For example, endophytic tumors often look like erosions
but when enlarged, the papillary surface and atypical
blood vessels are visible allowing a more accurate diagno-
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sis. Keratosis can mask the colposcopic finding of an
endophytic lesion, which is the reason, why biopsy is nec-
essary. Adenocarcinoma has no grossly visible to distin-
guish it from squamous cancers with all of the vascular
changes that have been described so far and a biopsy is
required for its diagnosis. If a firm diagnosis cannot be
made after the biopsy, diagnostic cone biopsy is recom-
mended.
Basic Directives
Colposcopy classifications and achievements evolved
with our understanding of cervical disease and the role of
Human papillomavirus (HPV) infection from the Graz
classification in 1975 to the Rome classification and fi-
nally the Barcelona classification in 20023–5. The Graz
classification3 stated that acetowhite epithelium is a suf-
ficient as an abnormal colposcopic finding. The Rome
classification4 then stated that such epithelium is almost
pathognomonic for HPV infection, and can be more or
less visible, with or without a borderline. Then, the Bar-
celona classification5 added that the acetowhitening can
appear quickly and disappear slowly, or appear slowly
and disappear quickly and this is related to the intensity
of the disruption of intracellular chromatine in the HPV
infected cells.
It is important to recognise that colposcopic classifica-
tion based on the grossly visible features of the cervix is
complemented by both cytological classification6 and pa-
thohistological classification7. This necessitates collabo-
ration between gynaecologists, cytologists and the patho-
logists, to establish protocols for diagnostics and treatment
to achieve the best results. Such a protocol established at
the conference celebrating 75 years of colposcopy in clini-
cal practice, is a protocol for diagnostics and treatment of
premalignant lesions of the cervix and lower genital tract
and this has become a landmark for all of us who deal
with the subject of preinvasive cervical lesions8,9.
G. Grubi{i}: Limitations of Colposcopy in Cervical Cancer Detection, Coll. Antropol. 31 (2007) Suppl. 2: 135–138
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Fig. 1. Slight acetowhitening on the anterior and posterior
lip of the uterine cervix – mild HPV change.
Fig. 2. Coarse acetowhitening – as sign of HPV induced
cervical intraepithelial neoplasia.
Fig. 4. Invasive cancer of the uterine cervix –
pathohistological verification is needed.
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At clinical training courses in colposcopy and early di-
agnostics and prevention of neoplastic changes in the
lower genital tract the theoretical practice ends with the
protocol, and then we present a series of colposcopic im-
ages in order to entice discussion on possible gravity of
lesions and pathohistological verification. Our great in-
terest in the issue led us to the introduction of those ab-
lation and destruction procedures that will spare the cervix
and therefore the reproductive system of our patients,
and their health on the whole.
The cytologic and colposcopic protocol that we estab-
lished for the follow-up after classic probatory excision
by forceps (Kevorkian, Thomas Gaylor) or after pro-
batory excision by loop decreases the number of unneces-
sary cone biopsies by scalpel and diathermic cone biop-
sies by loop.
In cases of persistent cytologic abnormalities, after bi-
opsy, and a second colposcopic examination, it could be
easier to decide on one of such procedures in order to pre-
serve the gynaecological and reproductive health. Al-
though it is necessary to inform the patient that dia-
thermic cone biopsy (LETZ) and classic cone biopsy with
scalpel will remove the site of a potentially serious lesion
the responsibility lies in the hands of the woman (and
her partner) to make sure that such situation does not
repeat in the future.
Common Questions in Colposcopic Practice
What happens when disease progresses? The collabo-
ration of the gynaecologist, the cytologist, and the pa-
thologist implies that the current state of a patient needs
to be discussed on several levels: the stage of the initial
invasion, the sample on which the initial invasion was
discovered, age and parity of the patient. After we con-
sider these levels, we can decide on further treatment of
the patient.
The earlier the cervical cancer is diagnosed, the better
the chances are of successful treatment. However, com-
mon issues that arise in clinical practice are:
• Treatment of microinvasive planocellular cervical can-
cer IA1 diagnosed after LETZ biopsy or classic test ex-
cision by forceps when the patient is a nulliparus, or
has had one or more full term pregnancies?
• Treatment of microinvasive planocellular cervical can-
cer IA2 diagnosed after LETZ biopsy, or after classic
test excision by forceps when the patient is a nul-
liparus, or has had one or more full term pregnancies?
• Treatment of microinvasive planocellular cervical can-
cer IA1 diagnosed after LETZ biopsy or after classic
cone biopsy by scalpel when the patient is a nulliparus
or has had one or more full term pregnancies?
• Treatment of microinvasive planocellular cervical can-
cer IA2 diagnosed after LETZ cone biopsy or after clas-
sic cone biopsy by scalpel. What if the patient is a
nullipara, or if she had a baby once, or more times?
What about the »grey area«? How to treat patients
with stromal invasion of more than 5 mm, the spread
larger than 7 mm, and the change still not visible to the
naked eye? Do they already belong to the IB1 group or
not? What about reproduction? What if the finding is an
incidental finding at hysterectomy, or at a diagnostic
cone biopsy, or at one of the mentioned excohleation of
the cervical canal or probatory excisions? All these issues
require thorough study keeping in mind FIGO classifica-
tion which is one of the more acceptable classification
systems for all those involved in cervical cancer diagnosis
and treatment10,11 (Table 1).
Training Courses in Colposcopy
From 2001 to 2006, the Croatian Society for Col-
poscopy and Cervical Pathology organised six courses on
the theme of the »Role of colposcopy in early diagnosis
and prevention of premalignant lesions of the uterine
cervix«, in cooperation with Medical Faculty of the Uni-
versity of Zagreb and the Croatian Medical Chamber12.
Leading presentations were the epidemiology of cervical
cancer, cytologic, colposcopic and pathohistologic classifi-
cation, HPV testing and role of male partner. After the
G. Grubi{i}: Limitations of colposcopy in cervical cancer detection, Coll. Antropol. 31 (2007) Suppl. 2: 135–138
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TABLE 1
EXISTING PROTOCOL ON TREATMENT OF PATIENTS WITH ABNORMAL PAP SMEAR AND UNSATISFACTORY COLPOSCOPIC
FINDING OR WITH MICROINVASIVE CARCINOMA OF SQUAMOUS CELLS ON PROBATORY EXCISION
Status of the excision of microinvasion up to 5 mm or less Recommendations
Margins clear with negative ECC, stage IA1 with
no spread to lymphovascular area
 cone biopsy if the patient wants to preserve fertility
Margins and/or ECC positive dysplasia  repeat cone biopsy
 modified radical hysterectomy
 If conisation not appropriate
 Hysterectomy +/– pelvic lymphadenectomy
Stage IA1 with invasion into lymphovascular area  pelvic lymphadenectomy + conisation, or
 radical trachelectomy (for fertility reasons)
 modified radical hysterectomy and pelvic lymphadenectomy
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theoretical lectures there was the practical course based
on series of colposcopic pictures as practical part of
course where attendees participated in colposcopic de-
scription and prediction of the underlying pathological
process. Among 500 gynecologists from Croatia, 60 of
them attended the course and gave the following ratings:
the average grade for quality of presentation was 3.98
points (maximum 5.2) and for quality in everyday prac-
tice was 3.95 points with the highest grading 5.2 points.
Numerous questions and answers due to diagnostic
protocol of early invasive cervical cancer were brought
up during the postgraduate clinical training course »Di-
agnostics, Treatment and Prognosis for Preinvasive Le-
sions and Carcinoma of the Cervix« held at the Obstet-
rics and Gynecology Clinic in Petrova in Zagreb, on 7th
and 8th April 2006. Critical scientific and practical think-
ing and the participation of gynaecologists, pathologists,
cytologists, radiologists and epidemiologists established
firm foundations for a comprehensive insight into this is-
sue.
Conclusion
These foundations created leeway both for experts
and young colleagues in these areas of medicine to work
on setting up a national programme for cervical cancer
screening. Necessary collaboration among complemen-
tary specialities, consulting with more experienced col-
leagues and regular publication of results will improve
women’s gynecologic health care.
G. Grubi{i}
Clinic of Obstetrics and Gynecology, University Hospital »Sisters of Charity«, Vinogradska 29, Zagreb, Croatia
e-mail: dr.goran.grubisic@gmail.com
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OGRANI^ENJA KOLPOSKOPIJE U OTKRIVANJU PO^ETNOG INVAZIVNOG
RAKA VRATA MATERNICE
S A @ E T A K
Kolposkopija je klju~ni korak u nizu dijagnosti~kih postupaka potrebnih u spre~avanju smrti od raka vrata maternice,
me|utim metoda ima svoje nedostatke u dijagnostici zlo}udne bolesti. Uvidom u kretanje pojavnosti raka vrata maternice
u Republici Hrvatskoj iskrsava potreba za sveobuhvatnim dijagnosti~ko terapijskom pristupom u {to ranijem otkrivanju,
lije~enju i pra}enju pacijentica s po~etnim invazivnim rakom vrata maternice. To je prioritetni zadatak Hrvatskog dru{tva
za kolposkopiju i bolesti vrata maternice. U okviru postupaka sekundarne prevencije istaknuta je uloga kolposkopije. U
razdoblju do 2001. do 2006. godine Hrvatsko dru{tvo za kolposkopiju i bolesti vrata maternice Hrvatskog lije~ni~kog
zbora organiziralo je u suradnji s Medicinskim fakultetom Sveu~ili{ta u Zagrebu i Klini~kom bolnicom Sestre milosrdnice
{est te~ajeva stalnog medicinskog usavr{avanja prve kategorije »Mjesto i uloga kolposkopije u ranoj dijagnozi i prevenciji
preinvazivnih promjena vrata maternice i donjeg genitalnog trakta. Vode}a poglavlja su bila o pojavnosti raka vrata ma-
ternice, zatim citolo{ka, kolposkopska i patohistolo{ka klasifikacija, testiranje na humani papilomavirus (HPV) te uloga
mu{kog partnera u pojavnosti HPV-a. Nakon teorijskog dijela nastavljen je prakti~ki dio u kojem su polaznici sudjelovali u
opisivanju kolposkopskih slika i o~ekivanju kakva je bila patohistolo{ka pozadina kolposkopskog ispoljavanja. Ovakav
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Treatment of Invasive Cervical Cancer:
Rijeka Experience
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A B S T R A C T
The aim of this retrospective analysis was to evaluate the survival rate in 661 patients with cervical cancer regarding
two time periods 1990–1996 and 1997–2003 and the specific stage related risk factors. The respective five-year survival
was 71.7% and 80.0%. Analyzing the risk factors in the univariate and multivariate regression modalities ultimately
only two parameters, the two time periods and FIGO staging were found to be independent prognostic factors. The ob-
served total improvement in the survival rate of the second time period is followed by an increase in conservative surgery
in stage T1A1, a reduction in the use of adjuvant radiotherapy among operable stages T1b1, T1b2 and T2A, while the
treatment of locally advanced cervical cancer did not differ significantly.
Key words: cervical cancer, treatment, staging, FIGO, TNM, survival
Introduction
Cervical cancer is the second most common malig-
nancy in women worldwide. Although it has been consid-
ered a preventable cancer because of cervical cytological
screening programs and effective treatment of prein-
vasive lesions, the mortality rate is still high.
In Croatia during last decade the incidence of cervical
cancer was about 16 patients per 100,000 women a year,
reaching an incidence of 13.7 patients per 100,000 wo-
men in 20031.
Risk factors in developing cervical cancer include
young age at first intercourse, multiple sexual partners,
cigarette smoking, high parity and low socioeconomic
status. There is some relationship to oral contraceptives
as risk factors in cervical cancer development with a pos-
sible small increase2. However, infection with the human
papillomavirus (HPV) has been detected in up to 99% of
women with squamous cervical cancer and is defined as
the principal risk factor in cervical cancer development3.
Until recently, major breakthroughs in reducing the
incidence and mortality of cervical cancer have occurred
because of the widely used screening programs. The
Papanicolaou test, known as the Pap test, has been the
most cost- effective cancer-screening test ever developed.
In Rijeka, Croatia, the Pap-test was introduced as a rou-
tine test in gynecologic examination since 19604.
Nevertheless, cervical cancer is still present in our
population and affected patients require diagnosing and
treatment that consists of four steps: establishing the di-
agnosis, defining the extent of the disease, determining
and conducting the optimal treatment and follow-up of
patients for evidence of recurrence and/or treatment re-
lated complications.
The diagnosis of cervical cancer is made exclusively
by histological analysis of a biopsy specimen or by co-
nization. Once histological diagnosis is arrived at, based
on the International Federation of Gynecology and Ob-
stetrics (FIGO) classification, clinical (preoperative) stag-
ing has to be defined. Conization may be part of diagnos-
tic workup, however, its role in definitive treatment will
be discussed later. Diagnostic workup is necessary to de-
139
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fine preoperative staging using only: physical examina-
tion, colposcopy, cervical or cone biopsy, cystoscopy, lower
gastrointestinal endoscopy or barium enema, intravenous
pyelography and chest radiography. Computed tomogra-
phy (CT) and magnetic resonance (MRI) and positron
emission tomography with computerized tomography
(PET-CT scan) are very useful tools for better definition
of the disease presence, but FIGO is not taken into ac-
count as a staging modality. The treatment strategies for
cervical cancer are related to the diagnosis and the clini-
cal staging system.
The aim of this retrospective analysis was to evaluate
the survival rate regarding two time periods 1990–1996
and 1997–2003 and the specific stage related risk factors.
Subjects and Methods
Medical records of all patients with cervical cancer
primarily treated at the Clinical Hospital Center Rijeka
between 1990 and 2003 were retrospectively reviewed.
The hospital is a tertiary referral center and educational
base of the University of Rijeka, School of Medicine for
the surrounding area of three counties including about
550,000 inhabitants. Six hundred and sixty one patients
with primary cervical cancer were identified.
The prognostic variables investigated for this study
included two time periods, the first from 1990 to 1996,
and the second from 1997 to 2003. December 31, 2006
was the cut off date for patient follow-up
In both time periods we analyzed the following prog-
nostic variables: T stage5, FIGO stage according to the
last revision of cervical cancer staging6 and compared the
5-year survival rate between each subgroup of patients
and the entire group. The stage indicated in this study
referred to pathologic examination after primary surgery
and clinically in cases where radiotherapy or chemo-
irradiation was the first therapeutic option. During the
observed period, cervical cancer treatment was based on
guidelines agreed at the national and hospital level. The
surgical approach was primarily applied to clinical FIGO
stages IA1 to IIA. In stage IIB the primary treatment ap-
proach depended on the clinician. In higher stages radio-
therapy was the treatment of choice. The guidelines on
adjuvant radiotherapy after surgery changed during the
two time periods as well as those on the conservative op-
tion in the treatment of the early stage.
The groups of patient with histology defined as FIGO
Ia1 stage (stromal invasion of not >3.0 mm in depth and
extension of not >7.0 mm) were analyzed separately to
compare the type of treatment and the 5-year survival
rate between the two time periods. Stage IA1 and stage
IA2 cervical cancer were diagnosed either on cone or hys-
terectomy (simple or radical) specimen.
All cone biopsies were bisected and each half was em-
bedded completely and serially processed into 40–90 indi-
vidual sections. The cervices of the extirpated uteri were
treated as a cone and sampled by conventional methods.
Groups of patients with stage disease of IB1 and higher
underwent clinical and instrumental staging. In particu-
lar, stage T1b1, T1b2 and T2a tumor size was assessed by
pelvic examination and under anesthesia at the time of
biopsy or surgery. The definitive tumor dimension in pa-
tients undergoing surgery was determined by measuring
the tumor after uterus removal, while in patients with-
out surgery the definitive dimension was determined
clinically. All patients treated before the last revision of
FIGO staging in 1994 were restaged according to the new
recommendations6.
In the group of patients with pathologic T stages
T1b1, T1b2 and T2a the following categorical variables
were evaluated and compared in the two time periods
(1990–1996 vs. 1997 to 2003): the tumor diameter (less
than 2 cm, 2 to 4 cm, more than 4 cm), age (under 40, 40
to 59, 60 years and over), histology (squamous and ade-
nocarcinoma), tumor differentiation (G1 – well, G2 –
moderate and G3 – poor), T stage, FIGO stage, lymph
node involvement (Nx – not assessed, No – negative
node, N1 – positive node), lymphovascular space involve-
ment (No – Yes) and the mode of treatment (assigned in
each table).
Statistics
Absolute numbers with percentages were used to
show the number of patients per group. The Chi-square
test was used where appropriate. The Kaplan-Meier me-
thod was used to estimate the survival curves. Survival
time was calculated in months from the date of surgery
or therapy beginning at either the date of death, or the
date of last follow-up visit for surviving patients. Uni-
variate analysis of categorical variables was performed
for prognostic significance using the Cox proportional
hazard model and the log-rank test for significance, re-
spectively. Variables with p<0.10 on univariate analysis
were then included in a multivariate Cox proportional
hazard regression analysis. Statistical analyses were per-
formed using MedCalc for Windows, version 9.2.0.2
(MedCalc Software, Mariakerke, Belgium).
Results
The distribution of »T stage« among cervical cancer
patients in the two time periods, the survival in each
stage and the survival per entire group are presented
(Table 1). Staging is the most important predictor of sur-
vival, reflecting the extent of the disease with the risk of
death being higher as a stage increases. Comparing total
survival between the two periods, there is a clear statisti-
cally significant higher 5-year survival rate among pa-
tients treated in the second time period. The group of pa-
tients in T1B1 stage treated in the second period had a
significantly better survival rate than the same staged
patients treated in the first period. However, there was
no difference in patient distribution per stage (Chi-
-square=0.9, p=0.34; not shown). The evaluated patient
age is equal in both time periods (48.7 vs. 48.6 years).
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Distribution of patients in the FIGO stage shows no
difference (Chi-square=14.8, p=0.098; not shown) be-
tween the two time periods (Table 2). The 5-year survival
rate in stages IA1 and IA2 is excellent in both time peri-
ods. Stages IB1, IB2, IIA, IIB and IIIB in the second time
period had better survival rates but without statistical
significance. Nevertheless, a total 5-year survival rate is
significantly higher in the second time period (Table 2).
In our study, FIGO stage IA1 was present in 260
(39.3%) out of 661 patients (Table 3). In the second time
period we found an increase from 37.6% to 40.8% with-
out statistical significance (Chi-square=0.60, p=0.4; not
shown) of patients with stage IA1 (Table 2). The types of
patient treatment in stage IA1 are presented in the Table
3. The distribution of patients regarding the mode of
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TABLE 1
DISTRIBUTION AND SURVIVAL OF CERVICAL CANCER PATIENTS (n=661) ACCORDING TO THE »T« STAGE AND TIME PERIOD
Stage








T1A1 115 (37.6) – 100% 145 (40.8) – 98.4% NS
T1A2 9 (2.9) – 100% 5 (1.4) – 100% NS
T1B1 69 (22.5) – 80.2% 85 (23.9) – 94.2% p=0.017
T1B2 14 (4.6) – 60.9% 25 (7.0) – 77.6% NS
T2A 8 (2.6) – 50.0% 6 (1.7) – 100% NS
T2B 43 (14.1) – 40.8% 26 (7.3) – 53.4% NS
T3A 2 (0.7) – 0.0% 2 (0.6) – 0.0% NS
T3B 43 (14.1) – 21.3% 56 (15.8) – 23.2% NS
T4 3 (1.0) – 0.0% 5 (1.4) – 0.0% NS
Total 306 – 71.7% 355 – 80.0% p=0.02
TABLE 2
DISTRIBUTION AND SURVIVAL OF CERVICAL CANCER PATIENTS (n=661) ACCORDING TO THE FIGO STAGE AND TIME PERIOD
Stage








IA1 115 (37.6) – 100% 145 (40.8) – 98.4% NS
IA2 9 (2.9) – 100% 5 (1.4) – 100% NS
IB1 59 (19.3) – 87.5% 76 (21.4) – 93.5% NS
IB2 13 (4.2) – 66.1% 18 (5.1) – 81.6% NS
IIA 7 (2.3) – 57.1% 6 (1.7) – 100% NS
IIB 36 (11.8) – 43.2% 18 (5.1) – 61.4% NS
IIIA 2 (0.7) – 0.0% 2 (0.6) – 0.0% NS
IIIB 61 (19.9) – 24.8% 74 (20.8) – 40.8% NS
IVA 2 (0.7) – 0.0% 4 (1.1) – 0.0% NS
IVB 2 (0.7) – 0.0% 7 (2.0) – 0.0% NS
Total 306 – 71.7% 355 – 80.0% p=0.02
TABLE 3
TREATMENT OF CERVICAL CANCER PATIENTS






n (%) n (%)
Conisation 54 (47.0%) 84 (58.0%)
Hysterectomy 35 (30.4%) 35 (24.1%)
Hysterectomy &
Lymphadenectomy
23 (20.0%) 16 (11.0%)
Radical hysterectomy
& Lymphadenectomy
*3 (2.6%) 10 (6.9%)
*2 patients treated with adjuvant radiotherapy
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treatment and the time periods shows high significance
(Chi-square=13.87, p=0.008). An increase in conserva-
tive surgical treatment requiring only conization is iden-
tified in 58% of cases in the second time period, while
hysterectomy decreased from 30.4% to 24.1%, also in the
second period. Radical procedures, including lymph node
assessment, mainly due to lymph-vascular space involve-
ment, were present in a similar percent in both observed
periods. The apparent increase in the use of radical hys-
terectomies in the second time period is due to dubious
biopsy material in some patients. However, in the second
time period lymph node staging and/or radical hysterec-
tomy dropped from 22.6% to 17.9% (not shown). During
the first time period two patients received adjuvant pel-
vic irradiation.
»T« stage was used to evaluate the dimension of pri-
mary tumor in women with cervical cancer localized in
the cervix (stage T1b1 and T1b2) and with only vaginal
involvement (T2a), excluding parametrial involvement.
In this group all patients with a concomitant serious
medical condition were not treated or were treated with
palliative radiotherapy. In the medically uncompromised
patients older than 75 years primary treatment included
primary radiotherapy. Patients with primary surgery
were divided into two groups with respect to the use of
adjuvant pelvic irradiation. The indications for adjuvant
pelvic irradiation were changed during the observed
time. The first group of patients consisted of those with
stage from T1B1 to T2A and a dimension of cervical can-
cer less than 2 cm in diameter. The next group of patients
included tumor diameters of 2 to 4 cm and the third
group of patients included tumors of a diameter larger
than 4 cm. Patients staged T2b and T3b were not divided
in the subgroups. Results are presented as a total num-
ber of patients while percents include the proportion of
the entire group within the stage categories (Table 4).
In the group of patients with the tumor diameter less
than 2 cm we observed an obvious inversion in the use of
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TABLE 4
TREATMENT OF CERVICAL CANCER PATIENTS REGARDING T STAGE AND TUMOR DIMENSION
T stage & tumor
dimension
Type of treatment
Period 1990–1996 Period 1997–2003
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adjuvant pelvic irradiation in the second time period
(Chi-square=17.04, p=0.0002; not shown) with a similar
five-year survival rate. In these groups of patients only
one patient with positive pelvic lymph node was identi-
fied in the second time period.
In the group of patients with primary cervical tumor
diameter of 2 to 4 cm an inversion of treatment modali-
ties was identified (Table 4). Namely, the majority of cer-
vical cancer patients in the first time period were treated
with adjuvant pelvic irradiation with a 5-year survival
rate of 69.3%. In the second time period there was a sig-
nificant difference in patients distribution (Chi-square
=20.44, p= 0.0001; not shown), with a decrease in the
use of adjuvant pelvic irradiation after radical surgery
and a total increase of the 5-year survival rate. In the
first time period 10 (23.2%) patients had positive lymph
nodes, while in the second time period positive nodes
were found in 8 patients (20.5%).
In the group of patients with primary cervical tumor
greater than 4 cm primary radiotherapy was applied in
about 11% (Table 4). All patients who underwent surgery
in the first time period were adjunctively treated with
pelvic irradiation. In the second time period one fourth of
patients were treated only with radical surgery. Although
there is no significant change in the modality of treat-
ment in the second time period, the 5-year survival rate
is significantly higher (Chi-square=6.05, p=0.014; not
shown). However, in the second time period a trend of de-
crease in the use of adjuvant radiotherapy was also ob-
served. Analyzing the rate of positive lymph nodes we
identified 10 out of 16 patients (62.5%) in the first time
group and 8 out of 24 (33.3%) patients in second time pe-
riod. The observed difference had no statistical signifi-
cance (Chi-square=2.26, p=0.135; not shown).
In patients with T2B stage in the first time period the
therapy mostly used was radiotherapy (Table 4). In the
second time period radical surgery with adjuvant pelvic
irradiation was encountered in a higher proportion. The
difference of the treatment modality distribution is not
significant. The 5-year survival rate, although higher in
the second time period, did not reach a statistical signifi-
cance.
Clinically staged patients in stage T3B in both time
periods received similar treatment options (Table 4). The
majority of patients were treated with primary radio-
therapy, while only a small number of patients after the
year 2001 received combined chemoirradiation. The rate
of survival in both time period groups was similar.
The patient groups staged T1B1 to T2B and T3B with
177 and 198 patients had a 5-years survival rate of 54.6%
and 68.1% in first and second time period, respectively
(Logrank test p=0.0124; not shown).
Univariate analysis of variables was performed in the
entire group of cervical cancer patients (n= 661). Vari-
ables, two time periods, histology, FIGO stage, degree of
differentiation (G), T stage, lymph node status, type of
treatment and patient age were categorized as shown
(Table 5). All analyzed variables were significant, and
were subsequently included in the multivariate model.
Using Cox proportional hazard regression only two vari-
ables remained significant: two time periods and FIGO
stage (Table 6).
Discussion
The distribution of cervical cancer patients regarding
T stage and FIGO stage are similar during the two ob-
served periods. Approximately 40% of patients with cer-
vical cancer presented with a microinvasive disease lim-
ited to the invasion of 3 mm and 7 mm or less in width.
The diagnosis of stage IA1 cervical cancer has to be es-
tablished at least via cone specimen. Acceptable methods
for diagnostic purposes are cold knife conization and loop
electrosurgical excision. The prognosis is excellent, as
shown in our series. A total 5-year survival for 260 pa-
tients presented with microinvasive cervical cancer in
our analysis is 99.1% (not shown). There is no difference
in the 5-year survival between the two time period groups.
In the last FIGO analysis 829 (7.12%) patients with cer-
vical cancer stage IA1 out of 11639 had a five-year sur-
vival rate of 97.5%7. There are a significantly smaller
proportion of patients with microinvasive cervical cancer
in world statistics compared to our patients (7.12% vs
39.3%). A relative increase in the total number as well as
in the proportion of the entire cervical cancer group
could be attributed firstly to the meticulous analysis of
cervices with multiple serial sections per specimen.
Surgical treatment of patients with cervical cancer
stage IA1 moved to conservative treatment is present in
almost 60%. Hysterectomy is reserved primarily for
women that are past childbearing. Lymphadenectomy is
reserved for those with lymph space involvement, al-
though there is little, if any risk of lymph node metasta-
sis, recurrence and death8–10. Of the 52 patients (not
shown) in our series treated with lymphadenectomy as
part of treatment option firstly due to lymph vascular
space involvement, none had lymph node metastasis.
The 5-year survival rate in our group of patients is
rather high but without statistical significance (99.1% vs
97.5%). In one series with median follow-up of 45 months,
10% of patients developed cervical intraepithelial neopla-
sia 3 – CIN III11. In our series of 126 patients with cervi-
cal cancer stage IA1 treated with a conservative surgical
procedure the cold knife conization and a median fol-
low-up of 72 months, we detected local recurrence in
form of cervical intraepithelial neoplasia irrespective of
their severity in 7 (4%) patients (data not shown).
Squamous lesions are predominantly present in the
early stage of cervical cancer stage IA1, while glandular
lesions are rarely recognized in the early stage. This is
mainly due to difficulties in measuring the glandular le-
sions invasion depth. In our series of 260 patients with
cervical cancer stage IA1 we identified 6 (2.3%) patients
with glandular lesions (data not shown). Currently, the
options of treatment modalities based on retrospective
data include the same procedures with the same indica-
tions as a squamous lesion12,13.
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TABLE 5











Period 1990–1996 (306) 72.0% Reference
1997–2003 (355) 80.0% 5.4 p=0.02 1.46 (1.06–2.02)
Histology Squamous (583) 77.3% Reference
Adeno (78) 65.5% 7.2 p=0.0074 0.57 (0.29–0.83)
FIGO IA1 (260) 99.1% Reference
IA2 (14) 100.0% 0.1 p=0.74 1.01 (0.01–1571)
IB1 (135) 91.0% 17.0 p<0.0001 0.08 (0.03–0.29)
IB2 (31) 74.4% 50.8 p<0.0001 0.03 (0.00–0.003)
IIA (13) 76.9% 38.1 p<0.0001 0.03 (0.00–0.0001)
IIB (54) 46.8% 161.0 p<0.0001 0.01 (0.00–0.003)
IIIA (4) 0.0% 315.0 p<0.0001 0.004 (0.00–0.00001)
IIIB (135) 33.3% 243.0 p<0.0001 0.008 (0.01–0.03)
IVA (6) 0.0% 271.9 p<0.0001 0.005 (0.0000–0.0000)
IVB (9) 0.0% 337.7 p<0.0001 0.005 (0.0000–0.0000)
Gradus G1 (42) 87.5% Reference
G2 (260) 57.8% 10.9 p=0.001 0.25 (0.25–0.70)
G3 (104) 59.5% 9.6 p=0.002 0.26 (0.20–0.69)
Undetermined (255) 99.1% 20.8 p<0.0001 0.06 (0.00–0.05)
T-stage T1A1 (260) 99.1% Reference
T1A2 (14) 100.0% 0.1 p=0.74 –
T1B1 (154) 88.1% 24.8 p<0.0001 0.06 (0.04–0.25)
T1B2 (39) 70.5% 64.9 p<0.0001 0.03 (0.0001–0.004)
T2A (14) 70.7% 54.6 p<0.0001 0.02 (0.0000–0.0000)
T2B (69) 45.2% 180.5 p<0.0001 0.01 (0.001–0.007)
T3A (4) 0.0% 315.9 p<0.0001 0.004 (0.0000–0.0000)
T3B (99) 21.7% 307.5 p<0.0001 0.007 (0.002–0.007)
T4 (8) 0.0% 327.6 p<0.0001 0.005 (0.0000–0.0000)
Lymph Nx (389) 69.9% Reference
node No (224) 92.3% 40.2 p<0.0001 4.6 (2.22–4.52)
status N1 (48) 49.0% 7.0 p=0.008 0.55 (0.27–0.82)
Therapy
Wertheim (W) (85) 94.5% Reference
Without therapy
(21) 0.0% 138.0 p<0.0001 41.5
(1416–2589
7)
Radiotherapy (138) 33.8% 74.0 p<0.0001 20.6 (4.19–9.77)
Conisation (138) 98.4% 2.2 p=0.1 0.3 (0.05–1.5)
Hysterectomy (71) 100.0% 3.5 p=0.06 0.0 (0.02–1.1)
Hysterect. & adj. radiotherapy (7) 68.6% 7.5 p=0.006 7.5 (3.7–2707)
Hysterect. & lymhadenect. (40) 100.0% 2.0 p=0.16 0.0 (0.03–1.79)
Hysterect. & lymhadenect. &
adjuvant radiotherapy (13) 44.0% 34.6 p<0.0001 15.4 (50.8–2573)
Wertheim & adj. radiotherapy (148) 77.3% 11.7 p=0.0006 0.2 (0.16–0.61)
Age < 40 (229) 93.8% Reference
(years) 40–59 (260) 79.2% 21.6 p<0.0001 0.26 (0.19–0.51)
³ 60 (172) 48.1% 111.2 p<0.0001 0.09 (0.07–0.18)
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The patients with cervical cancer stage IA2 are present
in a small percentage (2.9%). The rate (2.4%) of this stage
is similar to that in the last FIGO statistics7. The diagno-
sis of stage IA2 cervical cancer should also be established
via cone biopsy. Although the prognosis for these patients
is also excellent (in our statistics 14 patients had a 5-year
survival rate of 100%, while in previously mentioned sta-
tistics the survival rate in 275 patients was 94.8%) they
are at higher risk for lymph node metastasis and treat-
ment failure. In one series a 6.8% incidence of lymph node
metastasis in patients with cervical cancer stage IA2 is
reported10. Currently, there is a shortage of plausible re-
commendations for the management of cervical cancer in
stage IA2 based on reliable and prospective studies. Until
more data become available pelvic lymph node assessment
is necessary. Hysterectomy could be performed as a simple
procedure, while radical hysterectomy represents surgical
trauma without confirmed survival advantage. In patients
with desired childbearing, large conization with absolute
clear margins and negative lymph node could be the treat-
ment of choice14.
The treatment of choice in cervical cancer stages IB1
to IIA can be influenced by patient age, coexisting medi-
cal conditions and physician bias. Retrospective as well
as prospective studies comparing radical surgery with
pelvic radiation therapy showed similar survival rat-
es15,16. Radical surgery offers few advantages in respect
to preservation of ovaries with fewer detrimental effects
on vaginal function. The advantages of radical surgery
over radiotherapy can be eliminated in patients receiving
postoperative adjuvant radiotherapy. Indication for the
use of adjuvant radiotherapy includes positive lymph
node, positive margins and parametrial involvement.
Other indications for the use of postoperative radiother-
apy in cases without evidence of disease outside the cer-
vix include the presence of high risk factors in the hyster-
ectomy specimen like large tumor diameter, deep cervical
stromal invasion and the invasion of lymph vascular
space involvement17. As tumor diameter increases, the
risk of treatment failure is greater. Tumor diameter
greater than 4 cm leads to the use of various treatment
regimens. The T stage T1B2 includes radical hysterectomy
with pelvic and paraaortic lymphadenectomy followed by
tailored chemoradiation therapy for high-risk patients,
radiation therapy followed by extrafascial hysterectomy,
radiation therapy plus concurrent chemotherapy and
neoadjuvant chemotherapy followed by radical pelvic
surgery18,19. Although some authors recommend the use
of concurrent radiotherapy and chemotherapy as an opti-
mal treatment option19, radical hysterectomy with tai-
lored chemoirradiation for high-risk patients is the most
cost-effective strategy to manage Stage IB2 cervical can-
cer, resulting in a 5-year survival of approximately 70%.
In our series we present only 3 patients treated with pri-
mary radiotherapy, 7 treated with radical hysterectomy
and 17 patients treated with radical hysterectomy and
adjuvant radiotherapy with a total 5-year survival of
87.7%. Radical surgery followed by tailored radiotherapy
is especially suitable in settings where resources are lim-
ited. Adding radiotherapy and chemotherapy in form of
neoadjuvant chemotherapy unnecessarily increases the
total cost without clear advantage in a 5-year survival18.
Comparing the use of adjuvant radiotherapy between
the two time periods in our series we found that in cases
with a tumor diameter less than 2 cm reduction in the
use of radiotherapy did not influence the 5-year survival
rate. In the group of patients with cervical cancer of di-
ameters from 2 to 4 cm the observed reduction in the use
of adjuvant radiotherapy lead to a better 5-year survival.
In the group of patients with cervical cancer stage IB2
(tumor diameter greater than 4 cm) adjuvant radiother-
apy in the second time period was in part reduced with a
higher 5-year survival.
From our results, the philosophy of treatment in the
second time period is one of the significant points in the
treatment acceptance and success measured through a
5-year survival. The lack of this analysis precludes the
precise definition of all elements used in building the in-
dications for adjuvant radiotherapy during the observed
period. Moreover, the indications for adjuvant radiother-
apy after radical surgery changed several times, espe-
cially in the second time period. Conclusively, from the
retrospective results and the results of others20,21 adju-
vant radiotherapy seems to be useful only in the group of
patients with the disease beyond the cervix, i.e., lymph
node metastasis and parametrial involvement.
The standard accepted therapy in the last 15 years for
locally advanced cervical cancer includes radiotherapy
present in the majority of cases in our series. The addi-
tion of cisplatin or a cisplatin containing regimen to a ra-
diation therapy results in better disease control and a
5-year survival22,23. It is part of a standard recommended
therapy. A subsequent meta-analysis of 19 randomized
controlled trials including 4560 patients confirmed the
effectiveness of concurrent chemotherapy and radiation
therapy, which improved the overall survival of patients
with a locally advanced disease24. The new therapeutic
option in patients with locally advanced cervical cancer
promoted by Croatian authors25 seems to produce higher
survival rates, but the preliminary results have to be
confirmed in large multicenter trials.
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TABLE 6










Histology p=0.08 (NS) 1.47 (0.96–2.25)
FIGO p=0.0001 1.5 (1.23–1.83)
Tumor differentiation (G) p=0.21 (NS) 1.2 (0.91–1.57)
Lymph node status p=0.47 (NS) 0.8 (0.41–1.50)
T stage p=0.16 (NS) 1.16 (0.94–1.41)
Therapy p=0.92 (NS) 0.99 (0.85–1.15)
Patients age p=0.47 (NS) 1.11 (0.84–1.46)
Categories of variables as shown in Table 5, NS – non-significant
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In our series of patients in stage T2B or greater even
though the 5-year survival rate is better, the difference
has not reached statistical significance. In stage T2B a
more extensive use of radical surgery with adjuvant ra-
diotherapy and better survival had also no statistical sig-
nificance. A minor number of patients in stage T3B were
treated with the use of chemoirradiation, which was not
taken into account in the actual analysis, and we have
not performed statistical evaluation regarding the appli-
cation of concurrent chemotherapy and radiation ther-
apy in patients with locally advanced cervical cancer.
Conclusions
The comparison of two time periods, 1990–1996 and
1997–2003, showed an overall higher five-year survival
rate in the second time period denoting a significant in-
dependent prognostic parameter. The observed total im-
provement in survival rates was followed by an increase
in conservative surgery in stage T1A1, reducing the ap-
plication of adjuvant radiotherapy in operable stages
T1B1, T1B2 and T2A, while the treatment of locally ad-
vanced cervical cancer has not differed significantly.
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LIJE^ENJE INVAZIVNOG RAKA VRATA MATERNICE: ISKUSTVO RIJEKE
S A @ E T A K
Cilj ovoga retrospektivnog rada uklju~uje analizu pre`ivljavanja u 661 bolesnice s rakom vrata maternice obzirom
na dva razdoblja, 1990–1996 i 1997–2003 kao i specifi~nih ~imbenika rizika obzirom na stadije bolesti. Petogodi{nje
pre`ivljavanje prve skupine iznosilo je 71,7%, dok je u drugoj skupini ono iznosilo 80,0%. Analiziraju}i ~imbenike rizika
u univarijatnoj, te u multivarijatnom regresijskom modelu naposljetku samo dva parametra, vremenska razdoblja i
FIGO stadij imaju nezavisni prognosti~ki zna~aj. Opa`eno bolje pre`ivljavanje u drugom vremenskom razdoblju pra-
}eno je pove}anjem konzervativnih operativnih zahvata u FIGO stadiju IA1, smanjenjem primjene adjuvantne radio-
terapije me|u bolesnicama operabilnog stadija T1b1m T1b2 i T2A, dok se lije~enje lokalno uznapredovanog raka vrata
maternice nije bitno razlikovalo obzirom na vremenska razdoblja.
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Laporovaginal Surgery in Cervical Cancer:
A Croatian experience
Ante ]oru{i}, Dubravko Bari{i}, Andrea Plavec, Pavao Planini}, Lana [krgati},
Goran Vuji} and Mislav Herman
Department of Gynecology and Obstetrics, Medical School, University of Zagreb, Zagreb, Croatia
A B S T R A C T
With correct staging a large number of patients with cervical cancer FIGO stages IA2 and IB can be spared of unnec-
essary radiation therapy by laparoscopic assisted vaginal radical hysterectomy (LAVRH) as an option of radical surgical
treatment in such patients. The development of laparovaginal surgery, indication and contraindication were presented.
Also, the surgical technique was described in detail. Fifty-two patients were followed up in 2003 after LAVRH or open
surgery, performed in our single center. Only 5 (14%) patients died from cervical cancer within 3 years following the
treatment. They were all clinical stage IB treated with open surgery. There were 4 (11%) complications following treat-
ment and they were all in patients with clinical stage IB, also treated with open surgery. There was no complication in
LAVRH treated patients. The results and complications of the sole Croatian center performing LAVRH or open surgery
in patients with cervical cancer FIGO stages IA and IB were similar to those in centers across the world.
Key words: cervical cancer, FIGO stage IA2 and IB, laparoscopic assisted vaginal radical hysterectomy, Schauta operation
Introduction
Development of vaginal surgery
The first written traces on surgical treatment of cer-
vical carcinoma reach back to the 16th and 17th centuries1
when amputation of cervical tumors was performed. At
the end of the 18th century, Marschall and Schroder as
well as Osiander, at the beginning of the 19th century, rec-
ommend »partial trachelectomy« in patients with pro-
lapsing cervical carcinoma1. In 1813, Langenback per-
formed »subperitoneal removal« of prolapsed cervical
carcinoma1,2. He used tying of blood vessels as hemo-
stasis. In 1821, Sauter operated a patient with cervical
carcinoma through the vagina, by opening the perito-
neum and removing the uterus without the use of liga-
tures in bleeding control. The patient developed vasico-
vaginal fistula and died four weeks following the surgery
for unknown reasons, even though the author did not
mention perioperative bleeding3. This type of surgical
technique was developed for the following twenty years.
The five-year survival rate for all stages of the disease
was around 10%1. By developing surgical technique (hae-
mostatic clip) and introducing Lister’s aseptic principles,
Czerny reduced perioperational mortality to 32% 1,4. In
1880, the Czech gynecologist Pawlik performed extended
vaginal hysterectomy, in a patient with advanced cervical
carcinoma4. Thirteen years later, Schuhardt described
radical vaginal hysterectomy with help of »paravaginal
help incision«4.
Staude also performed extended vaginal hysterecto-
my in 1894, using two Schuhardt’s incisions to improve
the operating approach5. At this time, Reis, Rumpf, Kelly
and Wertheim developed abdominal radical hysterecto-
my as a method of choice in treating cervical carcinomas.
They emphasize that the mere removal of the organ is
not sufficient but it is necessary to remove the regional
lymph nodes as places of supposed spreading of the
disease1,4,6,7. However, high perioperative mortality (18.6%)
in that period distanced most gynecologists from the
laparotomy approach. In June 1901, in Vienna, Schauta
performed the first radical hysterectomy through the va-
gina, and published his experience in treating cervical
carcinoma in 258 cases in 19088. Since that time, radical
vaginal hysterectomy has mostly been called Schauta’s
operation, particularly emphasizing preparation of the
urinary bladder and preserving the ureter. Amreich fur-
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ther improved the original Schauta’s operation. His ex-
periences in 1505 cases were published in 19439. In com-
parison to Schauta’s operation, the Amreich’s approach
involves more radical resection of the dorsal part of lat-
eral parametria. In Germany, Stoeckel modified Schauta’s
operation and introduced the principle of mandatory
preparation of the ureter. While Schauta only inserted
the ureter proximally, Stoeckel introduced systematic
anatomical preparation of the ureter 10.
Bearing in mind the radical nature of removing the
parametria, Wertheim and Schauta’s operations are com-
plementary. Both approaches, according to the Routledge
classification, belong to the type II of radicalness, i.e. the
medial half of cardinal and sacrouterine ligaments is be-
ing removed. The Mackenrodt-Latzko-Meigs operation is
as radical as the Schauta-Amreich operation and, accord-
ing to the Routledge classification, falls into the type II-II
of radicalness11,12. Complete resection of the parametria
by vaginal approach is not possible.
Development of laparoscopy
Lymphogenic spreading of cervical carcinoma is the
primary route of transmission of the disease. In approxi-
mately 15% of stage I cervical carcinoma cases meta-
stases into pelvic lymph nodes were detected. As far back
as 1895, Ries supposed that the removal of iliacal lymph
nodes should be the key part of surgical treatment of cer-
vical carcinomas1,4.
With time, individual authors combined lymphade-
nectomy with radical vaginal hysterectomy. Stoeckel
combined radical vaginal hysterectomy with transperi-
toneal pelvic lymphadenectomy in individual cases10,13.
Mitra in India and Navratil in Austria, combined extra-
peritoneal lymphadenectomy according to Nathanson,
with radical vaginal hysterectomy13–15. Mitra performed
extraperitoneal lymphadenectomy three weeks after the
vaginal operation. In Europe this method was accepted
by van Bastiianse and Inquilla1,13,16. However, these op-
erative techniques were not widely accepted because, at
that time, the Wertheim’s operation was the »golden
standard« in surgical treatment of cervical carcinomas.
Due to this fact, radical vaginal operation was »neglect-
ed« for a long time in treating cervical carcinomas. De-
velopment of laparoscopy enabled the reaffirmation of
radical vaginal hysterectomy. In 1969, Bartel described
pelvic retroperitoneoscopy. By using the Carlens’ media-
stinoscope, modified according to Maasen, through an in-
cision cut along the spina iliaca anterior, he explored the
retroperitoneal region ventrally from spinae17. In 1973,
Wittmoser insufflated CO2 into the retroperitoneum to
have a better view when performing lumbar sympa-
thectomy18. With time, the retroperitoneoscopic tech-
nique was improved. In 1987 Dargent, using the pelvis-
cope (laparoscope), was the first to perform retroperitoneal
interiliacal lymphadenectomy in the same session as rad-
ical vaginal hysterectomy19. He was the first to actualize
the extended vaginal hysterectomy. Two years later, Qu-
erleu introduced transperitoneal pelvic lymphadenecto-
my laparoscopically. He removed the »interiliacal lymph
node packet« between the arteria umbilicalis and the
vena iliaca externa laparoscopically20. Canis was the first
to publish »endoscopic radical hysterectomy type II« in
199021. A year later, Querleu published the »laparosco-
pically assisted vaginal radical hysterectomy according to
Schauta«22. At that time Dargent improved the opera-
tional technique. He laparoscopically resected the proxi-
mal and dorsal part of the lateral parametria, prepared
the ureter vaginally and standardized this surgical oper-
ation in 1992 as the laparoscopically assisted radical vag-
inal hysterectomy (LAVRH)23–25.
Operative Procedures
Laparoscopic lymphadenectomy and radical
vaginal hysterectomy – LAVRH
Two surgeons operate, each operating a contralateral
side, the patient is in the lithotmic position (»supine posi-
tion«). The operation is performed under general anes-
thesia and indwelling of the urinary catheter is manda-
tory. Through an infraumbilical incision, a 10 mm trocar
is inserted and through it, a telescope. Under visual con-
trol we insert additional 5 mm of the trocar, one in the
medial line, two transversal fingers above the symphysis
and two lateral at around 3 cm, laterally and cranially
from the arteria epigastrica inferior. Our approach and
operative technique are based on the experiences of
Possover and Schneider26–30. The operation begins with
inspection of the whole abdomen. The patient is then put
into the Trendelenburg’s position at 30 degrees. Using
the bipolar electrodes and scissors, we mobilize the cae-
cum and the sigma in order to detach them from the lat-
eral pelvic wall. The right side is operated first. After
this, using the bipolar electrode and the scissors, we per-
form resection of the ligamentum teres uteri (Figure 1).
With the help of the blunt preparation procedure, we
open the Wagner’s pit and show the musculus iliopsoas.
Then we identify the ligamentum umbilicale laterale
(obliterated arteria umbilicalis) (Figure 2). Using firm
grasp forceps, we grip that ligament and pull it medially.
Medially and ventrally from it, where the urinary blad-
der is situated. Pushing the urinary bladder medially, we
secure access to the interiliacal lymph nodes and the
fossa obturatoria. Then we show the arteria iliaca exter-
na and remove it from the muscle iliopsoas. The fat tis-
sue with lymph nodes is situated between the muscle
iliopsoas and the arteria iliaca externa. Laterally from
this tissue, there is the nervus genitofemoralis requiring
extra precautions. During this preparation caution is
also required with numerous branches of arteria iliaca
externa, which need to be coagulated. The lower limit of
dissection of the lymph nodes along the arteria iliaca
externa is the vena circumflexa ilium profunda, which is
situated dorsally from the ligamentum inguinale. By
pulling the fat tissue with the lymph nodes dorsally, us-
ing blunt preparation we show the vena iliaca externa.
Laterally and dorsally from it, there is the nervus obtu-
ratorius which is showed with blunt preparation (Figure
3). Medially from the nerve in the fat tissue, the surface
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obturatory lymph nodes are situated, and laterally are
the deep obturatory lymph nodes. The lateral dissection
limit is the fascia musculi obturatori internusa. In the
obturatory opening, along with the nerve, the arteria and
vena obturatoria also enter. If these blood vessels are in-
jured during preparation, they can be coagulated with no
fear. During the preparation of the obturatory nerve, it
should not be injured because its injury causes paresis of
the adductor mucles of the upper leg. After »cleaning«
the obturatory pit, the fat tissue with the lymph nodes
»en block« is being pulled proximally and laterally. In the
triangle between a. and v. iliaca externa and the a. and v.
iliaca interna, caution is required because this region
contains numerous branches of the v. iliaca interna. By
pulling the fat tissue with the lymph nodes further proxi-
mally, by blunt preparation with coagulation with bipolar
electrodes we come to bifurcation of the arteria iliaca
communis. This is the upper limit of dissection. Thus,
»en block« resection of the iliacal, interiliacal and ob-
turatory lymph nodes has been performed (Figure 4).
The same procedure is repeated on the left side. Fol-
lowing this, we go on to the mobilization of the ureter
and proximal resection of the parametria. By removing
the obturatory lymph nodes, we show the fossa para-
vesicalis (Figure 5). Mobilization of the ureter shows the
starting point of the arteria iliaca interna. Dorsally and
caudally from the arteria uterina is the fossa pararec-
talis. The fossa pararectalis and the fossa paravesicalis
are divided by the ligamentum cardinale. When the
ligamentum cardinale is optimally shown using blunt
preparation and coagulation with a bipolar electrode, the
resection is performed »step by step« exclusively on the
vascular part of the cardinal ligament. When performing
the resection, we have to be careful about the pars
nervosa ligamenti cardinali because there the nervi splan-
chnici pelvini are situated, which are very important for
normal functioning of the rectum and urinary bladder. In
case there are problems with bleeding, we can easily coag-
ulate the arteria iliaca interna. The cardinal ligament is
resected caudally to the level of the arteria iliaca interna.
Then we coagulate and cut the arteria uterina on the level
of the starting point of the arteria iliaca interna. Then, in
several steps, we resect the proximal (supraureteral) part
of the »bladder pillars« and after this, using bipolar elec-
trodes and scissors, we detach the peritoneum of the uri-
nary bladder from the uterus (plica vesicouterina)28,29.
This finishes the laparoscopic part of the surgery and we
proceed with the transvaginal part of the surgery.
The patient is put into the position for a vaginal oper-
ation (candy kane position). The vaginal membrane is
clamped with six straight traumatic clamps and infil-
trated with vasocontricting solution (2% mixture of xy-
locain and adrenaline). Using a monopolar electrode, we
circumcise the whole circumference of the uterus to the
dorsal and ventral vaginal fascia. We circumcise 1.5–2 cm
of the uterine membrane from the vaginal-cervical point
of connection. A »vaginal cuff« is closed with an extended
stitch, then we remove the urinary catheter. By pulling
the vaginal cuff ventrally, we show the septum recto-
vaginale.
By pulling the vaginal cuff caudally and dorsally using
scissors, we detach the dorsal side of the urinary bladder
from the uterus and the cervix (Figure 6). The prepara-
tion must be exactly in the medial line to the plicae
vesicouterinae that was previously laparoscopically pre-
parated. When we have completely detached the bladder
from the vagina and the uterus a Breisky speculum is in-
troduced, and the bladder is pushed ventrally. Then we
proceed with opening of the fossae paravesicale. The me-
dial side of the bladder pillars was shown during the
preparation of the urinary bladder. Now preparation of
the lateral side follows.
The vaginal membrane is clamped with Kocher clamps
on the left side at »1 and 3 o’clock« and on the right side
at »9 and 11 o’clock«. Using scissors, we make blunt
preparation in the lateral-dorsal direction, thus detach-
ing the lateral part of the bladder pillars from the en-
dopelvic fascia. After this, identification of the ureter fol-
lows. The ureter is identified with help of the »click
manoeuvre«30. Namely, the collateral index finger is set
on the medial side of the bladder pillars and a Peham
clamp on the lateral side in a way that top of the clamp is
directed to the laterodorsal direction. Between the clamp
and the finger, we can clearly feel the ureter. By moving
the Peham clamp dorsomedially and using the finger to
push the ureter cranially, we detach the ureter from the
distal part of the bladder pillars. When we have showed
the ureter, we resect and bind the distal part of the blad-
der pillars (Figure 7). Using the ureteral clamp, we pull
the ureter caudally and see if there is some unresected
supraureteral part of the bladder pillars which are then
resected, using a clamp, and then bound. Then we intro-
duce a Breisky speculum into the Douglas and push the
rectum dorsally. At the same time, using another Breisky
speculum, we push the bladder and the ureter ventrally.
In this way we show the rectal pillars that are gripped by
a strong clamp (Wertheim clamps), we cut and bind. In
this way the preparation is completely removed (Figure
8).
The sacrouterine ligamentum is fixated to the back
membrane of the vagina using a 2.0 vycril stitches and
the uterus is closed using individual vycril 2.0 stitches.
In the end, the intraabdominal operation field is check-
ed laparoscopically and drained using the drain 14Ch
through a suprapubic cut.
Laparoscopically assisted radical vaginal
trachelectomy – LAVRT
Cervical carcinomas are spread primarily by meta-
stasing into the regional lymph nodes and infiltrating
into the parametria. Vertical invasion into the uterus
body is relatively rare and described only in cases when
the primary tumor is > 4 cm in diameter. Patients suffer-
ing from cervical carcinoma of the FIGO stage of the dis-
ease IA2 and IB1 have a 5–15% chance of metastasing
into the regional lymph nodes. In the IA2 stage of dis-
ease, risk of invasion into the parametria is negligible31.
Therefore, the fertile ability of those patients can be pre-
served. It is sufficient to perform thorough conization
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and laparoscopic pelvic lymphadenectomy in cases where
edges and top of the conus are free, and the lymph nodes
negative, for this stage of the disease31.
At the IB1 stage of the disease risk of invasion into
the parametria grows with size of the tumor and depth of
penetration into the stroma31. However, fertility can be
preserved in this stage of the disease as well. In 1995,
Dargent was the first to report on a modified Schauta-
-Amreich radical vaginal surgery where the body of the
uterus was preserved. He called this new operational
technique radical vaginal trachelectomy32. For the past
ten years several authors have reported on their experi-
ence with radical vaginal trachelectomy combined with
laparoscopic pelvic lymphadenectomy33–35. Debates on
which indications point to LAVRT are led as long as to-
day. Burnett has analyzed results of four large series
with a total of 152 patients with the follow-up period of
23–47 months. Four (2.5%) patients have developed a re-
lapse within the follow-up period35. Similar results were
published by Dargent 36.
Disease relapses occurred in patients where the pri-
mary tumor was > 2 cm. Hence, most authors consider
that LAVRT is indicated for patients under the age of 40
with cervical tumor < 2 cm and who want to preserve
their fertility. Presurgical procedures include the MRI
for accurate assessment of the tumor size or possible in-
vasion into the parametria.
The surgical technique is similar to that of the LAVRH.
First, laparoscopically, we remove all pelvic lymph nodes.
Frozen section is obligatory. In case the lymph node is
positive, the operation is discontinued and the patient is
referred to chemoirradiation therapy or LAVRH is per-
formed. In case the removed lymph nodes are negative,
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Fig. 1. Coagulation and resection of the ligamentum teres uteri
during LAVRH.
Fig. 2. Identifying of the ligamentum umbilcale laterale during
LAVRH.
Fig. 4. Bifurcation of the arteria iliaca communis – the upper
limit of dissection in LAVRH.
Fig. 3. Preparation of the nervus obturatorius during LAVRH.
LAVRH – laparoscopic assisted vaginal radical hysterectomy
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the vaginal part of the procedure is continued. The prep-
aration should ideally contain 1–2 cm of the uterus, the
whole cervix and 1–2 cm of the lateral parametria. After
removing the preparation, frozen section is performed.
In cases where edges of the preparation are free the pro-
cedure is finished by reconstructing the vagina and form-
ing the »new exocervix«, using the classical Sturmdof
technique.
In cases where edges of the preparation are positive to
frozen section, LAVRH is to be performed. All risks in-
volved must be carefully explained to the patient prior to
the procedure.
Numerous pregnancies have been described in pa-
tients who underwent LAVRT but with a large number
of spontaneous abortions (40%) and a significant number
of premature births37.
LARVT is a new surgical technique and represents an
important step in the development of surgical policy on
treating cervical carcinoma. It requires enormous experi-
ence of the surgeon, both in the area of vaginal surgery
and in the area of invasive (radical) laparoscopic pelvic
surgery. Therefore, LAVRT is to be performed exclu-
sively in highly specialized institutions that have a well
tuned-in surgical team and an expert pathology team
when interpretation of the frozen section pathohisto-
logical results is concerned.
Results and Discussion
In our single center 52 patients with cervical cancer
FIGO stage IA and IB underwent either open surgery or
LVRH in the 2003 and were followed up for at least 3
years. The distribution of patients according to clinical
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Fig. 5. Fossa paravesicalis and pararectalis after removing
obturatory lymph nodes in LAVRH.
Fig. 6. Detaching the dorsal side of the
Fig. 7. Right ureter and resection of the laterodorsal parametria
during LAVRH.
Fig. 8. Specimen of the resected uterus after
LAVRH – laparoscopic assisted vaginal radical hysterectomy
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stage, infiltration of parametrium, type of operation,
number of lymph nodes removed is presented (Table 1
and 2). Pathohistological findings include 10 (19%) pa-
tients with adenocarcinoma, 8 (16%) with adenosqu-
amous carcinoma and 34 (65%) with planocellular carci-
noma. The survival rate and time period to recurrence of
the disease according to clinical stage is presented (Table
3). Only 5 (14%) patients died from cervical cancer with-
in 3 years following the treatment. They were all FIGO
stage IB and all underwent open surgery. There were 4
(11%) complications following treatment and they were
all in patient FIGO stage IB, also only in open surgery
treated patients. Two postirradiation ileitis and two hydro-
nefrosis were reported. The distribution of complications
following treatment according to the type of surgery is
presented in Table 4. There were no complications in pa-
tients treated with LAVRH.
It was already mentioned that Wertheim performed
the first radical surgery of cervical carcinoma in 1898.
The same year, Marie Curie discovered radium, the appli-
cation of which in medicine began four years later1,37. A
whole century has passed in debates on which modality
of treating cervical carcinomas (surgical or via radiation
therapy) is more efficient. While gynecologists and onco-
logists agree that, for stages of the illness of IIB and
above, chemoirradiation is the optimal choice, there has
been continuous doubt about which modality of treat-
ment is best for stages IB and IIA. Landoni tried to re-
solve these doubts. According to his research, the sur-
vival rate of patients with stages IB and IIA depends
exclusively on the size of their tumor, not on the modality
of treatment38. The results of our study which include
patients treated by open surgery or LAVRH support this
conclusion because we show that survival rate in 3 years
for patients FIGO stage IA2 is 100% regardless the type
of surgery and 91.7% in patients with FIGO stage IB1
treated with LAVRH (Table 3).
The benefits of surgical treatment need to be pointed
out: preservation of the ovarian function and preserva-
tion of the vaginal function (lubrication, stenosis). Apart
from this, together with correct staging, a large number
of patients with disease stages IB and IIA can be spared
of unnecessary radiation therapy39. Therefore, Dargent
emphasizes: »Surgery in comparison with radiotherapy
is a single step treatment: instant treatment with com-
plete response obtained in a few hours«37.
Most gynecologists including our team today consider
the primary surgical treatment a method of choice for tu-
mors < 4 cm. With respect to the fact that only 15% of
cervical carcinomas of this size have regional metastases,
this stage of disease is ideal for »surgical-pathological
staging«. Regardless of the fact that FIGO has not ac-
cepted it so far. This approach includes postoperative ra-
diation of patients whom are found to have: metastases
into lymph nodes or infiltration of the parametria or in-
filtration > ½ of the cervix thickness or lymphovascular
space involvement (LVSI). This information is obtained
only after a radical surgery. This is the advantage of the
laparo-vaginal approach. Namely, a surgeon starts the
operation with laparoscopic pelvic lymphadenectomy.
During the procedure »ex tempore« the removed lymph
nodes are subject to pathohistologic examination. In cas-
es where metastases in the lymph node are found, the op-
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TABLE 1
THE DISTRIBUTION OF PATIENTS ACCORDING TO CLINICAL


















I A 1* 3 (8%) 37 0
I A 2 12 (31%) 36 0
I B 23 (61%) 43 3 (13%)
Total 38 38.7 3 (8%)
LAVRH
(14)
I A 2 2 (14%) 34 0
I B1 12 (86%) 40.5 1 (8%)
Total 14 37.4 1 (7%)
*radical surgery was performed only when lymphovascular spa-
ce involvement (LVSI) was positive in cone biopsy
TABLE 2
THE DISTRIBUTION OF TYPE OF SURGERY, NUMBER OF REMOVED LYMPH NODES ACCORDING TO CLINICAL








Mean number of lymph






I A 1* 1 (7%) 2 (8%) 42 21
I A 2 10 (71%) 2 (8%) 211 17.5
I B 3 (21%) 20 (84%) 454 19.7
Total 14 (37%) 24 (63%) 707 19.4
LAVRH
(14)
I A 2 2 (100%) 0 35 17.5
I B1 0 12 (100%) 228 19.0
Total 2 (14.3%) 12 (85.7 %) 263 18.8
*radical surgery was performed only when lymphovascular space involvement (LVSI) was positive in cone biopsy
U:\coll-antropolo\coll-antro-suppl-2-2007\21-Corusic.vp
4. travanj 2007 9:17:05
Color profile: Disabled
Composite  150 lpi at 45 degrees
eration is discontinued and the patient is referred to
chemo-irradiation treatment. In cases where there are
no metastases in the lymph nodes, radical vaginal hyster-
ectomy is continued. If the already mentioned risk fac-
tors are found on the removed preparation, the patient is
referred to additional radiation treatment. There is no
evidence that radio-therapy treatment following LAVRH
has the higher morbidity rate than following open abdo-
men operations38. Patients with a tumor < 2 cm are ideal
for this operation. Namely, regardless of histologic type
of the tumor, if parametria, lymph nodes and LVSI are
negative, there is no chance of a relapse.
In tumors > 2–4 cm we need to be more cautious in
setting the indication for LAVRH. In such patients, in
spite of the negative lymph nodes and negative LVSI, the
relapse risk is around 15%. If metastases were detected in
pelvic lymph nodes, or there is a case of histologically ag-
gressive tumor (small cell cancer, neuroendocrine cancer),
relapse of the disease is present in 30–50% of the cases26.
Contraindications for LAVRH include a tumor > 4 cm
or poor histologic type. When assessing the tumor size,
only MRI is used. The presence of enlarged regional
lymph nodes does not necessarily represent a contraindi-
cation for LAVRH. In case the MRI shows an enlarged
lymph node, laparoscopy is indicated. During the proce-
dure, the lymph node is removed and sent to urgent
histologic examination. If the frozen section result is
negative, laparoscopic lymphadenectomy is continued,
followed by radical vaginal hysterectomy. If the lymph
node is positive, the operation is discontinued and the pa-
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TABLE 3
THE DISTRIBUTION OF PATIENT ACCORDING TO NUMBER OF METASTASIS, RECURRENCE OF DISEASE FROM CERVICAL CANCER
AND SURVIVAL RATE














Open surgery I A 1* (3) 0 0 0 0 100%
I A 2 (12) 0 0 2 17 100%
I B (23) 6 (26%) 16 7 19 78%
LAVRH I A 2 (2) 0 0 0 0 100%
I B (12) 2 (17%) 3 1 18 91.7%
LAVRH – laparoscopic assisted vaginal radical hysterectomy, *radical surgery was performed only when lymphovascular space in-
volvement (LVSI) was positive in cone biopsy
TABLE 4
THE DISTRIBUTION OF COMPLICATION ACCORDING TO THE










Rutledge II (15) 0 1 1 (6.7%)
Rutledge III (23) 2 1 3 (13.0%)
Total (38) 2 (5%) 2 (5%) 4 (10.5%)
tient is referred to an oncologist for chemoirradiation. In
case during laparoscopy we find a »bulky« lymph node, it
is recommended to remove it and mark its spot with
metal clips to ease the radio-therapist’s plan for radio-
therapy.
Several key questions arise here: (1) Can the frozen
section be given absolute trust? In case the lymph node is
positive, (2) does the uterus need to be preserved for fu-
ture brachytherapy? (3) Do we need to continue with
lymphadenectomy because the removal of tumorous me-
tastases makes the following radiation treatment more
effective? (4) Do we need to continue the LAVRH or (5)
go on with the open abdomen surgery?
So far, we have no clear answers to these questions
but most gynecologists-oncologists believe that in such
situations »pelvic clearance« needs to be performed, and
then the patient referred to further chemoirradiation
treatment.
The efficacy of LAVRH was shown in a series of 200
patients with FIGO stage IA1 to IIB cervical cancer. This
is the largest reported study40. They reported follow up
for at least 40 months and overall survival rate was 83 %.
Comparing our overall survival rate in patients with cer-
vical cancer FIGO stage IA2 and IB which was 92.8%
show that we had the same success with the same com-
plications rate. We did not perform this procedure in pa-
tients with cervical cancer FIGO stage IIB, so this was
robably the reason why our survival rate is slightly
higher than in the study by .40 One possibility why we did
not have complication in LAVRH treated patients is the
small number of procedures (14), but the lack of compli-
cations in LAVRH treated patients supports the conclu-
sion that with correct staging a large number of patients
with cervical cancer FIGO stages IA2 and IB can be
spared of unnecessary abdominal radical surgery; be-
cause the survival rate, number and severity of complica-
tions is almost the same41,42. Several other observational
studies support these conclusions40–46. We had 4 (10.5%)
complications in open surgery treated patients which
were not different from other comparing studies between
these two operative types.41,42,46
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Conclusion
With correct staging a large number of patients with
cervical cancer FIGO stages IA2 and IB can be spared of
unnecessary abdominal radical surgery and treated with
LAVRH because the survival rate, number and severity
of complications is almost the same. Our results and expe-
riences from the sole Croatian center performing LAVRH
or open surgery in patients with cervical cancer FIGO
stage IA2 and IB were similar to those in centers across
the world. Primary surgical treatment is a method of
choice for tumors of the cervix < 4 cm.
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ULOGA LAPAROVAGINALNE KIRURGIJE U KIRUR[KOM LIJE^ENJU RAKA VRATA MATERNICE
S A @ E T A K
Korektnim odre|ivanjem stadija bolesti prema FIGO klasifikaciji veliki broj bolesnica s rakom vrata maternice stadija
IA2 i IB mogao bi se po{tediti nepotrebnog radikalnog abdominalnog kirur{kog lije~enja gdje je i laparoskopski asistirana
vaginalna radikalna histerektomija (LAVRH) mogu}a. Prikazani su povijesni pregled, indikacije i kontraindikacije za
LAVRH. Kirur{ka tehnika LAVRH je detaljno opisana. 52 bolesnice su pra}ene tijekom 2003. godine nakon provedenog
lije~enja LAVRH-om ili abdominalnom radikalnom kirur{kom operacijom izvedenom u na{em centru. U razdoblju pra-
}enja 5 (14%) bolesnica je umrlo od raka vrata maternice i sve su bile FIGO stadija IB, lije~ene abdominalnom radikalnom
operacijom. Prikazane su 4 (10.5%) komplikacije, sve u bolesnica s FIGO stadijem IB lije~enih abdominalnom radikalnom
operacijom. U bolesnica lije~enih LAVRH-om nisu zabilje`ene komplikacije. Pre`ivljenje, kao i broj komplikacija nakon
LAVRH ili radikalne abdominalne operacije, u na{em centru u Hrvatskoj, ne razlikuju se u usporedbi s drugim svjetskim
centrima.
A. ]oru{i} et al.: Laporovaginal Surgery in Cervical Cancer, Coll. Antropol. 31 (2007) Suppl. 2: 147–154
154
U:\coll-antropolo\coll-antro-suppl-2-2007\21-Corusic.vp
4. travanj 2007 9:17:05
Color profile: Disabled
Composite  150 lpi at 45 degrees
Coll. Antropol. 31 (2007) Suppl. 2: 155–158
Short communication
Adjuvant Therapy after Radical Surgery of
Cervical Cancer: Zagreb Experience
Vlastimir Kukura1, Sre}ko Ciglar1, Lijerka Markulin-Grgi}2 and Fedor [antek2
1 Department of Gynecology and Obstetrics School of Medicine Merkur University Hospital, Zagreb, Croatia
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A B S T R A C T
The results of the analysis of the treatment of 72 patients with carcinoma of the uterine cervix are presented. Sev-
enty-two patients with Stage IB1 carcinoma of the cervix underwent a radical hysterectomy and pelvic lymphadenec-
tomy. The low-risk group includes the patients without unfavourable prognostic factors that were treated by surgery
alone. The high-risk group included women with pelvic node metastases, clinical tumour size greater than 3.0 cm, depth
of stromal invasion greater than 1/3 of the cervical wall, Grade 3 tumours and the presence of lympho-vascular space in-
volvement. High-risk patients received whole pelvic radiotherapy between two and four weeks following surgery. Thirty-
four patients (47.2%) were in the low-risk group and thirty-eight patients (52.8%) were in the high-risk group. Locore-
gional recurrences were diagnosed in three cases (8.8%) in the surgery group and in four patients (10.5 %) assigned to
postoperative radiotherapy. The incidence of distant metastases was 2.9% in the group treated by surgery alone and 5.3%
in the group treated by surgery and radiotherapy. Overall survival at five years was 91.2% in the low-risk group and
89.5% in the high-risk group of patients. Five-year overall survival, locoregional and distant metastases were similar in
the low-risk and high-risk groups of patients, which emphasizes the value of whole pelvic radiation in patients with one
or more unfavourable prognostic factors after radical surgery in Stage IB1 cervical cancer.
Key words: cervical cancer, risk factors, adjuvant therapy
Introduction
Uterine cervical cancer is the most common gyne-
cological cancer worldwide with a yearly incidence of
500, 000 cases1. It is an important women’s health prob-
lem in developing countries. Risk factors for cervical can-
cer include early onset of sexual activity, multiple sexual
partners, lower socio-economic group and history of sex-
ually transmitted disease. Human papilloma virus has
been implicated as the major causative agent in this dis-
ease. Squamous cell carcinomas account for 80–85% of
cases with adenocarcinoma and adenosquamous carcino-
mas responsible for 15% and 3–5%, respectively2. At the
FIGO Congress in Montreal 1994, the Gynecologic On-
cology Committee made some changes in the staging for
cervical cancer. Stage IB comprises patients with micro-
scopic stromal invasion more than 5.0 mm or with hori-
zontal spread more than 7.0 mm and clinically visible le-
sion confirmed to the cervix. Stage IB1 presents clinical
lesions no greater than 4.0 cm in size and Stage IB2 clini-
cal lesions greater than 4.0 cm in size3. Signs range from
abnormal cervical smear only to a cervix with exophytic
or crater-like type lesions. Symptoms include abnormal
vaginal bleeding, postcoital spotting and vaginal dis-
charge.
The algorithm for the management of Stage IB cervi-
cal cancer includes radical hysterectomy and pelvic lym-
phadenectomy. Patients with lymph node metastases are
treated by postoperative adjuvant pelvic radiation4. Posi-
tive surgical margins, parametrial involvement, tumor
diameter, depth of stromal invasion, tumor grade and
lympho-vascular space involvement are also risk factors
for recurrences. Gynecology Oncology Group (GOG) stu-
dy in 1990, reported clinical tumor size, depth of invasion
of the cervix and lympho-vascular space involvement as
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independent prognostic factors. Patients with negative
lymph nodes in Stage IB cervical cancer have 25% high
risk factors5. Another GOG study in 1999, suggested that
postoperative pelvic radiation reduced the risk of recur-
rences in patients with at least two risk factors: large tu-
mor diameter, more than 1/3 stromal invasion and lym-
pho-vascular space involvement6. Women with Stage IB
or II cervical carcinoma with lymph node metastases
post Wertheim hysterectomy and pelvic lymphadenecto-
my who were given adjuvant radiotherapy treatment had
better survival than those undergoing surgery only in a
multivariate analysis. Patients without pelvic lymph no-
de metastases but with parametrial extension, tumour
size greater than 4 cm, full thickness cervical stromal in-
vasion and DNA index more than 1. 3 had significantly
better five-year recurrence free survival rate if receiving
postoperative radiotherapy7.
In previously published studies patients with cervical
cancer stage IB with unfavourable prognostic factors
were classified in two groups, those who were and those
who were not treated by radiotherapy after surgery. The
five-year survival was significantly higher in those wo-
men who were treated compared to non-treated women
by radiotherapy after surgery. Herein, we evaluate the
whole pelvic radiation in women with vs. those without
unfavourable prognostic factors after surgery of cervical
cancer stage IB1. The recurrence of the disease was the
endpoint of this evaluation.
Subjects, Material and Methods
Seventy-two patients were included into the study
with a mean age 44.2±10.4 years. Initial evaluation in-
cluded medical history, Pap smears and pelvic examina-
tion. When cytology has shown malignant cells in patients
with no visible tumour we made diagnostic conization. In
patients with clinically visible lesions confined to the cer-
vix, diagnosis was confirmed by a directed punch biopsy.
Preoperative evaluation included physical examination,
complete blood count, blood chemistry tests, chest radi-
ography, intravenous pyelogram, cystoscopy and sigmoi-
doscopy. All patients were treated by Wertheim hysterec-
tomy and pelvic lymphadenectomy. When no residual
tumour was found in the radical hysterectomy specimen,
presurgical data from cone biopsies were used. The diag-
noses of squamous cell carcinoma, adenocarcinoma or
adenosquamous cervical cancer were made by a patholo-
gist.
Low-risk group include the patients without unfa-
vourable prognostic factors and they were treated only
by surgery. High-risk group includes women with pelvic
node metastases, clinical tumour size greater than 3.0
cm, depth of stromal invasion greater than 1/3 cervical
wall, Grade 3 tumours and the presence of lympho-vas-
cular space involvement. High-risk patients received ra-
diotherapy between two and four weeks following sur-
gery.
Postoperative radiotherapy was administered to the
pelvic region according to a standardised protocol. The
radiation was delivered by 4 fields’ box technique or by
anteroposterior and posteroanterior parallel-opposed pair
of fields, using linear accelerator or cobalt-60 unit. The
total tumour dose was 40–48 Gy in 20–24 fractions using
2 Gy daily fractions, five days a week.
Patients were evaluated by physical examination, ul-
trasound, Pap smear, blood counts, blood chemistries and
chest radiography every three months for the first two
years, every six months during the next three years and
then annually. Computed tomography scan with contrast
or magnetic resonance imaging of the abdomen and pel-
vis were done at six months and then yearly. Sites of re-
currence were classified as local if detected in the pelvis
or vagina, and distant if detected in extra-pelvic loca-
tions.
The differences were evaluated by Chi-square test
with statistical significance set at p<0.05.
Results
From January 1995, to December 2001, seventy-two
patients with FIGO Stage IB1 cervical cancer were pri-
marily treated by radical surgery. The tumour cell type
was squamous in sixty-one (84.7%) women, adenocarci-
noma in nine (12.5%) and adenosquamous carcinoma in
two (2.8%). Thirty-four patients out of 72 (47.2%) were
low-risk and 38/72 (52.8%) were high-risk patients.
For the low-risk group of patients no further therapy
was applied, while high-risk patients received postopera-
tive whole pelvic radiation. The median interval between
the operation and the first radiotherapy session was 24
days. During radiotherapy the patients were treated with
medication or dietary measures, or both, for related
symptoms.
Local recurrences in the pelvis or vagina were diag-
nosed in three patients (8.8%) in the group treated by
surgery and in four patients (10.5%) treated by postoper-
ative radiotherapy. Distant metastases involving the ab-
domen or lung, or both locations were analyzed. The inci-
dence of distant metastases was 2.9% in the group trea-
ted by surgery alone and 5.3% in the group treated by
surgery and radiotherapy (Table 1). No significant differ-
ences was observed (Chi-square=0,08, p
0.05).
In four patients there were grade 3 or 4 adverse ef-
fects, of which one out of 34 (2.9%) patient was treated
by surgery alone and 3 out of 38 (7.9%) patients were
treated by both surgery and radiotherapy.
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TABLE 1








Local 3 (8.8%) 4 (10.5%)
Distant 1 (2.9%) 2 (5.3%)
Total 4 (11.7%) 6 (15.8%)
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Overall survival at five years was 91.2% in the low-
risk group and 89.5% in the high-risk group of patients
(Table 2); almost equal in both groups of patients.
Discussion
The role of postoperative irradiation was evaluated
for patients with Stage IB cervical cancer with tumour-
related risk factors. Three independent prognostic fac-
tors in the GOG study in 1990, clinical tumour size,
depth of tumour invasion and lympho-vascular space in-
volvement made GOG risk score. Score higher than 120
was correlated with 41% recurrence rate5. Sedlis et al.
used a modification of the GOG scoring system and re-
ported a 44% reduction of the risk of recurrences after
adjuvant radiotherapy when a combination of three risk
factors were present compared without postoperative ir-
radiation6. Ayhan et al. reported that tumour size larger
than 4 cm; lympho-vascular space involvement and vagi-
nal involvement were independent prognostic factors in
lymph node negative invasive cervical cancer. Depths of
stromal invasion, parametrial, endometrial and myome-
trial involvement, however, were not independent prog-
nostic factors. Women with one and two or more risk fac-
tors showed lower ratios of pelvic recurrences when
receiving postoperative radiotherapy8. Pieterse et al. be-
fore 1996 received adjuvant radiotherapy for patients
with pelvic node metastases, parametrial invasion or pos-
itive surgical margins. In 1997 they extended the indica-
tion for postoperative irradiation using a modification of
the GOG scoring system. Patients with at least two of the
three risk factors received total pelvic radiotherapy: pa-
thologic tumour size greater than 40 mm, depth of inva-
sion greater than 15 mm and presence of lympho-vascu-
lar space involvement. They found that a significantly
larger percentage of the high-risk group of patients who
did not receive radiotherapy had recurrence of disease
(41% vs. 12%). Differences in five-year cancer specific
survival and five-year disease free survival between the
high-risk groups treated with radiotherapy and without
radiotherapy after radical surgery were statistically sig-
nificant9. In the recent study they found that adjuvant
radiotherapy did not significantly increase the risk of
bladder dysfunction, bowel symptoms, lymphedema and
sexual function after 2-years follow-up10. Scharge et al.
reported that lympho-vascular space involvement is an
important prognostic variable and adjuvant pelvic radia-
tion may decrease the risk of recurrence in this pa-
tients11. GOG study in 2005 suggests that pelvic radio-
therapy after radical surgery significantly reduced the
risk of recurrence and prolongs progression-free survival
in women with Stage IB cervical cancer. Radiation ap-
pears to be particularly beneficial for patients with ade-
nocarcinoma or adenosquamous carcinoma12.
In another our study one hundred and forty eight pa-
tients with Stage IB squamous cell cervical cancer were
primarily treated by radical surgery. Low-risk group in-
cluded 70 patients without unfavourable prognostic fac-
tors that were treated by surgery alone. High-risk group
included 78 women with one or more risk factors: pelvic
node metastases, positive or close surgical margins, clini-
cal tumour size greater than 4.0 cm, stromal invasion
greater than 1/3 cervical wall, Grade 3 tumours and the
presence of lympho-vascular space involvement. High-
risk patients received postoperative whole pelvic radia-
tion. Eleven (15.6%) women in the low-risk group devel-
oped cancer recurrences, nine (12.8%) local, and two
(2.8%) distant. In high-risk patients there were sixteen
(20.5%) cancer recurrences, eleven (14.1%) local and five
(6.4%) distant. Overall survival at five years was 88.6%
in the low-risk group and 84.7% in the high-risk group of
patients13. More of recurrences in the high-risk group
were seen in patients with IB bulky tumours and we re-
duced primarily radical surgery treatment for FIGO
Stage IB1 cervical cancer.
In the recent study the low-risk group includes 34 pa-
tients without unfavourable prognostic factors who were
treated by surgery alone. The high-risk group includes
38 women with one or more risk factors: pelvic node
metastases, tumour size greater than 3.0 cm, stromal in-
vasion greater than 1/3 cervical wall, Grade 3 tumours
and presence of lympho-vascular space involvement. The
high-risk patients received postoperative radiotherapy.
Four (11.7%) women in the low-risk group developed
cancer recurrences, three (8.8%) local, and one (2.9%)
distant. In the high-risk group of patients there were six
(15.8%) cancer recurrences, four (10.5%) local and two
(5.3%) distant. Local relapses were treated by surgery
and patients with distant metastases received chemo-
therapy. Women with squamous cell carcinomas received
cisplatin-based regiments and patients with adenocarci-
noma or adenosquamous type tumours received paclita-
xel-based chemotherapy14. Five-year overall survival rate
in the low-risk group treated by surgery and high-risk,
surgery and radiotherapy treated group was similar, 91.2
and 89.5%, respectively. The adverse effects were not
more expressed in the group of patients treated by adju-
vant total pelvic irradiation after radical surgery. This
emphasizes the value of whole pelvic radiation in pa-
tients with unfavourable prognostic factors in Stage IB1
cervical cancer.
Conclusion
In this study on a relatively small number of patients
with cervical cancer stage IB1 with one or more unfa-
vourable prognostic factors we intended to show the
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TABLE 2
FIVE-YEAR SURVIVAL OF PATIENTS ACCORDING TO THE










Low-risk group 34 No 91.2%
High-risk group 38 Yes 89.5%
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value of postoperative adjuvant radiation. Our findings
indicate that the number of local and distal metastasis
were similar to those patients without unfavourable
prognostic factors. The five year survival is also similar
in both groups of patients. The adjuvant total pelvic irra-
diation after radical surgery might represent over treat-
ment in some women but did not generate any side ef-
fects. From all these observations we consider that it is
prove enough to practice whole pelvic radiation in pa-
tients with one or more unfavourable prognostic factors
after radical surgery in Stage IB1 cervical cancer.
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ADJUVANTNA TERAPIJA NAKON RADIKALNE OPERACIJE RAKA VRATA MATERNICE
S A @ E T A K
Prikazani su rezultati analize na{e studije lije~enja 72 bolesnice s rakom vrata maternice. Sedamdeset i dvije paci-
jentice s IB1 stadijem raka vrata maternice podvrgnute su radikalnoj histerektomiji i zdjeli~noj limfadenektomiji. Sku-
pinu niskog rizika ~ine bolesnice bez nepovoljnih prognosti~kih ~imbenika i lije~ene su samo operacijom. Skupinu visokog
rizika tvore `ene s presadnicama u zdjeli~nim limfnim ~vorovima, veli~inom tumora preko 3,0 cm, dubinom invazije
strome ve}om od 1/3, nezrelim tumor ima i nazo~no{}u tumora u limfo-vaskularnim prostorima. Visoko rizi~ne bo-
lesnice primile su zra~enje izvana na zdjelicu izme|u dva i ~etiri tjedna nakon operacije. Trideset ~etiri bolesnice
(47,2%) bile su niskog rizika, a trideset i osam (52,8%) ih je bilo visokog rizika. Lokalni recidiv bolesti je dijagnosticiran
u tri slu~aja (8,8%) u operiranoj skupini i u ~etiri bolesnice (10,5%) koje su odre|ene za radioterapiju. Incidencija udalje-
nih metastaza bila je 2,9% u operiranoj skupini i 5,3% u operiranoj i zra~enoj skupini. Peto-godi{nje pre`ivljenje je bilo
91,2% u skupini bolesnica s niskim rizikom, dok je u skupini bolesnica s visokim rizikom bilo 89,5%. Petogodi{nje
pre`ivljenje, lokalne i udaljene metastaze bile su sli~ne u bolesnica s niskim i visokim rizikom. Ovo isti~e vrijednost
zra~enja zdjelice u bolesnica s jednim ili vi{e nepovoljnih prognosti~kih ~imbenika nakon radikalne operacije IB1 stadija
raka vrata maternice.
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